docetaxel anhydrous profile

Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	148124
CHEMBL ID	92
CHEBI ID	4672
SCHEMBL ID	4419
MeSH ID	M0585054

Synonym
AC-383
AB01273941-01
AB01273941-02
nsc628503
nsc-628503
benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclod
taxotere
taxotere (aventis)
rp-56976
sdp-014
emdoc
anx-514
xrp-6976l
syp-0704a
(2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (ar,bs)-b-[[(1,1-dimethylethoxy)carbonyl]am
nsc 628503
docetaxolum [inn-latin]
benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-y
hsdb 6965
n-debenzoyl-n-tert-butoxycarbonyl-10-deacetyltaxol
benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano
txl ,
docetaxel
114977-28-5
docetaxel anhydrous
n-debenzoyl-n-(tert-butoxycarbonyl)-10-deacetyltaxol
DB01248
n-debenzoyl-n-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
HMS2089K08
cid148124
CHEBI:4672 ,
4-(acetyloxy)-13alpha-({(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
CHEMBL92
docetaxel (jan/inn)
D07866
docetaxel (tn)
zdzotljhxycwba-vcvyqwhssa-
NCGC00242509-01
docetaxolum
sid 530
unii-699121phca
docetaxel winthrop
699121phca ,
docefrez
taxoel
docetaxel [inn]
dtxcid8020464
cas-114977-28-5
tox21_112781
dtxsid0040464 ,
tox21_113088
D4102
DOCETAXEL - TAXOTERE
n-debenzoyl-n-boc-10-deacetyl taxol
docetaxel 114977-28-5
AKOS015960718
docetaxel, trihydrate
HY-B0011
CS-1144
W-60384
rp56976
docetaxel [jan]
docetaxel [mi]
docetaxel accord
docetaxel teva pharma
docetaxel mylan
cabazitaxel metabolite (rp56976)
docetaxel [hsdb]
docetaxel, anhydrous
docetaxel teva
(2r,3s)-n-carboxy-3-phenylisoserine, n-tert-butyl ester, 13-ester with 5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate
docetaxel kabi
bind 014 [who-dd]
docetaxel anhydrous [who-dd]
gtpl6809
docecad
[acetoxy-[(2r,3s)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate
bdbm36351
SCHEMBL4419
tox21_112781_1
NCGC00181306-04
(2ar,4s,4as,6r,9s,11s,12s,12ar,12bs)-12b-acetoxy-9-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1h-7,11-methanocyclodeca[3,4]benzo[1,2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
bind-014
[2ar-[2a?,4?,4a?,6?,9?(?r,?s),11?,12?,12a?,12b?]]-?-[[(1,1-dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca[3,4
Q-100074
taxotel
AKOS024457953
(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-(acetyloxy)-15-{[(2r,3s)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
EX-A1206
docetaxel, purum, >=97.0% (hplc)
KS-1452
114977-28-5, docetaxel
anhydrous docetaxel, european pharmacopoeia (ep) reference standard
sr-01000003023
SR-01000003023-5
(2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2r,3s)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
Q420436
Z1546621742
114915-20-7
BRD-K30577245-001-04-3
BRD-K30577245-341-01-9
EN300-123047
[(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-acetyloxy-1,9,12-trihydroxy-15-[(2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
AMY4356
BD164373
n debenzoyl n tert butoxycarbonyl 10 deacetyltaxol
docetaxel- bio-x
docetaxolum (latin)
benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2ar,4s,4ar,6r,9s,11s,12s,12as,12bs)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,4a,6,11-tetrahydroxy-8,12a,13,13-tetramethyl-5-oxo-7,11-m
docetaxelum
(2r,3s)-n-carboxy-3-phenylisoserine, n-tert-butyl ester, 13-ester with 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate
docetaxel (usp-rs)
docetaxel (usp monograph)
docetaxel trihydrate (ep monograph)
docetaxel (usp impurity)
(1s,2s,3r,4s,5r,7s,8s,10r,13s)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1,7,10-trihydroxy-9-oxotax-11-en-13-yl (2r,3s)-3-(1,1-dimethylethyl)oxycarbonylamino-2-hydroxy-3-phenylpropanoate
docetaxel (ep monograph)
l01cd02
4-(acetyloxy)-13alpha-(((2r,3s)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

Excerpt	Reference	Relevance
" Fluid retention was the most problematic adverse event in these 2 studies in which premedication was not routinely administered."	( A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Azli, N; Bougon, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, Y; Maugard-Louboutin, C; Misset, JL; Riva, A; Roche, H, 1996)	0.29
" The most common adverse events (AE) were neutropenia (97%), alopecia (97%, grade 1-2), fluid retention (89%, mainly mild to moderate) and neurosensory disorders (81%, mainly mild to moderate)."	( A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Azli, N; Bougon, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, Y; Maugard-Louboutin, C; Misset, JL; Riva, A; Roche, H, 1996)	0.29
" The main toxic effect is grade 3-4 neutropenia, which occurs in 57% of treatment cycles but is brief and manageable."	( Efficacy and safety of docetaxel in clinical trials. Fumoleau, P, 1997)	0.3
"Small patient numbers in phase I trials may result in a safe but ineffective dose being recommended for phase II trials."	( Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group. Fujiwara, K; Hirabayashi, K; Kohno, I; Noda, K; Ogita, S; Ohashi, Y; Sasaki, Y; Taguchi, T; Tanaka, K; Terashima, Y; Tsunematsu, R; Yakushiji, M, )	0.13
"Docetaxel 70 mg/m2 without premedication was identified as a safe and effective dose."	( Phase II dose escalation: a novel approach to balancing efficacy and toxicity of anticancer agents. Japanese Docetaxel Ovarian Cancer Study Group. Fujiwara, K; Hirabayashi, K; Kohno, I; Noda, K; Ogita, S; Ohashi, Y; Sasaki, Y; Taguchi, T; Tanaka, K; Terashima, Y; Tsunematsu, R; Yakushiji, M, )	0.13
" Dose-limiting toxicity for this schedule was defined as any grade > 2 antiproliferative toxic effect resulting in a > 2-week delay for re-administration of the drug, or any grade > 2 organ-specific toxicity."	( Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Anastasopoulos, D; Briasoulis, E; Fountzilas, G; Karavasilis, V; Kostadima, V; Pavlidis, N; Rammou, D; Tzamakou, E, 1999)	0.3
"Peripheral neurotoxicity is a crucial side effect of chemotherapeutic agents."	( [Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] . Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A, 2000)	0.31
"To report a newly recognized side effect of a commonly used antineoplastic agent, docetaxel, in three patients with metastatic breast cancer."	( Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ahmadi, MA; Booser, D; Esmaeli, B; Valero, V, 2001)	0.31
"Epiphora is a newly recognized side effect of docetaxel and may occur more frequently with weekly cycles of this drug."	( Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ahmadi, MA; Booser, D; Esmaeli, B; Valero, V, 2001)	0.31
" The most common side effect was neutropenia (G3 in 80% of pts) and alopecia, but the chemotherapy tolerance was satisfactory."	( [Evaluation of efficacy and toxicity of docetaxel (Taxotere) in patients with advanced mammary gland cancer]. Pawlicki, M; Rolski, J; Rysz, B; Utych, G; Wiczyńska, B; Zemełka, T, 2001)	0.31
" Each chemotherapeutic drug has the potential to induce various adverse events in the patients receiving chemotherapy."	( [Prevention and treatment for adverse events induced by chemotherapy]. Tsukuda, M, 2002)	0.31
"The current study was conducted to report the severity and management of canalicular and nasolacrimal duct stenosis as a side effect of docetaxel therapy and to report the outcomes of surgical intervention for this condition."	( Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V, 2003)	0.32
"Canalicular and nasolacrimal duct obstruction is a common side effect of weekly docetaxel therapy and can occur even when this drug is used in the neoadjuvant setting."	( Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V, 2003)	0.32
" This report shows that conventional-dose palliative chemotherapy regimens may be safe and effective after failure of high-dose chemotherapy."	( Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy. Baars, JW; de Boer, MM; Rodenhuis, S; Schornagel, JH; Schrama, JG, )	0.13
" Tween 80, albeit less toxic than Cremophor EL, may be responsible of some toxic effects."	( Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. Arpicco, S; Brusa, P; Cattel, L; Dosio, F; Immordino, ML; Stella, B, 2003)	0.32
" Neutropenia appears more prevalent with docetaxel than with paclitaxel, although clinical trial data show that this adverse effect is manageable and need not compromise dose delivery."	( The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Diéras, V; Guastalla, JP, 2003)	0.32
" Multivariate analysis demonstrated that morphologic type by CE-CT and histologic type were significant predictors of candidates for safe BCT."	( The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Akashi-Tanaka, S; Ando, M; Fukutomi, T; Hasegawa, T; Iwamoto, E; Katsumata, N; Miyakawa, K; Sato, N; Watanabe, T, 2004)	0.32
" The purpose of this study was to establish the most suitable dosing schedule to relieve severe adverse effects and improve the antitumor effects."	( Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H, 2004)	0.32
" Leukocyte counts and survival were measured to estimate adverse effects."	( Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H, 2004)	0.32
"In the present study, the findings suggest that ADR administered 12 h after DOC injection (DOC-ADR group) not only inhibits tumor growth more strongly but also significantly reduces leukopenia compared with results for the simultaneous-dosing (ADR/DOC) group and significantly reduced the number of toxic deaths compared with the other groups."	( Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H, 2004)	0.32
" The incidence of serious adverse events was low."	( Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. D'hondt, R; Dumez, H; Paridaens, R; Pauwelyn, K; Thomas, J; Van Oosterom, AT; Wildiers, H, 2004)	0.32
" Current trends in the treatment of human tumors are for drug combinations that result in improved responses as well as the ability to use less toxic concentrations of the drugs."	( Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Colomer, R; Lupu, R; Menendez, JA; Ropero, S, 2004)	0.32
" However, the study was prematurely closed because of a high incidence of severe pulmonary adverse events."	( High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A, 2004)	0.32
" Common adverse events were sensory neuropathy (45%) and nausea/vomiting (37."	( [Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer]. Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2004)	0.32
" There were no toxic deaths."	( Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II study. Amenedo, M; Firvida, JL; González, A; Losada, G; Ramos, M; Rodríguez, R; Salgado, M, 2004)	0.32
" Therapy was well tolerated with no grade 4 or 5 adverse events."	( A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Ford, J; Jatoi, A; Jett, JR; Loprinzi, CL; Novotny, P; Prabhakar, U; Sloan, J, 2004)	0.32
"Chemotherapy-associated enterocolitis is a very rare but potentially lethal side effect of cytostatic therapy."	( [Chemotherapy-associated enterocolitis--a rare but potentially lethal side effect of adjuvant breast cancer treatment: a case report]. Friese, K; Janni, JW; Klanner, E; Rack, B; Sommer, H, 2004)	0.32
" This article summarizes experience with epiphora and canalicular stenosis as a side effect of docetaxel and provides specific recommendations for management of this side effect."	( Management of excessive tearing as a side effect of docetaxel. Esmaeli, B, 2005)	0.33
"The weekly administration of docetaxel is highly efficient and safe as first-line treatment for MBC and may serve as an important treatment option specifically in elderly patients and patients with a reduced performance status."	( High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Abenhardt, W; Brudler, O; Deutsch, G; Dorn, B; Heinemann, V; Jackisch, C; Kentenich, C; Leinung, S; Mair, W; Malekmohammadi, M; Papke, J; Stamp, J; Stauch, M; Stemmler, J; Vehling-Kaiser, U, 2005)	0.33
" These two proteins had similar expression patterns in 5 patients, except one patient who experienced severe, acute, adverse effects."	( Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Aogi, K; Arikuni, H; Eguchi, K; Fujii, D; Heike, Y; Hosokawa, M; Ida, M; Osumi, S; Shiwa, M; Tajiri, H; Takashima, S; Takaue, Y; Takigawa, N; Wakatabe, R, )	0.13
" There was little difference in the number and severity of adverse events between the arms."	( Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Antón, A; Chan, S; Cognetti, F; Conte, P; Extra, JM; Green, M; Grimes, D; Kennedy, J; Lluch, A; Maraninchi, D; Marty, M; Mauriac, L; Mayne, K; O'Byrne, K; Snyder, R; Tubiana-Hulin, M; Ward, C, 2005)	0.33
" No toxic deaths occurred."	( A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study. Carboni, R; Caristi, N; Chiofalo, G; La Torre, F; Mafodda, A; Maisano, R; Mare, M; Picciotto, M, 2005)	0.33
" All myelosuppressive adverse events and the majority of non-hematological adverse events were typical and characteristic of the individual concomitant cytotoxic agents."	( Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D, 2005)	0.33
" In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events."	( [Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006)	0.33
" Previous limited studies with isolated human heart cytosol showed that paclitaxel was able to stimulate an NADPH-dependent reduction of doxorubicin to its toxic secondary alcohol metabolite doxorubicinol."	( Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. Calafiore, AM; Cascegna, S; Gianni, L; Liberi, G; Menna, P; Minotti, G; Salvatorelli, E, 2006)	0.33
"Epiphora due to canalicular stenosis is a recently described side effect of weekly docetaxel."	( Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Gilboa, M; Haim, N; Miller, B; Tsalic, M; Visel, B, 2006)	0.33
" Patients with reduced clearance of docetaxel and elevated markers of inflammation experienced worse adverse effects, while patients with weight loss, liver dysfunction and elevated markers of inflammation had worse survival."	( Predicting the toxicity of weekly docetaxel in advanced cancer. Beale, P; Beith, J; Boyer, M; Charles, KA; Clarke, SJ; Rivory, LP; Stockler, MR, 2006)	0.33
" This retrospective study aims to evaluate the adverse events, especially hematological, of docetaxel in Chinese patients with breast cancer."	( Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles. Chow, LW; Yip, AY, 2006)	0.33
" Among all the clinical adverse events, hematological toxicities were not excessively higher."	( Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles. Chow, LW; Yip, AY, 2006)	0.33
" Therapeutic safety was evaluated by analyses of adverse events with the recommended dose."	( [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006)	0.33
" No DLT was observed in level 2, and this combination therapy seemed safe and feasible for outpatients."	( [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006)	0.33
" In 29 treated patients, there were no unusual or unexpected adverse events."	( Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Farfan, N; Hamilton-Nelson, K; Lopes, G; Negret, LM; Raez, LE; Rocha-Lima, C; Roman, E; Rosado, MF; Santos, ES; Silva, O; Tolba, K, 2006)	0.33
" The most common grade 3/4 adverse events were neutropenia (26."	( [Efficacy and toxicity of combination treatment with epirubicin (EPI) plus docetaxel (DOC) in advanced breast cancer]. Hata, Y; Taguchi, K; Takahashi, H; Takahashi, M; Tamura, M; Todo, S; Watanabe, K, 2006)	0.33
" This review discusses the cardiac toxic effects of trastuzumab and trastuzumab-related regimens and how their mechanisms of action and physiologic effects differ from cardiac toxicity typically associated with anthracycline use."	( Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Ewer, MS; O'Shaughnessy, JA, 2007)	0.34
"We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly in clinical practice."	( Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Ando, Y; Araki, R; Higuchi, S; Kitahara, T; Kodama, A; Ohdo, S; Sakaguchi, H; Sasaki, H; Tabuchi, M; To, H; Tomonari, M, 2008)	0.35
"5 mg/kg) was changed, DOC caused a dose-dependent reduction in toxic death."	( Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Ando, Y; Araki, R; Higuchi, S; Kitahara, T; Kodama, A; Ohdo, S; Sakaguchi, H; Sasaki, H; Tabuchi, M; To, H; Tomonari, M, 2008)	0.35
"We conclude that pre-administration of DOC may protect against ADR-induced toxic death and cardiotoxicity."	( Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Ando, Y; Araki, R; Higuchi, S; Kitahara, T; Kodama, A; Ohdo, S; Sakaguchi, H; Sasaki, H; Tabuchi, M; To, H; Tomonari, M, 2008)	0.35
" No unexpected adverse events were noted."	( Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A, 2007)	0.34
"Weekly docetaxel seems to be safe and effective compared with traditional tri-weekly docetaxel as a second-line treatment for non-small cell lung cancer."	( Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers. Chen, JP; Hsu, C; Lo, Y; Shih, JY; Yang, CH; Yu, CJ, 2008)	0.35
" At least one grades 3-4 toxic event of any type was reported in 40 (75."	( Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Colozza, M; D'Aiuto, G; De Maio, E; de Matteis, A; De Placido, S; Di Rella, F; Gallo, C; Gori, S; Gravina, A; Labonia, V; Landi, G; Lauria, R; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, G; Thomas, R, 2008)	0.35
"Docetaxel is an effective treatment approved in five key cancers, but its effectiveness in clinical practice can be compromised by sub-optimal side-effect management."	( Docetaxel-related side effects and their management. Aapro, MS; Ajani, J; Baker, J; Martin, M; Scotté, F; von Minckwitz, G; Winther, D, 2008)	0.35
"Several antineoplastic drugs induce severe toxic damage of the peripheral nervous system and chemotherapy-induced peripheral neurotoxicity (CIPN) can be dose limiting."	( Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Cavaletti, G; Marmiroli, P; Nicolini, G, 2008)	0.35
" Also, the combination of docetaxel and ATRA might allow a reduction in docetaxel doses and by this way may diminish docetaxel adverse effects while maintaining the therapeutic effect in patients with HRPC."	( Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S, 2008)	0.35
"Sequential and combined doxorubicin/docetaxel/CMF regimens plus conventional RT in selected non high-risk cardiac patients are relatively safe without cardiac toxicity at mid-term follow-up."	( Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Castadot, P; Chargari, C; Di Leo, A; Magné, N; Philippson, C; Van Houtte, P, 2009)	0.35
"Docetaxel is an effective treatment approved in five key cancers, but its effectiveness in clinical practice can be compromised by sub-optimal side-effect management."	( Docetaxel-related side effects and their management. Aapro, MS; Ajani, J; Baker, J; Martin, M; Scotté, F; von Minckwitz, G; Winther, D, 2009)	0.35
" The purpose of this study was to establish a suitable dosing schedule to reduce adverse effects and improve the antitumour effects."	( Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. Higuchi, S; Ieiri, I; Kinoshita, T; Kodama, A; To, H, 2009)	0.35
" We remind the importance of screening for unusual adverse events in frail patients receiving chemotherapy."	( [Pneumocystis pneumonia in two breast cancer patients treated with docetaxel: an unusual adverse event of chemotherapy]. Blot, E; Clatot, F; Guillemet, C; Laberge-Le-Couteulx, S; Philippin-Lauridant, G; Rigal, O, 2010)	0.36
" Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases."	( The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010)	0.36
" The incidence of grade 3 or 4 adverse events were similar (78% v 72%), although a higher incidence of hand-foot syndrome (24% v 0%) and mucositis/stomatitis (12% v 1%) were observed in the PLD-docetaxel combination."	( Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin Balashova, OI; Bogdanova, NV; Bondarenko, IN; Chatikhine, VA; Makhson, AN; Manikhas, GM; Oliynychenko, GP; Rackoff, WR; Semiglazov, VF; Sparano, JA; Tjulandin, SA; Xiu, L; Yuan, Z; Zhuang, SH, 2009)	0.35
" The adverse effects after NIPS were mild and there was no treatment-related deaths."	( Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. Endou, Y; Hirano, M; Ichinose, M; Ikeda, M; Ikeda, S; Kimura, H; Masuda, S; Matsuda, T; Matsuki, N; Miura, M; Mizumoto, A; Mizuno, M; Nakajima, G; Sasaki, T; Shinbo, M; Takao, N; Yonemura, J; Yonemura, Y; Yuuba, T, 2009)	0.35
"Leukocytosis, bone pain, and headache were the most frequent adverse events, with incidence rates of 22%, 19%, and 8%, respectively."	( [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin]. Characiejus, D; Fokas, V; Juodzbaliene, E; Juozaityte, E; Kregzdyte, R; Liutkauskiene, S; Sveikata, A, 2009)	0.35
"The primary prophylaxis of neutropenia and its complications by rGCSF was safe and effective for women with metastatic breast cancer who received chemotherapy with docetaxel and doxorubicin."	( [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin]. Characiejus, D; Fokas, V; Juodzbaliene, E; Juozaityte, E; Kregzdyte, R; Liutkauskiene, S; Sveikata, A, 2009)	0.35
"These results indicate that the combination of docetaxel and cisplatin is a safe and effective regimen for patients with unknown primary cancer."	( Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Ando, M; Katsumata, N; Mukai, H; Watanabe, T, 2010)	0.36
" In conclusion, we considered that this S-1 plus docetaxel combination therapy was effective and safe in advanced gastric cancer, and convenient for outpatients."	( [Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer]. Ban, T; Fujiwara, K; Hayashi, K; Hori, Y; Iwasaki, H; Kurimoto, T; Nemoto, A; Nishiwaki, H; Orito, E; Shiroko, J; Tachi, K; Umemura, S; Yamada, T; Yamakawa, Y, 2009)	0.35
" Most treatment-emergent adverse events (TEAEs) occurred in the 10-mg/kg intetumumab group."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.37
"Intetumumab was generally safe and well tolerated in combination with docetaxel, with a higher incidence of TEAEs in the 10 mg/kg dose cohort."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.37
"Weekly administration of paclitaxel /docetaxel is a safe and active protocol for advanced NSCLCs."	( Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Huang, XE; Jiang, W; Li, C; Lin, Y; Shi, MQ; Shu, YQ; Sunh, WL; Ye, Z; Zhang, Q; Zhou, JN, 2009)	0.35
" Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0."	( Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010)	0.36
" Furthermore, DLE was as safe as DS in the safety investigation and displayed significant antitumor activities against the A549, BEL7402 and BCAP-37 cell lines in nude mice, similar to DS."	( Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Cai, C; He, H; Lin, X; Luo, Y; Su, M; Tang, X; Zhao, M, 2010)	0.36
" The use of most cytotoxic agents is associated with potential hypersensitivity reactions, and the constant increase of their administration has caused an increase in incidence of these adverse effects, thus becoming a relevant problem for clinicians."	( The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Pagani, M, 2010)	0.36
" From these results, TC therapy (75/600 mg/m2) is considered to be a safe and tolerable regimen in Japanese patients operated for breast cancer."	( [Safety and tolerance of docetaxel (especially 75 mg/m2) with cyclophosphamide (TC therapy) as adjuvant chemotherapy for Japanese patients with operable breast cancer]. Jotoku, H; Taguchi, K; Tamura, M; Watanabe, K; Yamamoto, M, 2010)	0.36
"Chemotherapy-induced peripheral neurotoxicity (CIPN) is a side effect limiting cisplatin (CDDP) and docetaxel (DOCE) treatment."	( Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study. Cavaletti, G; Chiorazzi, A; Maggioni, D; Meregalli, C; Nicolini, G; Tredici, G, 2010)	0.36
"We revealed that pre-treatment with docetaxel (DOC) 12 h before adriamycin (ADR) administration significantly reduced ADR-induced toxic death compared with the simultaneous dosing schedule that was commonly used in previous studies."	( Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity. Kurose, H; Mishima, T; Nishida, M; Sasaki, H; To, H; Tomonari, M, 2011)	0.37
" Toxicity from DCF therapy was grade 3 or 4 emergent adverse events (77."	( [Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer]. Ehara, K; Hasebe, S; Hayashi, M; Ito, T; Kinoshita, Y; Minowa, M; Ogawa, M; Takebayashi, K; Udagawa, H; Ueno, M, 2011)	0.37
" No severe adverse effects of more than grade 3 were encountered."	( [Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer]. Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M, 2011)	0.37
"Hand-foot syndrome is a highly unpleasant adverse reaction caused by treatment protocols containing capecitabine (an orally administered drug), docetaxel, liposomal doxorubicin infusions or continuously infused 5-fluorouracil."	( [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy]. Bartal, A; Liszkay, G; Mátrai, Z; Szûcs, A, 2011)	0.37
" Bevacizumab was well tolerated in elderly patients, the most common adverse effects were neutropenia and febrile neutropenia; there was no excess of grade⩾3 cardiovascular events."	( Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Benedetti, G; Chang, HT; Ciruelos, E; Duenne, AA; Miles, DW; Passos-Coelho, JL; Pivot, X; Schneeweiss, A; Thomssen, C; Verma, S; von Moos, R, 2011)	0.37
" Because of an apparent high incidence of side effects, especially febrile neutropenia (FN) and non-hematologic side effects, the DBCG (The Danish Breast Cancer Cooperative Group) initiated a retrospective study of adverse reactions to the newly introduced regime and all patients were offered primary prophylaxis with growth factors (G-CSF) pr 1/1-2008."	( TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Eckhoff, L; Knoop, A; Moeller, S; Nielsen, M, 2011)	0.37
" The incidence of non-hematological adverse events, in 2007 and 2008 combined, was for neuropathy 35%, mucositis 75%, muscle and joint pain 53%, skin rash 25% and fatigue 43% (all grades)."	( TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Eckhoff, L; Knoop, A; Moeller, S; Nielsen, M, 2011)	0.37
" The incidence of non-hematological adverse events had been reported in some, but not all adjuvant taxanes studies."	( TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Eckhoff, L; Knoop, A; Moeller, S; Nielsen, M, 2011)	0.37
" The most frequently reported adverse events were neutropenia, fatigue, alopecia, decreased appetite, constipation and injection site pain."	( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011)	0.37
" Weekly nab-paclitaxel resulted in less serious adverse events compared with all other regimens."	( Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S, 2011)	0.37
"Weekly nab-paclitaxel was safe and more efficacious compared with the q3w schedule and with solvent-based taxanes in older patients with MBC."	( Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S, 2011)	0.37
" This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients."	( Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Abe, K; Iwazawa, T; Morita, S; Nakabori, T; Osa, A; Oseto, S; Takimoto, T; Terada, H, 2012)	0.38
" Randomized studies and retrospective analyses have shown that, in patients who received capecitabine monotherapy, or in combination with docetaxel, dose modification of capecitabine is effective in the management of adverse events without compromising efficacy."	( Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J, 2011)	0.37
" In comparison with free DTX, NPs were both more efficient in inhibiting cell growth of breast and prostate cancer cells and less toxic in experimental animal models."	( Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. Abbruzzese, A; Arra, C; Barbieri, A; Caraglia, M; Conte, C; Maglio, G; Misso, G; Ostacolo, L; Quaglia, F; Ungaro, F, 2012)	0.38
" It is associated with various adverse effects one of which is nail toxicity."	( Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chan, TC; Hui, P; Lau, CP, 2011)	0.37
"Previously, adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) database were reviewed to confirm platinum agent-associated hypersensitivity reactions."	( Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M, 2011)	0.37
" However, the total number of adverse events occurring with procarbazine, asparaginase, teniposide, or etoposide was not large enough to detect signals."	( Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M, 2011)	0.37
"The FDA's adverse event reporting system, AERS, and the data mining methods used herein are useful for confirming drug-associated adverse events, but the number of co-occurrences is an important factor in signal detection."	( Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M, 2011)	0.37
" Cellax nanoparticles released DTX in serum with near zero order kinetics (100% in 3 weeks), was internalized in murine and human cancer cells, and induced significantly higher toxic effects against a panel of tumor cell lines (2- to 40-fold lower IC50 values) compared to free DTX."	( Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells. Ernsting, MJ; Li, SD; MacCallum, N; Tang, WL, 2011)	0.37
" Although a complete response of the primary tumor was achieved in all cases, various adverse events also occurred."	( [A review of toxicity superselective intra-arterial concurrent chemoradiotherapy(SIACC)for oral cancer]. Asahina, I; Ikeda, H; Ikeda, M; Kawasaki, T; Shiraishi, T; Tajima, N; Uehara, M, 2011)	0.37
"A total of 611 adverse events were reported."	( An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients. Characiejus, D; Juozaitytė, E; Liutkauskienė, S; Šeštakauskas, K; Sveikata, A; Tamošaitytė, L, 2011)	0.37
" The most common adverse events of grade 3 or higher were neutropenia (61 of 107 women in group A, 48 of 107 in group B, one of 108 in group C, and 52 of 94 in group D), febrile neutropenia (eight, nine, none, and seven, respectively), and leucopenia (13, five, none, and seven, respectively)."	( Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Bianchi, G; de la Haba-Rodriguez, J; Gianni, L; Im, SA; Im, YH; Liu, MC; Lluch, A; Morandi, P; Pedrini, JL; Pienkowski, T; Poirier, B; Ratnayake, J; Roman, L; Ross, G; Semiglazov, V; Srimuninnimit, V; Staroslawska, E; Szado, T; Tseng, LM; Valagussa, P, 2012)	0.38
"7%) patients, but no other serious adverse effects were detected."	( [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. Egawa, T; Eto, E; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Murakawa, M; Nagashima, A; Okamura, A, 2011)	0.37
" Taxanes showed a similar LD50 over the temperature range tested."	( The cytotoxic effect of combined hyperthermia and taxane chemotherapy on ovarian cancer cells: results of an in vitro study. Chérel, M; Classe, JM; Collet, M; Dupré, PF; Gouard, S; Muller, M, 2012)	0.38
"Although ABCB1 3435 T/T was significantly associated with docetaxel-related neutropenia in our study population, polymorphism of pharmacogenetic genes related to docetaxel metabolism did not appear to be evidently associated with docetaxel-related adverse events."	( Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Ahn, JH; Ahn, SH; Jung, KH; Kim, KP; Kim, SB; Lee, JS; Yoon, DH, 2012)	0.38
" Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy."	( Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L, 2012)	0.38
"Most common adverse events (AEs) (grade 3-5) included neutropenia (89%), leucopaenia (81%), hand-foot skin reaction (30%) and fatigue (30%)."	( Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M, 2012)	0.38
"The regimens in both arms A and B were safe regarding adjuvant chemotherapy for early breast cancer."	( Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Tani, T; Umeda, T, 2013)	0.39
" The most common ≥ grade 3 adverse drug reactions (ADRs) were neutropenia (71%)and leukocytopenia (51%), and they occurred more frequently in patients receiving ≥ 70 mg/m²."	( [Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan]. Akaza, H; Mera, T; Saijo, N, 2012)	0.38
"In this preplanned safety analysis of 100 patients, T treatment induced grade (G) 3 adverse events (AEs) in 15 patients (30%) and G4 AEs in 30 patients (60%), mainly due to bone marrow toxicity."	( Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial. Åström, L; Franzen, L; Ginman, C; Hjälm-Eriksson, M; Kellokumpu-Lehtinen, PL; Marttila, T; Seke, M; Taalikka, M; Thellenberg-Karlsson, C, 2012)	0.38
" It may also affect the incidence and severity of adverse events and efficacy of chemotherapy."	( Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA, 2012)	0.38
" The most frequent grade superior or equal to 3 adverse event (AE) was neutropenia (34."	( [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]. Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C, 2012)	0.38
"Breast cancer is the leading cause of neoplasia-related deaths among women, but no data are available in the literature on the safe use of oncological treatments in glucose 6-phosphate dehydrogenase (G6PD)-deficient patients."	( Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report. Bramati, A; Farina, G; Girelli, S; La Verde, N; Mihali, D; Moretti, A; Piva, S; Sburlati, P, 2012)	0.38
" All of these toxic effects were potentiated when cofilin-1 was down regulated in these cells by a siRNA delivered by the nanoparticle."	( Enhanced docetaxel-mediated cytotoxicity in human prostate cancer cells through knockdown of cofilin-1 by carbon nanohorn delivered siRNA. Carrión, B; Ceña, V; Herrero, MA; Lucío, MI; Pérez-Martínez, FC; Rubio, N; Vázquez, E, 2012)	0.38
" In the 29 treated patients, there were no unusual or unexpected adverse events in a total of 91 cycles for the chemotherapy setting."	( Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial. Chen, C; Di, GH; Fei, F; Liu, GY; Lu, JS; Shao, ZM; Wu, J; Xue, J, 2013)	0.39
" Adverse events of grade 1/2 were common."	( [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial]. Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P, 2012)	0.38
"Both EC-T and TP regimens as adjuvant chemotherapy are safe and tolerable for the treatment of triple-negative breast cancer patients, while the TP regimen has advantages with less grade III/IV alopecia and leukopenia."	( [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial]. Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P, 2012)	0.38
"Interindividual variability in drug response and the emergence of adverse drug effects are the main causes of treatment failure in cancer therapy."	( Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Annuar, MA; Ho, GF; Jabir, RS; Munisamy, M; Naidu, R; Stanslas, J, 2012)	0.38
" Only 1 patient experienced a grade 4 adverse event due to a nonsymptomatic pulmonary embolism."	( Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer. Arévalo, E; Carranza, OE; Castañón, E; Castillo, A; Collado-Gómez, V; Fusco, JP; Gil-Aldea, I; Gil-Bazo, I; López, I; Zudaire, ME, 2013)	0.39
"For Japanese CRPC patients, weekly low-dose DTX combined with estramustine has similar efficacy to standard-dose DTX but with fewer adverse events."	( Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Nakai, Y; Nakayama, M; Nishimura, K; Nonomura, N; Takayama, H; Tsujimura, A; Uemura, M, 2014)	0.4
"Our findings suggest that BCS after NCT in clinical stage III patients is oncologically safe in terms of LR if breast tumor size is ≤4 cm after NCT and Ki-67 is a predictor of LR after NCT."	( Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC, 2013)	0.39
" Grade 3/4 fatigue (65%), neutropenia (30%), myalgias (26%), neutropenic fever (26%), vomiting (9%), and rash (9%) were the most common serious adverse events."	( Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. Booser, DJ; Eckmann, K; Esparza-Guerra, L; Green, MC; Hortobagyi, GN; Kawedia, J; Madden, TL; Michaud, LB; Rivera, E; Valero, V, 2014)	0.4
" Diarrhea was the most common adverse event."	( Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Chia, S; Cortés, J; Eniu, A; Harvey, V; Hegg, R; Hickish, T; McNally, V; Ratnayake, J; Ross, G; Schneeweiss, A; Seo, JH; Tausch, C; Tsai, YF, 2013)	0.39
" National Cancer Institute Common Toxicity Criteria (version 4) for classification of adverse events."	( Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer. Atrash, F; Billan, S; Doweck, I; Haim, N; Kaidar-Person, O; Kuten, A; Ronen, O, 2013)	0.39
" Drug-related adverse events in the safety population were reported in 28% and 26% of patients in the lipegfilgrastim and pegfilgrastim groups, respectively."	( Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. Bias, P; Bondarenko, I; Buchner, A; Elsaesser, R; Gladkov, OA, 2013)	0.39
"This retrospective study aimed to determine whether adverse events are more common in docetaxel followed by cyclophosphamide (TC) as compared to the reverse infusion order (rTC)."	( Reduction of toxicity by reversing the order of infusion of docetaxel and cyclophosphamide. Hanaoka, M; Iwatani, T; Kawabata, H; Miura, D; Takano, T, 2013)	0.39
" No grade 3-4 adverse events were observed."	( Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E, 2015)	0.42
"AA appears to be safe and well tolerated even in patients with cardiovascular comorbidities or with increased risk factors for cardiovascular diseases."	( Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E, 2015)	0.42
"All patients had adverse event (100%) in three HHPG-19K groups, and increased ALP, ALT and AST were main events."	( Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. Chen, ZL; Han, BH; Jiang, LY; Lu, F; Yan, B; Zhang, W, 2013)	0.39
" Serious adverse event was defined as grade 3/4 hematological and non-hematological toxicities."	( Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response. Azmi, KS; Eswaran, P, )	0.13
"All patients (three in dose level 1 [5 mg/m(2)], level 2 [10 mg/m(2)] and level 3 [15 mg/m(2)]) did not experience any hematological serious adverse events."	( Concurrent chemoradiation with weekly cisplatin, docetaxel and gefitinib: A study to assess feasibility, toxicity and immediate response. Azmi, KS; Eswaran, P, )	0.13
" The response, time to progression (TTP) and adverse effects were observed in both arms."	( [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer]. Ding, CM; He, ZY; Li, K; Li, WL; Liu, W; Mao, WD; Sun, T; Wang, HM; Wang, J; Yao, Q; Zhang, MJ; Zhang, Y; Zhou, XL, 2013)	0.39
"Generic formulations are not necessarily identical to the original in terms of efficacy and adverse events."	( Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Cantin, G; Côté, I; Desbiens, C; Doyle, C; Hogue, JC; Leblond, AF; Lemieux, J; Poirier, B; Poirier, E; Provencher, L, 2014)	0.4
"To compare the occurrence of grade III to IV adverse events between original docetaxel and a generic formulation in breast cancer patients."	( Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Cantin, G; Côté, I; Desbiens, C; Doyle, C; Hogue, JC; Leblond, AF; Lemieux, J; Poirier, B; Poirier, E; Provencher, L, 2014)	0.4
" The primary outcome was the occurrence of grade III to IV adverse events related to docetaxel (febrile neutropenia, hand and foot syndrome, intestinal perforation, thrombotic event, and death)."	( Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients. Cantin, G; Côté, I; Desbiens, C; Doyle, C; Hogue, JC; Leblond, AF; Lemieux, J; Poirier, B; Poirier, E; Provencher, L, 2014)	0.4
"02) and grade III-IV adverse events."	( Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Chen, ML; Li, K; Zhang, J; Zhu, ZL, 2013)	0.39
" Of note, more adverse events will occur followed the use of trastuzumab, especially cardiac toxicity, with two treatment regimens."	( Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. Chen, ML; Li, K; Zhang, J; Zhu, ZL, 2013)	0.39
" Even though these taxanes display a favorable toxicity profile, their routine use in clinical practice requires knowledge about the most frequent and distinct adverse events that may result from their administration."	( Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. Buzaid, AC; Sartor, O; Schutz, FA, 2014)	0.4
" Therefore, it could be a promising template for safe and effective delivery of Doc and similar chemotherapeutic agents in cancer cells."	( Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells. Agrahari, V; Murowchick, JB; Youan, BB; Youm, I, 2014)	0.4
"In order to limit the adverse reactions caused by polysorbate 80 in Taxotere(®), a widely used formulation of docetaxel, a safe and effective nanocarrier for this drug has been developed based on micelles formed by a new class of well-defined polyoxyethylene sorbitol oleate (PSO) with sorbitol as the matrix in aqueous solution."	( Novel designed polyoxyethylene nonionic surfactant with improved safety and efficiency for anticancer drug delivery. Han, P; Li, C; Li, S; Ouahab, A; Shen, Y; Sun, C; Sun, H; Tu, J; Xiong, Y; Xu, Y, 2014)	0.4
"Early administration of G-CSF is safe and seems to be more effective than D7."	( Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Augereau, P; Breheret, R; Capitain, O; Laccourreye, L; Linot, B, 2014)	0.4
" Adverse events did not result in a reduction in the median number of study treatment cycles administered in patients from Asia."	( Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Baselga, J; Chan, V; Clark, E; Im, SA; Im, YH; Knott, A; Miles, D; Ross, G; Swain, SM, 2014)	0.4
" The primary endpoint was overall survival COS) and the secondary endpoint was adverse event (AE)."	( Intraperitoneal chemotherapy for peritoneal carcinomatosis improves efficacy with acceptable safety: results of 200 cycles for 41 patients. Huang, CQ; Li, G; Li, Y; Liu, Y; Yang, T, )	0.13
" Adverse events (AEs) possibly related to cabazitaxel occurred in 143 (93."	( Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A, 2014)	0.4
" Also, the combination of docetaxel and TQ might allow a reduction in docetaxel doses and diminish adverse effects of docetaxel while maintaining the therapeutic effect in patients with CRPC."	( Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Atmaca, H; Bozkurt, E; Dirican, A; Erten, C; Karaca, B; Uslu, R, 2015)	0.42
"These data support in vivo studies investigating the potential clinical use of HDAC4 inhibitors in combination with docetaxel for the treatment of gastric cancer, lowering treatment doses of docetaxel to reduce the burden of adverse side effects on patients."	( Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Aiello, E; Colarossi, C; Colarossi, L; Espina, V; Iuppa, A; Liotta, L; Memeo, L; Mueller, C, 2014)	0.4
" The end points were overall survival, progression-free survival (PFS), objective response rate, disease control rate, and grade 3 or 4 adverse events."	( Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment. Hong, W; Jin, Y; Shi, L; Shi, X; Sun, Y; Yu, X; Zhao, J, 2014)	0.4
" Studies generally reported lower incidence of CIN (4/7 studies), FN (11/14 studies), hospitalisations (9/13 studies), antibiotic use (6/7 studies) and adverse events (2/5 studies) with pegfilgrastim than filgrastim, no upfront pegfilgrastim or no G-CSF."	( Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Allcott, K; Pettengell, R; Pfeil, AM; Schwenkglenks, M; Szabo, Z; von Minckwitz, G, 2015)	0.42
" Categorical outcome measures including PSA response rate (PSA-RR) and incidence of toxic side-effects were compared using Fisher's exact test."	( Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. Alibhai, SM; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Sridhar, SS; Tannock, IF; Templeton, AJ, 2015)	0.42
"The fixed dose rate (FDR) gemcitabine infusion in combination with docetaxel is an effective treatment regimen for patients with relapsed/refractory soft tissue sarcoma, and with tolerable adverse reactions."	( [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma]. Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y, 2014)	0.4
" Moreover, DSNs improved the main side effect of Taxotere by greatly lowering myelosuppression toxicity to bone marrow cells from mice."	( Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Bi, X; Cong, W; Dai, Z; Ge, Y; Han, J; Li, Y; Ma, D; Yuan, Q, 2014)	0.4
" 322 (62%) of 518 patients previously treated with docetaxel had grade 3-4 adverse events, compared with 205 (54%) of 383 patients without docetaxel."	( Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPC Aksnes, AK; Bottomley, D; Fang, F; Helle, SI; Hoskin, P; Johannessen, DC; Logue, J; Nilsson, S; O'Sullivan, JM; Parker, C; Sartor, O; Vogelzang, NJ; Wahba, M, 2014)	0.4
" However, the benefits in PFS was accompanied by increasing the risk of developing grade 3-4 (RR: 1·19, 95% CI: 0·99-1·42, P = 0·062) and fatal (RR: 1·30, 95% CI: 1·01-1·66, P = 0·039) adverse events."	( Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. Fu, S; Guo, XM; Qi, WX; Zhang, Q, 2015)	0.42
" However, the adverse effects of prophylactic steroid use are often overlooked."	( Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. Kang, RY; Kim, HS; Kim, KS; Lee, BK; Lee, JY; Lee, SH; Lee, YJ; Suh, SY; Yoo, KE, 2015)	0.42
" This study suggests that adverse effects associated with prophylactic steroid use need to be recognized and optimally managed during docetaxel therapy."	( Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. Kang, RY; Kim, HS; Kim, KS; Lee, BK; Lee, JY; Lee, SH; Lee, YJ; Suh, SY; Yoo, KE, 2015)	0.42
" Spinal RT during the course of bevacizumab-based therapy was not associated with the occurrence of unexpected adverse effects."	( Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy: a bi-institutional case series. Annede, P; Bauduceau, O; Bosacki, C; Ceccaldi, B; Chargari, C; Dulou, R; Falk, AT; Ferrand, FR; Guy, JB; Helissey, C; Jacob, J; Langrand-Escure, J; Le Moulec, S; Magné, N; Mbagui, R; Mery, B; Vedrine, L, 2015)	0.42
"Patients (n = 507) received enzalutamide 160 mg/day until disease progression, intolerable adverse events (AEs), or commercial availability occurred."	( Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Berry, W; Chi, KN; Dmuchowski, C; Emmenegger, U; Foley, MA; Haas, NB; Hasabou, N; Hirmand, M; Joshua, AM; Mukherjee, SD; Olsson, CA; Perabo, F; Rathkopf, D; Saad, F; Scholz, M; Shore, ND; Winquist, E, 2015)	0.42
"The safety profile of enzalutamide was consistent over time, with little change in the rates of commonly reported adverse events (AEs) or the incidence of grade 3/4 AEs."	( Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. Beer, TM; Efstathiou, E; Forer, D; Higano, CS; Hirmand, M; Scher, HI; Taplin, ME, 2015)	0.42
" Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells."	( Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells. Anoopkumar-Dukie, S; Bernaitis, N; Chess-Williams, R; Christie, D; Davey, AK; Forbes, A; McDermott, CM; McFarland, AJ; Perkins, AV; Pickard, RD; Spencer, BH, 2015)	0.42
"We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel."	( Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. Cathomas, R; De Bono, JS; Gillessen, S; Omlin, A; Rothermundt, C; Sartor, O; Shen, L; Su, Z, 2015)	0.42
" The most common drug-related adverse events were nausea (65 %), fatigue (63 %), and neutropenia (53 %)."	( Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Bookman, M; Cohen, RB; Knoblauch, R; Li, J; Meropol, NJ; Parekh, T; Sherman, E; von Mehren, M; Weiner, LM, 2015)	0.42
"4%) treatment-related deaths due to adverse events, which were interstitial lung disease, and febrile neutropenia and bacterial pneumonia."	( Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. Adachi, H; Fukuta, F; Hirose, T; Itoh, N; Kitamura, H; Kunishima, Y; Masumori, N; Matsukawa, M; Miyake, M; Miyao, N; Shigyo, M; Taguchi, K; Takagi, S; Takahashi, A; Yanase, M, 2015)	0.42
" Although most patients safely received docetaxel and prednisolone, we must always keep interstitial lung disease in mind as a possible lethal adverse event."	( Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. Adachi, H; Fukuta, F; Hirose, T; Itoh, N; Kitamura, H; Kunishima, Y; Masumori, N; Matsukawa, M; Miyake, M; Miyao, N; Shigyo, M; Taguchi, K; Takagi, S; Takahashi, A; Yanase, M, 2015)	0.42
"Docetaxel-cisplatin and 5-fluorouracil (TPF) chemotherapy (days 1-21) represents a standard but toxic regimen for advanced head and neck cancer (HNC)."	( Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. Breheret, R; Capitain, O; Laccourreye, L; Linot, B; Peyraga, G; Yossi, S, 2015)	0.42
"Dose-dense mTPF (days 1-14) is safe and seems to be as effective as TPF (days 1-21)."	( Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. Breheret, R; Capitain, O; Laccourreye, L; Linot, B; Peyraga, G; Yossi, S, 2015)	0.42
" There were no incidences of anaphylaxis or Grade 4/5 adverse events."	( Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T, 2015)	0.42
" The evaluation of adverse events reported in the Phase III ALSYMPCA trial is summarized for the overall population and patient subpopulations (prior docetaxel, concomitant external beam radiation therapy and baseline opioid use)."	( Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Nilsson, S, 2015)	0.42
" Its novel mechanism of action underlies low rates of hematologic adverse events."	( Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Nilsson, S, 2015)	0.42
"Erlotinib appears to be a useful second-line option in PS0/1 patients with EGFR mutation-negative advanced non-squamous NSCLC given its mild adverse effects."	( Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Fujita, S; Hata, A; Iwasaku, M; Katakami, N; Korogi, Y; Mori, M; Morita, S; Namba, Y; Nishino, K; Nishiyama, A; Okuyama, T; Otsuka, K; Takeshita, J; Uchida, J; Yoshioka, H, 2015)	0.42
" We have demonstrated that abiraterone, a selective androgen biosynthesis inhibitor, is a safe and active therapeutic option in a subgroup of 47 very elderly adults (aged > 80 years) enrolled in the Italian named patient program, with a tolerability profile and clinical outcomes comparable to those of younger population."	( Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fraccon, AP; Fratino, L; Galligioni, E; Gasparro, D; Giordano, M; Lo Re, G; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Verderame, F; Vicario, G; Zagonel, V, 2016)	0.43
"Our data show that AA is active and safe in very elderly patients and leads to outcomes similar to those observed in younger patients, thus confirming that AA is a manageable therapeutic option for this patient population."	( Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fraccon, AP; Fratino, L; Galligioni, E; Gasparro, D; Giordano, M; Lo Re, G; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Verderame, F; Vicario, G; Zagonel, V, 2016)	0.43
" We evaluated the frequency of characteristic adverse events (AEs) commonly seen with existing anti-angiogenic agents."	( Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K, 2015)	0.42
"1%), and cutaneous adverse reactions (13."	( Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K, 2015)	0.42
" Surgery was carried out three weeks after the end of chemotherapy, and the chemotherapy efficacy and adverse reaction of both groups were evaluated."	( [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer]. Hao, X; Li, C; Su, W; Zhang, J; Zhang, S, 2015)	0.42
" Safety analysis indicated that all the occurrence rates of skin and nail toxic reaction, body fluid retention, oral mucositis, allergic reaction (such as facial blushing, chest distress, palpitation, dyspnea."	( [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer]. Hao, X; Li, C; Su, W; Zhang, J; Zhang, S, 2015)	0.42
"Compared with docetaxel, paclitaxel liposome has the same anti-tumor efficacy, but causes fewer and milder adverse reactions with a higher safety in the neoadjuvant chemotherapy for breast cancer."	( [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer]. Hao, X; Li, C; Su, W; Zhang, J; Zhang, S, 2015)	0.42
"Dexamethasone is commonly used to prevent the adverse effects of docetaxel in head and neck neoplasm treatment."	( Safe dose reduction of steroid pre-medication for docetaxel in head and neck neoplasm treatment. Chen, NX; Yan, F; Zhang, XX; Zhao, FF, 2016)	0.43
" Patient developed grade I thrombocytopenia and grade III leukopenia without any other severe adverse reactions."	( Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. Chen, J; Hu, AP; Shen, P; Yang, L; Yu, SF; Zhang, XC; Zhu, HQ, 2015)	0.42
"These results suggest that the standard TC regimen is mostly safe and could be used as postoperative adjuvant chemotherapy for hemodialysis patients with early stage breast cancer."	( Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. Chen, J; Hu, AP; Shen, P; Yang, L; Yu, SF; Zhang, XC; Zhu, HQ, 2015)	0.42
"Severe toxicity and interruption of radiotherapy were more frequent in patients with multiple adverse predictive factors."	( Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation. Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS, 2016)	0.43
" As a systemic adverse event, neutropenia was significantly milder in GroupA than in GroupB (p=0."	( [The Safety of Super-Selective Intra-Arterial Infusion Chemotherapy for Induction with Docetaxel, Cisplatin, and 5-Fluorouracil for Oral Cancer]. Hiraiwa, T; Koike, M; Okada, H; Senda, N; Suzuki, K, 2015)	0.42
" The aim of this study was to investigate the effects of synbiotics in esophageal cancer patients receiving neoadjuvant chemotherapy on the intestinal microbiota and the adverse events of chemotherapy."	( Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2017)	0.46
" The primary endpoint was the incidence of chemotherapy-related adverse events."	( Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2017)	0.46
"Synbiotics during neoadjuvant chemotherapy in esophageal cancer patients reduced the occurrence of adverse events of chemotherapy through adjustments to the intestinal microbiota."	( Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Akita, H; Asahara, T; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Nomoto, K; Noura, S; Ohue, M; Omori, T; Saito, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2017)	0.46
" Adverse event evaluation was carried out weekly for two treatment cycles."	( Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. Chan, D; Chuah, B; Goh, BC; Lee, SC; Soe, MY; Soo, RA; Syn, NL; Tan, SH; Wang, L; Wong, AL; Yong, WP, 2016)	0.43
" Furthermore, the relationship between such adverse events and quality of life (QOL) was evaluated."	( Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity. Bayo, J; Prieto, B; Rivera, F, 2016)	0.43
" The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL."	( Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer. Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M, 2016)	0.43
"Exploring the relationships among adverse events is important because those that arise from a common mechanism are amenable to a common intervention, which can improve symptom management, quality of life, and treatment adherence."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"The CTCAE data from a randomized clinical trial conducted by SWOG that compared docetaxel plus estramustine versus mitoxantrone plus predinsone in patients with advanced prostate cancer were used to identify severe adverse event clusters."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"A total of 109 adverse event types were captured using the CTCAE."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"Several severe adverse event clusters were identified in patients with advanced prostate cancer."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
" Adverse events (AEs) were recorded and analyzed."	( Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II. Ba, DN; Chao, TY; Hou, MF; Kim, SB; Sayeed, A; Shah, MA; Shen, ZZ; Thuan, TV; Villalon, AH; Yau, TK, 2016)	0.43
" Adverse events were reported in 86% of patients (anthracycline-containing regimens vs."	( Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II. Ba, DN; Chao, TY; Hou, MF; Kim, SB; Sayeed, A; Shah, MA; Shen, ZZ; Thuan, TV; Villalon, AH; Yau, TK, 2016)	0.43
" No unusual adverse events linked to Asia-Pacific region patients were observed."	( Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II. Ba, DN; Chao, TY; Hou, MF; Kim, SB; Sayeed, A; Shah, MA; Shen, ZZ; Thuan, TV; Villalon, AH; Yau, TK, 2016)	0.43
" Grade 3-4 adverse events included leukopenia (2/39), and neutropenia (3/39) in first-line therapy versus neutropenia (1/40) and thrombocytopenia (2/40) in second-line treatment."	( A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC). Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T, 2016)	0.43
"Cardiotoxicity remains an important adverse reaction of chemotherapy used in the treatment of breast cancer, leading to increased morbidity and mortality."	( Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer. Florescu, M; Mihalcea, DJ; Vinereanu, D, )	0.13
" The incidence of any toxic event was 73 and 67 % (P = 0."	( Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Cheng, HH; Gulati, R; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Yu, EY, 2016)	0.43
" We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC)."	( Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. Borges Dos Reis, R; Botrel, TE; Clark, O; Ferreira, U; Horta Bretas, FF; Lima Pompeo, AC; Sadi, MV, 2016)	0.43
" Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue."	( Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. Borges Dos Reis, R; Botrel, TE; Clark, O; Ferreira, U; Horta Bretas, FF; Lima Pompeo, AC; Sadi, MV, 2016)	0.43
"DP may be clinically safe and useful treatment for EC."	( Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer. Anan, H; Fukagawa, S; Katsuta, T; Kiyoshima, C; Maehara, M; Miyahara, D; Miyamoto, S; Miyata, K; Takahashi, Y; Yotsumoto, F, 2016)	0.43
" Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents."	( Dermatological adverse events with taxane chemotherapy. Belum, VR; Dalenc, F; Deslandres, M; Eche, A; Gladieff, L; Lacouture, ME; Lebœuf, NR; Montastruc, M; Roche, H; Sibaud, V; Vigarios, E, 2016)	0.43
" Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs."	( Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH, 2016)	0.43
" We selected 44 compounds that exhibited toxic effects on HEL cells in the dividing phase from a chemical library containing 325 anticancer drugs and enzyme inhibitors."	( Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents. Inagaki, Y; Matsumoto, Y; Sekimizu, K; Tang, W, )	0.13
" Most adverse events were mild to moderate."	( Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Aogi, K; Dalal, R; Gao, L; Ibrahim, A; Iwata, H; Masuda, N; Sasaki, Y; Xu, Y; Yoshikawa, R, 2016)	0.43
" There was no difference in adverse effects or response rate between the two groups."	( Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Dosaka-Akita, H; Honma, R; Iseki, K; Kasashi, K; Kinoshita, I; Kobayashi, M; Saito, Y; Shimizu, Y; Takeuchi, S; Yamada, T, 2017)	0.46
" Magnesium premedication is a simple nephroprotective method that does not influence other adverse effects or rate of response to chemotherapy."	( Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Dosaka-Akita, H; Honma, R; Iseki, K; Kasashi, K; Kinoshita, I; Kobayashi, M; Saito, Y; Shimizu, Y; Takeuchi, S; Yamada, T, 2017)	0.46
" The objective of this systematic review was to evaluate overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade (G) greater than or equal to 3 adverse event of mDCF chemotherapy in this setting."	( Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Tomasello, G, 2017)	0.46
" We describe the protocol for use of abiraterone in metastatic castration-resistant prostate cancer chemotherapy naive patients has been implanted in our centre and we review the cases of those patients whose adverse effects have forced the discontinuation of treatment."	( Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience. Balea-Filgueiras, J; Martín-Herranz, I; Ramudo-Cela, L; Vizoso-Hermida, JR, 2017)	0.46
" Select adverse events (those with a potential immunologic cause) of any grade were observed in six, four, six, and five patients in arms A, B, C, and D, respectively."	( Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N, 2016)	0.43
" OR for occurrence of any grade and grade 3 to 5 treatment-related adverse effect was calculated for evaluating the safety of PD-1/PD-L1 therapies."	( A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Wang, C; Wang, W; Yu, X, 2016)	0.43
"The PD-1/PD-L1 therapy significantly prolonged the OS and improved the ORR, simultaneously lowering the treatment-related adverse effect events versus docetaxel."	( A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Wang, C; Wang, W; Yu, X, 2016)	0.43
" The most frequently observed adverse event was hematotoxicity (neutropenia of G2 or greater: 100%)."	( The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. Akakura, K; Fujimoto, K; Gotoh, M; Hirao, Y; Ina, K; Nagata, H; Nishimura, K; Ogawa, O; Okajima, E; Tanaka, N; Teramukai, S, 2017)	0.46
" However, patients in the CCRT group exhibited more severe acute adverse events than did patients in the NACT + RT group during radiotherapy, including leukopenia (30."	( Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. Chen, L; Ma, J; Mao, YP; Sun, Y; Tang, LL; Yao, JJ; Yu, XL; Zhang, F; Zhang, WJ; Zhou, GQ, 2017)	0.46
" To increase its therapeutic efficiency, more effective with less side effect and patient acceptable administration approach is expected."	( A biocompatible and magnetic nanocarrier with a safe UV-initiated docetaxel release and cancer secretion removal properties increases therapeutic potential for skin cancer. Huang, X; Kong, F; Pan, J; Yue, D, 2017)	0.46
" Thirty-three (66%) patients completed the chemotherapy course, while the treatment was delayed or discontinued in the other 17 (34%) patients because of adverse events (AEs)."	( Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety. Fujiuchi, N; Hasebe, T; Hirokawa, E; Matsuura, K; Misumi, M; Osaki, A; Saeki, T; Sakurai, T; Shigekawa, T; Shimada, H; Sugitani, I; Takahashi, T; Takeuchi, H; Ueda, S, 2017)	0.46
"Rash and oral mucositis are major non-haematological adverse events (AEs) of docetaxel, in addition to fatigue, nausea, vomiting and diarrhoea, which restrict the use of the drug in cancer therapy."	( Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018)	0.48
" Toxicity assessment was determined using Common Terminology Criteria of Adverse Events v4."	( Plasma alpha-1-acid glycoprotein as a potential predictive biomarker for non-haematological adverse events of docetaxel in breast cancer patients. Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018)	0.48
" Grade 3 adverse events included oral mucositis, radiation dermatitis, reduced white blood cell and neutrophil counts, lung infection, aspiration, and hyponatremia; however, no grade 4 adverse events were observed."	( Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan. Arai, Y; Chiba, Y; Nishimura, G; Oridate, N; Sano, D; Shiono, O; Tanabe, T; Yabuki, K, 2017)	0.46
"Hematotoxicity is a life-threatening side effect of many chemotherapy regimens."	( Genetic background influences susceptibility to chemotherapy-induced hematotoxicity. Churchill, GA; Gatti, DM; Goodwin, NC; Lammert, F; Weber, SN, 2018)	0.48
" Nanopolymer therapeutics can be engineered to deliver anticancer agent specifically to cancer cells, thereby leaving normal healthy cells unaffected by toxic drugs such as DTX."	( Mixed Micelles as Nano Polymer Therapeutics of Docetaxel: Increased In vitro Cytotoxicity and Decreased In vivo Toxicity. Disouza, JI; Khopade, PS; Kumbhar, PS; Manjappa, AS; Patil, AB, 2018)	0.48
" Among propensity score-matched patients, we found no difference between regimens in health care use overall or for chemotherapy-related adverse events (ACTH, 34% v TCH, 36."	( Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. Carey, LA; Dusetzina, SB; Hinton, SP; Meng, K; Meyer, AM; Reeder-Hayes, KE, 2017)	0.46
" The incidences of any grade ≥3 adverse events in the second-line group and the third-line group were 60."	( Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Boku, N; Iizumi, S; Kawai, S; Matsushima, T; Muro, K; Nagashima, K; Narita, Y; Tajika, M; Takahari, D; Takashima, A; Yasui, H, 2017)	0.46
" Here, we reported a smart formulation of docetaxel developed by solid dispersion and effervescent techniques for efficient and safe delivery of chemical drug to lung tissue."	( Docetaxel-Loaded Lecithoid Nanoparticles with Enhanced Lung Targeting Efficiency and Reduced Systemic Toxicity: Developed by Solid Dispersion and Effervescent Techniques. Cheng, XG; Liu, Y; Liu, ZH; Xia, Z; Yu, Y; Zhang, L, 2017)	0.46
"A variety of anticancer chemotherapeutics induce adverse side effects including myelotoxicity."	( Aqueous extract of Phragmitis rhizoma ameliorates myelotoxicity of docetaxel in vitro and in vivo. Bang, OS; Cho, ES; Huh, E; Kim, J; Kim, NS; Kim, YA; Lee, YJ, 2017)	0.46
"Significant product-related differences were observed in the following non-hematological adverse events: injection site reaction (P = 0."	( Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer. Nakamura, S; Okuyama, H; Sasaki, T; Sasaki, Y; Sato, H; Sato, VH; Shimizu, H; Sugiyama, E; Tagawa, N; Tajima, M, 2017)	0.46
"Injectable docetaxel products had different adverse event profiles, which showed negative associations with the amounts of PS80 and ethyl alcohol present."	( Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer. Nakamura, S; Okuyama, H; Sasaki, T; Sasaki, Y; Sato, H; Sato, VH; Shimizu, H; Sugiyama, E; Tagawa, N; Tajima, M, 2017)	0.46
" Adverse events related to filgrastim were reported in 42."	( Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppres Blackwell, K; Gascon, P; Gattu, S; Harbeck, N; Krendyukov, A; Li, Y, 2018)	0.48
" With indirect comparison of overall safety, TDP, TDM-1, and TDM-1 plus pertuzumab demonstrated a lower risk of grade 3-4 adverse events compared to other regimens."	( Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis. Chan, ALF; Leung, HWC; Leung, JH, 2018)	0.48
" Most frequent adverse events (AEs) included: vomiting, decreased appetite, diarrhea, nausea and stomatitis (combination cohorts); gastrointestinal disorders, skin and subcutaneous tissue disorders (monotherapy cohorts)."	( Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Fukase, K; Fukino, K; Hirai, F; Kogure, Y; Niho, S; Saka, H; Sasai, M; Seto, T; Shimada, H; Yoh, K, 2018)	0.48
"The TCH protocol is an efficacious neoadjuvant chemotherapy regimen for locally advanced and oligometastatic breast cancer and is safe and well tolerated in this population."	( Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience. Deo, S; Gogia, A; Mathur, S; Sharma, DN; Shukla, NK; Tiwari, A, )	0.13
" Secondary: To describe the demographic and clinical characteristics of the study sample, as well as the adverse effects and survival."	( Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis. Aviñó, V; Bayo, J; Jiménez, F; Toscano, F, 2018)	0.48
" Adverse events (31."	( Safety and Efficacy of Prostatic Artery Chemoembolization for Prostate Cancer-Initial Experience. Bilhim, T; Costa, NV; Fernandes, L; Oliveira, AG; Pisco, J; Ribeiro, MP, 2018)	0.48
"2% of patients experienced one or more adverse event, 10."	( Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Ahn, JH; Bello, M; Bondarenko, I; Chatterjee, S; Dvorkin, M; Im, SA; Lim, J; Moiseyenko, V; Nowecki, Z; Pivot, X; Sarosiek, T; Semiglazov, V; Shparyk, Y; Song, S; Trishkina, E; Vinnyk, Y; Wojtukiewicz, MZ, 2018)	0.48
" In conclusion, DTX micelles were efficient and safe on breast carcinoma chemotherapy."	( Toxicity Evaluation and Anti-Tumor Study of Docetaxel Loaded mPEG-Polyester Micelles for Breast Cancer Therapy. Chen, LJ; Ma, BY; Peng, JR; Qian, ZY; Tan, LW; Zhang, L; Zhao, Q, 2017)	0.46
" The incidence of treatment-emergent adverse events was comparable between groups (SB3, 97."	( A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. Ahn, JH; Bello, M; Bondarenko, I; Chatterjee, S; Dvorkin, M; Im, SA; Lee, Y; Lim, J; Moiseyenko, V; Nowecki, Z; Pivot, X; Sarosiek, T; Semiglazov, V; Shparyk, Y; Trishkina, E; Wojtukiewicz, MZ, 2018)	0.48
" In contrast to adverse effects associated with systemic administration, intravesical taxane administration has thus far proven to be well-tolerated, with little to no systemic absorption."	( Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Pelletier, D; Liu, V; O'Donnell, M; Stone, MS, 2018)	0.48
" Efficacy endpoints including progression-free survival (PFS) and overall survival (OS), and safety endpoints (including treatment related deaths and selected adverse events) were assessed."	( Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. Abdel-Rahman, O; Kassem, L; Shohdy, KS, 2018)	0.48
" Treatment-related adverse events were mostly manageable, but one patient died as a result of febrile neutropenia."	( Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. Iguchi, T; Kato, M; Kuratsukuri, K; Nakatani, T; Nishihara, C; Takeyama, Y; Tamada, S; Yamasaki, T, 2018)	0.48
"Nonhematologic adverse events (AEs) of docetaxel constitute an extra burden in the treatment of cancer patients and necessitate either a dose reduction or an outright switch of docetaxel for other regimens."	( Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients. Annuar, MABA; Ho, GF; Jabir, RS; Stanslas, J, 2018)	0.48
" We analyzed the main outcomes, including the overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) response, tumor response and severe adverse events (AEs)."	( The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. Huang, C; Song, P; Wang, Y, 2018)	0.48
"Docetaxel and nab-paclitaxel are safe alternatives to paclitaxel after hypersensitivity reaction occurs."	( Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel. Brightwell, R; Eng, K; Frederick, P; Grzankowski, K; Lele, S; Odunsi, K, )	0.13
"6 mg pegfilgrastim is completely safe for female Japanese patients."	( Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients. Kai, M; Kubo, M; Kurata, K; Mori, H; Nakamura, M; Yamada, M, 2018)	0.48
"Treatment with BIND-014 at a dosage of 60 mg/m2 was given intravenously on day 1 of 21-day cycles in combination with prednisone until disease progression or unacceptable toxic effects occurred."	( Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. Alva, A; Anderson, J; Autio, KA; Dittamore, R; Dreicer, R; Garcia, JA; Graf, RP; Hart, LL; Milowsky, MI; Morris, MJ; Posadas, EM; Ryan, CJ; Scher, HI; Schreiber, NA; Summa, JM; Youssoufian, H, 2018)	0.48
" Treatment-related adverse events included grade 1 or 2 fatigue (29 of 42 patients [69%]), nausea (23 [55%]), neuropathy (14 [33%]), and neutropenic fever (1 [2%])."	( Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. Alva, A; Anderson, J; Autio, KA; Dittamore, R; Dreicer, R; Garcia, JA; Graf, RP; Hart, LL; Milowsky, MI; Morris, MJ; Posadas, EM; Ryan, CJ; Scher, HI; Schreiber, NA; Summa, JM; Youssoufian, H, 2018)	0.48
" Regarding bevacizumab-specific adverse events ≥ grade 3, incidence rates of thromboembolic events (1."	( Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N, 2019)	0.51
"H SC 600 mg confirmed to be a safe and tolerable option as adjuvant/neoadjuvant therapy in patients with HER2+ EBC and LABC."	( Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M, 2018)	0.48
"These results could evidence the efficiency of the targeted delivery system in concentrating the drug cargo mostly in its site of action leading to the elimination of its adverse effects caused by exposure of other tissues to the cytotoxic agent."	( Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex® Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer. Ghassami, E; Hoseini, SM; Minaiyan, M; Nasirikenari, M; Varshosaz, J, 2019)	0.51
" No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups."	( Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019)	0.51
" Incidence of adverse events was similar between age groups."	( Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019)	0.51
" Progression-free survival (PFS), overall survival (OS), drug responses, and adverse effects (AEs) were assessed as the primary endpoints."	( Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis. Wei, Y; Xu, J; Xu, Z; Yi, F; Yu, D; Zhang, W, 2019)	0.51
" Treatment-related adverse events of grade 3-5 did favor anti-PD1 over docetaxel (OR=0."	( Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer. Ru, CH; Zhuang, YB, 2018)	0.48
"To capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost-utility analyses."	( Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. de Freitas, HM; Hadi, M; Hall, F; Ito, T; Kerr, C; Lanar, S; Lloyd, AJ; Nafees, B; Penton, J; Pham, TP, 2019)	0.51
" The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed."	( Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. Eto, M; Harano, M; Hasegawa, S; Kuroiwa, K; Nakamura, M; Sakamoto, N; Seki, N; Shiota, M; Tomoda, T; Yokomizo, A; Yunoki, T, 2019)	0.51
"Nephrotoxicity is a well-known side effect of cisplatin for cancer treatment."	( Evaluating dose of cisplatin responsible for causing nephrotoxicity. Higuchi, K; Yanagawa, T, 2019)	0.51
"Lung cancer patients undergoing palliative chemotherapy exhibit many symptoms related to the disease, such as adverse events and infectious complications during treatment, which impacts directly their health-related quality of life (HRQOL)."	( Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial. Augusto, SB; Baston, MT; D'Almeida Preto, D; De Marchi, PRM; de Oliveira, MA; Dias, JM; Geraige, CC; Mamere, AE; Paiva, BSR; Paiva, CE; Pinto, GDJ, 2019)	0.51
" Thus, much research has been dedicated to the development of new and more effective and/or less toxic cancer therapies."	( Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial. Augusto, SB; Baston, MT; D'Almeida Preto, D; De Marchi, PRM; de Oliveira, MA; Dias, JM; Geraige, CC; Mamere, AE; Paiva, BSR; Paiva, CE; Pinto, GDJ, 2019)	0.51
" Polypathology and polymedication are often encountered in elderly patients, making this population especially at risk for adverse drug reactions, and particularly with cytotoxic drugs."	( Prediction of docetaxel toxicity in older cancer patients: a Bayesian network approach. Albrand, G; Bourguignon, L; Culine, S; Ducher, M; Falquet, B; Gourgou, S; Khayi, F; Lafarge, L; Terret, C, 2019)	0.51
"5% objective response) but an important morbidity with 10% toxic deaths in our very symptomatic population with a very important tumor burden."	( [Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N, 2019)	0.51
" The outcomes, including overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional failure-free survival (LRFFS) and incidence of adverse events, were pooled with the use of hazard ratio (HR) or odds ratio (OR)."	( The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Chen, X; Liu, Y; Wang, Y; Zhang, T; Zhou, R; Zhu, J, 2020)	0.56
", d1) plus oral apatinib (250 mg/d), 4 weeks as one cycle, until disease progression or intolerance to adverse events (AE)."	( Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. Fang, XD; Hu, X; Jiang, Q; Ma, DY; Tan, BX; Zhang, NL, 2019)	0.51
"Apatinib plus docetaxel, as the second or above line treatment, is effective and safe against advanced nonsquamous NSCLC, with good tolerance profile."	( Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. Fang, XD; Hu, X; Jiang, Q; Ma, DY; Tan, BX; Zhang, NL, 2019)	0.51
"With the standpoint ofref ining the chemotherapy regimen, we retrospectively reviewed adverse events encountered by the initial 10 cases during the first course of docetaxel plus ramucirumab for non-small-cell lung cancer that progressed after platinum-based chemotherapy."	( [Measures to Ensure Safety of Docetaxel plus Ramucirumab for Advanced Non-Small-Cell Lung Cancer as the Second- or Later-Line]. Fujii, Y; Iwasa, K; Shibata, K; Shimizu, M; Takahashi, M; Takase, M, 2019)	0.51
" Pembrolizumab and nivolumab ranked the best option for most of adverse events."	( Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Abraham, I; Alkhatib, N; Almutairi, AR; Babiker, HM; Garland, LL; Martin, J; McBride, A, 2019)	0.51
" Adverse drug reactions (ADRs) were evaluated according to CTCAE ver."	( Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study. Kazama, H; Matsubara, N; Matsuyama, H; Seto, T; Suzuki, K; Tsukube, S, 2019)	0.51
" Principal objectives were toxicity measured by the common criteria of adverse events terminology and response characterized by Prostate specific antigen decline and radiographic progression-free disease at restaging."	( Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Böhm, K; Borgmann, H; Dotzauer, R; Haferkamp, A; Höfner, T; Jäger, W; Mager, R; Savko, O; Thomas, A; Thomas, C; Tsaur, I, 2019)	0.51
" In mHSPC total number of grade 3 to 5 adverse events (24, median 0, interquartile range 0-1) was significantly less than in mCRPC (46, median 1, interquartile range 1-2) (P = 0."	( Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Böhm, K; Borgmann, H; Dotzauer, R; Haferkamp, A; Höfner, T; Jäger, W; Mager, R; Savko, O; Thomas, A; Thomas, C; Tsaur, I, 2019)	0.51
"The association of age with toxicity and of mHSPC stage with response resulted in significantly fewer grade 3 to 5 adverse events but higher response rates for upfront docetaxel in mHSPC compared with docetaxel in the later mCRPC stage."	( Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Böhm, K; Borgmann, H; Dotzauer, R; Haferkamp, A; Höfner, T; Jäger, W; Mager, R; Savko, O; Thomas, A; Thomas, C; Tsaur, I, 2019)	0.51
" We evaluated the relationships between the dysphagia score at diagnosis and clinicopathological factors, including DCF therapy-related adverse events, tumor response, and survival."	( Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M, 2019)	0.51
"DOC-RT can be a safe regimen for older adult patients with EC."	( Safety of radiotherapy with concurrent docetaxel in older patients with esophageal cancer. Kawamoto, T; Kosugi, Y; Oshima, M; Sasai, K; Shikama, N; Tsurumaru, M, 2020)	0.56
"Hand-foot syndrome (HFS) is the main side effect of capecitabine and affects the compression zones of the body such as the palms and soles, causing numbness, paresthesias, skin swelling or erythema, scaling, chapping, hard nodule-like blisters, and severe pain."	( Loss of Fingerprints as a Side Effect of Capecitabine Therapy: Case Report and Literature Review. Ban, L; Cui, X; Wang, D; Zhang, B; Zhang, X; Zhao, J, 2020)	0.56
" Food and Drug Administration (FDA) conducted a postmarketing review of fatal neutropenic enterocolitis cases reported with docetaxel using the FDA Adverse Event Reporting System (FAERS) and literature to determine whether the drug was a potential cause."	( Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System. Amiri Kordestani, L; Bersoff-Matcha, SJ; Christopher Jones, S; Fedenko, K; Nayernama, A; Prowell, T; Singh, P, 2020)	0.56
" Moreover, the incidence of adverse reactions was observed, and the clinical therapeutic efficacy was assessed."	( Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma. Han, L; Kuang, L, )	0.13
" The incidence rate of adverse reactions in DTX+DDP group was significantly lower than that in TAX+DDP group (p<0."	( Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma. Han, L; Kuang, L, )	0.13
" However, DTX+DDP is more efficacious in lowering indicators such as serum CA125, HE4 and MMP-2 and ROMA index and adverse reactions, thus providing a more efficient practice scheme with lower toxic side effects for the clinical treatment of ovarian carcinoma."	( Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma. Han, L; Kuang, L, )	0.13
" Of the most common grade 3 or higher adverse events, there was a higher incidence of neutropenia in the pertuzumab group (83 of 218 [38."	( Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. Althaus, B; Chang, YC; Cui, S; Eng-Wong, J; Jiang, Z; Kang, SY; Laohawiriyakamol, S; Li, J; Li, W; Liao, N; Mao, Y; Pang, D; Seo, JH; Shao, Z; Shen, K; Wang, C; Wang, H; Wang, S; Wang, Y; Yang, H; Zhou, J, 2020)	0.56
" The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs."	( Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. Chen, LF; Ji, ZH; Li, XB; Li, Y; Lin, YL; Ma, R; Yan, FC; Yang, ZR; Zhang, J, 2020)	0.56
" (iii) Evaluation of the relative risk (RR) and risk difference of serious toxicity defined as adverse events (AEs) with grade ≥ 3 specific AEs."	( Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M, 2020)	0.56
"A major dose-limiting side effect of docetaxel chemotherapy is peripheral neuropathy."	( Role of 1-Deoxysphingolipids in docetaxel neurotoxicity. Becker, KA; Bieberich, E; Bielawski, J; Doolen, S; Goins, L; Gulbins, E; McQuerry, KJ; Spassieva, SD; Sure, U; Taylor, BK; Uerschels, AK, 2020)	0.56
"Regardless of baseline renal function, DOC-RT is a safe regimen for elderly patients with EC."	( Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients. Kawamoto, T; Mine, S; Sasai, K; Shikama, N; Tsurumaru, M, 2020)	0.56
" The most common grade 3 or 4 adverse reactions were fatigue (14%) and diarrhea (13%)."	( Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma. Acevedo-Delgado, JA; Acosta-Espinoza, A; Alatorre-Alexander, JA; Astorga-Ramos, AM; Barriguete-Parra, L; Campos-Gomez, S; Capdeville-García, D; Cázarez-Price, JC; Ceja-García, JP; Fernández-Garibay, VM; Flores-Anaya, N; Flores-Mariñelarena, RR; García-Montes, V; Gerson-Cwilich, R; González-Espinoza, IR; Gonzalez-Villanueva, JI; Kuri-Exsome, R; Magallanes-Maciel, M; Martínez-Barrera, L; Noriega-Iriondo, MF; Perales-Rodríguez, E; Perez-Lozano, Y; Rodríguez-Cid, JR; Rodríguez-Silva, C; Suárez-García, D; Vázquez-Cortés, L; Villalobos-Prieto, A; Zuloaga-Fernandez, CJ, 2020)	0.56
"The experimental arm received docetaxel on day 1 (75 mg/m2) plus pembrolizumab on day 8 (200 mg) every 3 weeks for up to 6 cycles followed by pembrolizumab maintenance until progression or unacceptable toxic effects."	( Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. Aldaco, F; Arrieta, O; Barrón, F; Bautista, Y; Cardona, AF; Carmona, A; Díaz-García, D; Gerson, R; Mota-Vega, B; Peralta Álvarez, MP; Ramírez-Tirado, LA; Rolfo, C; Rosell, R; Yamamoto Ramos, M; Zatarain-Barrón, ZL, 2020)	0.56
" No unexpected severe adverse events or treatment-related deaths occurred."	( Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T, 2020)	0.56
"3%) discontinued RAM+DOC due to adverse events."	( The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer. Furuya, N; Hataji, O; Hida, N; Inoue, T; Ito, K; Komase, Y; Mineshita, M; Morikawa, K; Sakaguchi, T, 2020)	0.56
" Painful peripheral neuropathy is the most dose-limiting side effect of taxanes, affecting up to 97% of paclitaxel-treated patients."	( Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. Calixto, JB; Campos, MM; da Costa, R; Fernandes, ES; Maia, JRLCB; Passos, GF; Quintão, NLM, 2020)	0.56
" However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems."	( Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Alizadeh, N; Darjani, A; Mirpour, SH; Mohammadhoseini, M; Rafiei, E; Rafiei, R, 2020)	0.56
" Dermatologic adverse effects were significantly more frequent in the patients with an underlying disease."	( Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Alizadeh, N; Darjani, A; Mirpour, SH; Mohammadhoseini, M; Rafiei, E; Rafiei, R, 2020)	0.56
"These findings suggest that dermatologic adverse effects of adjuvant chemotherapy are common and could be induced by all components of AC-T regimen."	( Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature. Alizadeh, N; Darjani, A; Mirpour, SH; Mohammadhoseini, M; Rafiei, E; Rafiei, R, 2020)	0.56
" However, it can also induce peripheral neuropathic pain and neurotoxicity as adverse effects."	( Melatonin and Selenium Suppress Docetaxel-Induced TRPV1 Activation, Neuropathic Pain and Oxidative Neurotoxicity in Mice. Ataizi, ZS; Ertilav, K; Nazıroğlu, M; Yıldızhan, K, 2021)	0.62
" No toxic death was observed."	( Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J, 2020)	0.56
" The purpose is to analysis the efficacy and adverse events (AEs) among common paclitaxel (PTX), docetaxel and liposomal paclitaxel."	( Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer. Bi, Z; Chen, P; Liu, YB; Song, XR; Sun, X; Wang, YS; Zhao, T, 2020)	0.56
"To analyze the excipients and impurities contained in the various docetaxel products available on the market and find out whether they may be responsible for any of the different adverse events associated with the use of docetaxel in patients with breast cancer receiving adjuvant or neoadjuvant treatment."	( Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients. Aldaz-Pastor, A; Burgos-San José, A; Garrido-Siles, M; González-Haba-Peña, E; Mangues-Bafalluy, I; Martínez-Bautista, MJ, 2020)	0.56
" The cumulative incidence of adverse events of any grade was evaluated."	( Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients. Aldaz-Pastor, A; Burgos-San José, A; Garrido-Siles, M; González-Haba-Peña, E; Mangues-Bafalluy, I; Martínez-Bautista, MJ, 2020)	0.56
"The results of the study showed differences in the incidence of adverse events of the different docetaxel products available in Spain."	( Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients. Aldaz-Pastor, A; Burgos-San José, A; Garrido-Siles, M; González-Haba-Peña, E; Mangues-Bafalluy, I; Martínez-Bautista, MJ, 2020)	0.56
" Adverse event (AE) grade 3-4 appeared in 38 patients (68%) and mainly consisted of leukopenia (43%) and infections (29%)."	( Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. Balermpas, P; Becker, I; Brunner, T; Budach, W; Eckstein, M; Fietkau, R; Frey, B; Gaipl, US; Geppert, CI; Gostian, AO; Hartmann, A; Hautmann, MG; Hecht, M; Hinke, A; Illmer, T; Iro, H; Klautke, G; Laban, S; Rutzner, S; Semrau, S; von der Grün, J, 2020)	0.56
" Other adverse reactions such as fever, debilitation, and alopecia were also observed."	( Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience. Hu, YC; Jiang, JH; Ma, L; Ma, Q; Wang, KY; Zhang, LL, 2021)	0.62
"To investigate ophthalmic side effects of taxanes and compare side effect frequency, requirement for cessation of taxane therapy, visual acuity outcome, and concurrent systemic effects between paclitaxel and docetaxel."	( Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. Dalvin, LA; Fortes, BH; Liou, H, 2022)	0.72
"Patients taking taxanes at a single center from 1/1/2010 to 2/29/2020 were retrospectively reviewed for clinical characteristics, treatments, and concurrent systemic adverse effects."	( Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. Dalvin, LA; Fortes, BH; Liou, H, 2022)	0.72
"1%) experienced an ophthalmic side effect that came to the attention of an eye care provider."	( Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. Dalvin, LA; Fortes, BH; Liou, H, 2022)	0.72
"Ophthalmic taxane-related adverse events are rare with estimated frequency of ophthalmic side effects of about 1%."	( Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. Dalvin, LA; Fortes, BH; Liou, H, 2022)	0.72
"Management of chemotherapy-induced adverse effects and the associated pharmaceutical interventions as well as supportive care evidence creation are the most important responsibilities of oncology pharmacists."	( [Clinical and Fundamental Approach for Chemotherapy-induced Adverse Effect Attenuation by Oncology Pharmacy Specialists]. Saito, Y, 2020)	0.56
" The most common grade 3/4 adverse events were neutropenia (16."	( Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial. Hervonen, P; Huttunen, T; Jekunen, A; Kataja, V; Kautio, AL; Kellokumpu-Lehtinen, PL; Klintrup, K; Leskinen, M; Luukkaa, M; Marttila, T; Pulkkanen, K; Utriainen, T, 2020)	0.56
" The most common any-grade adverse events were diarrhea, alopecia, and asthenia; the most common grade ≥ 3 events were neutropenia, febrile neutropenia, and hypertension."	( Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Abraham, J; Benyunes, M; Cardona-Huerta, S; Hitre, E; Itrych, B; Juárez-Ramiro, A; Karaszewska, B; Kuemmel, S; Martín, M; Monturus, E; Morales-Vásquez, F; Nowecki, Z; Pérez-García, JM; Restuccia, E; Sequi, M; Tondini, CA, 2021)	0.62
" Other objectives were to evaluate the safety of HLX02 by monitoring adverse events and assessing its potential to induce antibody production (which can prevent a drug from being effective)."	( Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. Adamchuk, H; Bondarenko, I; Hu, X; Li, W; Shparyk, Y; Sun, T; Teng, Y; Tong, Z; Trukhin, D; Wang, Q; Wang, S; Xu, B; Zhang, L; Zhang, Q; Zheng, H, 2021)	0.62
"5% incidence of radiation cystitis and radiation rectitis in the SBRT group, and the degree and incidence of hormone-related and chemotherapy-related adverse events were similar between the two groups."	( Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study. Dai, J; Li, J; Li, Y; Liu, N; Song, Y; Tang, X; Wu, Y; Xian, P; Xiong, L; Zhou, H, 2021)	0.62
" We assessed the benefits and adverse effects of docetaxel and ADT in relation to advancing age."	( Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. Li, EV; Morgans, AK; Prizment, AE; Ryan, CJ; Siddiqui, MR; Weiner, AB, 2021)	0.62
" In the combination arm, the incidence of ≥1 adverse event (grade ≥3) and the number of adverse events per patient were compared for each age group using multivariable logistic and linear regressions, respectively."	( Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. Li, EV; Morgans, AK; Prizment, AE; Ryan, CJ; Siddiqui, MR; Weiner, AB, 2021)	0.62
" There was no significant difference in the odds ratio of ≥1 adverse event (P > ."	( Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. Li, EV; Morgans, AK; Prizment, AE; Ryan, CJ; Siddiqui, MR; Weiner, AB, 2021)	0.62
" Older men experienced a modest increase in adverse events per patient, highlighting the importance of balancing treatment benefits and adverse effects in this age group."	( Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial. Li, EV; Morgans, AK; Prizment, AE; Ryan, CJ; Siddiqui, MR; Weiner, AB, 2021)	0.62
" Adverse events (AEs) were generally consistent with previous reports for docetaxel monotherapy in NSCLC, except for higher incidence of musculoskeletal events, including myalgias, with PVHA plus docetaxel."	( Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer. Baumgart, M; Fathallah, AM; Gabrail, N; Heineman, T; Mager, DE; Maneval, DC; Nanavati, C; Sekulovich, RE; Van Wart, SA, 2021)	0.62
" There was no significant difference in grade 3-4 adverse events (AEs) between the two groups (p = 0."	( Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Wu, D; Zhang, J; Zhang, Z, 2022)	0.72
" Regarding adverse events, within 8 months of treatment initiation, some kind of treatment for haematological toxicity was documented in 31% of patients given docetaxel and in 61% of patients given cabazitaxel."	( Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer. Glaeske, G; Horenkamp-Sonntag, D; Kreis, K; Schneider, U; Weissbach, L; Zeidler, J, 2022)	0.72
" Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 58% versus 49% of older patients receiving cabazitaxel versus abiraterone/enzalutamide and 48% versus 42% of younger patients."	( Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C, 2021)	0.62
" A random-effects model in a single-arm meta-analysis was used to analyze the objective response rate and grade 3-4 adverse event rates based on various docetaxel-platinum regimens."	( Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer. Li, L; Wang, F; Wen, X; Zhao, C; Zheng, Q, 2021)	0.62
" Patient characteristics and adverse events (AEs) in both groups were compared using the Mann-Whitney's U and Fisher's exact tests for categorical variables."	( Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. Atagi, S; Inagaki, Y; Kawachi, H; Matsuda, Y; Matsumoto, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y; Tanizaki, S; Uchida, J; Ueno, K; Yanase, T, 2022)	0.72
" The objective response rate (ORR), disease control rate (DCR) and drug relevant adverse reactions were pooled and demonstrated by risk ratio (RR) and 95% confidence interval (95% CI)."	( Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis. Han, C; Li, H; Li, Z; Liu, Z; Sun, Z; Wu, Y; Zhang, J; Zhang, X, 2021)	0.62
" However, combined treatment with apatinib appears to increase the risk of a patient developing an adverse reaction, especially hypertension and hand-foot syndrome."	( Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis. Han, C; Li, H; Li, Z; Liu, Z; Sun, Z; Wu, Y; Zhang, J; Zhang, X, 2021)	0.62
"Oral mucositis (OM) is an unpleasant adverse event in patients receiving chemotherapy."	( Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). Baba, H; Emi, Y; Hamai, Y; Hihara, J; Kitagawa, Y; Kunisaki, C; Maehara, Y; Matsubara, H; Morita, S; Nagano, H; Nakashima, Y; Oki, E; Otsuji, E; Saeki, H; Takeuchi, H; Tanaka, Y; Tomizuka, K; Ueno, T; Yoshida, K, 2021)	0.62
"Renal impairment was associated with severe adverse events in cisplatin plus S-1 therapy but not with the efficacy in cisplatin plus S-1 and docetaxel plus cisplatin plus S-1 therapy."	( Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. Boku, N; Hironaka, S; Iwasa, S; Machida, N; Sadachi, R; Sasako, M; Terashima, M; Yamada, Y; Yoshikawa, T, 2022)	0.72
" Data on adverse events (AEs) and survival were collected electronically."	( Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan. Chen, Y; Katayose, T; Nagaoka, S; Sekine, N, 2022)	0.72
"To determine the burden of adverse events (AEs) in patients with multiple malignancies receiving nab-paclitaxel compared with that in patients receiving traditional taxanes."	( Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. He, F; Li, G; Li, Q; Liu, J; Shen, X; Wang, Z, 2022)	0.72
" Statistical analyses were conducted to calculate the summary odds ratio (OR) of the relevant adverse outcomes related to nab-paclitaxel and traditional taxanes."	( Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. He, F; Li, G; Li, Q; Liu, J; Shen, X; Wang, Z, 2022)	0.72
" The association between the gene polymorphism and risk of adverse clinical effects in docetaxel treated patients has been examined in several studies, but their conclusions are, to some extent, controversial."	( Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis. Fan, X; Jia, Y; Jiang, L; Liu, Y; Lv, X; Si, H; Wang, X; Wang, Z; Xia, Y; Yan, M; Yin, H, 2022)	0.72
" No statistically significant association between the CYP3A5 A6986G (rs776746) polymorphism and adverse effects was observed in this study."	( Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis. Fan, X; Jia, Y; Jiang, L; Liu, Y; Lv, X; Si, H; Wang, X; Wang, Z; Xia, Y; Yan, M; Yin, H, 2022)	0.72
"An association between the ABCB1 C3435T (rs1045642), ABCB1 G2677T/A (rs2032582) polymorphism and risk of adverse effects of docetaxel was found by our meta-analysis."	( Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis. Fan, X; Jia, Y; Jiang, L; Liu, Y; Lv, X; Si, H; Wang, X; Wang, Z; Xia, Y; Yan, M; Yin, H, 2022)	0.72
" Treatment-emergent adverse events related to DCVAC/PCa or placebo occurred in 69 of 749 (9."	( Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. Bahl, A; Bartunkova, J; Beer, TM; Cheung, E; Csöszi, T; Feyerabend, S; Filipovic, Z; Fricke, H; Gerritsen, W; Goncalves, F; Hajek, J; Hussain, A; Hussain, S; Kadlecova, P; Khoo, V; Korolkiewicz, RP; Kukielka-Budny, B; Oudard, S; Prokhorov, A; Samal, V; Scheiner, T; Sousa, N; Spisek, R; Stenzl, A; Vogelzang, NJ; Wiechno, P, 2022)	0.72
" Some exploratory studies administering modified chemotherapy regimens have reported noninferior oncologic outcomes with fewer adverse events, yet most are retrospective or small studies, and prospective randomized controlled trials have rarely been conducted."	( Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multice Chen, H; Chen, X; Li, Y; Pang, J; Tian, J; Wang, D; Xu, D; Yang, X, 2022)	0.72
" The incidence of all and ≥ grade 3 treatment-related adverse events (TRAEs) were 65% (26/40) and 17."	( Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China. Gong, H; Guo, J; Han, X; Hua, Y; Huang, W; Liu, Z; Meng, X; Sun, Y; Tang, X; Wang, L; Wang, Z; Yuan, S; Zhang, P; Zhang, X; Zhang, Y; Zhu, D; Zhu, H, 2023)	0.91
" Patient-related side effects measured by CTCAE (Common Terminology Criteria for Adverse Events)version 5 showed that the BCG group had higher toxicity profile as compared to Gem/Doce group."	( Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Kumar, S; Pareek, T; Parmar, K; Sharma, AP, 2022)	0.72
"In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer."	( The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Alacacioglu, A; Atci, MM; Avci, O; Ayhan, M; Aykan, MB; Cabuk, D; Cakar, B; Cevik, GT; Coban, E; Demir, A; Demir, H; Diker, O; Dincer, M; Dogan, I; Esen, SA; Garbioglu, DB; Gülbagci, BB; Gulmez, A; Gursoy, P; Hacibekiroglu, I; Inal, A; Kalkan, NO; Karadurmus, N; Karatas, F; Kemal, Y; Nayir, E; Özdemir, Ö; Ozden, E; Paydas, S; Pilanci, KN; Sakalar, T; Salim, DK; Sari, M; Sönmez, ÖU; Taskaynatan, H; Tasli, F; Telli, TA; Uluç, BO; Vatansever, S; Yildirim, ME; Yildiz, Y; Yilmaz, C; Yilmaz, M; Zengel, B, 2022)	0.72
"Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening."	( Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. Atsuta, M; Egawa, S; Enei, Y; Habuchi, T; Hata, K; Hatakeyama, S; Kimura, T; Kondo, Y; Mori, K; Narita, S; Obayashi, K; Oguchi, T; Ohyama, C; Sadakane, I; Shariat, SF; Yanagisawa, T; Yoshihara, K, 2022)	0.72
" Common terminology Criteria for Adverse Events (CTCAE) was applied to evaluate AEs."	( Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. Atsuta, M; Egawa, S; Enei, Y; Habuchi, T; Hata, K; Hatakeyama, S; Kimura, T; Kondo, Y; Mori, K; Narita, S; Obayashi, K; Oguchi, T; Ohyama, C; Sadakane, I; Shariat, SF; Yanagisawa, T; Yoshihara, K, 2022)	0.72
"Addition of immune checkpoint inhibitors to anti-ERBB2 treatment has shown synergistic efficacy in preclinical studies and is thus worth investigating as a neoadjuvant treatment to maximize efficacy and to minimize toxic effects."	( Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. Ahn, HK; Ahn, JH; Chae, H; Choi, YL; Im, SA; Jeong, JH; Jung, KH; Kim, JH; Kim, JY; Kim, MH; Lee, DW; Lee, KH; Lee, KS; Park, YH; Sim, SH; Sohn, JH; Suh, KJ, 2022)	0.72
" Secondary end points included clinical objective response rate, 3-year event-free survival rate according to pCR achievement, disease-free survival, overall survival, toxic effects, and quality-of-life outcomes."	( Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. Ahn, HK; Ahn, JH; Chae, H; Choi, YL; Im, SA; Jeong, JH; Jung, KH; Kim, JH; Kim, JY; Kim, MH; Lee, DW; Lee, KH; Lee, KS; Park, YH; Sim, SH; Sohn, JH; Suh, KJ, 2022)	0.72
" Grade 3 and 4 immune-related adverse events occurred in only 4 patients (grade 3 skin rash, encephalitis, hepatitis, and fever)."	( Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. Ahn, HK; Ahn, JH; Chae, H; Choi, YL; Im, SA; Jeong, JH; Jung, KH; Kim, JH; Kim, JY; Kim, MH; Lee, DW; Lee, KH; Lee, KS; Park, YH; Sim, SH; Sohn, JH; Suh, KJ, 2022)	0.72
"In this nonrandomized clinical trial, treatment with the neoadjuvant atezolizumab, docetaxel, trastuzumab, and pertuzumab regimen in patients with stage II or III ERBB2-positive breast cancer appears to have had an acceptable pCR rate and modest toxic effects."	( Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. Ahn, HK; Ahn, JH; Chae, H; Choi, YL; Im, SA; Jeong, JH; Jung, KH; Kim, JH; Kim, JY; Kim, MH; Lee, DW; Lee, KH; Lee, KS; Park, YH; Sim, SH; Sohn, JH; Suh, KJ, 2022)	0.72
"Our findings imply that Solute Carrier gene polymorphisms modulate the overall survival in lung cancer patients undergoing platin-based doublet chemotherapy, also these polymorphisms have a modifying impact on the associated adverse events/toxicity."	( Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy. Sharma, P; Sharma, S; Singh, N, 2022)	0.72
" Although much has been published on adverse events related to taxanes, data on ocular outcomes with these very important drugs are scant."	( Risk of Ocular Adverse Events With Taxane-Based Chemotherapy. Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN, 2022)	0.72
"To quantify the risk of 3 mutually exclusive ocular adverse events of epiphora, cystoid macular edema (CME), and optic neuropathy with taxane-based chemotherapy agents by undertaking a large pharmacoepidemiologic study."	( Risk of Ocular Adverse Events With Taxane-Based Chemotherapy. Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN, 2022)	0.72
" Ophthalmologists and oncologists should be aware of these adverse events in women with breast cancer who receive these drugs."	( Risk of Ocular Adverse Events With Taxane-Based Chemotherapy. Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN, 2022)	0.72
" The progression-free survival time (time from initiation of prostate cancer treatment to progression to CRPC), PSA response rate, and adverse reactions were compared between the two groups."	( Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis. Guo, Z; Lu, X; Qin, L; Wang, H; Wu, J; Yang, F; Yang, N, 2022)	0.72
"6%) had toxic reactions in the digestive system, and 3 case (4."	( Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis. Guo, Z; Lu, X; Qin, L; Wang, H; Wu, J; Yang, F; Yang, N, 2022)	0.72
"Docetaxel chemotherapy combined with endocrine therapy could be one of effective treatments for delaying castration resistance of HVD-mHSPC, which could prolong PFS effectively and obtain a higher PSA response rate, high safety under close monitoring, and controllable adverse reactions."	( Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis. Guo, Z; Lu, X; Qin, L; Wang, H; Wu, J; Yang, F; Yang, N, 2022)	0.72
" Encouraging clinical results indicate that local administration of LSAM-DTX may provide therapeutic benefits for non-muscle invasive bladder cancer and muscle invasive bladder cancer patients; treatments were well-tolerated with few local and systemic adverse events and negligible systemic docetaxel exposure."	( Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies. Baltezor, M; diZerega, G; Marin, A; Maulhardt, H; Verco, S, 2023)	0.91
" The treatment completion rate of 6 cycles, progression-free survival (PFS), cause-specific survival (CSS) and occurrence rate of adverse events were compared between the groups."	( Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel. Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y, 2022)	0.72
" In the pre-DOC compared with the post-DOC group, the occurrence rate of grade ≥3 adverse events tended to be lower (6% vs."	( Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel. Kamoto, T; Kimura, T; Mukai, S; Nagano, M; Okabe, KO; Onizuka, C; Otuka, I; Shirakawa, T; Takamori, H; Terada, N; Ueno, T; Yamashita, Y, 2022)	0.72
"Anlotinib combined with docetaxel is a safe and effective treatment for lung carcinoma to reduce the incidence of adverse reactions and improve the long-term survival rate."	( Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma. Huang, J; Ji, X; Jing, X; Liu, Y; Yang, S; Yun, Y, 2022)	0.72
" With the wide application of immunotherapy, its adverse reactions are also the object we need to pay attention to."	( Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. Chen, J; Liu, S; Ma, G; Song, W; Wang, H; Yu, G, 2022)	0.72
" In this study, we compared adverse events between the original and generic DTX, both of which did not contain alcohol."	( [Comparative Safety Study of Original and Generic Docetaxel without Alcohol in the Treatment of Breast Cancer]. Eto, T; Hara, M; Ijichi, H; Koga, C; Misumi, N; Nakamura, Y; Okamoto, M; Tajiri, W; Tokunaga, E, 2022)	0.72
"This study aimed to mine and compare the positive signals of adverse drug events (ADE) in paclitaxel, docetaxel, and nab-paclitaxel to evaluate the accuracy of current drug package information inserts and enable clinicians to select the appropriate treatment."	( Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database. Guo, YJ; Lei, CL; Li, Y; Liao, LF; Wang, LY; Wu, Q, )	0.13
"ADE data reported from January 2006 to December 2020 were extracted from the Food and Drug Adverse Drug Events Reporting System (FAERS) database, and the reporting odds ratio (ROR) was used to detect the risk signals of the 3 taxanes."	( Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database. Guo, YJ; Lei, CL; Li, Y; Liao, LF; Wang, LY; Wu, Q, )	0.13
"' Among the three taxanes, nab-paclitaxel had the highest positive signal for serious adverse events."	( Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database. Guo, YJ; Lei, CL; Li, Y; Liao, LF; Wang, LY; Wu, Q, )	0.13
" No clinically relevant differences in adverse events were observed between subgroups in either treatment group."	( Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Bossi, A; Brown, B; Buckley, D; Cookson, MS; George, DJ; Lu, S; Saad, F; Saltzstein, DR; Selby, B; Shore, ND; Tombal, B; Tutrone, R, 2023)	0.91
" This study aims to explore the impact of adverse events (AEs) supervision on reducing treatment-related AEs in patients."	( [Role of Adverse Events Supervision in Clinical Trials in Neoadjuvant Treatment of  Operable Stage III NSCLC]. Li, R; Tao, W; Zhang, Y; Zhou, S, 2023)	0.91
"2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30."	( Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. Badovinac, S; Bitar, L; Jakopovic, M; Janzic, U; Korsic, M; Kukulj, S; Ljubicic, L; Mohorcic, K; Plestina, S; Samarzija, M; Seiwerth, F; Terglav, AS; Unk, M, 2023)	0.91
" Adverse events (AEs) were also evaluated."	( Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC. Lorence, RM; Radonjic, D; Reck, M; Schuette, W; Urban, T; von Wangenheim, U; Westeel, V, 2023)	0.91

Excerpt	Reference	Relevance
" After short intravenous infusions of 70-115 mg/m2 every 3 weeks, a three phase disposition profile was observed with a terminal half-life of 12 hours and a plasma clearance of 21 l/hr/m2."	( Pharmacokinetics and metabolism of Taxotere (docetaxel). Bruno, R; Sanderink, GJ, 1993)	0.29
" At the highest doses, the Taxotere plasma profile was typically triphasic, with a terminal half-life of 13."	( Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Bruno, R; Clavel, M; Extra, JM; Le Bail, N; Marty, M; Rousseau, F, 1993)	0.29
" The tolerability of this strategy and its pharmacokinetic profile and pharmacodynamic correlates were also investigated."	( Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. Auguste, L; Baselga, J; Currie, V; Edelman, B; Fennelly, D; Francis, P; Gilewski, TA; Gollub, M; Hochhauser, D; Hudis, CA; Moynahan, ME; Norton, L; O'Donaghue, M; Salvaggio, R; Seidman, AD; Spriggs, D; Tong, W; Yao, TJ, 1996)	0.29
"A sparse sampling strategy (3 samples per patient, 521 patients) was implemented in 22 Phase 2 studies of docetaxel (Taxotere) at the first treatment cycle for a prospective population pharmacokinetic evaluation."	( A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. Bruno, R; De Phillips, SL; Montay, G; Sheiner, LB; Vergniol, JC; Vivier, N, 1996)	0.29
" Population pharmacokinetic and pharmacodynamic analysis of the results of 22 nonrandomized Phase II trials with nonlinear mixed-effects modeling showed that the interpatient variability of docetaxel pharmacokinetics is mainly related to body surface area and hepatic function."	( Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Bruno, R; Hille, D; Lebecq, A; Riva, A; Thomas, L, 1997)	0.3
" Pharmacokinetic studies revealed a marked non-linearity of paclitaxel in mice, which appeared to result exclusively from Cremophor EL, the major component present in the pharmaceutical formulation."	( Preclinical pharmacokinetics of paclitaxel and docetaxel. Beijnen, JH; Nooijen, WJ; Sparreboom, A; van Tellingen, O, 1998)	0.3
" Six optimal sampling strategies with one to six sampling times were computed, based on the D-optimality theory, using population pharmacokinetic parameters estimated from a large pharmacokinetic database of 547 patients treated in previous Phase II studies."	( Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Baille, P; Bruno, R; Millward, M; Montay, G; Schellens, JH; Verweij, J; Webster, LK, 1997)	0.3
" Pharmacokinetic data from women being treated with combination therapy for advanced breast cancer demonstrate that the administration of docetaxel following doxorubicin does not alter doxorubicin's area under the plasma concentration-time, curve, maximum plasma concentration, or time until maximum plasma concentration is reached."	( Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Colombo, T; D'Incalci, M; Riva, A; Schüller, J; Zucchetti, M, 1998)	0.3
" Population pharmacokinetic studies of docetaxel have demonstrated that clearance is significantly decreased with age, decreased body surface area, increased concentrations of alpha 1-acid glycoproteinand albumin."	( Clinical pharmacokinetics of docetaxel. Clarke, SJ; Rivory, LP, 1999)	0.3
"To assess whether there is a pharmacokinetic interaction between paclitaxel, docetaxel or their vehicles and Dx in mice."	( Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Colombo, T; D'Incalci, M; Goldhirsch, A; Parisi, I; Sessa, C; Zucchetti, M, 1999)	0.3
" This is likely explained by a pharmacokinetic interference of doxorubicin elimination by paclitaxel, an effect that is highly dependent on the interval between administration of the drugs and the duration of the paclitaxel drug infusion."	( Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Sparano, JA, 1999)	0.3
"The aim of the present study was to investigate possible pharmacokinetic interactions between epirubicin (EPI) and docetaxel (DTX) in rats."	( The pharmacokinetics of epirubicin and docetaxel in combination in rats. Freijs, A; Karlsson, MO; Sandström, M; Simonsen, LE, 1999)	0.3
" Pharmacokinetic evaluation was carried out using the NONMEM program."	( The pharmacokinetics of epirubicin and docetaxel in combination in rats. Freijs, A; Karlsson, MO; Sandström, M; Simonsen, LE, 1999)	0.3
"No pharmacokinetic interaction between the parent compound epirubicin and taxanes was detected."	( Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. Angiolini, C; Bergaglio, M; Del Mastro, L; Esposito, M; Garrone, O; Lunardi, G; Rosso, R; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M, 1999)	0.3
"There is no apparent pharmacokinetic interaction between the parent compound epirubicin and paclitaxel or docetaxel."	( Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. Angiolini, C; Bergaglio, M; Del Mastro, L; Esposito, M; Garrone, O; Lunardi, G; Rosso, R; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M, 1999)	0.3
" infusion of 5FU in patients with advanced solid tumors to determine the maximum tolerated dose, the recommended dose for Phase II studies, and the safety and pharmacokinetic profiles of this combination."	( A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H, 2000)	0.31
"Docetaxel, a taxane antitumor agent, was administered to 24 patients by a 1-h intravenous infusion at a dose level of 100 mg/m(2) with pharmacokinetic monitoring."	( Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ, 2000)	0.31
" Pharmacokinetic analyses were performed to evaluate the effect of irinotecan on the disposition of docetaxel."	( Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA, 2000)	0.31
" Blood samples were taken at selected times over the next 24 h for pharmacokinetic analysis."	( The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB, 2000)	0.31
" More than 2 days later, 60 mg/m(2) of docetaxel was administered intravenously with pharmacokinetic sampling."	( Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. Kamiya, Y; Kunitoh, H; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N, 2000)	0.31
" This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds."	( A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000)	0.31
"We conducted a phase I and pharmacokinetic study of docetaxel in combination with irinotecan to determine the dose-limiting toxicity (DLT), the maximum-tolerated dose (MTD), and the dose at which at least 50% of the patients experienced a DLT during the first cycle, and to evaluate the safety and pharmacokinetic profiles in patients with advanced solid tumors."	( Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P, 2000)	0.31
" A multiple regression analysis was performed for interactions between pharmacokinetic parameters and pretreatment characteristics."	( Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. Braess, J; Friedrichsen, S; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E, 2001)	0.31
" After oral administration of 1250 mg/m2, capecitabine is rapidly and extensively absorbed from the gastrointestinal tract [with a time to reach peak concentration (tmax) of 2 hours and peak plasma drug concentration (Cmax) of 3 to 4 mg/L] and has a relatively short elimination half-life (t(1/2)) [0."	( Clinical pharmacokinetics of capecitabine. Blesch, K; Reigner, B; Weidekamm, E, 2001)	0.31
"Paclitaxel and docetaxel each possess unique chemical and pharmacologic characteristics that account for significant differences in their potencies, toxicologic and pharmacokinetic profiles, and propensity for drug-drug interactions."	( Pharmacokinetic profiles of doxorubicin in combination with taxanes. Holmes, FA; Rowinsky, EK, 2001)	0.31
" CBCA Cmax and Cmin in 2-5 days and on day 15 and 29, as well as total plasma platinum on days 2, 3, 4, 5, 29 and 43 were also assayed."	( A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck. Airoldi, M; Bumma, C; Cattel, L; Delprino, L; Recalenda, V; Rocco, F; Tagini, V, 2001)	0.31
"We studied possible pharmacokinetic interactions between docetaxel (DTX) and vinorelbine (VNR) in patients affected by different types of cancer."	( A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Airoldi, M; Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Recalenda, V; Tagini, V, 2001)	0.31
" We conducted a clinical and pharmacokinetic pilot study to assess the feasibility and toxicity of the docetaxel plus amifostine combination and the absence of influence of amifostine on docetaxel pharmacokinetics."	( Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J, 2002)	0.31
"In order to explore activity and pharmacokinetic data of a docetaxel-epirubicin combination we analyzed a population of 60 metastatic breast cancer patients."	( Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V, 2001)	0.31
" Pharmacokinetic analysis was performed to investigate the pharmacokinetic interaction of the two agents."	( Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours. de Wit, R; Loos, WJ; Louwerens, M; Smorenburg, C; Sparreboom, A; Verweij, J, 2002)	0.31
"Previously we observed a pharmacokinetic interference of epirubicin elimination when paclitaxel is given in combination in a sequence-dependent manner (i."	( Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. Bighin, C; Del, ML; Esposito, M; Lunardi, G; Schettini, G; Tolino, G; Vannozzi, MO; Venturini, M, 2002)	0.31
" Pharmacokinetic data were normalised to the lower dose of each drug."	( Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. Bighin, C; Del, ML; Esposito, M; Lunardi, G; Schettini, G; Tolino, G; Vannozzi, MO; Venturini, M, 2002)	0.31
"Thirty-two patients were enrolled, of whom 31 had full pharmacokinetic data sets."	( Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. Fan, L; Goh, BC; Guo, JY; Lamba, J; Lee, HS; Lee, SC; Lim, HL; Lim, R; Ong, AB; Schuetz, E; Wang, LZ, 2002)	0.31
" No significant pharmacokinetic interaction was observed, but a transient increase in epirubicinol plasma concentration occurred during and after docetaxel infusion."	( Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J, 2002)	0.31
" At the highest dose level studied, pharmacokinetic parameters seem to maintain a linear profile."	( Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Camerlo, J; Catalin, J; Ciccolini, J; Genre, D; Giovanini, M; Gonçalves, A; Gravis, G; Maraninchi, D; Viens, P; Viret, F, 2003)	0.32
" In eight cases, peritoneal fluid and blood samples were obtained for pharmacokinetic analysis."	( Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Romanos, J; Rosing, H; Tsiftsis, DD, 2003)	0.32
" Such low-dose studies require a more sensitive, specific and rapid assay of docetaxel in biological fluids for the determination of pharmacokinetic parameters."	( Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA, 2003)	0.32
"The inclusion of the 48-h time-point had significant effects on the calculated pharmacokinetic parameters when using either a three-compartment or non-compartmental analysis."	( Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA, 2003)	0.32
"The results reflect the importance of accurate and sensitive analytical methods for the determination of pharmacokinetic parameters and the effect of this later time-point on docetaxel pharmacokinetic modeling."	( Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA, 2003)	0.32
"The aim of this study was to evaluate the pharmacokinetic parameters, efficacy and toxicity of a docetaxel and vinorelbine combination in metastatic breast cancer patients previously treated with anthracycline."	( Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V, 2003)	0.32
"The purpose of this study was to evaluate pharmacokinetic parameters, efficacy, and toxicity of a combination of docetaxel (DTX) and vinorelbine (VNB) in recurrent heavily pretreated squamous cell head and neck cancer."	( Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Airoldi, M; Beatrice, F; Bumma, C; Cattel, L; Marchionatti, S; Maria Gabriele, A; Pedani, F; Recalenda, V; Succo, G; Tagini, V, 2003)	0.32
"Equilibrium dialysis was used for determination of the fraction unbound (f(u)) docetaxel and was applied to study the pharmacokinetic behavior of unbound docetaxel in 23 patients with cancer receiving an intravenous infusion of the drug formulated in polysorbate 80 (Taxotere; Aventis Pharma SA, Vitry-sur-Seine Cedex, France)."	( Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Baker, SD; Boonstra, JG; Loos, WJ; Sparreboom, A; Verweij, J, 2003)	0.32
" The authors performed a Phase I study and a pharmacokinetic study evaluating the both tolerability of a docetaxel/ketoconazole combination as well as this potential drug interaction."	( Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M, 2003)	0.32
" Pharmacokinetic studies were performed after docetaxel infusions on Day 1 (prior to ketoconazole) and Day 22 (after starting ketoconazole)."	( Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M, 2003)	0.32
" The optimal sequence of chemotherapeutic agents was investigated by reversing the order of administration in the second cycle and by collecting a total of six pharmacokinetic blood samples per cycle from all patients during the first and second cycles."	( Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study. Hervonen, P; Jekunen, A; Kellokumpu-Lehtinen, P; Lefebvre, P, 2003)	0.32
" Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma."	( Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer. Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003)	0.32
"Previous pharmacokinetic studies of the 3-weekly regimen (100 mg m(-2) every 3 weeks) of docetaxel have shown that docetaxel clearance is affected by liver function, body surface area, age, serum alpha1-acid glycoprotein and cytochrome P450 3A4 (CYP3A4) activity."	( Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Blair, EY; Clarke, SJ; McLachlan, AJ; Rivory, LP; Slaviero, KA, 2004)	0.32
"A two-compartment pharmacokinetic model was used to describe the docetaxel concentration-time data from 54 patients with advanced cancer."	( Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Blair, EY; Clarke, SJ; McLachlan, AJ; Rivory, LP; Slaviero, KA, 2004)	0.32
" This final population pharmacokinetic model provided both precise and unbiased predictions of docetaxel concentrations in a validation group of patients and an estimate of the population mean (95% confidence interval) clearance of docetaxel was 30."	( Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Blair, EY; Clarke, SJ; McLachlan, AJ; Rivory, LP; Slaviero, KA, 2004)	0.32
"A population pharmacokinetic model has been developed and validated for weekly docetaxel (40 mg m(-2)) in patients with advanced cancer."	( Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Blair, EY; Clarke, SJ; McLachlan, AJ; Rivory, LP; Slaviero, KA, 2004)	0.32
" Plasma concentrations of PLD were quantified in two sets of samples per patient to compare the same pharmacokinetic parameters in each subject when treated with single-agent PLD and again with the combination."	( Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Briasoulis, E; Karavasilis, V; Pavlidis, N; Piperidou, C; Rammou, D; Soulti, K; Tzamakou, E, 2004)	0.32
"013) while other pharmacokinetic parameters were affected modestly."	( Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Briasoulis, E; Karavasilis, V; Pavlidis, N; Piperidou, C; Rammou, D; Soulti, K; Tzamakou, E, 2004)	0.32
"This study showed the presence of a pharmacokinetic interaction that led to higher plasma concentrations of PLD when combined with paclitaxel and to a minor extent when combined with docetaxel."	( Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Briasoulis, E; Karavasilis, V; Pavlidis, N; Piperidou, C; Rammou, D; Soulti, K; Tzamakou, E, 2004)	0.32
"Weekly administration of docetaxel has demonstrated comparable efficacy together with a distinct toxicity profile with reduced myelosuppression, although pharmacokinetic data with weekly regimens are lacking."	( Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Baker, SD; Brahmer, JR; Carducci, MA; Lee, CK; Sparreboom, A; Verweij, J; Wolff, AC; Zabelina, Y; Zhao, M, 2004)	0.32
" With extended plasma sampling beyond 24 h post-infusion, docetaxel clearance was 18% lower and the terminal half-life was 5-fold longer."	( Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Baker, SD; Brahmer, JR; Carducci, MA; Lee, CK; Sparreboom, A; Verweij, J; Wolff, AC; Zabelina, Y; Zhao, M, 2004)	0.32
" In 11 patients, pharmacokinetic parameters were evaluated."	( Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Airoldi, M; Bumma, C; Cattel, L; Cortesina, G; Danova, M; Gabriele, AM; Giordano, C; Pedani, F; Porta, C; Recalenda, V; Tagini, V, 2004)	0.32
"Current dosing strategies for anticancer drugs result in wide interindividual pharmacokinetic variability."	( Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Armstrong, DK; Baker, SD; Garrett-Mayer, ES; Rudek, MA; Sparreboom, A; Verweij, J; Wolff, AC, 2004)	0.32
" A population pharmacokinetic approach was used to determine individual pharmacokinetic parameters of both docetaxel and dexamethasone by Bayesian analysis, and to screen relationships between docetaxel CL and patients' demographic, phenotype and genotype covariates."	( Dexamethasone as a probe for docetaxel clearance. Azéma, J; Busi, F; Chatelut, E; Chevreau, C; Cresteil, T; Dalenc, F; Hennebelle, I; Lafont, T; Poublanc, M; Puisset, F; Roché, H, 2004)	0.32
" In the pharmacodynamic analysis, neutropenia was positively correlated with the area under the concentration-time curve for docetaxel but not for cisplatin."	( Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? Goto, K; Hanada, K; Kakinuma, R; Kubota, K; Minami, H; Niho, S; Nishiwaki, Y; Nokihara, H; Ogata, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I, 2004)	0.32
" This ZD9331/docetaxel regimen does not appear to be associated with either major pharmacokinetic or toxicologic drug-drug interactions."	( A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies. Garrison, M; Jones, CB; McCreery, H; Patnaik, A; Rowinsky, EK; Schwartz, GH; Skinner, M; Takimoto, C; Tolcher, AW, 2004)	0.32
"To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the Bcl-2 mRNA, with docetaxel to patients with hormone-refractory prostate cancer; to characterize the pertinent pharmacokinetic parameters, Bcl-2 protein inhibition in peripheral blood mononuclear cell(s) (PBMC) and tumor; and to seek preliminary evidence of antitumor activity."	( A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Bushnell, D; Fingert, H; Hammond, LA; Izbicka, E; Kreisberg, J; Kuhn, J; Malik, S; Patnaik, A; Rowinsky, EK; Schwartz, G; Smetzer, L; Thompson, I; Tolcher, AW, 2004)	0.32
" Plasma was sampled to characterize the pharmacokinetic parameters of both oblimersen and docetaxel, and Bcl-2 protein expression was measured from paired collections of PBMCs pretreatment and post-treatment."	( A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Bushnell, D; Fingert, H; Hammond, LA; Izbicka, E; Kreisberg, J; Kuhn, J; Malik, S; Patnaik, A; Rowinsky, EK; Schwartz, G; Smetzer, L; Thompson, I; Tolcher, AW, 2004)	0.32
" Pharmacokinetic analysis did not demonstrate a clear effect of exisulind on docetaxel pharmacokinetics and vice versa."	( A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Baron, A; Basche, M; Bunn, PA; Chan, DC; Eckhardt, SG; Gibbs, A; Gustafson, DL; Holden, SN; Kelly, K; Long, ME; Menter, A; O'Bryant, CL; Pallansch, P; Persky, M; Pierson, AS; Witta, SE; Zeng, C, 2004)	0.32
" This study was designed to assess whether the application of our method to individualized dosing could decrease pharmacokinetic (PK) and pharmacodynamic (PD) variability compared with body-surface area (BSA) -based dosing."	( Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N, 2005)	0.33
" Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy."	( Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. Baker, SD; Carducci, MA; Dawkins, F; Graveland, W; Pronk, T; Rogers, T; ten Tije, AJ; Verbruggen, MP; Verweij, J, 2005)	0.33
"Of 51 patients treated, 20 aged >/= 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity."	( Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. Baker, SD; Carducci, MA; Dawkins, F; Graveland, W; Pronk, T; Rogers, T; ten Tije, AJ; Verbruggen, MP; Verweij, J, 2005)	0.33
" We have compared the pharmacokinetic behaviour of docetaxel after intravenous and intraperitoneal administration in CD-1-nu/nu mice bearing MKN45P, a gastric cancer variant line producing peritoneal dissemination."	( Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. Endo, Y; Miyamoto, K; Nomura, M; Sasaki, T; Shimada, T; Yokogawa, K; Yonemura, Y, 2005)	0.33
" The pharmacokinetic profile of docetaxel was assessed over 30 h following docetaxel infusion."	( Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Ahmed, T; Cocquyt, V; de Smet, M; Fedgchin, M; Gottesdiener, KM; Hande, K; Majumdar, A; Murphy, MG; Nygren, P; Panebianco, D; Petty, KJ; van Belle, S; van Dyck, K, 2005)	0.33
" The corresponding harmonic mean half-life values were 10."	( Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Ahmed, T; Cocquyt, V; de Smet, M; Fedgchin, M; Gottesdiener, KM; Hande, K; Majumdar, A; Murphy, MG; Nygren, P; Panebianco, D; Petty, KJ; van Belle, S; van Dyck, K, 2005)	0.33
" The objectives of this study were to determine the maximal tolerated dose (MTD) of the combination of docetaxel and irinotecan administered weekly for four consecutive weeks every 42 days, to describe toxicities of this regimen, and to perform a pharmacokinetic analysis to evaluate changes in drug disposition as a function of dose as well as repeated dosing."	( Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M, 2005)	0.33
" There were no significant differences in pharmacokinetic parameters between day 1 and day 22 (n=20)."	( Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M, 2005)	0.33
" Pharmacodynamic correlations were noted between the docetaxel area under the curve and peripheral neuropathy or stomatitis."	( Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Barón, AE; Bearman, SI; Cagnoni, PJ; Gustafson, D; Jones, RB; Long, M; Matthes, S; McSweeney, PA; Nieto, Y; Shpall, EJ, 2005)	0.33
" The mechanism of the sequence effects on toxicity and tumor response could not be explained by the pharmacokinetic interactions."	( Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. Ando, M; Ando, Y; Hasegawa, Y; Kuzuya, T; Minami, H; Saka, H; Sakai, S; Shimokata, K; Watanabe, A; Yamamoto, M, 2005)	0.33
"To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with docetaxel in patients with hormone-refractory prostate cancer (HRPC) and to determine if relevant pharmacokinetic and pharmacodynamic variables of oblimersen or docetaxel influence response to this therapy."	( A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Berg, K; Chi, K; D'Aloisio, S; Frankel, SR; Gleave, M; Izbicka, E; Kuhn, J; Murray, N; Patnaik, A; Rowinsky, E; Schwartz, G; Takimoto, C; Thompson, I; Tolcher, AW, 2005)	0.33
" Plasma samples were analyzed to characterize the pharmacokinetic variables of both oblimersen and docetaxel, and paired collections of peripheral blood mononuclear cells were collected to determine Bcl-2 protein expression pretreatment and post-treatment."	( A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Berg, K; Chi, K; D'Aloisio, S; Frankel, SR; Gleave, M; Izbicka, E; Kuhn, J; Murray, N; Patnaik, A; Rowinsky, E; Schwartz, G; Takimoto, C; Thompson, I; Tolcher, AW, 2005)	0.33
"We studied the toxicities, potential pharmacokinetic interactions, and preliminary antitumor activity of the combination of docetaxel and irinotecan with celecoxib, a selective cyclooxygenase-2 inhibitor."	( Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Argiris, A; Avram, MJ; Kut, V; Luong, L, 2006)	0.33
" The alteration of irinotecan pharmacokinetic parameters observed may not be clinically relevant."	( Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Argiris, A; Avram, MJ; Kut, V; Luong, L, 2006)	0.33
" The peak concentration at the end of infusion (Cmax) and AUC of total and unbound drug were compared between patients who did or did not experience grade 4 neutropenia."	( Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Fujii, H; Igarashi, T; Itoh, K; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Tahara, M, 2006)	0.33
"The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions."	( A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006)	0.33
" A pharmacokinetic analysis was performed during the first two cycles."	( A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006)	0.33
"Full pharmacokinetic data was available for 12 of the 15 patients."	( A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006)	0.33
"No clinically relevant pharmacokinetic interactions between docetaxel, cisplatin and 5-FU used in combination were noticed in this study."	( A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006)	0.33
"We found no significant difference in the pharmacokinetic and pharmacodynamic parameters of docetaxel between the single dose of docetaxel and the combination of docetaxel and granisetron."	( The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients. Burioka, N; Endo, M; Igishi, T; Kurai, J; Miyata, M; Morita, M; Shigeoka, Y; Shimizu, E; Suyama, H; Takane, H; Yasuda, K, )	0.13
" Food and Drug Administration requirements and has been successfully applied for the pharmacokinetic investigation of docetaxel or paclitaxel."	( Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies. Aldaz Pastor, A; Aramendia Beitia, JM; Arrobas Velilla, J; Giraldez Deiró, J; Zufía López, L, 2006)	0.33
" Preclinical pharmacokinetic studies have shown that hepatobiliary extraction is the major route of elimination."	( Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Ghio, R; Mencoboni, M; Olivieri, R; Schettini, G; Vannozzi, MO; Viazzi, F, 2006)	0.33
" Pharmacokinetic analysis was performed following both infusions."	( Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Ghio, R; Mencoboni, M; Olivieri, R; Schettini, G; Vannozzi, MO; Viazzi, F, 2006)	0.33
"To determine the maximum tolerated dose and characterize the pharmacokinetic disposition of an orally administered combination of docetaxel and cyclosporin A (CSA) in dogs with tumors."	( Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Balkman, CE; Beaulieu, BB; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM, 2006)	0.33
" Plasma docetaxel concentrations were quantified by use of high-performance liquid chromatography, and pharmacokinetic disposition was characterized by use of noncompartmental analysis."	( Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Balkman, CE; Beaulieu, BB; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM, 2006)	0.33
" Disposition of docetaxel was dose independent over the range evaluated, and pharmacokinetic variables were similar to those reported in previous studies involving healthy dogs, with the exception that values for clearance were significantly higher in the dogs reported here."	( Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. Balkman, CE; Beaulieu, BB; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM, 2006)	0.33
"The aim of this study was to determine the safety and feasibility profile of paclitaxel (PTX) and docetaxel (DTX) in combination and the pharmacokinetic and pharmacodynamic interaction between these two drugs in two different alternated sequences of administration."	( A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours. Cardenal, F; García, M; Germà-Lluch, JR; Gil, M; Izquierdo, MA; Martínez, M; Mesía, R; Navarro, M; Pérez, X; Pontón, JL; Salazar, R; Valentí, V, 2006)	0.33
"With regard to the pharmacokinetic analysis, 58 patients were included."	( Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Alexandre, J; Dieras, V; Girre, V; Goldwasser, F; Jullien, V; Pons, G; Rabillon, F; Rey, E; Tran, A; Tréluyer, JM, 2006)	0.33
" Herein we provide the preclinical and clinical rationale for studies examining the concept of pharmacodynamic separation as a means for overcoming hypothesized antagonism of EGFR TKIs and chemotherapy."	( Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P, 2006)	0.33
" Pharmacokinetic analysis showed a possible effect of docetaxel on CI-1033 pharmacokinetics."	( A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP, 2006)	0.33
" The aim of this study was to evaluate qualitatively and quantitatively the influence of patient-specific characteristics on the neutrophil concentration-time course, to identify patient subgroups, and to compare covariates on system-related pharmacodynamic variable between drugs."	( Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J, 2006)	0.33
", age) had minor (clinically irrelevant) influences but consistently shifted the pharmacodynamic variable in the same direction."	( Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J, 2006)	0.33
" Large interindividual pharmacokinetic variability has been associated with variation in toxicity profiles."	( Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Beijnen, JH; Bosch, TM; Doodeman, VD; Huitema, AD; Jansen, R; Jansen, RL; Schellens, JH; Smit, WM; Soesan, M; van Herpen, CM; Witteveen, E, 2006)	0.33
" A population pharmacokinetic analysis of docetaxel was done using nonlinear mixed-effect modeling."	( Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Beijnen, JH; Bosch, TM; Doodeman, VD; Huitema, AD; Jansen, R; Jansen, RL; Schellens, JH; Smit, WM; Soesan, M; van Herpen, CM; Witteveen, E, 2006)	0.33
"In total, 92 patients were assessable for pharmacokinetic analysis of docetaxel."	( Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Beijnen, JH; Bosch, TM; Doodeman, VD; Huitema, AD; Jansen, R; Jansen, RL; Schellens, JH; Smit, WM; Soesan, M; van Herpen, CM; Witteveen, E, 2006)	0.33
"To evaluate the pharmacokinetics of weekly docetaxel in a cohort of older patients with metastatic cancer and to explore the relationship of pharmacokinetic variables, Erythromycin Breath Test results, age, geriatric assessment variables, and toxicity to therapy."	( Pharmacokinetics and toxicity of weekly docetaxel in older patients. Baker, SD; Caravelli, J; Cutchall, K; D'Andrea, G; Fleming, MT; Gomez, J; Hudis, C; Hurria, A; Kelly, WK; Kris, MG; Miller, VA; Norton, L; Panageas, K; Scher, HI; Yeung, H, 2006)	0.33
" Blood samples were collected for pharmacokinetic analysis with the first dose of docetaxel."	( Pharmacokinetics and toxicity of weekly docetaxel in older patients. Baker, SD; Caravelli, J; Cutchall, K; D'Andrea, G; Fleming, MT; Gomez, J; Hudis, C; Hurria, A; Kelly, WK; Kris, MG; Miller, VA; Norton, L; Panageas, K; Scher, HI; Yeung, H, 2006)	0.33
" There was an association between the Erythromycin Breath Test results and docetaxel pharmacokinetic variables; however, there was no association between Erythromycin Breath Test results or docetaxel pharmacokinetics with frequency of grade > or = 3 toxicity."	( Pharmacokinetics and toxicity of weekly docetaxel in older patients. Baker, SD; Caravelli, J; Cutchall, K; D'Andrea, G; Fleming, MT; Gomez, J; Hudis, C; Hurria, A; Kelly, WK; Kris, MG; Miller, VA; Norton, L; Panageas, K; Scher, HI; Yeung, H, 2006)	0.33
" The purpose of this study was to identify the maximally tolerated dosage and characterize the pharmacokinetic disposition of oral DT combined with CSA in cats with tumors."	( Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats. Bailey, DB; Balkman, CE; Beaulieu, BB; Flanagan, JL; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM, )	0.13
" Pharmacokinetic analyses were performed during both treatments."	( Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J, 2007)	0.34
" Pharmacokinetic models capable of predicting exposure under various dosing regimens would aid the rational development of clinical protocols."	( A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL, 2007)	0.34
"A pharmacokinetic study of docetaxel at 5 and 20 mg/kg was carried out in female BALB/c mice."	( A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL, 2007)	0.34
"Resulting simulation data were compared with actual measured data obtained from our pharmacokinetic study (mouse), or from published data (human), using pharmacokinetic variables calculated using compartmental or noncompartmental analysis to assess model predictability."	( A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL, 2007)	0.34
"Although the high incidence of febrile neutropenia necessitated a multiple scheduling adaptation of tipifarnib compared to the original protocol, the apparent lack of mutual pharmacokinetic interactions, the ability to coadminister tipifarnib and docetaxel near single-agent MTDs, and suggestive evidence of efficacy make this drug combination attractive for further examination."	( A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S, 2007)	0.34
" The pharmacokinetic behaviour of docetaxel injection, PDL, PEGDL and NDL were significantly different."	( Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes. Bin, N; Fei, X; Jia-Bi, Z; Liang, G, 2007)	0.34
" We observed no difference between African-American and Caucasian patients in the percentage decrease in ANC nor were docetaxel pharmacokinetic parameters related to the genotypes studied."	( A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Bies, RR; Dowell, JE; Egorin, MJ; Hollis, DR; Levine, EG; Lewis, LD; Millard, F; Miller, AA; Otterson, GA; Ratain, MJ; Relling, MV; Rosner, GL; Valdivieso, M, 2007)	0.34
" The objective of this study was to identify pharmacodynamic (PD) factors responsible for the neutropaenia caused by docetaxel."	( Clinical pharmacodynamic factors in docetaxel toxicity. Alexandre, J; Chatelut, E; Goldwasser, F; Puisset, F; Raoul, V; Roché, H; Treluyer, JM, 2007)	0.34
"The present study describes a population pharmacokinetic and pharmacodynamic (PK/PD) analysis based on data obtained from cancer patients treated with docetaxel at the National Cancer Center Hospital East in Japan."	( Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients. Minami, H; Ozawa, K; Sato, H, 2007)	0.34
"Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m2 and 100 mg/m2) or weekly regimens (35-40 mg/m2)."	( Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. Aamdal, S; Andersen, A; Brunsvig, PF; Kristensen, V; Olsen, H, 2007)	0.34
"This study aims to describe a population pharmacokinetic model for docetaxel in Asian breast cancer patients and to evaluate the effects of single-nucleotide polymorphisms (SNP) in the cytochrome P450 3A (CYP3A) gene expression regulators, constitutive androstane receptor (CAR), pregnane X receptor (PXR), and hepatic nuclear factor 4alpha (HNF4alpha), on the pharmacokinetics of docetaxel."	( Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Goh, BC; Holford, NH; Hor, SY; Lee, HS; Lee, SC; Lim, RC; Tan, T; Tham, LS; Wang, L, 2007)	0.34
" Docetaxel concentrations were measured using a liquid chromatography/tandem mass spectrometry method and its population pharmacokinetic variables, and the covariate effects of clearance predictors were estimated using a nonlinear mixed effects model."	( Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Goh, BC; Holford, NH; Hor, SY; Lee, HS; Lee, SC; Lim, RC; Tan, T; Tham, LS; Wang, L, 2007)	0.34
" The pharmacokinetic parameters were calculated and analyzed by 3p87 pharmacokinetic program."	( [Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. Huang, HB; Li, S; Liao, H; Lin, PL; Lin, ZC; Liu, JY; Liu, T; Tan, YY; Xu, YH; Zhong, JT, 2007)	0.34
" The half-life of distribution (T(1/2alpha)) were (0."	( [Preparation of docetaxel liposomes and their pharmacokinetics in rabbits]. Huang, HB; Li, S; Liao, H; Lin, PL; Lin, ZC; Liu, JY; Liu, T; Tan, YY; Xu, YH; Zhong, JT, 2007)	0.34
" Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM."	( Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Baker, SD; Carducci, MA; Garrett-Mayer, E; Gelderblom, H; Hooker, AC; Karlsson, MO; McGuire, WP; Ten Tije, AJ; Verweij, J; Weber, J, 2008)	0.35
" We hypothesize that cell cycle arrest induced by erlotinib accounts for these findings in the presence of wild-type EGFR and that pharmacodynamic separation of the 2 drug classes will ameliorate these effects."	( Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B, 2007)	0.34
" We performed a phase I dose-escalating and pharmacokinetic study to assess the safety profile of a new combination regimen and the pharmacokinetic interaction of vinorelbine and docetaxel."	( A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Chatelut, E; Dalenc, F; Delord, JP; Lochon, I; Nguyen, L; Pinguet, F; Poublanc, M; Roche, H, 2007)	0.34
" The weekly IP docetaxel demonstrated a low toxicity and high efficacy for peritoneal carcinomatosis with dual anti-cancer effects via the peritoneal surface and capillary blood supply due to its unique pharmacokinetic property."	( Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Fujimura, T; Funaki, H; Fushida, S; Kayahara, M; Kinami, S; Kinoshita, J; Ninomiya, I; Nishimura, G; Ohta, T; Yagi, Y, 2008)	0.35
" No pharmacokinetic interaction was observed."	( Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. Arya, N; Burris, HA; Fleming, RA; Gadgeel, S; Jones, SF; Koch, KM; Loftiss, J; LoRusso, PM; Pandite, L; Weber, BL, 2008)	0.35
"To investigate the relationship between the degree of liver dysfunction and the pharmacokinetics of docetaxel, a population pharmacokinetic model was developed in an oncology practice without excluding patients with moderate to severe liver dysfunction."	( Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Fujii, H; Igarashi, T; Itoh, K; Kawada, K; Minami, H; Ozawa, K; Saeki, T; Sasaki, Y; Sato, H; Tahara, M, 2009)	0.35
" We developed an interface model that transforms circulating pharmacokinetic concentrations to adequate exposures, destined to be inputs of the pharmacodynamic process."	( An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. Barbolosi, D; Frances, N; Freyer, G; Iliadis, A; Meille, C, 2008)	0.35
" Both viruses prolonged DTX half-life (t(1/2))."	( Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Croyle, MA; Dekker, JD; Strychor, S; Wonganan, P; Zamboni, WC, 2009)	0.35
" Pharmacokinetic studies of initial-dose docetaxel (in the absence of Jinfukang) and the third dose (in the presence of Jinfukang) were compared."	( Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cassileth, BR; Coleton, M; Deng, G; Guillen, S; Kris, MG; Rizvi, N; Vickers, A; Woo, D; Yeung, KS, 2009)	0.35
" Pharmacokinetics were studied with LC-MS/MS, standard, and population pharmacokinetic methods."	( Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y, 2011)	0.37
" In 24 patients, the mean Cmax and AUC erlotinib values increased with dose and following cumulative dosing (days 7 and 8 vs."	( Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y, 2011)	0.37
"The pharmacokinetic study in rats revealed that DLE exhibited higher plasma concentrations and AUC than DS, and a good correlation was observed between AUC and dose, while, in beagle dogs, the DLE was bioequivalent to DS."	( Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Cai, C; He, H; Lin, X; Luo, Y; Su, M; Tang, X; Zhao, M, 2010)	0.36
" The authors conducted a phase 1 and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC."	( Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Egorin, MJ; Fu, H; Harvey, RD; Kauh, J; Khuri, FR; Owonikoko, TK; Ramalingam, SS; Saba, N; Shin, DM; Strychor, S; Sun, SY; Tighiouart, M, 2010)	0.36
" The aim of this study was to develop a population pharmacokinetic (PK) model and to evaluate and quantify the influence of ritonavir on the PK of docetaxel."	( Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Beijnen, JH; Huitema, AD; Koolen, SL; Oostendorp, RL; Schellens, JH, 2010)	0.36
"Population pharmacokinetic (PK) analyses have been successfully incorporated into drug dosing optimization; however, these analyses necessitate relatively large patient cohorts that many clinical trials do not have the luxury of affording."	( Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis. Gustafson, DL; Hudachek, SF, 2011)	0.37
"P-glycoprotein (Pgp) antagonists have been difficult to develop because of complex pharmacokinetic interactions and a failure to show meaningful results."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.37
"Tariquidar is well tolerated, with less observed systemic pharmacokinetic interaction than previous Pgp antagonists."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.37
" The aim of this work was to evaluate the pharmacokinetic behavior, acute toxicity and in vivo antitumor efficacy in murine ovarian cancer model of docetaxel loaded solid lipid nanoparticles (DSN)."	( Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. Chen, L; Li, Y; Lin, L; Zhang, P; Zhang, Z, 2010)	0.36
"Docetaxel pharmacokinetic (PK) parameters, notably clearance and exposure (AUC), are characterized by large interindividual variability."	( Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. de Bruijn, P; Engels, FK; Loos, WJ; Mathijssen, RH; Mathot, RA; van der Bol, JM; Verweij, J, 2011)	0.37
" In the present study, we evaluated the possible pharmacokinetic interactions of Danshen extract with docetaxel and clopidogrel in rats."	( Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. Jang, YP; Kim, HJ; Lee, JH; Lee, YJ; Oh, JH; Shin, YJ, 2011)	0.37
" There was no clinically relevant pharmacokinetic drug-drug interaction."	( Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J, 2011)	0.37
" Docetaxel pharmacokinetic parameters were estimated by non-compartmental modelling."	( The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Chen, X; Chew, SC; Chowbay, B; Kulkarni, T; Lee, EJ; Lim, WT; Ramasamy, RD; Singh, O; Tan, EH, 2011)	0.37
" These findings have potential therapeutic implications for predicting human pharmacokinetic responses to hyperlipidaemia."	( Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. Lee, JH; Lee, YJ; Oh, JH, 2011)	0.37
" Studies based on pharmacokinetics, biodistribution, and antitumor efficacy indicated that DTX/HP-SBE-β-CD had similar pharmacokinetic properties and antitumor efficacy both in vitro and in vivo as Taxotere®."	( Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. Chen, C; Huang, XX; Ren, Y; Wang, H; Xu, Q; Yu, SQ; Zhou, CL; Zhu, YY, 2011)	0.37
" On the basis of preclinical models, we hypothesized pharmacodynamic separation, achieved by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors intercalated with chemotherapy, as a reasonable strategy to deliver combination therapy."	( Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R, 2011)	0.37
" The MTD for arm B was chosen for phase II evaluation given the feasibility of administration, number of responses (one complete response and three partial responses), and achievement of pharmacodynamic separation."	( Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R, 2011)	0.37
" The validated method was successfully applied to the pharmacokinetic study in rat plasma and tissue distribution study in mouse tissues of docetaxel after an intravenous administration of docetaxel injection (DTX injection), docetaxel-loaded nanostructured lipid carrier (DTX-NLC) and FA-PEG-PCHL-modified docetaxel-loaded nanostructured lipid carrier (FA-DTX-NLC), respectively."	( Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. Bi, K; Chen, X; Geng, L; Li, X; Liu, Z; Wang, D; Wang, X; Zhao, X; Zhao, Y, 2011)	0.37
" The physicochemical and pharmacokinetic properties of NOSC-modified DTX liposomes (NDLs) were evaluated compared with the conventional DTX liposomes (DLs) and commercial dosage form of DTX, Taxotere(®)."	( N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics. Qu, G; Wu, X; Yin, L; Zhang, C, 2012)	0.38
" This method was successfully applied for clinical pharmacokinetic investigation."	( A rapid and sensitive LC/ESI-MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study. Fujikawa, A; Furugen, A; Iseki, K; Ito, H; Kobayashi, M; Mano, N; Miyamori, K; Ogura, J; Takahashi, N; Tanaka, N; Yamada, T; Yamaguchi, H, 2012)	0.38
" In this study, a comparative pharmacokinetic study of 2 docetaxel parenteral solutions, SID530 and Taxotere, was carried out."	( Pharmacokinetic equivalence of Taxotere and SID530, a novel docetaxel formulation containing hydroxypropyl-beta-cyclodextrin in monkeys. Kim, EJ; Kim, TK; Lee, BY; Park, JH; Yoo, HH, 2012)	0.38
"Smoking status, toxicity profiles, and pharmacokinetic parameters (calculated by nonlinear mixed-effect modeling population analysis) were determined in 566 patients (429 nonsmokers and 137 smokers) treated with docetaxel or paclitaxel."	( Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA, 2012)	0.38
" Pharmacokinetic parameters were similar in smokers and nonsmokers for both taxanes."	( Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA, 2012)	0.38
"Cigarette smoking does not alter the pharmacokinetic determinants of docetaxel and paclitaxel."	( Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA, 2012)	0.38
" The validated method was applied in a comparative pharmacokinetic study in which two docetaxel formulations, SID530, a new parenteral formulation of docetaxel with hydroxypropyl-β-cyclodextrin (HP-β-CD), and Taxotere, were administered to rats at a dose of 5 mg/kg."	( Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. Kim, IS; Kim, TK; Yoo, HH, 2013)	0.39
" Thus the pharmacokinetic changes of taxanes observed in the DMIS rats were attributed to changes in P-gp and Cyp3A, predominant factors that control the absorption of paclitaxel and docetaxel, respectively."	( Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats. Lee, A; Lee, JH; Lee, YJ; Oh, JH, 2012)	0.38
" Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC)."	( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)	0.38
"For patients with mCRPC who received docetaxel, ≥grade 3 neutropenia on day 8 was prognostic for improved OS, which suggests its utility as a pharmacodynamic marker, in this hypothesis-generating analysis."	( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)	0.38
" Functional membrane drug transporters play important roles in altering pharmacokinetic profile, resistance to treatment, toxicity and patient survival."	( Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Annuar, MA; Ho, GF; Jabir, RS; Munisamy, M; Naidu, R; Stanslas, J, 2012)	0.38
" To further understand the role of ABCB1 in the biodistribution of docetaxel in mice, we utilized physiologically-based pharmacokinetic (PBPK) modeling that included ABCB1-mediated transport in relevant tissues."	( Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. Gustafson, DL; Hudachek, SF, 2013)	0.39
" A comparative pharmacokinetic study of a nanoscale micellar docetaxel (DTX) prodrug, Procet 8, and commercial DTX formulation, Taxotere, was conducted in bile duct cannulated rats."	( Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. Harasym, T; Liboiron, B; Mayer, LD; McNeil, SE; Skoczen, S; Stern, ST; Tardi, P; Xie, S; Zou, P, 2013)	0.39
" Pharmacokinetic analysis was performed for the first course of docetaxel (n = 84)."	( Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Antoine, M; Avenin, D; Beerblock, K; Bernaudin, JF; Fajac, A; Gligorov, J; Lévy, E; Lévy, P; Lokiec, F; Lotz, JP; Rezai, K; Saintigny, P; Selle, F, 2013)	0.39
" The secondary outcomes were pharmacokinetic data and efficacy in terms of time to disease progression."	( Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. Booser, DJ; Eckmann, K; Esparza-Guerra, L; Green, MC; Hortobagyi, GN; Kawedia, J; Madden, TL; Michaud, LB; Rivera, E; Valero, V, 2014)	0.4
" Pharmacokinetic results indicated that patients with more severe hepatic dysfunction may have been underdosed based on our conservative dosing strategy."	( Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. Booser, DJ; Eckmann, K; Esparza-Guerra, L; Green, MC; Hortobagyi, GN; Kawedia, J; Madden, TL; Michaud, LB; Rivera, E; Valero, V, 2014)	0.4
" In both cycles, pharmacokinetic parameters of docetaxel were determined."	( The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. Beijnen, JH; Burgers, JA; Goey, AK; Keessen, M; Marchetti, S; Meijerman, I; Mergui-Roelvink, M; Rosing, H; Schellens, JH, 2013)	0.39
" Nonsignificant alterations were also observed for the elimination half-life (from 30."	( The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. Beijnen, JH; Burgers, JA; Goey, AK; Keessen, M; Marchetti, S; Meijerman, I; Mergui-Roelvink, M; Rosing, H; Schellens, JH, 2013)	0.39
"A rapid, simple and sensitive ultra fast liquid chromatography-tandem mass spectrometry (UFLC-MS/MS) method coupled with one-step protein precipitation procedure has been developed and validated for the pharmacokinetic study of docetaxel in rat plasma to investigate the influence of polyethylene glycol (PEG) molecular weights (chain length) using in the modified formulations."	( A UFLC-MS/MS method coupled with one-step protein precipitation for determination of docetaxel in rat plasma: comparative pharmacokinetic study of modified nanostructured lipid carrier. Bi, K; Chen, X; Cui, Y; He, B; Liu, Z; Wang, D; Wang, X; Xue, X; Zhao, X, 2013)	0.39
" When the dealcoholized or untreated OTAX injection was intravenously injected in rats, no significant differences in the pharmacokinetic parameters of DOC were observed between those with dealcoholized and untreated OTAX injections."	( [Preparation of dealcholized onetaxotere®, docetaxel injection formulation and its pharmacokinetics in rats]. Abe, F; Hasegawa, T; Katoh, M; Matsuura, K; Nadai, M; Onishi, K; Saito, H; Tsukiyama, I; Ueyama, J, 2013)	0.39
" Herein, we characterized the efficacy, toxicity and pharmacokinetic properties of NP docetaxel formulations that have differential drug loading but are otherwise identical."	( Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Bowerman, CJ; Chu, KS; DeSimone, JM; Finniss, MC; Luft, JC; Madden, AJ; Peng, L; Schorzman, AN; Wang, AZ; Zamboni, WC, 2013)	0.39
" Thirty-seven patients participated in a pharmacokinetic (PK)/corrected QT interval substudy of CLEOPATRA, which evaluated potential PK drug-drug interaction (DDI)."	( Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Baselga, J; Brewster, M; Cortés, J; Garg, A; Grincuka, E; Hauschild, M; Kudaba, I; Lum, BL; Marier, JF; Masuda, N; McNally, V; Nijem, I; Patel, T; Ross, G; Swain, SM; Trinh, MM; Visich, J, 2013)	0.39
" Here, the potential pharmacokinetic interaction between SJW and the sensitive CYP3A4 substrate docetaxel was investigated."	( The effect of St John's wort on the pharmacokinetics of docetaxel. Beijnen, JH; Burgers, JA; Goey, AK; Keessen, M; Marchetti, S; Meijerman, I; Mergui-Roelvink, M; Rosing, H; Schellens, JH, 2014)	0.4
" The maximum plasma concentration and elimination half-life of docetaxel were (non-significantly) decreased after SJW supplementation."	( The effect of St John's wort on the pharmacokinetics of docetaxel. Beijnen, JH; Burgers, JA; Goey, AK; Keessen, M; Marchetti, S; Meijerman, I; Mergui-Roelvink, M; Rosing, H; Schellens, JH, 2014)	0.4
" After a single intravenous infusion dose (10 mg/kg) in male Sprague Dawley rats, the area under the curve of the microemulsion was higher and the half-time was longer compared with that of docetaxel solution alone, and showed superior pharmacokinetic characteristics."	( Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics. Ai, L; Chen, F; Dong, Y; Ma, S; Pan, W; Song, S; Xu, H; Xue, Y; Ye, X; Zhang, N; Zhang, W, 2013)	0.39
"9% reduction in Cmax (120 and 180 mg kg(-1), respectively) compared with the control."	( Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2. Chen, X; Deng, S; Fan, A; Gao, W; Li, C; Li, N; Liu, Q; Wang, C; Wen, X; Zhang, Q; Zhang, W; Zhang, Y; Zhao, D; Zhao, J, 2014)	0.4
" Pharmacokinetic parameters, including the maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC), were determined by non-compartmental analysis."	( Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer. Cho, EK; Kang, JH; Kim, YH; Lee, KH; Min, YJ; Park, JY; Song, HS, 2014)	0.4
" Other pharmacokinetic parameters including the plasma AUC, elimination half-life, and total body clearance exhibited similar values without a significant difference."	( Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer. Cho, EK; Kang, JH; Kim, YH; Lee, KH; Min, YJ; Park, JY; Song, HS, 2014)	0.4
"Docetaxel anhydrous CKD-810 use with patients suffering advanced or metastatic solid malignancies was equivalent to reference docetaxel in terms of pharmacokinetic parameters and safety profile."	( Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer. Cho, EK; Kang, JH; Kim, YH; Lee, KH; Min, YJ; Park, JY; Song, HS, 2014)	1.85
" Further, the in vivo pharmacokinetic characteristics of DTX-C/GP correlated well with the in vitro release."	( Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel. Chen, X; Dai, Y; Deng, S; Li, C; Liu, Q; Ren, S; Tian, F; Wang, X; Zhao, J; Zhou, S, 2014)	0.4
" Pharmacokinetic analyses did not show any relevant drug interactions."	( A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Dieras, V; Eskens, FA; Fontaine, H; Hospitel, M; Oprea, C; Tosi, D; Tresca, P; Van der Gaast, A; Van Doorn, L; Veyrat-Follet, C, 2014)	0.4
" See all articles in this CCR focus section, "Progress in pharmacodynamic endpoints."	( In vivo imaging as a pharmacodynamic marker. Lammertsma, AA; van der Veldt, AA, 2014)	0.4
" Ombrabulin clearance was high with a short terminal half-life and a medium volume of distribution."	( Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)	0.4
" The -1154A/G VEGF polymorphism, plasma VEGF, and bFGF after the first cycle of chemotherapy may represent useful pharmacodynamic markers to predict better outcomes."	( Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Antonuzzo, A; Biasco, E; Bocci, G; Danesi, R; Derosa, L; Di Desidero, T; Falcone, A; Farnesi, A; Fioravanti, A; Fontana, A; Francia, G; Galli, L; Marconcini, R; Orlandi, P, 2014)	0.4
" We performed population pharmacokinetic analyses to estimate pharmacokinetic parameters after oral administration of 1,000 mg/day of abiraterone acetate in patients with mCRPC, with or without prior chemotherapy, and after a single 1,000 mg dose in healthy volunteers."	( Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Griffin, TW; Nandy, P; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK, 2014)	0.4
" To this end, we analyze previously published mathematical models of neutropenia to identify a pharmacokinetic (PK) predictor of the neutrophil nadir, and confirm this PK predictor in an in vivo experimental system."	( Dose schedule optimization and the pharmacokinetic driver of neutropenia. Chakravarty, A; Mettetal, JT; Palani, S; Patel, M; Shyu, WC; Yang, J, 2014)	0.4
" To measure the liver-targeting effect of the G-DOC-L, relative uptake rate (Re), peak concentration ratio (Ce), targeting efficiency (Te) and relative targeting efficiency (RTe) were reduced as the evaluation parameters."	( Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase. Chen, J; Chen, YC; Cheng, Y; Luo, LH; Nie, H; Tong, D; Zheng, PJ, 2016)	0.43
"The objective of this study was to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction (DDI) between trastuzumab and carboplatin and to evaluate the potential effect of trastuzumab on the electrocardiogram QT interval."	( Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Eppler, S; Gordon, MS; Han, K; Lum, BL; Redfern, CH; Trudeau, C; Xu, N, 2015)	0.42
" The developed method was successfully applied to the pharmacokinetic study of the seven taxoids in rat plasma after oral administration of the crude extract of the twigs and leaves of Taxus yunnanensis."	( Simultaneous determination of seven taxoids in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Taxus yunnanensis extracts. Bai, X; Gou, X; Hou, X; Huang, M; Jin, J; Li, D; Liu, B; Zhong, G, 2015)	0.42
" This article reviews the pharmacokinetic, pharmacodynamic and toxicological profiles of docetaxel, and explains why there exists an ethnic difference in dose, and further discusses which direction we should go forward to solve this problem."	( Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Kenmotsu, H; Tanigawara, Y, 2015)	0.42
" Pharmacokinetic results for trabectedin plus docetaxel were similar to those previously reported for the single agents."	( Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Bookman, M; Cohen, RB; Knoblauch, R; Li, J; Meropol, NJ; Parekh, T; Sherman, E; von Mehren, M; Weiner, LM, 2015)	0.42
" The pharmacokinetic of DTX loaded FA-PF127-Chol micelles in comparison with Taxoter(®) was investigated in male Wistar rats."	( Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles. Hassanzadeh, F; Javanmard, SH; Mahzouni, P; Taymouri, S; Varshosaz, J, 2016)	0.43
" The results of the in vivo pharmacokinetic study indicated that the AUC0-t of cNLCs (1533."	( Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study. Chao, Y; Fang, G; Gou, J; Tang, B; Tang, X; Xu, H; Zhang, Y, 2015)	0.42
" In conclusion, our results describe important molecular events that occur during combination breast cancer therapies and might modulate pharmacokinetic DOX resistance and/or behaviour."	( Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Havrankova, J; Hofman, J; Skarka, A; Wsol, V, 2015)	0.42
"Applying physiologically-based pharmacokinetic (PBPK) modelling in paediatric cancer drug development is still challenging."	( Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel. Cartot-Cotton, S; Mazuir, F; Thai, HT; Veyrat-Follet, C, 2015)	0.42
" This phase I dose-finding study was designed to assess the tolerability and drug-drug interactions in this combination using full pharmacokinetic (PK) samplings."	( Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N, 2015)	0.42
" A two-compartment pharmacokinetic model was used to calculate the area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)."	( A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Fujita, K; Ishida, H; Kaneta, T; Kawara, K; Kusuhara, H; Maeda, K; Sasaki, Y; Sugiyama, Y; Yokoyama, T; Yoshino, E, 2015)	0.42
" Therefore, pharmacokinetic data and absolute neutrophil counts (ANCs) of 213 docetaxel-treated cancer patients were collected."	( Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. de Bruijn, P; de Graan, AM; de Wit, R; Elbouazzaoui, S; Eskens, FA; Hamberg, P; Martens, JW; Mathijssen, RH; Nieuweboer, AJ; Smid, M; Sparreboom, A; van Schaik, RH, 2016)	0.43
" The conjugate was further characterized for drug loading, micromeritics, drug release, morphology and evaluated for in-vitro cytotoxicity, haemolysis and in-vivo pharmacokinetic profile."	( C60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile. Bhatia, A; Bhushan, S; Guru, SK; Joshi, M; Katare, OP; Kumar, P; Kumar, V; Malik, R; Raza, K; Sharma, G; Thotakura, N, 2015)	0.42
" This trial demonstrates that modulators of resistance can be evaluated in combination with chemotherapy, and pharmacokinetic and pharmacodynamic endpoints can be useful in determination of recommended dose in children and adolescents."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.42
" Although there are some pharmacokinetic studies on cyclophosphamide in kidney insufficiency patients, to the best of our knowledge, the pharmacokinetics and safety of combination of cyclophosphamide and docetaxel as postoperative chemotherapy in a patient with early stage breast cancer undergoing hemodialysis is unclear thus far."	( Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. Chen, J; Hu, AP; Shen, P; Yang, L; Yu, SF; Zhang, XC; Zhu, HQ, 2015)	0.42
" Pharmacokinetic analyses indicated that compared with the reference data, the in vivo half-life (66."	( Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. Chen, J; Hu, AP; Shen, P; Yang, L; Yu, SF; Zhang, XC; Zhu, HQ, 2015)	0.42
"The purpose of this study was to develop folic acid functionalized long-circulating co-encapsulated docetaxel (DTX) and curcumin (CRM) solid lipid nanoparticles (F-DC-SLN) to improve the pharmacokinetic and efficacy of DTX therapy."	( Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats. Burman, R; Gill, MS; Pawar, H; Singh, C; Surapaneni, SK; Suresh, S; Tikoo, K, 2016)	0.43
" The aim of this study is to obtain the population pharmacokinetic parameters of docetaxel in Japanese female patients with breast cancer."	( Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Hanai, A; Ishiguro, H; Itohara, K; Masuda, S; Matsubara, K; Motohashi, H; Onoue, H; Tanaka, A; Yano, I, 2016)	0.43
"A two-compartment model adequately described the pharmacokinetic profiles of docetaxel."	( Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Hanai, A; Ishiguro, H; Itohara, K; Masuda, S; Matsubara, K; Motohashi, H; Onoue, H; Tanaka, A; Yano, I, 2016)	0.43
" Since the clearance of paclitaxel was not affected by the age, it is possible that the pharmacokinetic mechanisms of docetaxel might be specifically affected by age in females."	( Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Hanai, A; Ishiguro, H; Itohara, K; Masuda, S; Matsubara, K; Motohashi, H; Onoue, H; Tanaka, A; Yano, I, 2016)	0.43
" To compare the disposition of docetaxel (DTX) in male/female rats after intravenous administration of simple injection and folate-poly(PEG-cyanoacrylate-co-cholesteryl cyanoacrylate)-modified liposomes utilising a physiologically based pharmacokinetic (PBPK) modelling method, and extrapolate this model to mice and humans by taking into account the interspecies differences in physiological- and chemical-specific parameters."	( Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes. Bi, K; Chen, X; Lu, XF, 2016)	0.43
" The pharmacokinetic profile was studied in rats."	( Dextran-PLGA-loaded docetaxel micelles with enhanced cytotoxicity and better pharmacokinetic profile. Bhushan, S; Guru, SK; Katare, OP; Kaushik, L; Kumar, N; Kumar, P; Malik, R; Misra, C; Raza, K, 2016)	0.43
" The pharmacokinetic profile of DTX was exceptionally improved by the conjugation, in general, and coadministration with piperine, in specific vis-à-vis plain drug."	( Conjugation of Docetaxel with Multiwalled Carbon Nanotubes and Codelivery with Piperine: Implications on Pharmacokinetic Profile and Anticancer Activity. Arora, S; Bhushan, S; Guru, SK; Katare, OP; Kiran, C; Kumar, D; Kumar, M; Kumar, P; Raza, K; Sharma, G, 2016)	0.43
"In this study, a more rapid and more sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method is developed and validated for the pharmacokinetic study of a new lung-targeting docetaxel liposome (DTX-LP) at low dose (1 mg/kg) in rabbits."	( A Rapid and Sensitive UPLC-MS/MS Method for Determination of Docetaxel in Rabbit Plasma: Pharmacokinetic Study of New Lung-Targeting Docetaxel Liposome at Low Dose. Guo, H; Lan, Z; Liu, Z; Wang, J; Yu, Y; Zhang, L, 2015)	0.42
" The pharmacokinetic parameters of three formulations were significantly different."	( Pharmacokinetics, tissue distribution and anti-tumor effect of low density lipoprotein peptide conjugated submicron emulsions. Hua, H; Liang, Q; Miao, J; Sun, P; Xu, Y; Zhang, N; Zhao, Y, 2016)	0.43
" Pharmacokinetic analysis revealed low total body clearance and long apparent terminal elimination half-life (~7-12 days)."	( Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Aogi, K; Dalal, R; Gao, L; Ibrahim, A; Iwata, H; Masuda, N; Sasaki, Y; Xu, Y; Yoshikawa, R, 2016)	0.43
"Increased exposure to paclitaxel and subsequently docetaxel due to interaction with amiodarone was suspected and confirmed on pharmacokinetic sampling."	( Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Cesana, P; Conen, K; Gotta, V; Hammann, F; Medinger, M; Rochlitz, C; Taegtmeyer, AB, 2017)	0.46
" A pharmacokinetic evaluation carried out intravenous administration in healthy Charles Foster rats displayed enhanced systemic bioavailability and plasma drug concentration."	( Development of long-circulating docetaxel loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles: Optimization, pharmacokinetic, cytotoxicity and in vivo assessments. Adena, SKR; Mishra, B; Mittal, P; Upadhyay, M; Vardhan, H, 2017)	0.46
"The aim of this study was to develop docetaxel-incorporated lipid nanoparticles (DTX-NPs) to improve the pharmacokinetic behaviour of docetaxel (DTX) after oral and parenteral administration via sustained release."	( Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration. Choi, JS; Kang, JH; Kim, HS; Kim, JK; Kim, MS; Kwon, JE; Park, JS; Qureshi, OS; Ryou, C; Zeb, A, 2017)	0.46
" In whole animal studies, erlotinib and docetaxel were given to WT and KO rats individually or jointly, and the pharmacokinetic profiles of these two drugs were analyzed and compared among different groups."	( Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats. Liu, M; Lu, J; Qin, X; Wang, P; Wang, X; Xu, P, 2017)	0.46
"A comprehensive literature search has been conducted and dedicated to compile most relevant and up-to-date material about pharmacokinetic consequences of PLGA nanoparticles in docetaxel drug delivery."	( Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery. Haddadi, A; Rafiei, P, 2017)	0.46
"Association of PLGA nanoparticles and docetaxel has demonstrated to modify the drug's pharmacokinetic and biodistribution profile."	( Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery. Haddadi, A; Rafiei, P, 2017)	0.46
" The validated method was successfully applied to a pharmacokinetic study of a docetaxel micelle formulation in rat plasma after intravenous administration at a dose of 10 mg/kg."	( Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC-MS/MS: application to pharmacokinetic studies. Ho, HO; Sheu, MT; Su, CY; Wu, CY, 2017)	0.46
" The results of in vivo studies indicated significant increment in pharmacokinetic parameters including the area under the plasma concentration-time curve, mean residence time, and elimination half-life."	( Pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted Ecoflex Ghassami, E; Hayati, E; Jahanian-Najafabadi, A; Minaiyan, M; Rajabi, P; Varshosaz, J, 2018)	0.48
" The phamacokinetic parameters AUC and Cmax were significantly increased, indicating that coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel, and their effects were in the following order: oxypeucedanin> isoimperatorin> imperatorin."	( [Effect investigation of coumarin constituents in Angelica dahurica on pharmacokinetics of docetaxel by LC-MS]. Dong, W; Guan, XJ; Guan, YM; Liang, XL; Liao, ZG; Zhao, GW; Zhu, WF, 2017)	0.46
" The aim of the study was to explore a method for the simultaneous determination of voriconazole and docetaxel in plasma and investigate pharmacokinetic interaction of voriconazole and docetaxel in rats."	( A robust LC-MS/MS method for the simultaneous determination of docetaxel and voriconazole in rat plasma and its application to pharmacokinetic studies. Ding, F; Hao, K; Jiang, W; Li, P; Lu, L; Pei, X; Sun, Y; Wang, G, 2018)	0.48
" In this study we investigate the safety/tolerability and pharmacodynamic effects of docetaxel used in sequential combination with the novel VEGFR-TKI X-82."	( Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Binger, K; Bruce, JY; Carmichael, L; Dukart, G; Eickhoff, J; Harrow, K; Heideman, J; Jeraj, R; Kolesar, J; Liang, C; Liu, G; Perlman, S; Rampurwala, M; Scarpelli, M, 2018)	0.48
" Further, decrease in FLT uptake during cycle 2 (X-82 plus docetaxel) was greater than in cycle 1 (X-82 alone), suggesting sequential chemotherapy enhances the pharmacodynamic effect of therapy."	( Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Binger, K; Bruce, JY; Carmichael, L; Dukart, G; Eickhoff, J; Harrow, K; Heideman, J; Jeraj, R; Kolesar, J; Liang, C; Liu, G; Perlman, S; Rampurwala, M; Scarpelli, M, 2018)	0.48
" The plasma DTX concentration was evaluated in pharmacokinetic studies."	( Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration. Kim, JH; Kim, JS; Shin, DH, 2018)	0.48
" In this study, we compared the physicochemical property, anti-cancer activity, tumor targeting and pharmacokinetic behavior of docetaxel-loaded folic acid-conjugated liposomes (LPs-DTX-FA) with those of dry powder prepared by co-spray-drying LPs-DTX-FA."	( Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy. Chen, X; Kong, Y; Li, N; Liu, Q; Lu, X; Lu, Y; Xing, H; Xu, J; Yang, Y; Zhao, D; Zhu, X, 2019)	0.51
"MBRI-001, a deuterium-substituted plinabulin derivative, has been reported to have better pharmacokinetic and similar antitumor effects in comparison with plinabulin."	( Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor. Ding, Z; Li, W; Li, Z; Ma, L; Ma, M; Wang, S; Wang, Y; Yang, J; Zhong, L, 2019)	0.51
" The pharmacokinetics of plasma DTX was analyzed using an ultra-performance liquid chromatography-tandem mass spectrometry system, and pharmacokinetic parameters were estimated via noncompartmental analysis."	( Effect of the Phragmitis Rhizoma Aqueous Extract on the Pharmacokinetics of Docetaxel in Rats. Bang, OS; Kim, NS; Kim, YA; Oh, HR; Shin, S, 2019)	0.51
" Consecutively pretreated EPR for 6 days slightly altered AUC0-t and Cmax of DTX by 122 and 145."	( Effect of the Phragmitis Rhizoma Aqueous Extract on the Pharmacokinetics of Docetaxel in Rats. Bang, OS; Kim, NS; Kim, YA; Oh, HR; Shin, S, 2019)	0.51
" The aim of the current study was to develop a population pharmacokinetic (PK) model for docetaxel and ritonavir based on the phase 1 studies and to support drug development of this combination treatment."	( A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development. Beijnen, JH; de Weger, VA; Huitema, ADR; Janssen, JM; Nuijen, B; Sawicki, E; Schellens, JHM; van Hasselt, JGC; Yu, H, 2020)	0.56
" The aim of this study was to establish a pharmacodynamic model that captures the effect of docetaxel, SCO-101, and the combination on cell survival in docetaxel resistant MDA-MB-231 TNBC cells."	( Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. Bagger, SO; Brünner, N; Lund, TM; Nøhr-Nielsen, A; Stenvang, J, 2020)	0.56
" The aim of current analysis was to develop a pharmacokinetic (PK)-toxicodynamic (TOX) model to quantify the relationship between docetaxel plasma exposure and DLTs."	( Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir. Beijnen, JH; de Weger, VA; Dorlo, TPC; Huitema, ADR; Janssen, JM; Marchetti, S; Nuijen, B; Schellens, JHM; Stuurman, RE; Yu, H, 2020)	0.56
" Pharmacokinetic sampling was conducted until 48 h after both study drug administrations."	( Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours. Beijnen, JH; de Weger, VA; Huitema, ADR; Janssen, JM; Keessen, M; Lopez-Yurda, MI; Marchetti, S; Rosing, H; Thijssen, B; Vermunt, MAC, 2021)	0.62
"The anticancer drug docetaxel exhibits large interpatient pharmacokinetic and pharmacodynamic variability."	( Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. Beijnen, JH; Dorlo, TPC; Huitema, ADR; Marchetti, S; Pluim, D; van Eijk, M, 2021)	0.62
" Blood samples were collected up to 180 minutes after dosing to analyze docetaxel concentrations and determine individual pharmacokinetic parameters."	( Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity. Detert Oude Weme, SEH; Hoge, RHL; Jacobs, MS; Jansman, FGA; Mathôt, RAA; Roorda, L; van Berlo-van de Laar, IRF; van Erp, NP; van Herpen, CML; Vervenne, WL, 2022)	0.72
"By incorporating gestational changes into existing population pharmacokinetic models, it is possible to adequately predict plasma concentrations of drugs in pregnant patients which may inform dose adjustments in this population."	( Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs. Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC, 2023)	0.91

Excerpt	Reference	Relevance
" Following encouraging preclinical results of taxoid combinations, this phase I, nonrandomized trial was designed to evaluate a 1-hour intravenous infusion of docetaxel (Taxotere) on day 1 combined with fluorouracil (5-FU) as a daily intravenous bolus for 5 consecutive days."	( Docetaxel in combination with fluorouracil: study design and preliminary results. Aylesworth, C; Bellet, R; Burris, H; Drengler, R; Peacock, N; Ravdin, P; Rodriguez, G; Rowinsky, E; Smith, L; Von Hoff, D; White, L, 1997)	0.3
" This review summarizes results from key phase I and II studies demonstrating the antitumor activity and tolerability of docetaxel combined with platinum compounds for patients with advanced non-small-cell lung cancer."	( Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Belani, CP, 1997)	0.3
"The rationale for the development of a new drug combination is to combine optimal doses of drugs with single-agent activity that are not cross-resistant or have similar toxicities."	( Docetaxel in combination with doxorubicin or vinorelbine. Azli, N; Diéras, V; Fumoleau, P; Kalla, S; Misset, JL; Pouillart, P, 1997)	0.3
"Combinations of nucleoside analog drugs, such as F-araA and ara-C, combined with Topoisomerase II inhibitors, such as anthracyclines, are synergistic against human leukemic T-cells and induce apoptotic cell death."	( Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Avramis, VI; Cohen, LJ; Danenberg, P; Kwock, R; Mukherjee, SK; Nandy, P; Solorzano, MM, )	0.13
"To determine the maximum-tolerated dose of monthly docetaxel combined with fixed-dose weekly gemcitabine and describe the dose-limiting toxicities (DLTs) of the combination."	( Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K, 1998)	0.3
"Gemcitabine 800 mg/m2 days 1,8, and 15 can be safely combined with docetaxel 100 mg/m2 day 1 of a 28-day cycle."	( Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K, 1998)	0.3
" Encouraging response rates also have been seen in studies in which paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with doxorubicin, although cardiotoxicity was a significant factor in some studies."	( Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer. Dieras, V, 1998)	0.3
" The use of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) in combination with anthracyclines is also active and could represent a safe and favorable alternative."	( Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer. Pagani, O, 1998)	0.3
"To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)."	( Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999)	0.3
" We have recently shown that a mixed backbone oligonucleotide targeting RIalpha can cooperatively inhibit human cancer cell growth when combined with selected cytotoxic drugs."	( Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Agrawal, S; Bianco, AR; Caputo, R; Ciardiello, F; Mendelsohn, J; Pepe, S; Pomatico, G; Tortora, G, 1999)	0.3
"Following encouraging preclinical evidence suggesting anticancer synergy when docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and vinorelbine are administered together, a clinical trial was designed to determine the maximum tolerated dose of the combination when given with granulocyte colony-stimulating factor support to 27 patients with advanced non-small cell lung cancer."	( Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer. Miller, V, 1999)	0.3
" Bisphosphonates are powerful inhibitors of osteoclast activity, and are therefore used in combination with standard chemotherapy or hormonal therapy for the treatment of cancer-associated osteolytic metastases."	( Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S, 1999)	0.3
"The effects of docetaxel alone and in combination with irradiation were experimentally investigated in terms of induction of apoptosis."	( Experimental study of the effects on apoptosis of docetaxel alone and in combination with irradiation. Hasegawa, M; Hayakawa, K; Kawashima, M; Matsuura, M; Mitsuhashi, N; Nakamura, Y; Nasu, S; Niibe, H, )	0.13
" In conclusion, our findings further support the potential cytotoxic role of TPT in combination with other active drugs when the correct schedule of administration is applied."	( Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Abad, A; Guillot, M; Martin, C; Plasencia, C; Taron, M, 2000)	0.31
" The pharmacokinetics of docetaxel are not influenced by combination with ifosfamide, regardless of the drug sequence, but ifosfamide pharmacokinetics are changed by docetaxel, depending on the sequence of administration."	( Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Bruno, R; De Bruijn, E; Highley, M; Locci-Tonelli, D; Pronk, L; Schrijvers, D; Van Oosterom, AT; Verweij, J, 2000)	0.31
"This phase I study evaluated the maximum tolerated dose, dose-limiting toxicity and recommended dose of docetaxel in combination with 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy."	( Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study. Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L, 2000)	0.31
" Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema (NPE) while on treatment with gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor (G-CSF) support."	( Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I, 2000)	0.31
" Based on in vitro study showing that the introduction of bax gene enhanced the sensitivity to anticancer drugs, we examined whether the intratumoral administration of bax gene could enhance the anti-tumor effect in combination with anticancer drugs in gastric cancer."	( Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Kim, R; Minami, K; Nishimoto, N; Toge, T, 2001)	0.31
" The observation of increased antitumor activity between trastuzumab and some chemotherapeutic agents in preclinical models has prompted its use in combination with several drugs."	( Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Esteva, FJ; Fornier, M; Seidman, AD, 2000)	0.31
"Two cases of advanced and metastatic breast cancers were treated by docetaxel (TXT) in combination with intra-arterial infusion of adriamycin (ADM)."	( [Two cases of advanced and metastatic breast cancers treated by docetaxel in combination with intra-arterial infusion of adriamycin]. Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S, 2001)	0.31
"Docetaxel (Taxotere; Aventis, Antony, France) is among the most effective agents for the treatment of non-small cell lung cancer and its use in combination with cisplatin is a logical development."	( Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Belani, C; Lynch, T, 2001)	0.31
" Docetaxel combined with other new agents, particularly gemcitabine, may offer another useful alternative to cisplatin-based chemotherapy in patients with good performance status."	( Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G, 2001)	0.31
"Docetaxel in combination with gemcitabine is an active front-line chemotherapy regimen against non-small cell lung cancer (NSCLC) with acceptable toxicity."	( Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N, 2001)	0.31
"To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)."	( Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001)	0.31
"Docetaxel in combination with mitoxantrone and G-CSF support is an intensified and active front-line regimen for patients with MBC; despite its hematological toxicity, this regimen merits further comparison with other standard anthracycline- and/or taxane-based combinations."	( Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001)	0.31
"Clinically significant drug interactions have been reported to occur when paclitaxel is administered with doxorubicin, cisplatin, or anticonvulsants (phenytoin, carbamazepine, and phenobarbital)."	( Drug interactions with the taxanes: clinical implications. Baker, AF; Dorr, RT, 2001)	0.31
" This two-step study firstly aimed at determining the maximum tolerated and recommended doses of docetaxel given every 3 weeks in combination with a fixed dose of gemcitabine; the phase I study paid particular attention to pharmacokinetics."	( Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Ardiet, C; Azarian, MR; Morere, JF; Pujol, JL; Quantin, X; Rebattu, P; Schuller-Lebeau, MP, )	0.13
"The following range of docetaxel dosages were tested in the phase I study; 60, 75, 85, and 100 mg m(-2) given on day 8 in combination with gemcitabine 1000 mg m(-2) delivered on days 1 and 8 of a 3-week cycle."	( Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Ardiet, C; Azarian, MR; Morere, JF; Pujol, JL; Quantin, X; Rebattu, P; Schuller-Lebeau, MP, )	0.13
"Gemcitabine, 1000 mg m(-2) days 1 and 8 in combination with docetaxel, 85 mg m(-2), day 8, given every 3 weeks could be considered as an active regimen with manageable toxicities in locally advanced or metastatic NSCLC."	( Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Ardiet, C; Azarian, MR; Morere, JF; Pujol, JL; Quantin, X; Rebattu, P; Schuller-Lebeau, MP, )	0.13
"Paclitaxel and docetaxel each possess unique chemical and pharmacologic characteristics that account for significant differences in their potencies, toxicologic and pharmacokinetic profiles, and propensity for drug-drug interactions."	( Pharmacokinetic profiles of doxorubicin in combination with taxanes. Holmes, FA; Rowinsky, EK, 2001)	0.31
"The phase I study was conducted to evaluate the maximum tolerated dose (MTD) and toxicity of weekly administered docetaxel combined with cisplatin in patients with non-small-cell lung cancer (NSCLC)."	( Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer. Fujimoto, K; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Nomura, H; Okada, K; Tsunoda, T, 2001)	0.31
" In this report, we evaluated the effects of exisulind, a novel proapoptotic agent that is a sulfone metabolite of sulindac, in combination with docetaxel on the growth of the human non-small cell lung cancer cell line A549 in vitro and in vivo."	( Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Alila, H; Baron, A; Bunn, PA; Chan, DC; Earle, KA; Helfrich, B; Nelson, P; Pamukcu, R; Piazza, G; Thompson, WJ; Whitehead, CM; Zeng, C; Zhao, TL, 2002)	0.31
"The authors conducted a single-institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5-fluorouracil (5-FU) combined with docetaxel in patients with metastatic breast carcinoma."	( Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V, 2002)	0.31
" Radiation (total 48 Gy) and 3 courses of chemotherapy with docetaxel (60 mg/m2) in combination with carboplatin (AUC = 6,600 mg) resulted in a remarkable reduction in the size of the mass, to less than 50%, and normalized serum CEA."	( [A case of large-cell lung cancer successfully treated with docetaxel in combination with carboplatin and radiotherapy]. Kato, Y; Kitagaki, H; Maruyama, R; Nishiki, M; Tumori, M; Uchida, N; Yamane, Y; Yamauti, M; Yoshida, M, 2002)	0.31
" The choice of treatment and dose was based on a series of four phase II studies that indicated the combination of docetaxel (75 to 100 mg/m(2)) and cisplatin (75 to 100 mg/m(2)) was active and feasible; carboplatin may have a more favorable therapeutic index than cisplatin, particularly with regard to nonhematologic toxicities, and had proven activity in combination with docetaxel in phase II study; and randomized studies had shown the combination of vinorelbine plus cisplatin was superior to either vinorelbine alone or cisplatin alone and was considered as a reference study regimen in the clinical setting upon initiation of this phase III study."	( Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Belani, CP, 2002)	0.31
"This phase I was study conducted to establish the maximum tolerated dose, dose-limiting toxicity, and recommended dose of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer."	( Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Azli, N; Bisset, D; Kaye, SB; Ramazeilles, C; Riva, A; Roché, H; Terret, C; Twelves, CJ; Vasey, PA; Vernillet, L, 2002)	0.31
"The present study shows that at least additive interactions are observed when trastuzumab is combined with either paclitaxel or docetaxel in weak to moderate or more than moderate HER2-expressing cells."	( In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines. Bachmann, N; Barberi-Heyob, M; Merlin, JL, 2002)	0.31
" Our purpose was to determine the therapeutic efficacy of a selective-spectrum MMPI, ONO-4817 (inhibits MMP-2 and MMP-9 but not MMP-1), against established lung micrometastasis in combination with a cytotoxic anticancer drug, DOC, in a nude mouse model."	( A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Goto, H; Miki, T; Ogawa, H; Shiraga, M; Sone, S; Yamamoto, A; Yano, S; Zhang, H, 2003)	0.32
"The purpose of our study was to assess the feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when administered with granulocyte colony-stimulating factor (G-CSF) support every 3 weeks."	( Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Camerlo, J; Catalin, J; Ciccolini, J; Genre, D; Giovanini, M; Gonçalves, A; Gravis, G; Maraninchi, D; Viens, P; Viret, F, 2003)	0.32
"The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first-line treatment for patients with locally advanced/metastatic breast carcinoma."	( Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M, 2003)	0.32
"A multicenter cooperative study of docetaxel (60 mg/m2) combined with cisplatin (60 mg/m2) was performed in stage III and IV patients with inoperable non-small cell lung cancer from March 1998 to September 1999."	( [Efficacy of docetaxel (TXT) combined with cisplatin (CDDP) in non-small cell lung cancer]. Aoki, Y; Furukawa, T; Haruta, Y; Hayashi, S; Iwanaga, K; Kato, O; Koyanagi, K; Kuroki, S; Nagata, M; Naitoh, K; Soejima, Y; Takahashi, K, 2003)	0.32
" The aim of this phase II study is to determine the feasibility, efficacy and toxicity of docetaxel at a dose of 75 mg/m2 in combination with Carboplatin at an area under the curve (AUC) of 6, as first line treatment in patients with advanced ovarian cancer."	( Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. Chasen, MR; Cohen, GL; Karime, M; Mahomed, R; Rapoport, BL; Vorobiof, DA, )	0.13
" It is becoming clear that certain chemotherapeutic drugs such as docetaxel are not simply inhibitors of mitosis and may interact with these tumorigenic mechanisms at a number of levels."	( Mode of action of docetaxel - a basis for combination with novel anticancer agents. Herbst, RS; Khuri, FR, 2003)	0.32
" We designed a biweekly administration regimen of TXT combined with CPT-11 for 4 weeks as one cycle in patients with inoperable or recurrent gastric cancer, and conducted a dose-escalation study."	( Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T, 2003)	0.32
" The present study was undertaken to evaluate the antitumor mechanisms of EGFR antisense (AS) oligonucleotides administered in combination with docetaxel in preclinical models of SCCHN."	( Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Gooding, WE; Grandis, JR; Li, M; Lui, VW; Niwa, H; Wentzel, AL, 2003)	0.32
"SCCHN cells lines and xenografts were treated with an EGFR AS oligonucleotide targeting region 760-779 of EGFR mRNA (GenBank accession XM_004738) alone and in combination with docetaxel."	( Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Gooding, WE; Grandis, JR; Li, M; Lui, VW; Niwa, H; Wentzel, AL, 2003)	0.32
" The pharmacologic features of this drug enable its combination with other antiblastic agents, such as vinorelbine, gemcitabine, paclitaxel and docetaxel."	( Antiblastic drug combinations with ifosfamide: an update. Badalamenti, G; Fulfaro, F; Gebbia, N; Russo, A; Valerio, MR, 2003)	0.32
" This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines."	( Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S, 2004)	0.32
"These studies demonstrate that irofulven displays strong activity as monotherapy and in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer in vitro and in vivo; thus, supporting the clinical investigation of irofulven against hormone-refractory prostate cancer."	( Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S, 2004)	0.32
" These data provide a proof-of-principle for the clinical use of LErafAON in combination with chemotherapy for cancer treatment."	( Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Pei, J; Rahman, A; Zhang, C, 2004)	0.32
" The liver metastases responded completely to chemotherapy with trastuzumab combined with docetaxel, but the pleural carcinomatosis was refractory to the therapy."	( A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Fujii, H; Ichihara, F; Inoue, S; Kono, K; Kunitomo, K; Matsumoto, Y; Ooi, A, 2004)	0.32
" Fifty-two patients were treated with docetaxel alone (group 1A/B, n = 35) or in combination with trastuzumab (group 2, n = 17)."	( Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Hopkins, U; Malik, U; Manalo, JM; Negassa, A; Novik, Y; Raff, JP; Rajdev, L; Sarta, C; Sparano, JA, 2004)	0.32
"Recent approval of docetaxel in combination with cisplatin (DP) for non-small cell lung cancer (NSCLC) treatment means that an assessment of its effectiveness and toxicity is necessary."	( [Docetaxel in combination with cisplatin for first-line treatment of locally advanced or metastatic non-small cell lung cancer: meta-analysis of randomized and controlled clinical trials]. Guillén Grima, F; Peñuelas Sánchez, I; Sánchez Lerma, B, 2004)	0.32
"The purpose of this study was (i) to determine the maximum tolerated dose (MTD) of docetaxel that can be administered in combination with Doxil, given without and with granulocyte colony stimulating factor (G-CSF), (ii) to define the pharmacokinetics (PK) of docetaxel when used in combination with Doxil, and (iii) to make preliminary observations on the anti-tumor activity of this combination in patients with metastatic solid tumors."	( A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor. Chodkiewicz, C; Downey, A; Hamilton, A; Hochster, H; Liebes, L; Muggia, F; Pavlick, AC; Phillips, Z; Sorich, J; Speyer, J; Wasserheit, C, 2004)	0.32
"Cisplatin combined with weekly administration of docetaxel is efficacious against NSCLC with low hematotoxicity, and this schedule may be an alternative for the treatment of NSCLC."	( Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Fujimoto, K; Hayasaka, M; Hirai, K; Koizumi, T; Koyama, S; Kubo, K; Takabayashi, Y; Tsunoda, T, 2004)	0.32
"This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(-2) and 5-fluorouracil (5-FU) 200 mg m(-2) day(-1)."	( Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S, 2004)	0.32
"Docetaxel combined with 72-hour flavopiridol was not feasible because of dose-limiting neutropenia."	( Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Berman, A; Brahim, JS; Chow, C; Figg, WD; Parr, AL; Sparreboom, A; Steinberg, SM; Swain, SM; Tan, AR; Yang, X; Zhai, S, 2004)	0.32
" The purpose of this study was to determine the degree of enhancement of the oral uptake of docetaxel on combination with orally administered OC144-093, a potent P-gp inhibitor."	( Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Beijnen, JH; Bosch, TM; Fitzpatrick, A; Kuppens, IE; Rosing, H; Schellens, JH; van Maanen, MJ, 2005)	0.33
" Because the toxicity profile of weekly docetaxel differs from the standard 21-day docetaxel schedule, we performed a phase I/II trial to test the efficacy and safety of weekly docetaxel in combination with capecitabine given for 14 days every 21 days."	( Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004)	0.32
"To determine the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of docetaxel infused over 1 hour when given in combination with oral zosuquidar to patients with resistant solid tumors."	( Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Andre, VA; Arquette, MA; Burgess, MF; de Alwis, DP; Fears, CL; Fracasso, PM; Gazak, RJ; Goldstein, LJ; Goodner, SA; Rader, JS; Schellens, JH; Slapak, CA; Wright, LP, 2004)	0.32
" In subsequent cycles, zosuquidar was administered with docetaxel, which was escalated from 75 to 100 mg/m2."	( Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Andre, VA; Arquette, MA; Burgess, MF; de Alwis, DP; Fears, CL; Fracasso, PM; Gazak, RJ; Goldstein, LJ; Goodner, SA; Rader, JS; Schellens, JH; Slapak, CA; Wright, LP, 2004)	0.32
" Zosuquidar minimally alters the pharmacokinetics of docetaxel, allowing full dose docetaxel to be given with this P-glycoprotein modulator."	( Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Andre, VA; Arquette, MA; Burgess, MF; de Alwis, DP; Fears, CL; Fracasso, PM; Gazak, RJ; Goldstein, LJ; Goodner, SA; Rader, JS; Schellens, JH; Slapak, CA; Wright, LP, 2004)	0.32
" We examined the cytotoxic effects of imatinib in combination with other anticancer agents in the human prostate cancer cell lines LNCaP, PC-3, and DU 145."	( In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S, 2005)	0.33
" In combination with etoposide imatinib produced additive effects in two of three cell lines."	( In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S, 2005)	0.33
"Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of metastatic androgen-independent (hormone-refractory) prostate cancer."	( Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R, 2004)	0.32
"Capecitabine in combination with docetaxel given every 3 weeks has shown a high degree of activity in a number of tumor types, but at the expense of significant toxicity."	( Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Belani, CP; Chatta, GS; Egorin, MJ; Fakih, M; Friedland, DM; Jacobs, SA; Jung, LL; Potter, DM; Ramalingam, S; Ramanathan, RK; Shin, DM; Strychor, S; Tutchko, S; Zamboni, WC, 2005)	0.33
"The purpose of this study was to define the maximal tolerated dose (MTD), extramedullary toxicities, and pharmacokinetics of docetaxel combined with high-dose melphalan and carboplatin with autologous hematopoietic progenitor cell support."	( Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Barón, AE; Bearman, SI; Cagnoni, PJ; Gustafson, D; Jones, RB; Long, M; Matthes, S; McSweeney, PA; Nieto, Y; Shpall, EJ, 2005)	0.33
"Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity."	( Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Antón, A; Chan, S; Cognetti, F; Conte, P; Extra, JM; Green, M; Grimes, D; Kennedy, J; Lluch, A; Maraninchi, D; Marty, M; Mauriac, L; Mayne, K; O'Byrne, K; Snyder, R; Tubiana-Hulin, M; Ward, C, 2005)	0.33
" When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone."	( Which drug combination for hormone-refractory prostate cancer? Doggrell, SA, 2005)	0.33
" This open-label pilot trial investigated the safety, pharmacokinetics, and efficacy of 2 doses of gefitinib (250 and 500 mg per day) combined with docetaxel (75 mg/m2) in patients with locally advanced or metastatic NSCLC as first- and second-line chemotherapy."	( A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Buchholz, E; Fandi, A; Gatzemeier, U; Manegold, C; Smith, RP, 2005)	0.33
"0) in combination with exisulind (125-250 mg orally twice daily)."	( A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Kuhn, JG; Raefsky, EL; Thompson, DS; White, MB; Willcutt, NT, 2005)	0.33
" The present work has assessed the activity of NM-3 against human non-small-cell lung cancer (NSCLC) cells when used alone and in combination with docetaxel."	( The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S, 2005)	0.33
" Parthenolide was effective either alone or in combination with docetaxel in reducing colony formation, inducing apoptosis and reducing the expression of prometastatic genes IL-8 and the antiapoptotic gene GADD45beta1 in vitro."	( The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Badve, S; Campbell, RA; Kumar, S; Mehrotra, S; Murry, DJ; Nakshatri, H; Roman, Y; Sadaria, MR; Sheridan, C; Shortle, NH; Sweeney, CJ, 2005)	0.33
"Patients with solid tumors received one of three escalating dose levels of daily celecoxib in combination with docetaxel and irinotecan administered on days 1 and 8 of an every 21-day cycle."	( A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP, 2005)	0.33
"Published data suggests that docetaxel combined with 5-fluorouracil (5-FU) may have synergistic activity in treating advanced gastric cancer."	( Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. Bang, SM; Cho, EK; Chung, M; Lee, JH; Lee, WK; Park, SH; Shin, DB, 2005)	0.33
"The purpose of this study was to investigate the safety and tolerability of MS209, a potent inhibitor of P-glycoprotein, when given in combination with docetaxel and to determine whether MS209 affects docetaxel pharmacokinetics."	( Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Bonneterre, J; Bonneterre, ME; Degardin, M; Diéras, V; Fumoleau, P; Lacombe, D; Laurence, V; Marreaud, S; Pierga, JY, 2005)	0.33
" Pharmacokinetic analysis failed to show a strong pharmacokinetic interaction between the two compounds, but at the highest dose levels, there is a trend to an increase of docetaxel AUC when this agent is given in combination with MS209."	( Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Bonneterre, J; Bonneterre, ME; Degardin, M; Diéras, V; Fumoleau, P; Lacombe, D; Laurence, V; Marreaud, S; Pierga, JY, 2005)	0.33
"MS209 can be given in combination with docetaxel, with limited effect on docetaxel toxicity or pharmacokinetics."	( Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies. Bonneterre, J; Bonneterre, ME; Degardin, M; Diéras, V; Fumoleau, P; Lacombe, D; Laurence, V; Marreaud, S; Pierga, JY, 2005)	0.33
" Despite the experimental evidence of its radiosensitizing properties, trastuzumab has never been used in combination with radiotherapy for the treatment of patients with locally advanced disease."	( Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. Giatromanolaki, A; Koukourakis, MI; Liberis, V; Manavis, J; Simopoulos, C; Sivridis, E, 2005)	0.33
"Trastuzumab has been repeatedly shown to result in significant clinical benefits and was subsequently accepted as the treatment of choice for HER2-positive advanced breast cancer - particularly as first-line treatment in combination with taxanes and as monotherapy in the second-line or third-line setting."	( Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D, 2005)	0.33
" trastuzumab (8 mg/kg followed by 6 mg/kg) every 3 weeks in combination with chemotherapeutic agents administered in 3-weekly courses (docetaxel, vinorelbine and capecitabine) in 31 patients with HER2-positive recurrent locoregional and/or metastatic breast cancer."	( Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Alexopoulos, A; Ardavanis, A; Karamouzis, M; Orfanos, G; Rigatos, G; Scorilas, A; Tryfonopoulos, D, 2005)	0.33
"The primary objective of study is to evaluate cardiac safety of trastuzumab in combination with epirubicin and docetaxel."	( Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Bighin, C; Cappuzzo, F; Del Mastro, L; Durando, A; Lambiase, A; Monfardini, S; Nicoletto, O; Olmeo, N; Puglisi, F; Venturini, M, 2006)	0.33
" We have experienced four cases of esophageal cancer treated by weekly DOC in combination with concomitant radiotherapy."	( [Weekly docetaxel in combination with concomitant radiotherapy for esophageal cancer]. Ami, K; Ando, M; Nagahama, T; Ohbu, M, 2005)	0.33
" We performed intrathecal MTX and Ara-C in combination with systemic docetaxel treatments in the patient, a 44-year-old woman with carcinomatous meningitis from invasive lobular carcinoma previously treated with anthracycline and paclitaxel."	( [Improved quality of life in a patient with carcinomatous meningitis from invasive lobular carcinoma treated with intrathecal MTX and Ara-C in combination with systemic docetaxel]. Jida, M; Kubo, M; Maeda, H; Miyatani, K; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Yamane, M, 2005)	0.33
"This is the first study investigating neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with chemotherapy in patients with breast cancer."	( Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N, 2006)	0.33
" The patients received a neoadjuvant protocol consisting of systemic chemotherapy combined with fractionated HDR brachytherapy (2 x 5 Gy/day, total dose 30 Gy)."	( Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N, 2006)	0.33
" The MTD of DOC on the SS and CS in combination with CDDP (25 mg/m2/week) was 25 and 20 mg/m(2)/week, respectively."	( Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Fukuoka, M; Matsui, K; Nakagawa, K; Nishimura, Y; Yamamoto, N, 2006)	0.33
" Seventy-seven patients were randomly assigned to receive paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on day 1, in combination with 5-FU 500 mg/m2 continuous infusion on days 1-5."	( Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Bang, SM; Cho, EK; Chung, M; Han, SH; Lee, JH; Lee, WK; Lee, Y; Park, SH; Shin, DB, 2006)	0.33
" In this pilot Phase I trial, the authors evaluated the tolerability, efficacy, and pharmacokinetics of gefitinib combined with estramustine and docetaxel in patients with HRPC."	( Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G, 2006)	0.33
"The results of the current study demonstrated that gefitinib combined with estramustine and docetaxel had acceptable and predictable tolerability."	( Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G, 2006)	0.33
" Individual, selective sensitivities were found for each drug combination tested."	( Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Dietz, A; Dollner, R; Granzow, C; Neudert, M, )	0.13
" Preclinical studies have demonstrated synergistic antitumor activity when GEM231 is combined with docetaxel."	( A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers. Desai, K; Einstein, M; Fields, A; Goel, S; Goldberg, G; Macapinlac, M; Mani, S; Martin, R; Volterra, F; Wadler, S; Wong, B, 2006)	0.33
"We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC)."	( Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T, 2006)	0.33
"One-hundred fifty-eight treatment cycles were administered with a median of six cycles (range 1-15 cycles) per patient."	( Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Allen, J; Chen, HX; Dodley, A; Eckhardt, SG; Elias, AD; Hauger, M; Kelbick, NT; Kendra, K; Morrow, M; Ramaswamy, B; Rhoades, C; Shapiro, CL, 2006)	0.33
"Bevazicumab in combination with weekly docetaxel is active with acceptable toxicities in MBC."	( Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Allen, J; Chen, HX; Dodley, A; Eckhardt, SG; Elias, AD; Hauger, M; Kelbick, NT; Kendra, K; Morrow, M; Ramaswamy, B; Rhoades, C; Shapiro, CL, 2006)	0.33
" The authors hypothesized that the intratumoral administration of a nonreplicating adenoviral vector (Ad5) that contains the human wild-type p53, AdCMV-p53, combined with chemotherapy, could increase the efficacy of PST as measured by pathologic complete response."	( A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Arun, B; Booser, DJ; Broglio, K; Cristofanilli, M; Guerra, L; Hortobagyi, GN; Krishnamurthy, S; Menander, K; Valero, V; Van Wart Hood, J, 2006)	0.33
": Ad5CMV-p53 combined with PST is safe, active, and associated with local immunomodulatory effects."	( A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Arun, B; Booser, DJ; Broglio, K; Cristofanilli, M; Guerra, L; Hortobagyi, GN; Krishnamurthy, S; Menander, K; Valero, V; Van Wart Hood, J, 2006)	0.33
" The p53 status did not contribute directly to the effect of drug alone or in combination with radiation."	( Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Attarpour, M; Balcer-Kubiczek, EK; Jiang, J; Kennedy, AS; Suntharalingam, M, 2006)	0.33
"We report the first phase I trials of 2-methoxyestradiol (2ME2, Panzem Capsules, EntreMed, Rockville, MD), alone and in combination with docetaxel, in patients with metastatic breast cancer (MBC)."	( Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM, 2007)	0.34
" When combined with docetaxel, three patients had significant transaminase elevations that returned to normal with continued treatment (in two of three patients)."	( Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM, 2007)	0.34
"2ME2, alone or in combination with docetaxel, was well tolerated in patients with MBC but systemic exposure remained below the expected therapeutic range."	( Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. James, J; Miller, KD; Murry, DJ; Sidor, C; Sledge, GW; Storniolo, AM; Treston, AM, 2007)	0.34
" MZ-J-7-138 alone or in combination with docetaxel significantly reduced protein levels of K-Ras, Cox-2, and pAkt by 56-63%."	( Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Buchholz, S; Datz, C; Halmos, G; Heinrich, E; Hohla, F; Kanashiro, CA; Kannadka, C; Köster, F; Rick, FG; Schally, AV; Szepeshazi, K; Varga, JL, 2006)	0.33
"The TEXAS (Taxotere EXperience with Anthracyclines Study) study examined docetaxel in combination with an anthracycline, as first line treatment of metastatic breast cancer (MBC), in everyday practice, and compared the findings with a randomised controlled trial."	( TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Barrett-Lee, P; Grieve, R; Houston, S; Howell, A; Johnston, S; Leonard, R; Malinovszky, K; O'Reilly, S; Verrill, M; Wardley, A, 2007)	0.34
"Bortezomib has modest single-agent activity in patients with relapsed or refractory advanced NSCLC using this schedule, with minor enhancement in combination with docetaxel."	( Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S, 2006)	0.33
"To evaluate the efficacy and safety of combination chemotherapy of Docetaxel (Taxotere, TXT) combined with cisplatin (DDP) for anthracycline (ANT)-resistant advanced breast cancer (ABC)."	( [Docetaxel combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer]. Wang, JY; Xu, BH; Yuan, P; Zhao, LM, 2006)	0.33
"A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC)."	( A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R, 2007)	0.34
" In the present study, we evaluate the antitumour effects of docetaxel combined with trastuzumab (Herceptin), an anti-HER2 antibody."	( Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Boyé, K; de Cremoux, P; de Pinieux, G; Dutrillaux, B; Guyader, C; Judde, JG; Legrier, ME; Oudard, S; Poupon, MF, 2007)	0.34
"The proteasome inhibitor PS-341 (Bortezomib, Velcade) is currently being combined with taxanes in several clinical trials for treatment of patients with various solid tumors including lung cancers."	( Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Jung, CS; Khuri, FR; Sun, SY; Zhou, Z, 2007)	0.34
"Although the high incidence of febrile neutropenia necessitated a multiple scheduling adaptation of tipifarnib compared to the original protocol, the apparent lack of mutual pharmacokinetic interactions, the ability to coadminister tipifarnib and docetaxel near single-agent MTDs, and suggestive evidence of efficacy make this drug combination attractive for further examination."	( A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Awada, A; De Porre, P; de Valeriola, D; Gil, T; Lalami, Y; Piccart-Gebhart, MJ; Zhang, S, 2007)	0.34
" In vitro, gefitinib, an orally administered tyrosine kinase inhibitor, has shown a significant increase in antitumor activity when combined with chemotherapy."	( An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G, 2007)	0.34
"In this phase II study, the safety and efficacy of gefitinib in combination with docetaxel, a chemotherapeutic agent commonly used for prostate cancer, was investigated in patients with hormone-refractory prostate cancer (HRPC)."	( An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G, 2007)	0.34
"Dose escalation studies were performed with eight squamous cell carcinoma cell lines using bortezomib alone or in combination with TAX or CDDP."	( Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J, 2008)	0.35
" In patients with lung cancer, motexafin gadolinium has been shown to increase the time to neurologic progression when given in combination with whole-brain radiotherapy in randomized phase III studies."	( Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. Glisson, BS; Karp, DD; Oh, YW; Phan, SC; Stewart, DJ; William, WN; Zinner, RG, 2007)	0.34
" FK228 appears to be a promising second-line option in combination with docetaxel."	( Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. Frenkel, E; Hsieh, JT; Kabbani, W; Stanfield, J; Zhang, Z, 2007)	0.34
" The patient consented to and received 2 courses of systemic chemotherapy consisting of cisplatin (CDDP 40 mg/m(2); day 1, 8) and docetaxel (DOC 40 mg/m(2); day 1, 8) combined with concurrent radiation (2 Gy/day; total 46 Gy) with no severe adverse events."	( [Successfully resected stage IIIA non-small cell lung cancer with mediastinal lymphnode metastasis after chemotherapy of cisplatin and docetaxel combined with concurrent radiation]. Fujiwara, T; Kagawa, S; Takeda, H; Takigawa, N; Tanaka, N; Teraishi, F; Uno, F, 2007)	0.34
"We performed a phase I/II study of bi-weekly docetaxel in combination with concurrent radiotherapy to enhance the cytotoxic effect and radiosensitization and improve the rate of laryngeal preservation."	( A phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx. Abe, K; Hiramatsu, H; Itoh, H; Nakamura, K; Okamoto, I; Shimizu, S; Suzuki, M; Takada, D; Tokashiki, R; Tsukahara, K; Yoshida, T, 2007)	0.34
"The purpose of this trial was to define the maximum tolerated duration (MTD), dose-limiting toxicity (DLT), regimen-related toxicities (RRT), and pharmacokinetics of gemcitabine infused at a fixed dose rate (FDR) of 10 mg/m2/min, combined with docetaxel/melphalan/carboplatin, using autologous stem cell transplantation (ASCT)."	( Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L, 2007)	0.34
"To observe the effects and toxicity of docetaxel given once weekly combined with cisplatin and 5-fluororacil in the treatment of advanced gastric cancer (AGC)."	( [Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer]. Ye, S; Zhang, AM, 2007)	0.34
"Weekly dosage of docetaxel combined with cisplatin and 5-fluororacil is an effective regimen for AGC with only mild toxic reactions and good patient tolerance."	( [Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer]. Ye, S; Zhang, AM, 2007)	0.34
" Patients in the treatment group (34 patients) received chemotherapy of DCF (docetaxel/cisplatin/5-fluorouracil) regimen combined with Chinese herbal medicine, and patients in the control group (32 patients) were treated with chemotherapy of the same regimen alone."	( [Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction]. Gao, H; Wang, HB; Wang, HZ, 2007)	0.34
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))."	( Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007)	0.34
" Because intratumoral delivery of therapeutic agents has limited clinical application, the present study was undertaken to examine the therapeutic mechanisms of systemically delivered phosphorothioate-modified EGFR antisense oligonucleotides alone, or in combination with docetaxel, in a SCCHN xenograft model."	( Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Freilino, ML; Gooding, WE; Grandis, JR; Ogagan, MJ; Strychor, S; Thomas, SM; Walsh, DR; Zamboni, WC, 2008)	0.35
"5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer."	( The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. McKeage, MJ, 2008)	0.35
"Inhibition of MEK is cytostatic as a monotherapy in melanoma, but cytotoxic when combined with docetaxel."	( The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Contractor, R; Haass, NK; Herlyn, M; Medina, CA; Nathanson, KL; Nguyen, TK; Smalley, KS; Sproesser, K, 2008)	0.35
"To determine the safety profile and activity of IP docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer, a multi-centric phase I/II study has started."	( [A multi-centric phase I/II study of intraperitoneal docetaxel combined with S-1 for patients with peritoneal dissemination of gastric cancer]. Fujimura, T; Fukushima, N; Fushida, S; Goda, F; Hirono, Y; Imano, M; Kaji, M; Kurita, A; Kurita, N; Nashimoto, A; Ohta, T; Tanemura, H; Tsujitani, S; Watanabe, Y; Yamaguchi, K, 2007)	0.34
" The objective of this study was to determine a recommended phase II dose of OGX-011 in combination with docetaxel."	( A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Chi, KN; Eisenhauer, E; Gleave, M; Guns, E; Hirte, H; Hotte, SJ; Knox, J; Kollmansberger, C; Powers, J; Siu, LL; Tu, D; Walsh, W, 2008)	0.35
"This study aimed to define the maximum tolerated dose of weekly docetaxel combined with daily erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor."	( A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M, 2008)	0.35
"Although no maximum tolerated dose was reached in cycle 1 with 35 mg/m(2) docetaxel, repetitive dosing proved intolerable in a substantial number of patients; thus, the recommended phase II dose of weekly docetaxel is 30 mg/m(2) when combined with 150 mg of daily erlotinib."	( A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M, 2008)	0.35
"To determine the maximum-tolerated dose (MTD) of a 24-h continuous infusion of 5-fluorouracil (5-FU) when administered in combination with a fixed weekly dose of docetaxel and cisplatin in patients with advanced gastric cancer."	( Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer. Guo, Y; Hong, X; Li, J; Wang, B; Zhang, W, 2009)	0.35
" The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid."	( RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL, 2008)	0.35
"We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC)."	( Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Bae, JM; Choi, IJ; Kim, CG; Kim, HK; Kim, NK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW, 2008)	0.35
" This multicentric phase I study was carried out to evaluate maximum tolerated dose (MTD), safety and preliminary efficacy of oblimersen in combination with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment (NST) in primary breast cancer (PBC)."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	0.35
"Previously untreated patients with PBC T2-4a-c N0-3 M0 received one cycle of docetaxel 75 mg/m(2), adriamycin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) administered on day 5 combined with escalating doses of oblimersen as a 24-h continuous infusion on days 1-7 followed by five cycles of combination of docetaxel, adriamycin and cyclophosphamide (TAC) without oblimersen every 3 weeks."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	0.35
" Following oblimersen combined with TAC, the most severe toxicity was neutropenia [National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grades 1-2/3/4] which developed in 0/0/56% of patients (cohort I), 11/0/56% of patients (cohort II) and 20/20/50% of patients (cohort III)."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	0.35
"Oblimersen up to a dose of 7 mg/kg/day administered as a 24-h infusion on days 1-7 can be safely administered in combination with standard TAC on day 5 as NST in patients with PBC."	( Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Eichbaum, M; Eiermann, W; Kaufmann, M; Marmé, F; Rom, J; Scharf, A; Schlehe, B; Schneeweiss, A; Schuetz, F; Sievert, M; Sinn, HP; Sohn, C; von Minckwitz, G, 2008)	0.35
"The aim of the study was to evaluate the activity of the antiangiogenic agent SU-11248 (sunitinib malate, Sutent), alone or in combination with docetaxel."	( Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cumashi, A; Iacobelli, S; Lattanzio, R; Natoli, C; Piantelli, M; Rossi, C; Tinari, N, 2008)	0.35
" This study was conducted to determine the activity of imatinib in combination with docetaxel in patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC)."	( Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Baldridge, LA; Breen, T; Emerson, RE; Johnson, CS; Matei, D; McClean, J; Menning, N; Schilder, J; Stephens, D; Sutton, G; Whalen, C, 2008)	0.35
" and oral vinorelbine in combination with docetaxel."	( Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Blasinska-Morawiec, M; Brandely, M; Campone, M; Douville, I; Koralewski, P; Pouget, JC; Tekiela, A, 2009)	0.35
" vinorelbine in combination with docetaxel is effective and manageable."	( Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Blasinska-Morawiec, M; Brandely, M; Campone, M; Douville, I; Koralewski, P; Pouget, JC; Tekiela, A, 2009)	0.35
" Chemotherapy combined with trastuzumab can significantly improve the treatment efficacy and survival of Her-2/neu overexpressing breast cancer patients."	( [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer]. Jiang, WQ; Lin, XB; Liu, DG; Teng, XY; Zhong, JT; Zhou, NN, 2008)	0.35
"Trastuzumab combined with docetaxel is an effective and well-tolerated therapy for Her-2/neu overexpressing metastatic breast cancer."	( [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer]. Jiang, WQ; Lin, XB; Liu, DG; Teng, XY; Zhong, JT; Zhou, NN, 2008)	0.35
" When administered in combination with carboplatin and docetaxel, a commonly used regimen for advanced NSCLC, cetuximab has exhibited synergistic interaction in preclinical studies."	( Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Belani, CP; Butler, EH; Guidice, RA; Marsland, TA; Ramalingam, SS; Schreeder, MT; Steis, RG, 2008)	0.35
"Preclinical data showed enhancement of breast cancer cell death when G3139 was combined with anthracyclines and taxanes."	( Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J, 2008)	0.35
" for 5 days) in combination with AT."	( Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J, 2008)	0.35
"G3139 in combination with doxorubicin and docetaxel is well tolerated."	( Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Booser, DJ; Brewster, AM; Buchholz, TA; Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hunt, KK; Lipsanen, C; Madden, TL; Moulder, SL; Symmans, WF; Valero, V; Yuan, L; Zwiebel, J, 2008)	0.35
"Cetuximab in combination with docetaxel was examined in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer (NSCLC) to determine response rate, survival, safety, and pharmacokinetics (PK)."	( A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Herbst, RS; Hong, WK; Kim, ES; Lee, JJ; Liu, D; Mauer, AM; Tran, HT; Vokes, EE; William, WN; Windt, P, 2009)	0.35
"Cetuximab in combination with docetaxel was well tolerated."	( A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Herbst, RS; Hong, WK; Kim, ES; Lee, JJ; Liu, D; Mauer, AM; Tran, HT; Vokes, EE; William, WN; Windt, P, 2009)	0.35
"The aim of this study was to investigate the inhibitory effects of cytokine-induced killer (CIK) cells combined with docetaxel (DTX) on the growth of drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo."	( The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Chen, L; Huang, X; Liu, P, 2009)	0.35
" On the day 14, normal saline, docetaxel, CIK cells, and CIK cells combined with docetaxel were administered intraperitoneally, respectively."	( The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Chen, L; Huang, X; Liu, P, 2009)	0.35
" The animal data also suggested that CIK cells combined with DTX had a stronger suppressive effect on tumor growth in vivo."	( The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Chen, L; Huang, X; Liu, P, 2009)	0.35
" In the present study, we conducted a phase I study to examine local control of S-1 in the combination with DOC using super-selective intra-arterial infusion with oral cancer."	( [Clinical phase I trial of S-1 in the combination with DOC using super-selective intra-arterial infusion with oral cancer]. Harada, K; Horinaga, D; Mano, T; Mihara, M; Okafuji, M; Uchida, K; Ueyama, Y; Wada, N, 2009)	0.35
"We conducted a phase II study to evaluate the efficacy and toxicity of weekly docetaxel combined with epirubicin on D15 as second-line chemotherapy in Taiwanese patients with advanced non small cell lung cancer (NSCLC) who failed or relapsed after the frontline platinum-based chemotherapy."	( Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Chang, JW; Chen, CH; Lin, CM; Tsao, TC, 2009)	0.35
"To evaluate the effects and toxicity of the neoadjuvant chemotherapy of docetaxel combined with epirubicin or pirarubicin on breast cancer, and to investigate the influencing factors of the response to neoadjuvant chemotherapy."	( [Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases]. Chen, YQ; Jin, YC; Kong, QL; Li, J; Li, R; Li, XR; Ma, B; Wang, JD; Zhang, YJ; Zheng, YQ, 2009)	0.35
" This trial was designed to establish the maximum tolerated dose (MTD) of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC)."	( A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Boytim, M; Dhillon, N; Dorr, R; Hersh, E; Hong, D; Kurzrock, R; La Paglia, A; Moulder, S; Naing, A; Ng, C; Tse, S; Wheler, J, 2010)	0.36
" The MTD was imexon 1,300 mg/m(2) IV on days 1-5 in combination with docetaxel."	( A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Boytim, M; Dhillon, N; Dorr, R; Hersh, E; Hong, D; Kurzrock, R; La Paglia, A; Moulder, S; Naing, A; Ng, C; Tse, S; Wheler, J, 2010)	0.36
" Along with the case studies, several hurdles for drug development such as dose selection, frequency of dosing, and duration of the clinical studies, picking the right surrogate(s) for efficacy, evaluation of drug-drug interaction potential with other co-substrates have been discussed in line with the current day requirements for a sound clinical and regulatory strategy."	( Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Srinivas, NR, 2009)	0.35
"To evaluate the efficacy of Endosteal(TM) (rh-endostatin, YH-16) combined with docetaxel and carboplatin (TP) regimen for the adjuvant treatment of non-small lung cancer (NSCLC) and its impact on circulating blood markers."	( [rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer]. Cui, Y; Feng, K; Liu, ZJ; Qi, DL; Qiao, YF; Wang, QS; Xin, L; Yang, YZ, 2009)	0.35
"Endosteal(TM) combined with TP regimen seem to be superior to TP alone in some short term index for the treatment of postoperative NSCLC even though long-term survival is still anticipated."	( [rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer]. Cui, Y; Feng, K; Liu, ZJ; Qi, DL; Qiao, YF; Wang, QS; Xin, L; Yang, YZ, 2009)	0.35
"To evaluate the efficacy of hypofractionated radiotherapy combined with docetaxel for treatment of bone metastasis of lung cancer and explore the factors related to the prognosis."	( [Efficacy of hypofractionated radiotherapy combined with docetaxel for treatment of bone metastasis of lung cancer]. Feng, ZF; Liu, X; Liu, ZM; Song, HS; Tang, RM, 2009)	0.35
"This study investigated the safety, pharmacokinetics (PK) and clinical antitumor activity of ABT-751, a novel sulfonamide antimitotic and vascular disrupting agent, in combination with docetaxel (Taxotere) in patients with castration-resistant prostate cancer (CRPC)."	( A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Carr, R; Chi, KN; Ellard, SL; Kollmannsberger, C; Le, L; Michels, J; Murray, N; Tomlinson Guns, ES, 2010)	0.36
"As there is no standard treatment for advanced gastric cancer refractory to first-line chemotherapy, the feasibility of S-1 plus weekly docetaxel combined with concurrent radiotherapy was evaluated."	( Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy. Fujitani, K; Hirao, M; Kurokawa, Y; Tsujinaka, T; Yamasaki, H; Yoshida, K, 2009)	0.35
"S-1 plus weekly docetaxel combined with concurrent RT exhibited a tolerable toxicity profile with sufficient symptom palliation and prolonged survival in patients with advanced gastric cancer refractory to first-line chemotherapy."	( Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy. Fujitani, K; Hirao, M; Kurokawa, Y; Tsujinaka, T; Yamasaki, H; Yoshida, K, 2009)	0.35
" The current report describes four patients with advanced/metastatic breast cancer who experienced clinically meaningful responses following treatment with sunitinib in combination with docetaxel."	( Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Bergh, J; Castany, R; Liljegren, A, 2009)	0.35
" The purpose of this phase II study was to evaluate the activity and safety of cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma."	( Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Artale, S; Bardelli, A; Barone, C; Cascinu, S; Di Fabio, F; Falcone, A; Giannetta, L; Giaquinta, S; Martoni, AA; Mutri, V; Pinto, C; Rojas Llimpe, FL; Schinzari, G; Siena, S; Stella, G, 2009)	0.35
" While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics."	( Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. Halldén, G, 2009)	0.35
"The objective of this study was to evaluate the efficacy and toxicity of docetaxel in combination with prednisolone in Japanese patients with hormone refractory prostate cancer."	( Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M, 2010)	0.36
"Patients received non-pegylated liposomal doxorubicin in combination with either cyclophosphamide (n = 14) or docetaxel (n = 20) for up to eight cycles, and efficacy and safety were assessed according to standard criteria."	( Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis. Biti, G; Bruni, A; Cardillo, Cde L; Cataliotti, L; Galardi, A; Greto, D; Livi, L; Mangoni, M; Meattini, I; Petrucci, A; Rampini, A, )	0.13
" We explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study."	( Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA, 2009)	0.35
"We conducted a multicentre open-label phase I/II trial of PI-88 in combination with docetaxel."	( Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Begbie, S; Boyce, A; de Souza, P; Harvie, R; Khasraw, M; Lim, V; Marx, G; McCowatt, S; Parnis, F; Pavlakis, N; Underhill, C, 2010)	0.36
"This phase II study is performed to evaluate the safety, efficacy and tolerability of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer (NSCLC)."	( Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer. Hou, XH; Jiang, L; Tang, LF; Wang, DF; Wang, DY; Xie, Z; Zhao, HD; Zhu, ZH, 2010)	0.36
"Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC."	( Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010)	0.36
"The purpose of the study was to explore the antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation (UTMA) on VX2 rabbit liver tumors."	( Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. Kang, J; Ran, H; Wang, Z; Wu, J; Wu, X; Xu, C; Zhang, Y, 2010)	0.36
" VX2 liver tumor models were established in 90 rabbits, which were randomly divided into 6 groups, including control, docetaxal-loaded lipid microbubbles alone, docetaxal alone, docetaxal combined with ultrasound, pure lipid microbubbles combined with ultrasound, and docetaxel-loaded lipid microbubbles combined with ultrasound (DOC+MB/US)."	( Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. Kang, J; Ran, H; Wang, Z; Wu, J; Wu, X; Xu, C; Zhang, Y, 2010)	0.36
"Docetaxel-loaded lipid microbubbles combined with UTMA could inhibit the growth of VX2 rabbit liver tumors by deferring proliferation and promoting apoptosis, which may provide a novel targeted strategy for chemotherapy of liver carcinoma."	( Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. Kang, J; Ran, H; Wang, Z; Wu, J; Wu, X; Xu, C; Zhang, Y, 2010)	0.36
"Sunitinib in combination with docetaxel enhances antitumor activity in xenograft models of human breast and non-small cell lung cancer."	( Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L, 2010)	0.36
" There were no pharmacokinetic drug-drug interactions with either schedule."	( Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L, 2010)	0.36
"5 mg/day on Schedule 2/1 with docetaxel 75 mg/m(2) IV q21d is a clinically feasible regimen with a manageable safety profile, no pharmacokinetic drug-drug interactions, and shows antitumor activity in patients with advanced solid tumors."	( Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L, 2010)	0.36
" MK-5108 is currently tested in clinical trials and offers a new therapeutic approach to combat human cancers as a single agent or in combination with existing taxane therapies."	( MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Hasako, S; Ichikawa, K; Iwasawa, Y; Kawanishi, N; Kodera, T; Kotani, H; Miki, S; Mita, T; Miyamoto, M; Nakatsuru, Y; Nambu, T; Ohkubo, M; Sakai, T; Shimomura, T; Takahashi, I, 2010)	0.36
"We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.37
"Intetumumab was generally safe and well tolerated in combination with docetaxel, with a higher incidence of TEAEs in the 10 mg/kg dose cohort."	( A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)	0.37
"To evaluate the cardiotoxicity, general toxicity, and activity of non-pegylated liposomal doxorubicin, in combination with docetaxel and trastuzumab, as first-line therapy in metastatic breast cancer."	( A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Aitini, E; Baconnet, B; Barbato, A; Bighin, C; Colucci, G; Crinò, L; Del Mastro, L; Garrone, O; Mansutti, M; Marini, G; Olmeo, N; Paccagnella, A; Puglisi, F; Venturini, M, 2010)	0.36
" Paclitaxel was delivered at 80-100mg/m2 on days 1 and 8 (11 cases), or 50-80 mg/m2 on days 1, 8 and 15 (23 cases), while docetaxel was given with the same schedules at 35-45 mg/m2 (30cases), or 25-35 mg/m2 (14 cases)."	( Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Huang, XE; Jiang, W; Li, C; Lin, Y; Shi, MQ; Shu, YQ; Sunh, WL; Ye, Z; Zhang, Q; Zhou, JN, 2009)	0.35
" We aimed to define the maximum tolerated dose, toxicity, activity, and pharmacokinetics of oral panobinostat, a pan-deacetylase inhibitor, alone and in combination with docetaxel for the treatment of castration-resistant prostate cancer (CRPC)."	( A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W, 2010)	0.36
" In arm II, oral panobinostat (15 mg) was administered on the same schedule in combination with docetaxel 75 mg/m(2) every 21 days."	( A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W, 2010)	0.36
" Treatment consisted of capecitabine (2,000 mg/m(2) days 1-14) in combination with docetaxel (40 mg/m(2) day 1) and mitomycin C (4 mg/m(2) day 1)."	( Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010)	0.36
" This study evaluated inhaled doxorubicin combined with cisplatin and docetaxel in patients with non-small cell lung cancer."	( Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Ellerton, JA; Gettinger, SN; Hicks, W; Murren, JR; Otterson, GA; Pan, X; Villalona-Calero, MA, 2010)	0.36
" We investigated the in vitro and in vivo activities of sunitinib as single agent and in combination with cisplatin or docetaxel in NPC cell lines and tumor xenografts."	( Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Wong, CS, 2011)	0.37
" When combined with chemotherapy, sequential instead of concurrent administration schedule should be further explored."	( Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Wong, CS, 2011)	0.37
" Here we report greatly improved antitumor efficacy for both attenuated (dl1520) and highly potent (dl922–947) oncolytic mutants in combination with the current standard of care for late-stage hormone-independent prostate cancers, mitoxantrone or docetaxel."	( Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Ekblad, M; Halldén, G; Holford, A; Lemoine, NR; Miranda, E; Pizarro, MT; Radhakrishnan, S, 2010)	0.36
" The effect of CN in combination with docetaxel on prostate cancer cell lines in vitro and in vivo is evaluated in the present study."	( The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Groshen, S; Jadvar, H; Lin, E; Markland, FS; Pinski, J; Swenson, S; Wang, Q; Ye, W, 2010)	0.36
"This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel."	( The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Arkenau, HT; de Bono, JS; Demers, L; Fong, PC; Gualberto, A; Karavasilis, V; Leitzel, K; Lipton, A; Molife, LR; Olmos, D; Paccagnella, L; Postel-Vinay, S; Reid, AH; Shaw, HM; Spicer, J; Vidal, L; Yap, TA; Yin, D, 2010)	0.36
" Vorinostat and docetaxel pharmacokinetics were comparable to previous reports in the literature, without obvious drug-drug interactions."	( Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC, 2012)	0.38
"Docetaxel is one of the few chemotherapeutic drugs that are considered highly effective when used to treat prostate cancer patients that have relapsed and/or metastatic disease, it is therefore reasonable to expect further improvements in treatment outcomes when it is combined with other therapeutic agents active in prostate cancer."	( Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E, 2010)	0.36
"Rh2 and aPPD can be combined with docetaxel to yield additive or synergistic activity in vitro and in vivo."	( Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E, 2010)	0.36
"To evaluate the efficacy and safety of weekly or 3-week docetaxel in combination with capecitabine."	( [A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer]. Bai, YX; Cheng, Y; Jiang, ZF; Jiao, SC; Li, X; Liu, DQ; Liu, JW; Liu, WC; Ren, J; Sun, Q; Tang, LL; Wang, HQ; Wang, Y; Wang, YS; Wei, Y; Xiao, JX; Xie, XD; Zhang, SH, 2010)	0.36
" Here we report the results of a pharmacokinetic and pharmacodynamic trial using a third-generation, potent, noncompetitive inhibitor of Pgp, tariquidar (XR9576), in combination with docetaxel."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.37
"In the first treatment cycle, the pharmacokinetics of docetaxel (40 mg/m(2)) were evaluated after day 1 and day 8 doses, which were administered with or without tariquidar (150 mg)."	( A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM, 2011)	0.37
"To observe and analyze the antitumor effect of endostar combined with docetaxel under different administration sequences."	( [Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences]. Li, K; Liu, ZJ; Wei, XY; Wu, CW; Yuan, J, 2010)	0.36
" We conducted this study to investigate its efficacy and safety when combined with chemotherapy in patients with advanced solid tumors."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)	0.36
"5 mg/m2 /day as an intravenous infusion for more than 7 days, in combination with chemotherapy."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)	0.36
"Our study revealed that toxicity of Endostar combined with chemotherapy in the treatment of solid tumors was tolerable with moderate efficacy."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)	0.36
"To investigate the therapeutical effect and side-effect of docetaxel combined with cisplatin (DDP) on the treatment of local advanced esophageal cancer with concomitant radiation therapy."	( [Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy]. Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T, 2010)	0.36
" The aim of this study was to evaluate the activity and safety of capecitabine combined with weekly docetaxel for the treatment of anthracycline-resistant metastatic breast cancer (MBC) in older Chinese patients."	( Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer. Hao, XS; Hou, Y; Li, LF; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Xie, CH; Zhang, HL; Zhou, SY, 2010)	0.36
" Efficacy and tolerability compare favourably with previously reported trials evaluating higher capecitabine doses in combination with 3-weekly or weekly docetaxel."	( Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer. Hao, XS; Hou, Y; Li, LF; Liu, XM; Qian, ZZ; Qiu, LH; Wang, HQ; Xie, CH; Zhang, HL; Zhou, SY, 2010)	0.36
"A phase II trial to evaluate Im in combination with D in patients with recurrent NSCLC was conducted."	( Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK, 2011)	0.37
"Im in combination with D did not achieve its primary objective of improving response rate in patients with recurrent NSCLC."	( Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK, 2011)	0.37
" We evaluated the efficacy of TRA-8, an agonistic antibody to DR5, combined with docetaxel and carboplatin in vitro in an intraperitoneal (IP) ovarian cancer model."	( Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Amm, H; Bevis, KS; Buchsbaum, DJ; Della Manna, D; Londoño Joshi, A; McNally, LR; Sellers, JC; Straughn, JM, 2011)	0.37
"Conventional chemotherapy combined with TRA-8 reduced cell-viability via activation of apoptotic pathways, reduced tumor burden and improved survival in this ovarian cancer model."	( Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Amm, H; Bevis, KS; Buchsbaum, DJ; Della Manna, D; Londoño Joshi, A; McNally, LR; Sellers, JC; Straughn, JM, 2011)	0.37
"To compare the curative effect, safety and survival of Nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced NSCLC."	( [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer]. Chen, ZW; Gu, LP; Shen, SP, 2010)	0.36
"From Sep 2005 to Mar 2009, fifty-eight patients with NSCLC treated in the Shanghai Chest Hospital who failed first-line chemotherapy and receiving docetaxel or docetaxel combined with nedaplatin were retrospectively analyzed."	( [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer]. Chen, ZW; Gu, LP; Shen, SP, 2010)	0.36
"Compared with the treatment with docetaxel alone, Nedaplatin combined with docetaxel as a second line treatment for NSCLC has a better curative effect and acceptable toxicity."	( [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer]. Chen, ZW; Gu, LP; Shen, SP, 2010)	0.36
"Neoadjuvant docetaxel combined with cisplatin yielded a high response rate with well tolerable toxicity for LACC and could decrease pathological risk factors in NAC responders."	( Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience. Cao, X; Guo, Y; Huang, H; Huang, X; Huang, Y; Lan, C; Liu, J; Wan, T; Zhang, Y, 2011)	0.37
"Part A was an open-label, dose-finding phase to determine the safety and toxicity profile of zibotentan in combination with docetaxel."	( Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Burris, HA; de Bono, JS; Hubner, A; Miller, K; Morris, T; Nathan, F; Payne, H; Stephenson, J; Taboada, M; Trump, DL, 2011)	0.37
" No dose-limiting toxicity was observed, thus zibotentan 15 mg in combination with docetaxel was evaluated in part B (n = 20, zibotentan plus docetaxel; n = 11, placebo plus docetaxel)."	( Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Burris, HA; de Bono, JS; Hubner, A; Miller, K; Morris, T; Nathan, F; Payne, H; Stephenson, J; Taboada, M; Trump, DL, 2011)	0.37
" Disease progression was followed in animals treated with Dt alone and in combination with QLT0267, an Integrin Linked Kinase inhibitor."	( Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor Anantha, M; Bally, MB; Kalra, J; Masin, D; Osooly, M; Strut, D; Warburton, C; Waterhouse, D; Yan, H; Yang, YJ, 2011)	0.37
"In pre-clinical models enhanced anti-tumour activity was observed when SU-014813, an oral multi-targeted tyrosine kinase inhibitor was combined with docetaxel."	( Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J, 2011)	0.37
"In this phase I study successive patient cohorts received docetaxel 60 or 75mg/m(2) every 3weeks in combination with chronic daily dosing of SU-014813."	( Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J, 2011)	0.37
" The recommended phase II dose was determined to be docetaxel 75mg/m(2) in combination with SU-014813 50mg/day."	( Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J, 2011)	0.37
" Based on 3 dose limiting toxicities (DLT) (grade 4 neutropenia) in 13 patients at dose levels 1 and -1 (docetaxel 60 mg/m(2) plus satraplatin 40 mg/m(2) and docetaxel 60 mg/m(2) plus satraplatin 50 mg/m(2)) GCSF was administered with subsequent cohorts."	( A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Cetnar, J; Eickhoff, J; Liu, G; LoConte, NK; McFarland, TA; McNeel, D; Wilding, G, 2013)	0.39
"To test the efficacy and safety of a triweekly reduced-dose docetaxel (60 mg/m(2)) regimen combined with a standard dose of cisplatin in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)."	( Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Chang, PM; Chang, SY; Chang, YF; Chen, MH; Hwang, WS; Su, WC; Tsao, CJ; Tzeng, CH; Yang, MH, 2011)	0.37
" All eligible patients received intravenous docetaxel 60 mg/m(2) combined with cisplatin 75 mg/m(2) on day 1 and then every 3 weeks thereafter."	( Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Chang, PM; Chang, SY; Chang, YF; Chen, MH; Hwang, WS; Su, WC; Tsao, CJ; Tzeng, CH; Yang, MH, 2011)	0.37
"Triweekly reduced-dose docetaxel 60 mg/m(2) combined with cisplatin is effective and feasible for Taiwanese patients with R/M HNSCC."	( Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Chang, PM; Chang, SY; Chang, YF; Chen, MH; Hwang, WS; Su, WC; Tsao, CJ; Tzeng, CH; Yang, MH, 2011)	0.37
" The objective of this study was to evaluate retrospectively the efficacy and toxicity of low-dose docetaxel in combination with dexamethasone."	( [Low-dose docetaxel in combination with dexamethasone for hormone-refractory prostate cancer]. Aoki, K; Azuma, K; Kikugawa, T; Miura, N; Nishida, T; Sasaki, T; Sato, H; Shimamoto, K; Takeda, H; Tanji, N; Yanagihara, Y; Yokoyama, M, 2011)	0.37
"0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy."	( Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. Debus, J; Desta, A; Habl, G; Jensen, AD; Krauss, J; Mavtratzas, A; Münter, MW; Potthoff, K; Windemuth-Kiesselbach, C, 2011)	0.37
"The primary objective of TPF-C-HIT is to evaluate efficacy and toxicity of cetuximab in combination with combined IMRT/carbon ion therapy following TPF induction in locally advanced SCCHN."	( Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. Debus, J; Desta, A; Habl, G; Jensen, AD; Krauss, J; Mavtratzas, A; Münter, MW; Potthoff, K; Windemuth-Kiesselbach, C, 2011)	0.37
"This paper presents a summary of the evidence review group (ERG) report into the use of bevacizumab (Avastin®, Roche) in combination with a taxane for the treatment of untreated metastatic breast cancer (mBC)."	( Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H, 2011)	0.37
" conclusion: The MTD of docetaxel was 30 mg/m(2) in combination with daily bexarotene at 400mg/m(2)."	( A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors. Collins, B; Hwang, J; Malik, SM; Marshall, J; Pishvaian, M; Ramzi, P, 2011)	0.37
" Here, we evaluated the therapeutic potential of YM155, a selective survivin suppressant, alone and in combination with docetaxel using human melanoma models."	( Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Kaneko, N; Kita, A; Kiyonaga, F; Nakahara, T; Sasamata, M; Takeuchi, M; Yamanaka, K; Yamauchi, T, 2011)	0.37
" Furthermore, the efficacy of YM155 combined with docetaxel was further examined in established xenograft models."	( Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Kaneko, N; Kita, A; Kiyonaga, F; Nakahara, T; Sasamata, M; Takeuchi, M; Yamanaka, K; Yamauchi, T, 2011)	0.37
" YM155 in combination with docetaxel is well tolerated and shows greater efficacy than either agent alone in mouse xenograft models."	( Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Kaneko, N; Kita, A; Kiyonaga, F; Nakahara, T; Sasamata, M; Takeuchi, M; Yamanaka, K; Yamauchi, T, 2011)	0.37
"To evaluate the therapeutic effect and toxicity of intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy combined with chemotherapy (3-DCRT) with docetaxel and cisplatin in the treatment of locally advanced esophageal carcinoma."	( [Intensity-modulated or 3-D conformal radiotherapy combined with chemotherapy with docetaxel and cisplatin for locally advanced esophageal carcinoma]. Lin, XD; Shi, XY; Zhang, WJ; Zhou, TC, 2011)	0.37
"Sixty patients with locally advanced esophageal carcinoma were randomly assigned in two equal groups to receive IMRT or 3-DCRT, both combined with the chemotherapy with docetaxel and cisplatin."	( [Intensity-modulated or 3-D conformal radiotherapy combined with chemotherapy with docetaxel and cisplatin for locally advanced esophageal carcinoma]. Lin, XD; Shi, XY; Zhang, WJ; Zhou, TC, 2011)	0.37
"When combined with the chemotherapy with docetaxel and cisplatin, IMRT appears to be a more effective treatment than 3-DCRT for locally advanced esophageal cancer."	( [Intensity-modulated or 3-D conformal radiotherapy combined with chemotherapy with docetaxel and cisplatin for locally advanced esophageal carcinoma]. Lin, XD; Shi, XY; Zhang, WJ; Zhou, TC, 2011)	0.37
"The present study was conducted to determine the efficacy of novel flavonoid vicenin-2 (VCN-2), an active constituent of the medicinal herb Ocimum Sanctum Linn or Tulsi, as a single agent and in combination with docetaxel (DTL) in carcinoma of prostate (CaP)."	( Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Awasthi, S; Fast, S; Nagaprashantha, LD; Roby, R; Singhal, J; Singhal, SS; Vatsyayan, R, 2011)	0.37
"This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients."	( Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ, 2012)	0.38
"This Phase I study was carried out to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the flavonoid tumor-vascular disrupting agent ASA404 (vadimezan) in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors."	( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011)	0.37
" Overall, the study demonstrated that ASA404 has an acceptable tolerability profile when combined with docetaxel at doses up to 75 mg/m(2) in Japanese patients with advanced solid tumors."	( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011)	0.37
"The study supports the enrollment of Japanese patients in the Phase III study (ATTRACT-2) of ASA404 in combination with docetaxel for the second-line treatment of advanced non-small cell lung cancer."	( The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors. Daga, H; Hida, T; Horio, Y; Ishikawa, S; Kobayashi, K; Shimizu, J; Takeda, K; Tokunaga, S, 2011)	0.37
" Optimal effects are obtained when these compounds are used in combination with chemotherapy, as shown in preclinical models and more recently in clinical trials."	( Docetaxel combined with targeted therapies in metastatic breast cancer. Cortes, J; Roché, H, 2012)	0.38
" Two cycles of intraperitoneal chemotherapy with docetaxel combined with S-1, were administrated and gastrectomy with lymph node dissection was performed in cases without macroscopic PC at post-NIPS staging laparoscopy."	( Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2012)	0.38
"This study indicated that the NIPS combined with surgery was highly active and well tolerated by advanced gastric cancer patients with PC."	( Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. Doki, Y; Fujiwara, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2012)	0.38
" Drug-drug interactions and a maximum tolerated dose were not identified."	( Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Agrawal, S; Araujo, JC; Armstrong, AJ; Braud, EL; Gallick, GE; Logothetis, CJ; Lonberg, M; Mathew, P; Paliwal, P; Posadas, E; Trudel, GC, 2012)	0.38
"Fifteen patients with metastatic breast cancer were treated with docetaxel (doses of 40-75 mg/m(2) intravenously on day 1 of a 21-day cycle) in combination with everolimus (doses ranging from 20 to 50 mg orally on days 1 and 8 of a 21-day cycle) in a phase 1 trial using the continuous reassessment method to determine maximum tolerated dose."	( A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Booser, D; Brewster, A; Cristofanilli, M; Ensor, J; Giordano, SH; Gladish, G; Gonzalez-Angulo, AM; Hortobagyi, GN; Moore, J; Moulder, S; Murray, JL; Rivera, E; Tran, HT, 2012)	0.38
"Weekly everolimus in combination with docetaxel every 3 weeks was associated with excessive neutropenia and variable clearance of both drugs, making combination therapy unpredictable, even at low doses of both drugs."	( A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Booser, D; Brewster, A; Cristofanilli, M; Ensor, J; Giordano, SH; Gladish, G; Gonzalez-Angulo, AM; Hortobagyi, GN; Moore, J; Moulder, S; Murray, JL; Rivera, E; Tran, HT, 2012)	0.38
" Aim of this work is to compare OS, TTP, and ORR in patients with MBC receiving docetaxel alone or in combination with chemotherapy using a formal meta-analysis."	( Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. Belfiglio, M; Fanizza, C; Ficorella, C; Iacobelli, S; Natoli, C; Tinari, N, 2012)	0.38
"We performed a systematic review of all published trials comparing docetaxel alone or in combination with other chemotherapeutic agents in MBC."	( Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. Belfiglio, M; Fanizza, C; Ficorella, C; Iacobelli, S; Natoli, C; Tinari, N, 2012)	0.38
"AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC)."	( Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012)	0.38
"AT-101 was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high-risk patients."	( Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA, 2012)	0.38
" We have treated with biweekly nedaplatin (CDGP 40 mg/m²) in combination with docetaxe (l DOC 30 mg/m²) as second-line chemotherapy and investigated its efficacy and safety."	( [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. Egawa, T; Eto, E; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Murakawa, M; Nagashima, A; Okamura, A, 2011)	0.37
"The purpose of this study is to evaluate the efficacy of the enhancement of docetaxel by pulsed focused ultrasound (pFUS) in combination with radiotherapy (RT) for treatment of prostate cancer in vivo."	( MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment. Chen, L; Chen, X; Cvetkovic, D; Ma, CM; Mu, Z; Pollack, A, 2012)	0.38
"This phase I study cohort investigated aflibercept in combination with docetaxel in patients with advanced solid tumors."	( Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Assadourian, S; Falandry, C; Favier, L; Freyer, G; Fumoleau, P; Isambert, N; Soussan-Lazard, K; Trillet-Lenoir, V; You, B; Zanetta, S; Ziti-Ljajic, S, 2012)	0.38
" Primary objectives were to evaluate dose-limiting toxicities (DLT) during cycle 1 and to determine the aflibercept recommended phase II trial dose (RP2D) for combination with docetaxel."	( Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Assadourian, S; Falandry, C; Favier, L; Freyer, G; Fumoleau, P; Isambert, N; Soussan-Lazard, K; Trillet-Lenoir, V; You, B; Zanetta, S; Ziti-Ljajic, S, 2012)	0.38
"Low-dose metronomic (LDM) chemotherapy represents a new strategy to treat solid tumors by stronger antiangiogenic activity and less side-effects, especially in combination with other antiangiogenic agents."	( Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Wu, H; Xiao, Y; Xin, Y; Zhao, J, 2012)	0.38
" It is likely that clinical testing of these agents will be in combination with standard therapies to harness the apoptotic potential of both the agents."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
"The aim of this study was to identify agents, which would be likely to offer clinical benefit when combined with selumetinib."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
" In several models we observed that continuous exposure to selumetinib in combination with docetaxel results in tumour regression."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
"The data presented suggests that MEK inhibition in combination with several standard chemotherapeutics or an Aurora B kinase inhibitor is a promising clinical strategy."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
"Patients pretreated with up to four prior chemotherapy regimens received increasing adecatumumab doses either every 3 weeks (q3w) or weekly (qw) combined with docetaxel (100 mg/m(2) q3w)."	( Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Baeuerle, PA; Eiermann, W; Göppel, G; Hanusch, CA; Lang, A; Marschner, N; Oruzio, D; Rüttinger, D; Schlimok, G; Schmidt, M; Schuler, M; Sebastian, M; Steger, GG; Wolf, A; Wolf, C, 2012)	0.38
" Maximum tolerated doses of adecatumumab given in combination with docetaxel were 550 mg/m(2) q3w and 360 mg/m(2) qw."	( Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Baeuerle, PA; Eiermann, W; Göppel, G; Hanusch, CA; Lang, A; Marschner, N; Oruzio, D; Rüttinger, D; Schlimok, G; Schmidt, M; Schuler, M; Sebastian, M; Steger, GG; Wolf, A; Wolf, C, 2012)	0.38
" This open-label, non-comparative, multicenter phase II study evaluated TSU-68 in combination with docetaxel in patients with metastatic breast cancer that had relapsed within 1 year despite prior treatment with an anthracycline-containing regimen."	( A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y, 2014)	0.4
"TSU-68 in combination with docetaxel produced objective responses in 21."	( A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y, 2014)	0.4
"TSU-68 in combination with docetaxel showed a promising antitumor response with manageable toxicity in patients with anthracycline-resistant metastatic breast cancer."	( A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y, 2014)	0.4
" In this study, we assessed the in-vitro and in-vivo activities of lobaplatin alone or in combination with antitubulin agents against human non-small-cell lung cancer (NSCLC)."	( Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Jin, W; Lou, LG; Xie, CY; Xu, YP, 2012)	0.38
" The combination of lobaplatin with antitubulin agents, especially with paclitaxel, led to significantly enhanced activity, which was superior to that of cisplatin combined with antitubulin agents."	( Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Jin, W; Lou, LG; Xie, CY; Xu, YP, 2012)	0.38
"These data demonstrate that the use of lobaplatin alone or in combination with antitubulin agents might be a rational and novel therapeutic strategy for human NSCLC and warrants further clinical investigation."	( Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Jin, W; Lou, LG; Xie, CY; Xu, YP, 2012)	0.38
"This study evaluates the efficacy and safety of trastuzumab combined with docetaxel-based chemotherapy in previously treated metastatic gastric carcinoma of Chinese patients with HER2 over-expression."	( Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Chen, L; Dai, GH; Lv, YL; Shi, Y; Zhong, M, )	0.13
" Trastuzumab combined with docetaxel-based chemotherapy was well tolerated."	( Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Chen, L; Dai, GH; Lv, YL; Shi, Y; Zhong, M, )	0.13
"This study examined the efficacy and tolerability of docetaxel(DOC)in combination with epirubicin(EPI)as the first-line treatment for patients with advanced and recurrent breast cancer."	( [Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study]. Anan, K; Arime, I; Chijiiwa, K; Fujii, T; Hara, S; Imamura, S; Inoue, H; Ishikawa, E; Mitsuyama, S; Nishimura, R; Ohchi, T; Ohkido, M; Ohno, S; Oikawa, T; Shimada, K; Tamura, K; Tanaka, M; Taniguchi, H; Yano, H, 2012)	0.38
" ATHENA is an international phase-IIIb study conducted in 2,251 patients with locally advanced or mBC, treated in first-line with bevacizumab combined with taxanes-based chemotherapy."	( [Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]. Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C, 2012)	0.38
"We performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)."	( Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012)	0.38
"Three-weekly docetaxel and prednisone could be combined with sorafenib at 400 mg BID on days 1-21 without reaching MTD."	( Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012)	0.38
" We assessed the safety and tolerability of siltuximab in combination with docetaxel, the pharmacokinetics of docetaxel alone and with siltuximab, and the efficacy and pharmacodynamics of siltuximab plus docetaxel."	( A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Cornfeld, M; Eisenberger, M; Hudes, G; Puchalski, TA; Qi, M; Qin, X; Reddy, M; Tagawa, ST; Whang, YE, 2013)	0.39
"These results suggest that siltuximab in combination with docetaxel is safe and shows preliminary efficacy in patients with CRPC, although alternative siltuximab schedules may be better tolerated for future studies."	( A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Cornfeld, M; Eisenberger, M; Hudes, G; Puchalski, TA; Qi, M; Qin, X; Reddy, M; Tagawa, ST; Whang, YE, 2013)	0.39
"The results of this phase II clinical study suggest that docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen in TNLABC patients is active and well tolerated, and should be further investigated as a favorable treatment alternative for TNLABC patients."	( Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial. Chen, C; Di, GH; Fei, F; Liu, GY; Lu, JS; Shao, ZM; Wu, J; Xue, J, 2013)	0.39
" We investigated the antitumor activity of motesanib, a selective antagonist of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor, and Kit, alone and combined with chemotherapy in five human NSCLC xenograft models (A549, Calu-6, NCI-H358, NCI-H1299, and NCI-H1650) containing diverse genetic mutations."	( Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B, 2012)	0.38
" When combined with cisplatin, motesanib significantly inhibited the growth of Calu-6, NCI-H358, and NCI-H1650 tumor xenografts compared with either single agent alone (P < 0."	( Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B, 2012)	0.38
"These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel."	( Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B, 2012)	0.38
" This prospective phase II study evaluated the activity and toxicity of a modified regimen with lower doses of docetaxel and cisplatin combined with oral capecitabine instead of fluorouracil for patients with advanced gastric cancer."	( Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I, 2012)	0.38
" This phase I study investigated the safety, tolerability, pharmacokinetics and antitumour activity of axitinib combined with chemotherapy."	( Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M, 2012)	0.38
"Axitinib combined with paclitaxel or capecitabine was well tolerated; no additive increase in toxicities was observed."	( Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M, 2012)	0.38
"This exploratory study assessed the safety, pharmacokinetics, and antitumor activity of sunitinib combined with docetaxel and trastuzumab."	( An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L, 2012)	0.38
" Sunitinib and docetaxel levels were consistent with known single-agent levels, suggesting that there were no clinically relevant drug-drug interactions."	( An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L, 2012)	0.38
"Sunitinib combined with docetaxel and trastuzumab had an acceptable toxicity profile and showed preliminary antitumor activity as first-line treatment for metastatic HER2+ breast cancer."	( An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L, 2012)	0.38
"In the present study, to take full advantage of adenovirus in gene expression, we prepared mannan-modified recombinant adenovirus using the PTEN gene (Man-Ad5-PTEN) and investigated the effect of Man-Ad5-PTEN combined with docetaxel (Man-Ad5-PTEN-docetaxel) on tumor growth in a murine model of hepatocellular carcinoma."	( Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice. Huang, J; Jiang, X; Ke, F; Li, J; Liu, Z; Qi, Q; Zhong, Z, 2012)	0.38
"The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours."	( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)	0.38
"PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2 on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two or administrated with gemcitabine 800 mg/m2 on days one and eight, of a 21-day treatment cycle."	( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)	0.38
" The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200 mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF."	( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)	0.38
" A recommended dose was identified for phase II trials of PR-104 of 770 mg/m2 combined with docetaxel 60 to 75 mg/m2 both given on day one of a 21-day treatment cycle supported by prophylactic G-CSF (NCT00459836)."	( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012)	0.38
"A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid tumors."	( Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P, 2013)	0.39
" Afatinib doses were escalated to 160 mg/day in combination with 75 mg/m(2) docetaxel."	( Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P, 2013)	0.39
"This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors."	( A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Chiorean, EG; Dipaola, RS; Jung, DT; Kroll, S; Kurtoglu, M; Lampidis, TJ; Langmuir, VK; Papadopoulos, K; Raez, LE; Ricart, AD; Rocha Lima, CM; Rosenblatt, J; Schlesselman, JJ; Stein, MN; Tolba, K, 2013)	0.39
"The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects."	( A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Chiorean, EG; Dipaola, RS; Jung, DT; Kroll, S; Kurtoglu, M; Lampidis, TJ; Langmuir, VK; Papadopoulos, K; Raez, LE; Ricart, AD; Rocha Lima, CM; Rosenblatt, J; Schlesselman, JJ; Stein, MN; Tolba, K, 2013)	0.39
"To observe efficacy and side effects, as well as the impact on quality of life, of Kanglaite® (Coix Seed Oil) injections combined with chemotherapy in the treatment of advanced gastric cancer patiensts."	( Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, X; Ye, LH; Zhan, YP, 2012)	0.38
"A consecutive cohort of 60 patients were divided into two groups:the experimental group receiving Kanglaite® Injection combined with chemotherapy and the control group with chemotherapy alone."	( Clinical safety and efficacy of Kanglaite® (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, X; Ye, LH; Zhan, YP, 2012)	0.38
"Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell lung cancer."	( Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Chougule, MB; I, T; Patel, AR; Patlolla, R; Singh, M; Wang, G, 2013)	0.39
"We studied the inhibitory effects of lentinan alone or lentinan combined with docetaxel and cisplatin on growth of gastric cancer cell line BGC823."	( Effect of lentinan combined with docetaxel and cisplatin on the proliferation and apoptosis of BGC823 cells. Xiao, N; Xiao, Y; Zhao, L, 2013)	0.39
"We conducted a phase II study of docetaxel in combination with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, for salvage therapy of advanced non-small-cell lung cancer (NSCLC) based on promising preclinical and early-phase clinical data."	( Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Behera, M; Chen, Z; Fu, H; Gal, AA; Govindan, R; Harvey, RD; Khuri, FR; Klass, CM; Kono, SA; Owonikoko, TK; Ramalingam, SS; Saba, NF; Shin, DM; Sica, G; Subramanian, J; Sun, SY, 2013)	0.39
" Bortezomib, a proteasome inhibitor,markedly enhanced the cytotoxic effects of panobinostat combined with gemcitabine."	( Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system. Budman, DR; Calabro, A; Lesser, M; Rosen, L, 2012)	0.38
"For Japanese CRPC patients, weekly low-dose DTX combined with estramustine has similar efficacy to standard-dose DTX but with fewer adverse events."	( Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Nakai, Y; Nakayama, M; Nishimura, K; Nonomura, N; Takayama, H; Tsujimura, A; Uemura, M, 2014)	0.4
"Three-dimensional conformal external beam radiotherapy combined with docetaxel is an active and safe regimen for inoperable patients with esophageal cancer."	( Phase II study of docetaxel (Aisu®) combined with three- dimensional conformal external beam radiotherapy in treating patients with inoperable esophageal cancer. Huang, XE; Liu, J; Lu, YY; Shen, K; Wu, XY; Xiang, J, 2012)	0.38
" This study aimed to select the dose of AVE1642 alone and then combined with docetaxel 75mg/m(2) (D)."	( A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Deslandes, A; Lazar, V; Massard, C; Mery-Mignard, D; Ozoux, ML; Soria, JC; Tolcher, AW, 2013)	0.39
"AVE1642 was administered alone at cycle (cy) 1 and then combined with D from cy2, q3w."	( A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. Deslandes, A; Lazar, V; Massard, C; Mery-Mignard, D; Ozoux, ML; Soria, JC; Tolcher, AW, 2013)	0.39
"PURPOSE As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific endothelin A receptor antagonist, has been investigated in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (CRPC)."	( Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Fizazi, K; Fizazi, KS; Gleave, M; Higano, CS; McIntosh, S; Miller, K; Morris, T; Moul, JW; Nathan, FE; Nelson, JB; Pemberton, K, 2013)	0.39
"PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor receptor 2 (HER2) -positive locally recurrent/metastatic breast cancer (LR/MBC)."	( AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Andre, F; Chan, A; Chan, S; Gianni, L; Greil, R; Lichinitser, M; Lipatov, O; Mansutti, M; Mariani, P; Moore, N; Pallaud, C; Pivot, X; Prot, S; Romieu, GH; Semiglazov, V; Serrano, SV; Wardley, A, 2013)	0.39
"The purpose of this study is to observe and compare the preliminary efficacy and side effects of docetaxel, 5-fluorouracil and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy for the treatment of advanced gastric cancer."	( Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Kan, W; Ke, Z; Pengjun, Z; Qinghua, D; Ruzhen, Z; Shenglin, M; Xiadong, L; Zhibing, W, )	0.13
"Retrospectively analyzed 101 patients with advanced gastric cancer receiving docetaxel, 5-fluorouracil, leucovorin and cisplatin intravenous chemotherapy or intravenous administration of docetaxel, 5-fluorouracil and leucovorin combined with cisplatin hyperthermic intraperitoneal perfusion chemotherapy, 49 patients in intravenous chemotherapy (VC) group, 52 patients in hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) group."	( Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Kan, W; Ke, Z; Pengjun, Z; Qinghua, D; Ruzhen, Z; Shenglin, M; Xiadong, L; Zhibing, W, )	0.13
" CCL2 blockade inhibited the growth of PCa in bone, with even more pronounced inhibition in combination with docetaxel."	( Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone. Brown, LG; Corey, E; Kirk, PS; Koreckij, T; Nguyen, HM; Snyder, LA; Vessella, RL, 2013)	0.39
"Pertuzumab (P) combined with trastuzumab (H)-based chemotherapy improves efficacy in early and advanced HER2-positive breast cancer."	( Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Chia, S; Cortés, J; Eniu, A; Harvey, V; Hegg, R; Hickish, T; McNally, V; Ratnayake, J; Ross, G; Schneeweiss, A; Seo, JH; Tausch, C; Tsai, YF, 2013)	0.39
"The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma."	( Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014)	0.4
"Aflibercept in combination with docetaxel and prednisone given as first-line chemotherapy for men with metastatic castrate-resistant prostate cancer resulted in no improvement in overall survival and added toxicity compared with placebo."	( Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Arén, O; Bavbek, S; Birtle, A; Elliott, T; Fizazi, K; Fléchon, A; Gil, T; Gravis, G; Hatteville, L; Ivanov, S; Karlsson, CT; Karyakin, O; Magherini, E; Matveev, V; Orlandi, F; Petrylak, D; Rosenthal, M; Skoneczna, I; Tannock, IF; Tombal, B; Viana, L, 2013)	0.39
" Food and Drug Administration (FDA) approved pertuzumab (Perjeta, Genentech) for use in combination with trastuzumab (Herceptin, Genentech) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease."	( First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Blumenthal, GM; Chattopadhyay, S; Chi, B; Cortazar, P; Graham, L; Hughes, P; Ibrahim, A; Justice, R; King, KE; Liu, Q; Pazdur, R; Pilaro, AM; Rellahan, BL; Ringgold, K; Scher, NS; Song, P; Tang, S; Thomas, C; Tilley, A; Weinberg, WC, 2013)	0.39
"The escalating doses and cycles of intraperitoneal phIL-12/PPC when combined with carboplatin/docetaxel chemotherapy in recurrent ovarian cancer patients were well tolerated and did not appear to exacerbate the side effects or attenuate the efficacy of the chemotherapy treatment."	( Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Alvarez, RD; Anwer, K; Chu, C; Fewell, JG; Kelly, FJ; Lewis, D, 2013)	0.39
" Here, we report results from a randomized open-label phase II trial in castration-resistant prostate cancer patients in which TroVax was administered in combination with docetaxel and compared against docetaxel alone."	( Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Blount, D; Chu, F; Ferrari, A; Gabrail, N; Harrop, R; Srinivas, S, 2013)	0.39
"This phase IB, open-label, dose-escalation study evaluated the safety, tolerability, and optimally tolerated regimen (OTR) of lapatinib in combination with docetaxel and trastuzumab in patients with previously untreated stage IV metastatic breast cancer (MBC) tumors overexpressing human epidermal growth factor receptor 2 (HER2)."	( Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Burris, HA; Crown, J; DeSilvio, M; Diéras, V; Espie, M; Kennedy, MJ; Koch, KM; Kothari, D; Lau, MR; Marty, M; Tresca, P, 2013)	0.39
"This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), pharmacokinetics, and antitumour activity of PX-866, a phosphatidylinositol 3-kinase inhibitor, combined with docetaxel in patients with incurable solid tumours."	( A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Adjei, AA; Bowles, DW; Brahmer, JR; Davies, M; Hausman, D; Jimeno, A; Lazar, AJ; Ma, WW; Peterson, S; Rudin, CM; Senzer, N; Vo, A; Walker, L, 2013)	0.39
" The aim of the study was to assess the benefit of ICT with docetaxel, cisplatin and 5-fluorouracil (5-FU) (TPF) when combined with concurrent cisplatin chemoradiotherapy (CRT) for HNSCC."	( The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis. Coyle, C; Dyker, KE; Karakaya, E; Prestwich, RJ; Sen, M; Teo, M; Young, CA, 2013)	0.39
" Combined with trastuzumab plus docetaxel, pertuzumab improved progression-free and overall survival versus trastuzumab plus docetaxel in the phase III CLEOPATRA trial (NCT00567190) in first-line HER2-positive metastatic breast cancer."	( Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Baselga, J; Brewster, M; Cortés, J; Garg, A; Grincuka, E; Hauschild, M; Kudaba, I; Lum, BL; Marier, JF; Masuda, N; McNally, V; Nijem, I; Patel, T; Ross, G; Swain, SM; Trinh, MM; Visich, J, 2013)	0.39
"The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown."	( Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013)	0.39
") in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)."	( Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Aziz, R; Ghosh, D; Ibrahim, A; Justice, R; Kluetz, PG; Maher, VE; Mehrotra, N; Ning, YM; Palmby, T; Pazdur, R; Pfuma, E; Sridhara, R; Tang, S; Tilley, A; Zhang, L; Zirkelbach, JF, 2013)	0.39
" Single docetaxel and that combined with endostar were conducted in two arms."	( [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer]. Ding, CM; He, ZY; Li, K; Li, WL; Liu, W; Mao, WD; Sun, T; Wang, HM; Wang, J; Yao, Q; Zhang, MJ; Zhang, Y; Zhou, XL, 2013)	0.39
"To compare the efficacy and side effects of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma (NPC)."	( [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma]. Guo, CY; Han, SH; Song, HP; Yu, L; Zhang, PJ; Zhang, Z, 2013)	0.39
"This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer."	( S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J, 2013)	0.39
"Given all axillary lymph node positive diseases, neoadjuvant S-1 combined with docetaxel following AC showed a favorable anti-tumor activity but gastrointestinal discomfort should be carefully considered for future studies."	( S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. Chung, HC; Kim, EK; Kim, JH; Kim, MJ; Kim, SI; Koo, JS; Lee, S; Moon, YW; Park, BW; Park, S; Sohn, J, 2013)	0.39
"Obatoclax was administered with docetaxel in patients with relapsed or refractory NSCLC- docetaxel as a 1-hour infusion on day 1 and obatoclax as a 24-hour infusion on days 1 and 2-every 3 weeks for up to eight cycles."	( Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. Adams, JW; Berger, MS; Chiappori, A; Edelman, MJ; Haura, EB; Malik, S; Northfelt, DW; Rosen, P; Van Echo, DA; Williams, C, 2014)	0.4
"To investigate the effects of abnormal Savda Munziq (ASMq) total phenolics combined with cisplatin and docetaxel on the Hela cell growth."	( Mechanisms of hela cell apoptosis induced by abnormal Savda Munziq total phenolics combined with chemotherapeutic agents. Abliz, G; Buranjiang, G; Li, XW; Mutalipu, Z; Upur, H; Wang, HQ; Ye, WJ; Zhang, YX, 2014)	0.4
"ASMq total phenolics, combined with cisplatin and docetaxel, could promote the apoptosis of Hela cells possibly through reducing the expression of Bcl-2 and survivin."	( Mechanisms of hela cell apoptosis induced by abnormal Savda Munziq total phenolics combined with chemotherapeutic agents. Abliz, G; Buranjiang, G; Li, XW; Mutalipu, Z; Upur, H; Wang, HQ; Ye, WJ; Zhang, YX, 2014)	0.4
"This Phase 1 study aimed to determine the recommended Phase 2 dose of LY2334737, an oral gemcitabine prodrug, when combined with standard dose docetaxel treatment in patients with advanced solid tumors."	( Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER, 2014)	0.4
" PK data were consistent with the first-in-man study of LY2334737 and did not reveal any drug-drug interaction between LY2334737 and docetaxel."	( Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER, 2014)	0.4
" We sought to assess the preclinical efficacy of MK-5108 in a panel of non-small-cell lung cancer cell lines as a single agent and in combination with cisplatin and docetaxel."	( Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. Chinn, DC; Holland, WS; Mack, PC, 2014)	0.4
"MK-5108 has potent anti-proliferative activity in lung cancer cell lines alone and in combination with chemotherapies."	( Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. Chinn, DC; Holland, WS; Mack, PC, 2014)	0.4
"The aim of this open-label, multicenter, randomized phase II trial was to evaluate the efficacy and safety of zoledronic acid in combination with docetaxel in previously treated patients with non-small-cell lung cancer (NSCLC) and bone metastases."	( Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T, 2014)	0.4
" The secondary aim of this study is to assess the progression-free survival and overall survival of recurrent or metastatic nasopharyngeal carcinoma (NPC) patients treated with lobaplatin in combination with docetaxel."	( Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients. Hu, GQ; Hu, GY; Lin, JW; Liu, DB; Long, GX; Mei, Q; Yuan, XL; Zhou, XY, 2014)	0.4
"Lobaplatin in combination with docetaxel demonstrated clinical activity and an acceptable toxicity profile in recurrent and metastatic NPC patients."	( Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients. Hu, GQ; Hu, GY; Lin, JW; Liu, DB; Long, GX; Mei, Q; Yuan, XL; Zhou, XY, 2014)	0.4
" Ombrabulin was combined with two standard taxane/platinum doublets in a phase I study to determine the recommended combination doses."	( Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A, 2014)	0.4
" Carlumab could be safely administered at 10 or 15 mg/kg in combination with standard-of-care chemotherapy and was well-tolerated, although no long-term suppression of serum CCL2 or significant tumor responses were observed."	( Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B, 2015)	0.42
" The antitumor activity of MLN8237 when combined with docetaxel or paclitaxel was evaluated in in vivo models of triple-negative breast cancer grown in immunocompromised mice."	( Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib). Chakravarty, A; Dorner, A; Ecsedy, JA; Huck, JJ; Hyer, ML; Kannan, K; Kleinfield, R; Manfredi, MG; Mettetal, J; Shinde, V; Shyu, WC; Venkatakrishnan, K; Zhang, M; Zhou, X, 2014)	0.4
" Patients received 2-weekly docetaxel (30 mg/m(2) [dose level (DL)1] or 40 mg/m(2) [DL2] with a 3 + 3 design in phase I, on days 1 and 15) in combination with fixed-dose CF (80 mg/m(2) cisplatin, day 1; 800 mg/m(2) fluorouracil, days 1-5) repeated every 4 weeks."	( Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Chin, K; Doki, Y; Fujitani, K; Hironaka, S; Kato, K; Kii, T; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Nakamura, T; Okuno, T; Seki, S; Taira, K; Taniki, T; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T, 2014)	0.4
"High EGFR gene copy number or activating EGFR mutations may identify patient subgroups who receive increased clinical benefit from vandetanib in combination with docetaxel in second-line NSCLC."	( EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Herbst, RS; Heymach, JV; Johnson, BE; Lockwood, SJ; Ryan, AJ, 2014)	0.4
"To assess side effects on Cantharidin sodium and Shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively."	( Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Cao, J; Huang, XE; Wang, L, 2014)	0.4
"Patients with breast cancer receiving postoperative chemotherapy were retrospectively collected, and divided into four groups: group A with cantharidin sodium injection combined with chemotherapy; group B with Shenmai injection combined with chemotherapy; group C with both cantharidin sodium and Shenmai injection combined with chemotherapy; while group D (control group) received chemotherapy alone."	( Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Cao, J; Huang, XE; Wang, L, 2014)	0.4
"Thus cantharidin sodium and Shenmai injection combined with chemotherapy reduce side effects and deserve to be further investigated in randomized clinical control trials."	( Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Cao, J; Huang, XE; Wang, L, 2014)	0.4
"To observe the curative effects of rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer and analyze the correlation of CT perfusion (CTP) parameters and the expression of vascular endothelial growth factor (VEGF)."	( Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer. Deng, WY; Li, N; Li, X; Luo, SX; Song, T, 2014)	0.4
"Rh-endostatin can down-regulate the expression of VEGF in esophageal cancer, change the state of hypertransfusion and high permeability of tumor vessels and had the better curative effect and slighter adverse reactions when combined with chemotherapy."	( Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer. Deng, WY; Li, N; Li, X; Luo, SX; Song, T, 2014)	0.4
"PDT in combination with either doxorubicin or taxotere was found to be more cytotoxic in comparison to either single-treatment."	( Differential expression of VEGF and IL-1alpha after photodynamic treatment in combination with doxorubicin or taxotere. Dabkeviciene, D; Kirveliene, V; Kvietkauskaite, R; Leman, E; Sasnauskiene, A, 2014)	0.4
"This phase I, open-label study evaluated the safety/tolerability and maximum tolerated dose of second-line nintedanib combined with docetaxel in Japanese patients with advanced non-small-cell lung cancer."	( Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N, 2015)	0.42
"5), respectively, in combination with 75 mg/m(2) of docetaxel."	( Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N, 2015)	0.42
"Continuous treatment with second-line nintedanib combined with docetaxel was manageable and showed promising signs of efficacy in Japanese patients with advanced non-small-cell lung cancer."	( Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N, 2015)	0.42
" Preclinical studies demonstrated that indoximod combined with chemotherapy was synergistic in a mouse model of breast cancer."	( A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Antonia, S; Dees, EC; Han, H; Harvey, RD; Ismail-Khan, R; Jackson, E; Link, C; Minton, S; Neuger, T; Soliman, HH; Sullivan, DM; Vahanian, NN, 2014)	0.4
" No drug-drug interactions were noted."	( A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Antonia, S; Dees, EC; Han, H; Harvey, RD; Ismail-Khan, R; Jackson, E; Link, C; Minton, S; Neuger, T; Soliman, HH; Sullivan, DM; Vahanian, NN, 2014)	0.4
"To evaluate the efficacy and safety of fixed dose rate (FDR) gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma."	( [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma]. Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y, 2014)	0.4
"The fixed dose rate (FDR) gemcitabine infusion in combination with docetaxel is an effective treatment regimen for patients with relapsed/refractory soft tissue sarcoma, and with tolerable adverse reactions."	( [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma]. Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y, 2014)	0.4
" The safety profile of trastuzumab in combination with carboplatin and docetaxel was consistent with the known safety profile of this combination."	( Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Eppler, S; Gordon, M; Lum, BL; Redfern, CH; Trudeau, C; Xu, N, 2014)	0.4
"Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer."	( Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O, 2014)	0.4
" Patients received docetaxel 60 mg/m2 plus cisplatin 60 mg/m2 (day 1) combined with capecitabine 1650 mg/m2 (days 1-14) every 3 weeks."	( Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O, 2014)	0.4
" We have then explored the antitumor effects as single agent and in combination with docetaxel in triple-negative breast (TNBC) and prostate cancer models."	( Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Barlaam, B; Barry, ST; Castriotta, L; Cosulich, S; Crafter, C; Cumberbatch, M; D'Cruz, C; Davies, BR; Dry, H; Ellston, R; Fitzek, M; Foster, E; Green, S; Hancox, U; Hanson, L; Harrington, EA; Lawson, M; Lenaghan, C; Ogilvie, D; Powell, S; Smith, PD; Trigwell, C; Ward, L; Wedge, SR, 2015)	0.42
"To evaluate the efficacy and safety of lobaplatin combined with docetaxel in the treatment of the recurrent ovarian carcinoma."	( [Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer]. Li, X; Li, Y, 2014)	0.4
"The chemotherapy of lobaplatin combined with docetaxel is effective on recurrent and refractory ovarian cancer with low side effects, which has advantages over the second-line chemotherapy protocols."	( [Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer]. Li, X; Li, Y, 2014)	0.4
" Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once every 21 days per the investigator was administered with apricoxib or placebo 400 mg once per day."	( Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL, 2015)	0.42
"For patients with metastatic castration-resistant prostate cancer (CRPC), the efficacy and safety of molecular targeted agents (MTAs) in combination with docetaxel are still unclear."	( Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. Fu, S; Guo, XM; Qi, WX; Zhang, Q, 2015)	0.42
" Conclusively, pertuzumab was approved by the US FDA in June 2012 for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer."	( Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Hirakawa, K; Kashiwagi, S; Kawajiri, H; Noda, S; Onoda, N; Takashima, T, 2015)	0.42
"The objective of this study was to evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with stage III non-small-cell lung cancer (NSCLC)."	( Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer. Bao, Y; Chen, L; Chen, M; Chen, YY; Cheng, ZB; Deng, XW; Hu, X; Li, JC; Lu, RB; Ma, HL; Peng, F; Wang, J; Wang, Y; Xu, ZM; Yu, ZH; Zhou, QC, 2015)	0.42
" In this study, lobaplatin as a single agent and in combination with taxanes was investigated in-vitro and in an in vitro model of ovarian carcinoma."	( Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells. Lou, LG; Sui, DH; Sun, X; Wu, XH, 2014)	0.4
"Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens."	( Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer. Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K, 2014)	0.4
" They all received nedaplatin (80 mg/m2, nedaplatin group) or oxaliplatin (130 mg/m2, oxaliplatin group) combined with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) as first-line treatment."	( Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer. Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K, 2014)	0.4
"To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late gastric cancer."	( Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. Xu, CD, 2014)	0.4
"Nimotuzumab combined with DCF plan is effective in treating late stage gastric cancer."	( Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. Xu, CD, 2014)	0.4
"To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer."	( Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. Huang, H; Li, PH; Lu, MD; Qi, DS; Sun, WJ; Wang, FH; You, T; Yu, YJ; Zhang, Y; Zheng, ZQ, 2014)	0.4
"Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III/IV gastric cancer."	( Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. Huang, H; Li, PH; Lu, MD; Qi, DS; Sun, WJ; Wang, FH; You, T; Yu, YJ; Zhang, Y; Zheng, ZQ, 2014)	0.4
"The aim of this paper was to evaluate the activity and tolerability of weekly docetaxel (D) combined with weekly epirubicin (EPI) in patients with advanced castrate-resistant prostate cancer (CRPC) previously exposed to D and abiraterone acetate (AA)."	( Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. Barbanti, G; Bianco, V; Brozzetti, S; De Rubertis, G; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G, 2015)	0.42
" We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807)."	( A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods o Chin, K; Fukuda, H; Hironaka, S; Kataoka, K; Katayama, H; Kato, K; Kii, T; Kitagawa, Y; Mizusawa, J; Shibuya, Y; Tsubosa, Y; Tsushima, T, 2015)	0.42
" This study was performed to examine the efficacy, toxicity, and tolerability of pirarubicin (THP) and epirubicin (EPI) in combination with docetaxel and cyclophosphamide in a NACT setting for BC."	( Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel. Gu, X; Jia, S; Wei, W; Zhang, WH, 2015)	0.42
" In this study, we investigated the possible synergistic apoptotic effects of DTX in combination with OCT in prostate and breast cancer cell lines."	( Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Atmaca, H; Bozkurt, E; Degirmenci, M; Karabulut, B; Karaca, B; Ozveren, A; Sanli, UA; Uslu, R, 2015)	0.42
"Adjuvant trastuzumab in combination with chemotherapy improves survival of women with HER2-positive early breast cancer."	( Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N, 2015)	0.42
" In order to accentuate the potential of hsa-miR-24-2 to reduce cellular viability under experimental conditions, in vitro studies in the presence and absence of anti-cancer drugs, such as docetaxel resulted in a significant decrease in cellular viability even at a 200-fold reduced dose of the drug in combination with hsa-miR-24-2."	( miR-24-2 regulates genes in survival pathway and demonstrates potential in reducing cellular viability in combination with docetaxel. Bamezai, RN; Kalaiarasan, P; Mangalhara, KC; Manvati, S; Srivastava, N, 2015)	0.42
"This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination."	( A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B, 2015)	0.42
"Advanced lung adenocarcinoma patients treated with ganetespib in combination with docetaxel had an acceptable safety profile."	( A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Andric, Z; Bondarenko, I; Ceric, T; Ciuleanu, T; Felip, E; Fennell, D; Goss, G; Hirsh, V; Khuri, F; Komov, D; Ramalingam, S; Rosell, R; Salgia, R; Samarzija, M; Schmid-Bindert, G; Shapiro, G; Sheldon, E; Spicer, J; Teofilovici, F; Vukovic, V; Wehler, T; Zaric, B, 2015)	0.42
" The efficacy of TRAMP-H6 and TRAMP-H11 in combination with docetaxel was evaluated."	( Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. Dams-Kozłowska, H; Dondajewska, E; Kazimierczak, U; Kotlarski, M; Kozłowska, A; Kwiatkowska, E; Mackiewicz, A; Mackiewicz, J; Nowicka-Kotlarska, A; Wysocki, PJ, 2015)	0.42
" Vaccination with TRAMP-H6 alone and TRAMP-H11 combined with docetaxel augmented tumor infiltration by activated CD8(+) and CD4(+) T-cells and attracted higher number of activated, mature DCs infiltrating tumors."	( Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. Dams-Kozłowska, H; Dondajewska, E; Kazimierczak, U; Kotlarski, M; Kozłowska, A; Kwiatkowska, E; Mackiewicz, A; Mackiewicz, J; Nowicka-Kotlarska, A; Wysocki, PJ, 2015)	0.42
" Our data indicate that E10A in combination with docetaxel exert enhanced antiangiogenic activities and inhibit prostate cancer growth and metastases."	( E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases. Fu, L; Huang, W; Li, H; Liang, Z; Liu, R; Luo, R; Wu, J; Xiao, X; Xie, F; Zhao, P; Zhu, X; Zhu, Y, 2010)	0.36
"We conducted an open-label, single-arm Phase I/II clinical trial in metastatic CRPC (mCRPC) patients eligible for docetaxel combined with treatment with autologous mature dendritic cells (DCs) pulsed with killed LNCaP prostate cancer cells (DCVAC/PCa)."	( Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Babjuk, M; Bartunkova, J; Becht, E; Bilkova, P; Fucikova, J; Gasova, Z; Horvath, R; Hromadkova, H; Jarolim, L; Kayserova, J; Kubackova, K; Lastovicka, J; Podrazil, M; Rozkova, D; Sochorova, K; Spisek, R; Vavrova, K; Vrabcova, P, 2015)	0.42
" We conducted a systematic review of the efficacy of bevacizumab in combination with taxane or non-taxane containing regimens for untreated, nonsquamous non-small-cell lung cancer patients."	( Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C, 2015)	0.42
" Phase 2 and randomized trials reporting on the efficacy of bevacizumab combined with taxane or non-taxane regimens were selected."	( Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C, 2015)	0.42
"The outcomes between taxane and non-taxane regimens when given in combination with bevacizumab for patients with nonsquamous non-small-cell lung cancer are comparable."	( Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. Behera, M; Belani, CP; Chen, Z; Khuri, FR; Kim, S; Owonikoko, TK; Pillai, RN; Ramalingam, SS; Saba, NF; Steuer, C, 2015)	0.42
" Docetaxel was administered in combination with ADT to men with hormone-naïve metastatic prostate cancer, in the attempt to improve the duration and quality of patient survival."	( Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer. Bonomi, M; Ceresoli, GL; De Vincenzo, F; Sauta, MG; Zucali, PA, 2015)	0.42
" Both drugs are mainly metabolized by CYP3A4, and drug-drug interactions are a major concern."	( Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N, 2015)	0.42
"The tolerability of 60 mg/m(2) docetaxel with 250 mg/day gefitinib was confirmed, and we observed no drug-drug interaction in this combination."	( Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N, 2015)	0.42
"To study the effectiveness of human recombinant endostatin injection (Endostar®) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging."	( Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y, 2015)	0.42
"The response rate with Endostar® administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes."	( Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y, 2015)	0.42
" To assess the toxicity, pharmacokinetics (PK), and pharmacodynamics of tariquidar, we conducted a phase I trial of tariquidar in combination with doxorubicin, docetaxel, or vinorelbine in children and adolescents with recurrent or refractory solid tumors."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.42
"5, or 2 mg/kg) was administered alone and in combination with doxorubicin, docetaxel, or vinorelbine."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.42
" When administered in combination with tariquidar, the clearance of docetaxel and vinorelbine was reduced compared to prior studies."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.42
" This trial demonstrates that modulators of resistance can be evaluated in combination with chemotherapy, and pharmacokinetic and pharmacodynamic endpoints can be useful in determination of recommended dose in children and adolescents."	( Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Balis, FM; Chen, CC; Cole, D; Fox, E; Pastakia, D; Widemann, BC; Yang, SX, 2015)	0.42
" 2006-001177-25) investigated aflibercept, a vascular endothelial growth factor decoy receptor protein (VEGF Trap), in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid tumors."	( Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Ajani, JA; Assadourian, S; Bahleda, R; Baker, J; Boelle, E; Deutsch, E; Gadgeel, SM; Garris, JL; Izzedine, H; Khan, A; Massard, C; Rogers, JE; Soria, JC, 2016)	0.43
"Aflibercept 6 mg/kg administered every 3 weeks in combination with docetaxel, cisplatin, and 5- fluorouracil is the recommended dose for further clinical development based on tolerability, pharmacokinetics, and antitumor activity."	( Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Ajani, JA; Assadourian, S; Bahleda, R; Baker, J; Boelle, E; Deutsch, E; Gadgeel, SM; Garris, JL; Izzedine, H; Khan, A; Massard, C; Rogers, JE; Soria, JC, 2016)	0.43
" Thus, continuing EGFR-TKI therapy in combination with super-selective arterial infusion chemotherapy beyond PD for patients with advanced EGFR-mutant NSCLC is feasible, and this approach warrants further investigation."	( Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer. Hu, Q; Jiang, S; Ni, H; Qi, H; Yu, D; Zhang, J, 2015)	0.42
" These data suggest for the first time that fatostatin alone or in combination with docetaxel could be exploited as a novel and promising therapy for metastatic PCa harboring p53 mutations."	( Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations. Chung, LW; Huang, WC; Li, X; Wu, JB, 2015)	0.42
" The objective of this study was to retrospectively evaluate the efficacy and toxicity of low-dose docetaxel in combination with dexamethasone."	( Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer. Asai, S; Kikugawa, T; Miura, N; Miyauchi, Y; Nishimura, K; Noda, T; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M, 2016)	0.43
"Low-dose docetaxel in combination with dexamethasone is feasible in Japanese CRPC patients."	( Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer. Asai, S; Kikugawa, T; Miura, N; Miyauchi, Y; Nishimura, K; Noda, T; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M, 2016)	0.43
"To investigate the efficacy of bevacizumab and trastuzumab combined with docetaxel, oxaliplatin, and capecitabine (B-DOCT) as first-line treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC)."	( Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Beeker, A; Beerepoot, LV; Beijnen, JH; Boers, JE; Boot, H; Cats, A; de Groot, JW; de Jong, RS; Goey, SH; Kuiper, M; Los, M; Meulendijks, D; Polee, MB; Portielje, JE; Schellens, JH; Sikorska, K; Tesselaar, ME; Vanhoutvin, SA, 2016)	0.43
" Consequently, we performed a multicentric pilot Phase II neoadjuvant trial of cetuximab (anti-EGFR antibody) combined with docetaxel for patients with operable, Stage II-III TNBC."	( Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Abrial, C; Bahadoor, MR; Benmammar, KE; Bignon, YJ; Cayre, A; Chalabi, N; Chollet, P; Dauplat, MM; Durando, X; Jacquin, JP; Kullab, S; Kwiatkowski, F; Mouret-Reynier, MA; Nabholtz, JM; Penault-Llorca, F; Radosevic-Robin, N; Servent, V; Van Praagh, I, 2016)	0.43
" However, its anti-tumor effects and mechanism of action in combination with low-frequency ultrasound (LFUS) in vivo are still unclear."	( The Effect of Docetaxel-Loaded Micro-Bubbles Combined with Low-Frequency Ultrasound in H22 Hepatocellular Carcinoma-Bearing Mice. Han, SP; He, XY; Liao, YR; Ren, ST; Shen, S; Sun, PF; Tian, T; Wang, B; Wang, YL; Zhao, WB, 2016)	0.43
"This Phase II trial was designed to evaluate the efficacy and safety of docetaxel combined with nedaplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma."	( Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma. Cheng, ZB; Liao, H; Lin, Z; Liu, YM; Lv, BJ; Peng, PJ; Tang, C; Wang, SY; Wang, ZH, 2015)	0.42
"Docetaxel combined with nedaplatin offers a satisfactory clinical activity and an acceptable safety profile as first-line chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma."	( Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma. Cheng, ZB; Liao, H; Lin, Z; Liu, YM; Lv, BJ; Peng, PJ; Tang, C; Wang, SY; Wang, ZH, 2015)	0.42
" The DC-based vaccine pulsed with HHP-treated tumor cells combined with docetaxel chemotherapy significantly inhibited growth of both TC-1 and TRAMP-C2 tumors."	( Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Bartůňková, J; Bieblová, J; Fučíková, J; Indrová, M; Mikyšková, R; Moserová, I; Reiniš, M; Šímová, J; Špíšek, R; Štěpánek, I; Truxová, I, 2016)	0.43
" Here, we report preclinical pharmacology of ASP9853 and the impact of ASP9853 in combination with a taxane on tumor volume in vivo."	( ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T, 2016)	0.43
"The preclinical efficacy of ASP9853 in combination with a taxane was studied in tumor-bearing mice."	( ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T, 2016)	0.43
"ASP9853 in combination with docetaxel showed greater tumor growth inhibition than docetaxel alone against non-small lung cancer xenografts."	( ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T, 2016)	0.43
"Inhibition of iNOS by ASP9853 in combination with docetaxel was not tolerable and resulted in the possible potentiation of neutropenia."	( ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors. Arai, Y; Dmuchowski, C; Fakhoury, A; Infante, JR; Krivoshik, A; LoRusso, P; Luke, JJ; Schuster, R; Shapiro, GI; Yamazaki, T, 2016)	0.43
" In a recent phase II study, selumetinib (AZD6244, ARRY-142886), an oral, potent and selective, allosteric MEK1/2 inhibitor with a short half-life, combined with docetaxel, improved clinical outcome as second-line treatment for patients with KRASm NSCLC."	( Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (S Ghiorghiu, D; Jänne, PA; Mann, H, 2016)	0.43
" Approximately 634 patients will be randomized 1:1 to receive selumetinib (75 mg twice daily on a continuous oral administration schedule) in combination with docetaxel (75 mg/m(2), intravenously on day 1 of every 21-day cycle) or placebo in combination with docetaxel (same schedule), until objective disease progression."	( Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (S Ghiorghiu, D; Jänne, PA; Mann, H, 2016)	0.43
" This phase Ib study assessed the safety, tolerability, and pharmacokinetics of docetaxel when administered with enzalutamide as first-line systemic chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC)."	( Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Fleming, MT; Gibbons, JA; Khondker, Z; Morris, MJ; Novotny, W; Ouatas, T; Peterson, AC; Rathkopf, DE; Scher, HI, 2016)	0.43
"There have been three randomised trials investigating docetaxel in combination with androgen deprivation therapy as first-line therapy for hormone-sensitive metastatic and locally advanced/high-risk prostate cancer."	( Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate Crabb, SJ; Davda, R; Hughes, S; Jones, R; Payne, H; Troup, J, 2016)	0.43
" Granulocyte colony-stimulating factor (G-CSF) was given with docetaxel to 41."	( Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia- Pacific Breast Initiatives I and II. Ba, DN; Chao, TY; Hou, MF; Kim, SB; Sayeed, A; Shah, MA; Shen, ZZ; Thuan, TV; Villalon, AH; Yau, TK, 2016)	0.43
"This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after progression during or within 12 months of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma."	( Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Aragon-Ching, JB; Burke, JM; Canil, C; Cavanaugh, CT; Chi, KN; Eisen, A; Gao, L; Kauh, JS; Kim, JJ; Kohli, M; Pan, CX; Petrylak, DP; Quinn, DI; Shaffer, D; Spira, A; Sridhar, SS; Tagawa, ST; Tang, S; Vogelzang, NJ; Walgren, RA; Yu, EY; Zhang, H, 2016)	0.43
" It has been shown that compound kushen injection in combination with chemotherapy can enhance the efficacy and reduce the toxicity."	( A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz Hou, W; Lin, HS; Liu, J; Wang, XQ, 2016)	0.43
" Three hundred seventy elderly patients with advanced non-small cell lung cancer will be randomly divided into experimental (n = 185) and control groups (n = 185) to receive compound kushen injection in combination with single-agent chemotherapy or standard platinum-based doublet chemotherapy for two cycles."	( A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz Hou, W; Lin, HS; Liu, J; Wang, XQ, 2016)	0.43
" This study will determine whether or not the efficacy of compound kushen injection in combination with single-agent chemotherapy is comparable to that of platinum-based doublet chemotherapy, and whether or not the toxicity of compound kushen injection in combination with single-agent chemotherapy is lower than that of platinum-based doublet chemotherapy."	( A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz Hou, W; Lin, HS; Liu, J; Wang, XQ, 2016)	0.43
" In this study we investigated the antitumor effects of a recombinant immunotoxin targeting the prostate specific membrane antigen (PSMA) in combination with DOC in vitro and in vivo."	( In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. Bogatyreva, L; Hauschke, D; Michalska, M; Schultze-Seemann, S; Wetterauer, U; Wolf, P, 2016)	0.43
"The current study was a multicenter, single-arm, phase 2 study performed to investigate the feasibility and efficacy of bevacizumab combined with docetaxel, oxaliplatin, and capecitabine (B-DOC) in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, previously untreated, gastric or gastroesophageal adenocarcinoma."	( Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Beeker, A; Beerepoot, LV; Beijnen, JH; Boers, JE; Cats, A; de Groot, JW; de Jong, RS; Goey, SH; Grootscholten, C; Kuiper, M; Los, M; Meulendijks, D; Pluim, D; Polee, MB; Portielje, JE; Schellens, JH; Sikorska, K; Tesselaar, ME; Vanhoutvin, SA, 2016)	0.43
"5 mg/kg, docetaxel at a dose of 50 mg/m(2) , and oxaliplatin at a dose of 100 mg/m(2) (all on day 1) combined with capecitabine at a dose of 850 mg/m(2) twice daily (days 1-14) every 3 weeks followed by maintenance with capecitabine and bevacizumab in patients with disease control."	( Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. Beeker, A; Beerepoot, LV; Beijnen, JH; Boers, JE; Cats, A; de Groot, JW; de Jong, RS; Goey, SH; Grootscholten, C; Kuiper, M; Los, M; Meulendijks, D; Pluim, D; Polee, MB; Portielje, JE; Schellens, JH; Sikorska, K; Tesselaar, ME; Vanhoutvin, SA, 2016)	0.43
" This study evaluated the efficacy and safety of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of PPSC."	( Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study. Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yonemura, Y; Zhang, Q, 2016)	0.43
"To evaluate the efficacy and safety of lobaplatin combined with docetaxel as neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy (IMRT) for high-risk positive lymph node (N+) nasopharyngeal carcinoma (NPC)."	( Lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy increases the survival of patients with high-risk lymph node positive nasopharyngeal carcinoma. Hu, L; Lin, S; Zhang, S, )	0.13
"In patients with high-risk N+ NPC, lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with IMRT yielded excellent short-term results with mild and tolerable toxicities."	( Lobaplatin combined with docetaxel neoadjuvant chemotherapy followed by concurrent lobaplatin with intensity-modulated radiotherapy increases the survival of patients with high-risk lymph node positive nasopharyngeal carcinoma. Hu, L; Lin, S; Zhang, S, )	0.13
" Given the evidence of activity in xenograft models, treatment with AT-101 in combination with docetaxel is a therapeutic doublet of interest in metastatic head and neck squamous cell carcinoma."	( A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP, 2016)	0.43
" In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsquamous non-small-cell lung cancer were evaluated."	( Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Belani, CP; Gerber, DE; Giorgadze, D; Menander, KB; Ponomarova, OV; Shan, JS; Shtivelband, M; Spigel, DR, 2016)	0.43
"Patients were randomized 1:1:1 to receive docetaxel 75 mg/m(2) every 21 days for up to 6 cycles combined with weekly, blinded infusions of placebo, bavituximab 1 mg/kg, or bavituximab 3 mg/kg until disease progression or unacceptable toxicity."	( Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Belani, CP; Gerber, DE; Giorgadze, D; Menander, KB; Ponomarova, OV; Shan, JS; Shtivelband, M; Spigel, DR, 2016)	0.43
" Nevertheless, the effect of such drug combination usage on the in vivo exposure of PIP has not been investigated due to lack of assay for the simultaneous determination of PIP and other drugs such as DOX."	( Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. Chow, MSS; Lam, CWK; Li, C; Ren, T; Wang, Q; Zhang, Y; Zuo, Z, 2016)	0.43
"Low temperature sensitive liposome (LTSL) encapsulated docetaxel were combined with mild hyperthermia (40-42°C) to investigate in vivo biodistribution and efficacy against a castrate resistant prostate cancer."	( Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. Benjamin, CJ; Chokshi, S; Chung, PH; Dreher, MR; Linehan, WM; Negussie, AH; Pinto, PA; Ranjan, A; Volkin, D; Wood, BJ; Yeram, N, 2016)	0.43
" These results support phase 2 testing of SGT-53 in combination with docetaxel."	( Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Adams, J; Chang, EH; Leung, PK; Nemunaitis, J; Nunan, R; Pirollo, KF, 2016)	0.43
"Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy."	( Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report. Asensi Diez, R; Clopes Estela, A; Espinosa Bosch, M; García Agudo, S, 2016)	0.43
"The primary objective of this study was to investigate the safety and tolerability and to confirm the recommended dose of the anti-vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab in combination with docetaxel in Japanese patients with metastatic/locally advanced breast cancer."	( Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Aogi, K; Dalal, R; Gao, L; Ibrahim, A; Iwata, H; Masuda, N; Sasaki, Y; Xu, Y; Yoshikawa, R, 2016)	0.43
" Four serious adverse events were possibly related to ramucirumab in combination with docetaxel."	( Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Aogi, K; Dalal, R; Gao, L; Ibrahim, A; Iwata, H; Masuda, N; Sasaki, Y; Xu, Y; Yoshikawa, R, 2016)	0.43
" This single-center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)."	( Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N, 2016)	0.43
" Oral PF-03084014 was administered twice daily continuously in combination with intravenous docetaxel given on day 1 of each 21-day cycle."	( Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Aftimos, P; Awada, A; Cesari, R; Curigliano, G; Dees, EC; Huang, B; Jiang, Y; Kern, KA; Locatelli, MA; LoRusso, PM; Pegram, MD; Shaik, MN, 2017)	0.46
" No effect was observed on the pharmacokinetics of docetaxel when administered in combination with PF-03084014."	( Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Aftimos, P; Awada, A; Cesari, R; Curigliano, G; Dees, EC; Huang, B; Jiang, Y; Kern, KA; Locatelli, MA; LoRusso, PM; Pegram, MD; Shaik, MN, 2017)	0.46
"Previously, one randomized control trial (TAX327) revealed the efficacy of docetaxel-based chemotherapy combined with prednisone."	( The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. Akakura, K; Fujimoto, K; Gotoh, M; Hirao, Y; Ina, K; Nagata, H; Nishimura, K; Ogawa, O; Okajima, E; Tanaka, N; Teramukai, S, 2017)	0.46
" Seventy-five patients received docetaxel-based chemotherapy combined with dexamethasone."	( The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. Akakura, K; Fujimoto, K; Gotoh, M; Hirao, Y; Ina, K; Nagata, H; Nishimura, K; Ogawa, O; Okajima, E; Tanaka, N; Teramukai, S, 2017)	0.46
"This study investigated the anticancer effect of Shenqi Fuzheng (SQFZ) injection combined with docetaxel on lung cancer cell lines of A549 and Lewis lung cancer (LLC)."	( Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells. Dong, BY; Du, SY; Lu, Y; Tan, L; Tan, N; Wang, C; Zhao, MD, )	0.13
" This analysis of pertuzumab aimed to (1) compare its pharmacokinetics (PK) in patients with EBC versus advanced cancers, (2) to further evaluate PK drug-drug interactions (DDIs) when given in combination with trastuzumab, and (3) to assess the relationship between exposure and efficacy to assess the clinical dosing regimen in the EBC patients."	( Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Benyunes, MC; Garg, A; Jin, JY; Li, H; Lum, BL; McNally, V; Nijem, I; Quartino, AL; Viganò, L; Wada, DR, 2017)	0.46
"This analysis further supports the lack of DDI between the two therapeutic proteins and the appropriateness of the approved fixed non-body-weight-adjusted pertuzumab dose in the treatment of neoadjuvant EBC with pertuzumab in combination with trastuzumab and docetaxel."	( Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Benyunes, MC; Garg, A; Jin, JY; Li, H; Lum, BL; McNally, V; Nijem, I; Quartino, AL; Viganò, L; Wada, DR, 2017)	0.46
"We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective trials of patients with inflammatory breast cancer (IBC) treated with neoadjuvant chemotherapy combined with neoadjuvant and adjuvant bevacizumab."	( Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Andre, F; Autret, A; Bachelot, T; Bertucci, F; Bidard, FC; Boher, JM; Bonneterre, J; Campone, M; Charafe-Jaufret, E; Dalenc, F; Eymard, JC; Ferrero, JM; Gligorov, J; Hardy-Bessard, AC; Kerbrat, P; Lemonnier, J; Lerebours, F; Levy, C; Lortholary, A; Mouret-Reynier, MA; Petit, T; Pierga, JY; Proudhon, C; Romieu, G; Soulie, P; Viens, P, 2017)	0.46
"Nonmetastatic T4d patients were enrolled in two phase II multicentre trials, evaluating bevacizumab in combination with sequential neoadjuvant chemotherapy of four cycles of FEC followed by four cycles of docetaxel in HER2-negative tumour (BEVERLY-1) or docetaxel and trastuzumab in HER2-positive tumour (BEVERLY-2)."	( Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Andre, F; Autret, A; Bachelot, T; Bertucci, F; Bidard, FC; Boher, JM; Bonneterre, J; Campone, M; Charafe-Jaufret, E; Dalenc, F; Eymard, JC; Ferrero, JM; Gligorov, J; Hardy-Bessard, AC; Kerbrat, P; Lemonnier, J; Lerebours, F; Levy, C; Lortholary, A; Mouret-Reynier, MA; Petit, T; Pierga, JY; Proudhon, C; Romieu, G; Soulie, P; Viens, P, 2017)	0.46
" In both dose levels, cabazitaxel (4 cycles of cabazitaxel 25 mg/m + 2 cycles of cabazitaxel 20 mg/m in level 1, and 6 cycles of cabazitaxel 25 mg/m in level 2) were combined with 2 cycles of Re-HEDP 40 MBq/kg (1."	( A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial. Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW, 2017)	0.46
" The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer."	( Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P, 2017)	0.46
" Our work addressed the inhibition of APE1 redox function using E3330, as single agent or in combination with docetaxel (DTX), in human breast cancer MDA-MB-231 cells."	( The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel. Castro, M; Corvacho, E; Costa, JG; Fernandes, AS; Guerreiro, PS; Miranda, JP; Oliveira, NG; Saraiva, N, 2017)	0.46
" Here we investigated the effects of soy isoflavone extracts alone or in combination with Docetaxel on the drug resistance, angiogenesis, apoptosis, and tumor volume in mouse 4T1 breast tumor model."	( Investigating the Antiangiogenic, Anti-drug Resistance and Apoptotic Effects of Soy Isoflavone Extract Alone or in Combination with Docetaxel on Murine 4T1 Breast Tumor Model. Amiri, Z; Edalatkhah, H; Hejazi, E; Hejazi, J; Houshyari, M; Idali, F; Jeddi-Tehrani, M; Kimiagar, M; Nasrollahzadeh, J; Tavakoli, M, 2017)	0.46
"To provide perspective for the National Health Insurance Bureau (NHIB), we determined the cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel (TDP) versus trastuzumab and docetaxel (TD) as a first-line treatment for HER-2 positive metastatic breast cancer."	( Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer. Chan, ALF; Leung, HWC; Leung, JH; Muo, CH, 2018)	0.48
" We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel."	( Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS, 2017)	0.46
" Selumetinib pharmacokinetic profile was similar when administered as a monotherapy or in combination with docetaxel."	( Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Fukase, K; Fukino, K; Hirai, F; Kogure, Y; Niho, S; Saka, H; Sasai, M; Seto, T; Shimada, H; Yoh, K, 2018)	0.48
"Trastuzumab when combined with fluoropyrimidine and cisplatin was proven to improve survival in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) in the ToGA study."	( A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). Fujiwara, T; Hamano, R; Kagawa, S; Kambara, T; Kikuchi, S; Kishimoto, H; Kuroda, S; Kuwada, K; Muraoka, A; Nakayama, H; Nishizaki, M; Noma, K; Shigeyasu, K; Shirakawa, Y; Tanaka, N; Tanakaya, K, 2018)	0.48
"Trastuzumab in combination with docetaxel and S-1 showed effective antitumor activity and manageable toxicities as first-line treatment for patients with HER2-positive GC."	( A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). Fujiwara, T; Hamano, R; Kagawa, S; Kambara, T; Kikuchi, S; Kishimoto, H; Kuroda, S; Kuwada, K; Muraoka, A; Nakayama, H; Nishizaki, M; Noma, K; Shigeyasu, K; Shirakawa, Y; Tanaka, N; Tanakaya, K, 2018)	0.48
" Vitamin D compounds have been shown to exert synergistic effects when used in combination with different agents used in anticancer therapies in different cancer models."	( Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J, 2018)	0.48
" We previously showed, using the LTL-313H subrenal capsule patient-derived metastatic PCa xenograft model, that docetaxel combined with Aneustat (OMN54), a multivalent plant-derived therapeutic, led to marked synergistic tumour growth inhibition."	( Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. Ci, X; Clermont, PL; Collins, CC; Dong, X; Gout, PW; Hao, J; Lin, D; Qu, S; Wang, Y; Wu, R; Xue, H, 2018)	0.48
" The drug combination markedly downregulated expression of cancer driver genes such as FOXM1 (and FOXM1-target genes)."	( Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. Ci, X; Clermont, PL; Collins, CC; Dong, X; Gout, PW; Hao, J; Lin, D; Qu, S; Wang, Y; Wu, R; Xue, H, 2018)	0.48
"5-35 mg/m2) in combination with docetaxel (60 or 75 mg/m2) and cisplatin (75 mg/m2), agents were administered 24 h apart every 3 weeks to Japanese patients with advanced solid tumors."	( Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors. Ecstein-Fraisse, E; Hida, T; Horiike, A; Horio, Y; Nishio, M; Satouchi, M; Sunaga, Y, 2018)	0.48
"This was the first large-scale prospective observational Japanese study evaluating the safety and efficacy of bevacizumab combined with paclitaxel and carboplatin for newly diagnosed advanced ovarian cancer."	( Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N, 2019)	0.51
" We report a case of ocular KS successfully treated with HAART combined with 8 cycles of weekly docetaxel."	( A Case of Ocular Kaposi's Sarcoma Successfully Treated with Highly Active Antiretroviral Therapy (HAART) Combined with Docetaxel. Gotlieb, V; Jin, C; Kaur, A; Kodali, S; Minhas, H, 2018)	0.48
" CDDP combined with DTX had synergistic effects at lower concentrations and promoted apoptosis, but did not increase the side effects of chemotherapy."	( Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice. Cai, L; Guo, W; Jin, L; Luo, Y; Tang, X; Tao, F; Tao, H; Zhang, Z; Zhao, Y, 2018)	0.48
"Subcutaneous trastuzumab in combination with pertuzumab and docetaxel is well tolerated and effective in HER2-positive advanced breast cancer."	( Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer. Ardavanis, A; Dede, M; Drizou, M; Kapiris, M; Kokkali, S; Magou, E; Nasi, D; Ntokou, A; Prevezanou, M; Stefanou, D; Tripodaki, ES; Zylis, D, 2018)	0.48
"The purpose of this study was to analyze the efficacy and safety of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma (NPC)."	( An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma. Chen, J; Huang, X; Lin, J; Lin, S; Wu, G; Yang, S; Zhang, S; Zhou, L, )	0.13
" Owing to the complexity of drug combination, the mechanism of SQFZ injection in combination with docetaxel on lung cancer remains unclear."	( Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer. Baochen, Z; Cheng, W; Li, T; Shouying, D; Wantong, Z; Yali, W; Yang, L; Yue, Z; Zongxi, S, 2019)	0.51
"To report long-term outcome survival analysis of docetaxel-based chemotherapy combined with dexamethasone in castration-resistant prostate cancer patients (Japan-Multinational Trial Organization Pca10-01 trial)."	( Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. Akakura, K; Fujimoto, K; Gotoh, M; Hirao, Y; Ina, K; Nagata, H; Nishimura, K; Ogawa, O; Okajima, E; Tanaka, N; Teramukai, S, 2019)	0.51
"Docetaxel-based chemotherapy combined with dexamethasone can achieve excellent survival efficacy not only in M0 castration-resistant prostate cancer patients, but also in M1 castration-resistant prostate cancer patients."	( Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. Akakura, K; Fujimoto, K; Gotoh, M; Hirao, Y; Ina, K; Nagata, H; Nishimura, K; Ogawa, O; Okajima, E; Tanaka, N; Teramukai, S, 2019)	0.51
"To determine the maximum tolerated dose and tolerability of (1) afatinib in combination with postoperative radiation therapy (PORT) for patients with intermediate-risk squamous cell carcinoma of the head and neck (SCCHN) and (2) afatinib in combination with PORT and weekly docetaxel for high-risk SCCHN."	( A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Bacay, A; Bakst, RL; Catalano, PJ; Chau, NG; Gupta, V; Haddad, RI; Hanna, GJ; Mahmood, U; Margalit, DN; McHugh, P; Misiukiewicz, KJ; Posner, M; Rabinowits, G; Rath, L; Rawal, B; Schoenfeld, JD; Tishler, RB, 2019)	0.51
"Afatinib in combination with PORT for mucosal SCCHN was difficult to tolerate because of grade 3 toxicity, mostly mucositis, in a cohort of patients requiring high-dose PORT to the oral cavity."	( A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Bacay, A; Bakst, RL; Catalano, PJ; Chau, NG; Gupta, V; Haddad, RI; Hanna, GJ; Mahmood, U; Margalit, DN; McHugh, P; Misiukiewicz, KJ; Posner, M; Rabinowits, G; Rath, L; Rawal, B; Schoenfeld, JD; Tishler, RB, 2019)	0.51
"Radium-223 in combination with docetaxel at the RP2D was well tolerated."	( Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Antonarakis, ES; Carrasquillo, JA; Deandreis, D; Fizazi, K; Higano, CS; Jacene, HA; Loriot, Y; Lu, C; Morris, MJ; Pandit-Taskar, N; Petrenciuc, O; Ryan, CJ; Shevrin, DH; Sweeney, CJ; Vesselle, H, 2019)	0.51
" A paradigm shift in the treatment of patients with mCSPC has now been initiated by the results of three major phase 3 clinical trials (CHAARTED, STAMPEDE, LATITUDE): They demonstrated a significant advantage of ADT in combination with docetaxel or abiraterone/prednisone over ADT alone."	( [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer]. Hammerer, P; Manka, L, 2019)	0.51
"This review presents the current evidence for the use of docetaxel or abiraterone/prednisone in combination with ADT and discusses-in the absence of directly comparing studies-which patients may have an advantage of ADT plus abiraterone/prednisone over ADT plus docetaxel or vice versa."	( [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer]. Hammerer, P; Manka, L, 2019)	0.51
"This was a multicenter, single-arm phase I/II study to evaluate the efficacy of intermitted erlotinib in combination with docetaxel in patients with EGFR-negative NSCLC who failed one prior chemotherapy."	( Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L). Asai, K; Chiba, Y; Hayashi, H; Kasai, T; Kawaguchi, T; Kijima, T; Kimura, T; Kogure, Y; Nakagawa, K; Nakanishi, Y; Niwa, T; Oguri, T; Ono, A; Tanaka, H; Watanabe, K; Yamamoto, N; Yano, S; Yoshimura, N; Yoshioka, H, 2019)	0.51
"Docetaxel has been shown to be an effective chemotherapy agent when combined with androgen deprivation therapy for hormone sensitive metastatic prostate cancer (CaP)."	( Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. Chi, C; Dong, B; Karnes, RJ; Pan, J; Qian, H; Sha, J; Shao, X; Wang, Y; Xu, F; Xue, W; Zhu, Y, 2019)	0.51
"To compare the clinical efficacy and safety of FOLFOX6 regimen and docetaxel-cisplatin-fluorouracil (DCF) regimen as neoadjuvant chemotherapy (NACT) combined with radical gastrectomy in treating advanced gastric cancer."	( A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Li, E; Liu, Y; Shao, H; Tai, Q; Zhao, R, )	0.13
"The clinical data of 96 patients with advanced gastric cancer admitted and subjected to NACT combined with radical gastrectomy in our hospital from September 2013 to September 2017 were collected, and the patients were divided into FOLFOX6 group (n=48) and DCF group (n=48) according to the NACT regimens received."	( A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Li, E; Liu, Y; Shao, H; Tai, Q; Zhao, R, )	0.13
"The FOLFOX6 regimen and DCF regimen as NACT combined with radical gastrectomy have curative effects in treating locally advanced gastric cancer, preferable clinical response rate and disease control rate can be obtained, and the adverse reactions of the chemotherapy are tolerable."	( A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer. Li, E; Liu, Y; Shao, H; Tai, Q; Zhao, R, )	0.13
"This study evaluated the efficacy and safety of docetaxel combined with lobaplatin, relative to docetaxel combined with gemcitabine, for treating patients with recurrent metastatic breast cancer (rMBC)."	( Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer. Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H, 2019)	0.51
" However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear."	( Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter rando Chen, D; Gao, J; Huang, C; Huang, H; Liang, J; Liu, M; Liu, W; Lu, Y; Luo, Z; Ning, X; Wang, R, 2019)	0.51
" The aim of this phase II trial was to examine whether KRM-20 in combination with docetaxel and dexamethasone enhances the antitumor effects in patients with castration-resistant prostate cancer (CRPC)."	( Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Arai, G; Egawa, S; Eto, M; Itoh, K; Kakuma, T; Matsumoto, K; Naito, S; Nakagawa, M; Nasu, Y; Noguchi, M; Ohyama, C; Sasada, T; Shichijo, S; Suekane, S; Uemura, H; Yamada, A, 2020)	0.56
"The objectives of this study were to evaluate survival in 141 patients with stage II-IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors."	( Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma. Endo, M; Hasegawa, H; Kaneko, T; Kanno, C; Kano, M; Kitabatake, T; Monma, T; Sato, E; Takeishi, E; Yamazaki, M, 2020)	0.56
"To explore the therapeutic effects and prognosis of osimertinib combined with docetaxel for non-small cell lung cancer (NSCLC)."	( Analysis of efficacy and prognosis of Osimertinib combined with docetaxel for non-small cell lung cancer. Huang, Y; Shi, Y; Yin, X; Zhang, Q, )	0.13
" Patients in the control group took osimertinib tablets, while patients in the drug combination group were given intravenous docetaxel in addition to the oral administration of osimertinib."	( Analysis of efficacy and prognosis of Osimertinib combined with docetaxel for non-small cell lung cancer. Huang, Y; Shi, Y; Yin, X; Zhang, Q, )	0.13
"The overall response rate (RR) and disease control rate (DCR) in the drug combination group were 25."	( Analysis of efficacy and prognosis of Osimertinib combined with docetaxel for non-small cell lung cancer. Huang, Y; Shi, Y; Yin, X; Zhang, Q, )	0.13
"The therapeutic effect of osimertinib combined with docetaxel is better than that of osimertinib alone, but the toxic and side effects of combined use are significantly higher, suggesting that enteral administration should be conducted during the medication period."	( Analysis of efficacy and prognosis of Osimertinib combined with docetaxel for non-small cell lung cancer. Huang, Y; Shi, Y; Yin, X; Zhang, Q, )	0.13
"To explore the efficacy and safety of bevacizumab combined with docetaxel in the treatment of human epidermal growth factor receptor-2 (HER-2)-negative recurrent metastatic breast cancer."	( Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer. Geng, J; Gong, J; Kong, X; Wu, M; Yu, W; Zeng, L, )	0.13
" Sixty-four patients were treated with bevacizumab combined with docetaxel (Bevacizumab group), while the remaining 64 patients were treated with docetaxel alone (Docetaxel group)."	( Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer. Geng, J; Gong, J; Kong, X; Wu, M; Yu, W; Zeng, L, )	0.13
"Bevacizumab combined with docetaxel has more excellent efficacy than docetaxel alone in the treatment of HER-2-negative recurrent metastatic breast cancer, and it prolongs the survival of patients, with tolerable adverse reactions, which is worthy of further clinical application."	( Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer. Geng, J; Gong, J; Kong, X; Wu, M; Yu, W; Zeng, L, )	0.13
"To explore the efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on the expressions of esophageal cancer-related gene 4 (ECRG4) and vascular endothelial growth factor (VEGF)."	( Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. Deng, M; Gao, Y; Liu, G; Zuo, D, )	0.13
" Chemotherapy combining cisplatin with fluorouracil was administered in the control group, while nedaplatin combined with docetaxel was given in the observation group."	( Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. Deng, M; Gao, Y; Liu, G; Zuo, D, )	0.13
"Nedaplatin combined with docetaxel has better short-term efficacy in nasopharyngeal carcinoma, with milder adverse reactions, and it can reduce the levels of serum HIF-1α and VEGF, and up-regulate ECRG4 expression in patients, exerting an anti-carcinoma effect."	( Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. Deng, M; Gao, Y; Liu, G; Zuo, D, )	0.13
" Various natural compounds, including epigallocatechin-3-gallate (EGCG) in combination with taxane, have the potential to be developed as anticancer therapeutics."	( Multifunctional nanoparticles for targeting the tumor microenvironment to improve synergistic drug combinations and cancer treatment effects. Chen, ML; Huang, CM; Lai, CJ; Lin, YH; Lin, YN, 2020)	0.56
" This report describes a Phase Ib clinical trial investigating PG-11047 in combination with cytotoxic and anti-angiogenic chemotherapeutic agents in patients with advanced refractory metastatic solid tumors or lymphoma."	( A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH, 2021)	0.62
"The maximum tolerated dose (MTD) of PG-11047 in combination with bevacizumab, erlotinib, cisplatin, and 5-FU was 590 mg."	( A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH, 2021)	0.62
"Results of this Phase Ib trial indicate that PG-11047 can be safely administered to patients in combination with bevacizumab, erlotinib, cisplatin, and 5-FU on the once weekly dosing schedule described and may provide therapeutic benefit."	( A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH, 2021)	0.62
" PVHA appeared to demonstrate an acceptable safety profile when given with docetaxel without significantly changing the plasma PK of docetaxel in patients with stage IIIB/IV NSCLC."	( Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer. Baumgart, M; Fathallah, AM; Gabrail, N; Heineman, T; Mager, DE; Maneval, DC; Nanavati, C; Sekulovich, RE; Van Wart, SA, 2021)	0.62
"This study described the application of topical ALA-PDT combined with TPF (docetaxel, cisplatin, and 5-fluorouracil) ICT in eleven patients treated due to locally advanced in the oral cavity."	( The use of topical ALA-photodynamic therapy combined with induction chemotherapy for locally advanced oral squamous cell carcinoma. Li, N; Meng, J; Wang, X; Wen, N, )	0.13
" Then ten patients with surgery experienced radical surgery alone or combined with radiotherapy except a patient with serious heart condition."	( The use of topical ALA-photodynamic therapy combined with induction chemotherapy for locally advanced oral squamous cell carcinoma. Li, N; Meng, J; Wang, X; Wen, N, )	0.13
"We describe here characterization of the response of local and metastatic disease and immunomodulation following intratumoral (IT) injection of submicron particle docetaxel (SPD) administered alone or in combination with systemic antibody anti-mCTLA-4 (anti-mCTLA-4) in the metastatic 4T1-Luc2-1A4 (4T1) murine breast cancer model."	( Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions. diZerega, G; Hesseltine, H; Marin, A; Maulhardt, H, 2021)	0.62
"To observe the early efficacy and toxicity of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer (mCRPC)."	( [Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer]. Bai, GC; He, ZS; Jin, J; Song, Y; Yu, W, 2021)	0.62
" They were given the chemotherapy of docetaxel combined with carboplatin."	( [Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer]. Bai, GC; He, ZS; Jin, J; Song, Y; Yu, W, 2021)	0.62
"This report is a case series study of docetaxel combined with carboplatin in the treatment of mCRPC reported in China and the conclusions are representative."	( [Clinical efficacy of docetaxel combined with carboplatin in patients with metastatic castration-resistant prostate cancer]. Bai, GC; He, ZS; Jin, J; Song, Y; Yu, W, 2021)	0.62
" There are few studies on whether docetaxel combined with PD-1/PD-L1 inhibitor can increase the efficacy and make patients better benefit."	( [Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer]. Chen, Q; Guo, Q; Li, Y; Shi, W; Wang, C; Yang, S; Zhang, W, 2021)	0.62
"049) were independent prognostic factors for the effect of docetaxel combined with PD-1/PD-L1 inhibitor."	( [Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer]. Chen, Q; Guo, Q; Li, Y; Shi, W; Wang, C; Yang, S; Zhang, W, 2021)	0.62

Excerpt	Reference	Relevance
" This could be ascribed to faster metabolism, faster excretion or other bioavailability problems."	( Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel). Bissery, MC; Combeau, C; Duclos, O; Lavelle, F; Ojima, I; Riou, JF; Vrignaud, P; Zucco, M, 1994)	0.29
" In the present study, we have used HYB 165, a novel DNA/RNA hybrid mixed backbone oligonucleotide that exhibits improved pharmacokinetic and bioavailability properties in vivo and is presently undergoing Phase I trials."	( Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Agrawal, S; Bianco, AR; Caputo, R; Ciardiello, F; Mendelsohn, J; Pepe, S; Pomatico, G; Tortora, G, 1999)	0.3
"Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp)."	( Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW, 2001)	0.31
" The absolute bioavailability of oral docetaxel was 8% +/- 6% without and 90% +/- 44% with CsA."	( Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW, 2001)	0.31
"Coadministration of oral CsA strongly enhanced the oral bioavailability of docetaxel."	( Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW, 2001)	0.31
" The objectives of our study were to characterize the in vitro effects of NaBt and/or docetaxel on the growth, cell cycle and apoptosis of human bladder cancer cells, and to determine whether tumor growth in vivo is inhibited by isobutyramide, an orally bioavailable Bt analogue, and/or docetaxel by using Bcl-2-transfected human bladder cancer cell line KoTCC-1/BH and control vector only-transfected cell line KoTCC-1/C."	( Overexpression of Bcl-2 regulates sodium butyrate- and/or docetaxel-induced apoptosis in human bladder cancer cells both in vitro and in vivo. Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H, 2001)	0.31
" For the taxanes paclitaxel and docetaxel, however, low oral bioavailability has limited development of treatment by the oral route."	( Oral delivery of taxanes. Beijnen, JH; Malingré, MM; Schellens, JH, 2001)	0.31
" In addition, the reduced recognition of several compounds by multi-drug-resistance related transport systems has yielded some orally bioavailable compounds with marked in vivo antitumor activity."	( Preclinical evaluation of new taxoids. Bissery, MC, 2001)	0.31
" However, due to the low oral bioavailability of R101933 and high interpatient variability, no further attempts to increase the level of P-gp inhibition were made."	( Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J, 2002)	0.31
" We have now explored the mechanisms responsible for the low oral bioavailability of docetaxel, a structurally related taxane drug."	( Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Bardelmeijer, HA; Beijnen, JH; Buckle, T; Huisman, MT; Ouwehand, M; Schellens, JH; van Tellingen, O, 2002)	0.31
" The apparent first-order absorption rate constant from the peritoneal cavity (k(a)) of TXL was about one-twentieth of that of TXT."	( Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles. Furui, N; Furukawa, H; Fushida, S; Ishizaki, J; Jin, M; Miwa, K; Miyamoto, K; Nomura, M; Yamazaki, M; Yokogawa, K; Yoshihara, H, 2004)	0.32
"Docetaxel given orally as monotherapy results in low bioavailability of <10%."	( Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Beijnen, JH; Bosch, TM; Fitzpatrick, A; Kuppens, IE; Rosing, H; Schellens, JH; van Maanen, MJ, 2005)	0.33
"The apparent relative oral bioavailability of docetaxel was 26+/-8%."	( Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Beijnen, JH; Bosch, TM; Fitzpatrick, A; Kuppens, IE; Rosing, H; Schellens, JH; van Maanen, MJ, 2005)	0.33
"The relative apparent bioavailability of 26% was most likely caused by a significant effect of OC144-093 on the oral uptake of docetaxel."	( Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Beijnen, JH; Bosch, TM; Fitzpatrick, A; Kuppens, IE; Rosing, H; Schellens, JH; van Maanen, MJ, 2005)	0.33
"The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1 H-2-benzopyran-3-yl) propionic acid (NM-3) has completed phase I clinical evaluation as an orally bioavailable angiogenesis inhibitor."	( The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. Agata, N; Bamberg, M; Kharbanda, S; Kufe, D; Milhollen, M; Nogi, H; Pu, M; Weitman, S, 2005)	0.33
" The bioavailability and distribution in different organs were also studied."	( Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. Ben Reguiga, M; Bonhomme-Faivre, L; Farinotti, R, 2007)	0.34
" In this respect various prodrug and drug targeting strategies have been envisioned either to improve oral bioavailability or tumor specific delivery of taxoids."	( Improved biochemical strategies for targeted delivery of taxoids. Ganesh, T, 2007)	0.34
"First-pass metabolism is a common cause of incomplete and variable absolute bioavailability for an orally dosed drug."	( Gut instincts: CYP3A4 and intestinal drug metabolism. Thummel, KE, 2007)	0.34
"These data suggest that GCP, an isoflavone-enriched compound with minimal side-effects and far superior intestinal absorption rate of genistein, has significant clinical potential in combination with docetaxel, bicalutamide or targeted agents for the treatment of advanced CaP."	( Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. Burich, RA; Holland, WS; Mack, PC; Tepper, C; Vinall, RL; White, RW, 2008)	0.35
" Case studies discussed in this review include: a) the use of probenecid to block the organic anion renal transport of oseltamivir carboxylate (a key active metabolite of oseltamivir phosphate) to reduce the oral dose of oseltamivir phosphate; b) the use of rifampicin to induce the CYP2C19 enzyme and thereby, promote the formation of a potent active metabolite M8 (nelfinavir hydroxyl-t-butylamide) and achieve sustained blood levels to combat HIV infection along with ritonavir; c) the use of CYP3A4 inhibitors such as ketoconazole, cyclosporin A, ritonavir etc to overcome the extensive presystemic metabolism of docetaxel and enhance the oral bioavailability of docetaxel."	( Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Srinivas, NR, 2009)	0.35
" The apparent oral bioavailability of docetaxel combined with ritonavir simultaneously or ritonavir given 60 minutes before docetaxel was 131% +/- 90% and 161% +/- 91%, respectively."	( Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Beijnen, JH; Huitema, A; Jansen, RS; Keessen, M; Oostendorp, RL; Rosing, H; Schellens, JH; Ter Heine, R, 2009)	0.35
"Coadministration of ritonavir significantly enhanced the apparent oral bioavailability of docetaxel."	( Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Beijnen, JH; Huitema, A; Jansen, RS; Keessen, M; Oostendorp, RL; Rosing, H; Schellens, JH; Ter Heine, R, 2009)	0.35
" The first-order peritoneal cavity-systemic circulation absorption rate constant of paclitaxel was 1/8 that of docetaxel."	( Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats. Ito, C; Kamijo, Y; Miyamoto, K; Nomura, M; Sai, Y, 2010)	0.36
"A microemulsion system of docetaxel was prepared and evaluated for its solubilization capacity and oral bioavailability improvement."	( Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. Choi, MK; Chung, SJ; Cui, FD; Kim, DD; Kim, JS; Mu, CF; Shim, CK; Yin, YM, 2009)	0.35
" By comparing the interactions of each analogue with beta-tubulin, the structure-activity relationships are summarized as follow: C-2 benzoyl and taxane ring systems are the essential groups for microtubule binding, the improvements of bioactivity and bioavailability are dependent on the substituents at positions C-1, C-4, C-7, C-9, C-10, and C-14, whereas the C-13 side chain mainly provides a specific binding."	( Structure-activity relationship of taxol inferring from docking taxol analogues to microtubule binding site. Ma, Y; Xiang, F; Yin, R; Yu, J; Yu, L, )	0.13
"A mixed micelle that comprised of MPEG-PLA (MPP) and Pluronic copolymers was developed for enhanced bioavailability and to overcome multidrug resistance of docetaxel in cancer therapy."	( The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Balakrishnan, P; Choi, HG; Chung, SJ; Cui, FD; Kim, DD; Lee, YB; Mu, CF; Shim, CK; Yin, YM; Yong, CS, 2010)	0.36
"Docetaxel has a low oral bioavailability due to affinity for P-glycoprotein and cytochrome P450 (CYP) 3A4 enzymes."	( Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Beijnen, JH; Huitema, AD; Koolen, SL; Oostendorp, RL; Schellens, JH, 2010)	0.36
"Gut bioavailability of docetaxel increased approximately two-fold from 19 to 39% (CV 13%) with ritonavir co-administration."	( Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Beijnen, JH; Huitema, AD; Koolen, SL; Oostendorp, RL; Schellens, JH, 2010)	0.36
" Tesmilifene did not increase the values of AUC or of absolute oral bioavailability (F) for docetaxel after oral administration of docetaxel with tesmilifene."	( Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. Cho, IH; Choi, YH; Lee, JH; Lee, MG; Suh, JH, 2010)	0.36
" This study assesses the combination of well tolerated and orally bioavailable formulations of ginsenoside Rh2 or its aglycone aPPD with docetaxel."	( Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer. Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E, 2010)	0.36
" The developed and validated method was successfully applied to relative bioavailability study for the preclinical evaluation of a new injectable DTX-sulfobutyl ether beta-cyclodextrin (DTX-SBE-beta-CD) inclusion complex freeze-dried powder (test preparation), compared with the reference preparation (DTX injection, Taxotere) in healthy rabbits."	( Development and validation of a nylon6 nanofibers mat-based SPE coupled with HPLC method for the determination of docetaxel in rabbit plasma and its application to the relative bioavailability study. Gu, Z; Shen, Y; Wang, M; Xu, Q; Xu, S; Yin, X; Zhang, L; Zhang, N, 2010)	0.36
" In order to improve the oral bioavailability of docetaxel, a component of turmeric, curcumin, which can down-regulate the intestinal P-glycoprotein and CYP3A protein levels, was used for the pre-treatment of rats before the oral administration of docetaxel."	( Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Choi, HG; Kim, DH; Sung, JH; Yan, YD; Yong, CS, 2010)	0.36
" Another disadvantage of the drug is that it has a very low oral bioavailability and can, therefore, only be administered intravenously."	( Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Beijnen, JH; Lagas, JS; Rosing, H; Schinkel, AH; van Waterschoot, RA; Wagenaar, E, 2010)	0.36
"Docetaxel, an efficient chemotherapeutic drug, exhibits low and variable oral bioavailability due to the active efflux by P-glycoprotein (P-gp) and more so to CYP3A4 gut metabolism."	( High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Attili-Qadri, S; Benita, S; Farber, S; Harush-Frenkel, O; Lazarovici, P; Lecht, S; Nassar, T, 2011)	0.37
" The bioavailability of the DTX-S-sSEDDS(1) compared with other formulations of DTX was evaluated in rats."	( Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Chen, C; Chen, Y; Chen, Z; Liu, H; Shi, Q; Zheng, J, 2011)	0.37
" Because docetaxel has a very low permeability and a very low aqueous solubility (biopharmaceutical classification system class IV), a pharmacokinetic booster was combined with a newly developed solid dispersion formulation to improve the oral bioavailability of docetaxel."	( Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Beijnen, JH; Huitema, AD; Koolen, SL; Moes, JJ; Nuijen, B; Schellens, JH, 2011)	0.37
" Oral bioavailability in rats was 48-73% of parenteral administration, and antitumor activity in mice was equivalent by both routes."	( Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Amedio, J; Jones, B; Komarnitsky, P; Miller, GT; Wallner, BP, 2012)	0.38
" Morin did not increase AUC or the absolute oral bioavailability (F) for docetaxel after the oral administration of docetaxel in control and DMBA rats with and without morin."	( Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. Kim, SH; Lee, DY; Lee, JH; Lee, MG; Lyuk, KC; Yang, SH, 2011)	0.37
" Thus, the enhanced bioavailability of oral docetaxel by curcumin SEDDS seemed to be likely due to an inhibition function of cytochrome P450 (CYP) 3A and P-glycoprotein (Pgp) in the intestines of the rats."	( Effect of dose and dosage interval on the oral bioavailability of docetaxel in combination with a curcumin self-emulsifying drug delivery system (SEDDS). Choi, HG; Choi, YK; Kim, JO; Marasini, N; Woo, JS; Yan, YD; Yong, CS, 2012)	0.38
"In our era there has been several anti-cancer drugs which have undergone both experimental and clinical trials; however, due to their poor solubilities, numerous side effects, insufficient bioavailability and poor compliance, many have resulted into poor outcomes."	( Novel hydrophilic taxane analogues inhibit growth of cancer cells. Dong, Z; Fauzee, NJ; Juan, P; Li, QG; Lu, X; Mandarry, MT; Wang, T; Wang, YL, 2012)	0.38
" The current study was intended to determine whether GDC-0941, an orally bioavailable class I selective PI3K inhibitor, enhances the antitumor activity of docetaxel in human breast cancer models in vitro and in vivo."	( GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Belmont, LD; Belvin, M; Berry, L; Friedman, LS; Guan, J; Koeppen, H; Lee, LB; Prior, WW; Sampath, D; Wallin, JJ, 2012)	0.38
"The aim of this research is to develop novel chitosan nanoparticles including cyclodextrins complexes for docetaxel (DTX), evaluate the performance of nanoparticles which could enhance the oral permeability and bioavailability of DTX in vitro and in vivo."	( Sulfobutylether-β-cyclodextrin/chitosan nanoparticles enhance the oral permeability and bioavailability of docetaxel. Fang, L; Shen, Q; Wu, J, 2013)	0.39
" Both compounds had favorable drug-like properties, and acceptable oral bioavailability (21-50 %) in mice, rats, and dogs."	( Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Ahn, S; Chen, J; Costello, TA; Dalton, JT; Dalton, MN; Li, CM; Li, W; Lu, Y; Miller, DD; Narayanan, R; Snyder, LM, 2012)	0.38
"These studies highlight the potent and broad anticancer activity of two orally bioavailable compounds, offering significant pharmacologic advantage over existing drugs of this class for multidrug resistant or taxane-refractory cancers."	( Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Ahn, S; Chen, J; Costello, TA; Dalton, JT; Dalton, MN; Li, CM; Li, W; Lu, Y; Miller, DD; Narayanan, R; Snyder, LM, 2012)	0.38
"The aim of this research work was to investigate the potential of lecithin nanoparticles (LNs) in improving the oral bioavailability of docetaxel."	( Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Cao, S; Feng, J; Hu, F; Hu, K, 2012)	0.38
" administration and an increase in the oral bioavailability of orally given DTX following an IFN-α treatment."	( Interferon-alpha improves docetaxel antitumoral and antimetastatic efficiency in Lewis lung carcinoma bearing mice. Ben Reguiga, M; Bonhomme-Faivre, L; Bouquet, C; Farinotti, R, 2012)	0.38
" Unlike paclitaxel, docetaxel is extensively metabolized by CYP3A4 and its oral bioavailability can be enhanced in mice and humans by coadministration of the potent CYP3A inhibitor ritonavir."	( P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Beijnen, JH; Hendrikx, JJ; Lagas, JS; Rosing, H; Schellens, JH; Schinkel, AH, 2013)	0.39
" Its physicochemical properties and oral bioavailability were investigated compared to a clear docetaxel solution administered intravenously or orally to rats."	( Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel. Choi, HG; Kim, DH; Kim, DW; Kim, JK; Kim, JO; Marasini, N; Quan, Q; Yong, CS, 2013)	0.39
"To investigate the potential of thermosensitive and biadhesive nanomicelles in improving the bioavailability of docetaxel (DCT) and its chemotherapeutic effect."	( Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect. Choi, HG; Kim, DW; Kim, JA; Kim, JK; Kim, JO; Ku, SK; Oh, DH; Oh, YK; Park, YJ; Ramasamy, T; Seo, YG; Yeo, WH; Yong, CS, 2013)	0.39
" We observed a high rectal bioavailability of 29% DCT compared to that following oral administration in rats, as it successfully evaded the multidrug efflux transporters and hepatic first-pass metabolism."	( Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect. Choi, HG; Kim, DW; Kim, JA; Kim, JK; Kim, JO; Ku, SK; Oh, DH; Oh, YK; Park, YJ; Ramasamy, T; Seo, YG; Yeo, WH; Yong, CS, 2013)	0.39
"Taken together, our novel thermosensitive and biadhesive nanomicelles demonstrated the ability to improve the bioavailability and chemotherapeutic potential of DCT in vivo."	( Docetaxel-loaded thermosensitive and bioadhesive nanomicelles as a rectal drug delivery system for enhanced chemotherapeutic effect. Choi, HG; Kim, DW; Kim, JA; Kim, JK; Kim, JO; Ku, SK; Oh, DH; Oh, YK; Park, YJ; Ramasamy, T; Seo, YG; Yeo, WH; Yong, CS, 2013)	0.39
" 2017h×ng/mL, respectively), resulting in an absolute bioavailability estimate of 38%."	( Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. Harasym, T; Liboiron, B; Mayer, LD; McNeil, SE; Skoczen, S; Stern, ST; Tardi, P; Xie, S; Zou, P, 2013)	0.39
"The main purpose of this study was to investigate the potential of self-nano-emulsifying drug delivery system (SNEDDS) in improving the bioavailability of docetaxel (DCT) and its chemotherapeutic effect."	( Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Choi, HG; Kim, DH; Kim, DW; Kim, JH; Kim, JK; Kim, JO; Marasini, N; Oh, YK; Ramasamy, T; Seo, YG; Yong, CS, 2013)	0.39
"The aim of this study was to evaluate a nanoparticulate system with mucoadhesion properties composed of a core of polymethyl methacrylate surrounded by a shell of thiolated chitosan (Ch-GSH-pMMA) for enhancing oral bioavailability of docetaxel (DTX), an anticancer drug."	( Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies. Atyabi, F; Dinarvand, R; Kebriaeezadeh, A; Ostad, SN; Saremi, S, 2013)	0.39
"Metronomic CYC exerts anti-tumoral effects in an in vivo model of prostate cancer and in patients with CRPC, and also increases the bioavailability of docetaxel."	( Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. Arigoni, M; Baldi, A; Boccardo, F; Boccellino, M; Calogero, RA; Cantarella, D; Cardillo, I; Carlini, P; Cognetti, F; Contestabile, M; Crispi, S; Dell'Anna, ML; Felici, A; Ferretti, G; Galluzzo, P; Picardo, M; Piccolo, MT; Quagliuolo, L; Spugnini, EP, 2013)	0.39
" The oral bioavailability studies were conducted in rats and the pharmacokinetic parameters were evaluated."	( Preparation and evaluation in vitro and in vivo of docetaxel loaded mixed micelles for oral administration. Dou, J; Liu, X; Zhai, G; Zhang, H; Zhang, M, 2014)	0.4
"Dichloroacetate (DCA) is a highly bioavailable small molecule that inhibits pyruvate dehydrogenase kinase, promoting glucose oxidation and reversing the glycolytic phenotype in preclinical cancer studies."	( Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. Bahng, A; Black, A; Britten, CD; Christofk, HR; Crabtree, MJ; Dubinett, SM; Garon, EB; Hong, CS; Hosmer, W; Kabbinavar, F; Kamranpour, N; Michelakis, ED; Patel, C; Pitts, S; Slamon, DJ; von Euw, E, 2014)	0.4
" Tween 80-emulsified SLNs showed enhanced intestinal absorption, lymphatic uptake, and relative oral bioavailability of docetaxel compared with Taxotere in rats."	( Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Cho, HJ; Kim, DD; Park, JW; Yoon, IS, 2014)	0.4
" The resulting low oral bioavailability can be boosted by co-administration of P-gp or CYP3A4 inhibitors."	( Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Beijnen, JH; Hendrikx, JJ; Lagas, JS; Rosing, H; Schellens, JH; Schinkel, AH; Wagenaar, E, 2014)	0.4
" More important, the pharmacokinetic study revealed that the DTX-micelle-hydrogel significantly improved the oral bioavailability of docetaxel (75."	( PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy. Chen, L; Luo, F; Qian, Z; Tan, L; Wang, Y; Wei, Y; Zhao, Q, 2014)	0.4
"Micro- and nanoparticle formulations are widely used to improve the bioavailability of low solubility drugs."	( Docetaxel load biodegradable porous microspheres for the treatment of colorectal peritoneal carcinomatosis. Fan, R; Guo, G; Han, B; Luo, Y; Peng, X; Wang, Y; Wu, M; Zheng, Y; Zhou, L, 2014)	0.4
"The primary aim of this work was to investigate the potential of bile salt, sodium taurocholate (NaTC), in improving the bioavailability and anti-tumor efficacy of docetaxel (DCT) upon rectal administration."	( The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles. Choi, HG; Choi, JY; Kim, DW; Kim, JH; Kim, JO; Ramasamy, T; Yong, CS, 2014)	0.4
", between-subject coefficient of variation (CV%) for relative bioavailability for the modified fasting state was 61."	( Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Griffin, TW; Nandy, P; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK, 2014)	0.4
" The fat content of food affected relative bioavailability of abiraterone, though the extent of this effect is dependent on health status."	( Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Griffin, TW; Nandy, P; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK, 2014)	0.4
" This blended NP system can be achieved through a simple and effective nanoprecipitation technique, and possesses unique properties: i) improved long-term compatibility brought by PEG-based polymers; ii) reduced multidrug resistance mediated by P-glycoprotein (P-gp) in tumor cells and increased bioavailability of anticancer drugs by incorporation of TPGS; iii) the regulation of controlled release through polymer ratios and active targeting by FA."	( Blended nanoparticle system based on miscible structurally similar polymers: a safe, simple, targeted, and surprisingly high efficiency vehicle for cancer therapy. Huang, L; Liu, D; Liu, G; Liu, Y; Mei, L; Tao, W; Yu, Q; Zeng, X; Zhang, J; Zhu, X, 2015)	0.42
"Very low oral bioavailability due to extensive pre-systemic metabolism and P-gp efflux has constrained the oral metronomic chemotherapy of docetaxel (DTX)."	( Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. Boakye, CHA; Chowdhury, N; Doddapaneni, R; Godugu, C; Patel, K; Singh, M, 2015)	0.42
"Nanoparticulation of insoluble drugs improves dissolution rate, resulting in increased bioavailability that leads to increased stability, better efficacy, and reduced toxicity of drugs."	( Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs. Choi, EK; Choi, J; Chung, HK; Jeong, SY; Ju, EJ; Jung, J; Kim, KS; Ko, E; Lee, JH; Lee, JS; Lim, HK; Park, I; Son, WC; Song, SY, 2015)	0.42
" The relatively improved oral bioavailability and better antitumour efficacy indicated that the dual-drug CD/CS NPs developed in our study possessed significant advantages and might be a promising strategy for the development of drug, delivery systems for cancer chemotherapy."	( Co-Delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Enhancing Bioavailability and Anticancer Activities. Bu, X; Dou, L; Fang, L; Shen, Q; Wu, J, 2015)	0.42
"38-fold) and higher bioavailability (AUC0-t, 14."	( Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Ai, X; Guo, M; Guo, W; He, Z; Liu, D; Ren, G; Wang, M; Wang, Y; Wu, C, 2016)	0.43
" The pharmacokinetic profile was substantially modified and about 16-folds enhancement in bioavailability was observed vis-à-vis plain drug."	( Dextran-PLGA-loaded docetaxel micelles with enhanced cytotoxicity and better pharmacokinetic profile. Bhushan, S; Guru, SK; Katare, OP; Kaushik, L; Kumar, N; Kumar, P; Malik, R; Misra, C; Raza, K, 2016)	0.43
" Curcumin is a potential anticancer agent with p-glycoprotein (p-gp) inhibiting activity may be co-administered with docetaxel as a nanosuspension to enhance its anticancer effect by increasing the oral bioavailability and decreasing drug efflux."	( Curcumin-docetaxel co-loaded nanosuspension for enhanced anti-breast cancer activity. Baishya, R; Bharadwaj, R; Das, MK; Dash, S; Hazarika, H; Loying, P; Sahu, BP, 2016)	0.43
" The SD prepared with F68 alone significantly enhanced the dissolution but not intestinal permeation of docetaxel, leading to only limited enhancement of oral bioavailability (1."	( Poloxamer-based solid dispersions for oral delivery of docetaxel: Differential effects of F68 and P85 on oral docetaxel bioavailability. Kim, DD; Song, CK; Yoon, IS, 2016)	0.43
"8 nm) showed very high physical stability, negligible hemolysis, 428% enhancement in bioavailability with significantly higher intratumoral uptake."	( Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Behl, G; Boakye, CH; Chowdhury, N; Doddapaneni, R; Patel, K; Singh, M, 2016)	0.43
"Poor bioavailability of Docetaxel (DCT) arising due to its low aqueous solubility and permeability limits its clinical utility."	( Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity. Datta, D; Dave, KM; Gayen, JR; Gupta, AP; Mitra, K; Riyazuddin, M; Singh, A; Syed, AA; Valicherla, GR, 2016)	0.43
" Besides, the reported pharmacokinetics of PIP varied a lot without appropriate bioavailability determined from the same dose."	( Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats. Chow, MSS; Lam, CWK; Li, C; Ren, T; Wang, Q; Zhang, Y; Zuo, Z, 2016)	0.43
" In addition, the GI mucosa irritation and oral bioavailability of SLNs were also evaluated in rats."	( Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel. Cao, QR; Cao, Y; Cui, JH; Liu, JY; Lu, J; Shi, LL; Zhang, H; Zhang, XX, 2017)	0.46
"The positively charged HACC-DTX-SLNs with a stable particle size could provide the enhanced oral bioavailability of DTX in rats."	( Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel. Cao, QR; Cao, Y; Cui, JH; Liu, JY; Lu, J; Shi, LL; Zhang, H; Zhang, XX, 2017)	0.46
"Recent years, docetaxel (DTX)-loaded intelligent polymeric micelles have been regarded as a promising vehicle for DTX for the reason that compared with conventional DTX-loaded micelles, DTX-loaded intelligent micelles not only preserve the basic functions of micelles such as DTX solubilization, enhanced accumulation in tumor tissue, and improved bioavailability and biocompatibility of DTX, but also possess other new properties, for instance, tumor-specific DTX delivery and series of responses to endogenous or exogenous stimulations."	( Intelligent polymeric micelles: development and application as drug delivery for docetaxel. Li, Y; Zhai, GX; Zhang, H, 2017)	0.46
"The bioavailability of DTX-loaded Alg-BioPf-M was 27."	( Sequentially dual-targeting vector with nano-in-micro structure for improved docetaxel oral delivery in vivo. Hu, M; Qiu, L; Shen, Y, 2016)	0.43
" Although a few of them show potential in treatment of cancer, but success rate is limited due to their poor bioavailability and lack of specificity."	( Synergistic Anticancer Effect of Peptide-Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine. Biswas, A; Ghosh, S; Jana, B; Mohapatra, S; Mondal, P; Saha, A, 2017)	0.46
" As the mean particle diameter of the AuNPs decreased, their rate of absorption by the intestinal epithelium cells increased."	( Polymer decorated gold nanoparticles in nanomedicine conjugates. Capek, I, 2017)	0.46
"A novel oral drug delivery system, TPGS modified docetaxel proniosomes (DTX-TPGS-PNs), was designed to enhance the oral bioavailability and antitumor efficiency of the poorly water-soluble drug docetaxel."	( Improved Bioavailability and Antitumor Effect of Docetaxel by TPGS Modified Proniosomes: In Vitro and In Vivo Evaluations. Dang, Z; Du, J; Feng, J; Hu, K; Liu, H; Tu, L; Wang, L; Zhou, Y, 2017)	0.46
"In spite of being a very potent and promising drug against many types of cancer, docetaxel suffers the disadvantage of low solubility and poor bioavailability rendering it unsuitable for oral administration."	( P-gp modulatory acetyl-11-keto-β-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel. Banala, VT; Gayen, JR; Jajoriya, AK; Mishra, DP; Mishra, PR; Mitra, K; Mittapelly, N; Pandey, G; Sharma, S; Shukla, RP; Urandur, S; Valicherla, GR, 2017)	0.46
" Similarly, for pharmacokinetic (PK) studies, higher oral bioavailability was observed from DTX-CS-PLGA-NPs (5."	( Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Ahmad, FJ; Ahmad, N; Ahmad, R; Alam, MA; Naqvi, AA, 2018)	0.48
" A pharmacokinetic evaluation carried out intravenous administration in healthy Charles Foster rats displayed enhanced systemic bioavailability and plasma drug concentration."	( Development of long-circulating docetaxel loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles: Optimization, pharmacokinetic, cytotoxicity and in vivo assessments. Adena, SKR; Mishra, B; Mittal, P; Upadhyay, M; Vardhan, H, 2017)	0.46
"The aim of this study was to develop polyunsaturated fatty acid (PUFA) long chain glyceride (LCG) enriched self-nanoemulsifying lipidic nanomicelles systems (SNELS) for augmenting lymphatic uptake and enhancing oral bioavailability of docetaxel and compare its biopharmaceutical performance with a medium-chain fatty acid glyceride (MCG) SNELS."	( Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar systems. Beg, S; Burrow, AJ; Katare, OP; Kaur, S; Kesharwani, P; Khurana, RK; Singh, B; Singh, KK; Vashishta, RK, 2017)	0.46
" The phamacokinetic parameters AUC and Cmax were significantly increased, indicating that coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel, and their effects were in the following order: oxypeucedanin> isoimperatorin> imperatorin."	( [Effect investigation of coumarin constituents in Angelica dahurica on pharmacokinetics of docetaxel by LC-MS]. Dong, W; Guan, XJ; Guan, YM; Liang, XL; Liao, ZG; Zhao, GW; Zhu, WF, 2017)	0.46
" This nanoprimer was able to increase the blood bioavailability of nanomedicine correlated with a lower hepatic accumulation."	( Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile. Bergere, M; Berjaud, C; Germain, M; Levy, L; Meyre, ME; Mpambani, F; Paolini, M; Pottier, A; Poul, L, 2018)	0.48
" Moreover, bioavailability of DTX from BI-CHI-DTX-NC was increased by 10-folds with longer circulation time and slower plasma elimination with low tissue distribution as compared to DTX solution."	( Development of novel biotinylated chitosan-decorated docetaxel-loaded nanocochleates for breast cancer targeting. Ahiwale, R; Bothiraja, C; Mahadik, K; Pawar, A; Poudel, I, 2018)	0.48
" Its hydrophobic and high crystallization structure results in limited bioavailability in vivo."	( α-Lipoic acid stabilized DTX/IR780 micelles for photoacoustic/fluorescence imaging guided photothermal therapy/chemotherapy of breast cancer. Chen, L; Chen, X; Li, W; Peng, J; Qian, Z; Yang, Q; Zhang, L, 2018)	0.48
"The aim of this work was to investigate the potential of pegylated poly(anhydride) nanoparticles to enhance the oral bioavailability of docetaxel (DTX)."	( Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel. Espuelas, S; Irache, JM; Larrañeta, E; Reviakine, I; Ruiz-Gatón, L; Yate, LA, 2018)	0.48
" However, lack of optimal bioavailability due to poor solubility and high toxicity at its therapeutic dose has hampered the clinical use of this anticancer drug."	( Excipient selection and aerodynamic characterization of nebulized lipid-based nanoemulsion loaded with docetaxel for lung cancer treatment. Abdul Rahman, MB; Abdulmalek, E; Ahmad, H; Asmawi, AA; Masarudin, MJ; Ngan, CL; Salim, N, 2019)	0.51
" Although the cytotoxicity of DTX-LA LMs was reduced in comparison with DTX solution, the pharmacokinetic study demonstrated increased bioavailability (p < 0."	( Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer. Guan, J; Li, M; Liu, D; Wang, Y; Yang, B; Yang, R; Yu, J; Zhang, D; Zhang, H; Zhang, S; Zhang, T, 2018)	0.48
" Utilization of drug delivery system cannot just enhance particular medication conveyance to liver tissue and enhance the bioavailability of medication, yet additionally can lessen the reactions of medications when it is uniquely changed in the regards of structure adjustment or particular target particles improvement."	( Docetaxel-decorated anticancer drug and gold nanoparticles encapsulated apatite carrier for the treatment of liver cancer. Han, S; Ma, X; Wan, J; Xu, D; Yang, B; Yang, S, 2018)	0.48
" Moreover, the L-valine-valine modified NPs with shorter PEG chain exhibit distinct advantages in terms of intestinal permeability and oral absorption, resulting in significantly improved oral bioavailability of DTX."	( Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: new insights into PepT1-mediated targeting strategy. Du, Y; He, Z; Huang, D; Kan, Q; Kou, L; Li, L; Liu, K; Liu, Y; Luo, C; Sun, B; Sun, J; Tian, C; Wang, M; Wei, W, 2018)	0.48
" Recent advances in pharmaceutical research have focused on designing new and efficient drug delivery systems for site-specific targeting, thus leading to improved bioavailability and pharmacokinetics."	( Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Bukhari, NI; Hussain, I; Naveed, S; Rehman, M; Salman, O; Sarwar, HS; Shahnaz, G; Sohail, MF; Webster, TJ, 2018)	0.48
" The in vivo study revealed significant enhancement in DTX bioavailability from CS-decorated PLGA NPs with more than 4-fold increase in AUC compared to DTX solution."	( Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability. Alomrani, AH; Ashour, AE; Badran, MM; Harisa, GI; Kumar, A; Yassin, AE, 2018)	0.48
" Following oral administration, the DTX-Ag-NCPs increased bioavailability due to enhanced drug transport across gut (9 times), circulation half-life (~6."	( Polymeric nanocapsules embedded with ultra-small silver nanoclusters for synergistic pharmacology and improved oral delivery of Docetaxel. Huma, ZE; Hussain, I; Hussain, SZ; Jahan, S; Javed, I; Nadhman, A; Rehman, M; Saeed, H; Sarwar, HS; Shahnaz, G; Sohail, MF, 2018)	0.48
"5-fold increase in bioavailability of DTX was achieved with improved antitumor efficacy and reduced in vivo toxicity."	( Chemosensitizer and docetaxel-loaded albumin nanoparticle: overcoming drug resistance and improving therapeutic efficacy. Desale, JP; Jain, S; Katiyar, SS; Kushwah, V; Swami, R, 2018)	0.48
"The current study aims to improve the dissolution and oral bioavailability of a BCS IV drug docetaxel (DOC) by coamorphization with a natural P-gp inhibitor myricetin (MYR)."	( Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin. Gao, Y; Hao, T; Qian, S; Wei, Y; Zhang, J; Zhou, S, 2019)	0.51
" The findings for the co-amorphous formulation were in agreement with the pharmacokinetics data, showing a quicker onset in plasma concentration as well as a higher bioavailability for both DTX (15-fold) and BIC (3-fold) compared to the crystalline drugs alone."	( Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Bohr, A; Grohganz, H; Harmankaya, N; Löbmann, K; Nascimento, TL; Rades, T; Wang, Y; Weisser, JJ, 2019)	0.51
" This limits the bioavailability in vivo of injected hydrophobic drugs encapsulated in micellar systems."	( Micelles with ultralow critical micelle concentration as carriers for drug delivery. Cao, Z; Lu, Y; Wang, W; Xie, J; Yue, Z; Zhang, E; Zhu, H, 2018)	0.48
" However, the hydrophobicity of TXT and the poor solubility and low bioavailability of LY294002 limit their clinical application."	( PLGA nanoparticle-based docetaxel/LY294002 drug delivery system enhances antitumor activities against gastric cancer. Bian, Y; Cai, J; Liu, B; Qian, H; Qian, K; Wei, J; Yang, J; Yue, W; Zhao, W; Zuo, X, 2019)	0.51
" Pharmacokinetic properties and kinome selectivity were optimized, resulting in the identification of a new series of potent, selective, and orally bioavailable TTK inhibitors."	( Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy. Bahmanyar, S; Boylan, JF; Cashion, D; Condroski, K; Elsner, J; Fenalti, G; Fultz, KE; Krishna Narla, R; Kulkarni, A; LeBrun, L; Leftheris, K; Nagy, M; Pagarigan, B; Peng, X; Riggs, JR; Robinson, D; Tehrani, L; Tran, T; Zhu, D, 2019)	0.51
" To address these challenges, we developed a novel SNEDDS co-loaded with DTX and cyclosporine A (CsA) to achieve effective inhibition of P-gp efflux and P450 enzyme metabolization, improving oral bioavailability of DTX."	( Co-encapsulation of docetaxel and cyclosporin A into SNEDDS to promote oral cancer chemotherapy. Chen, Y; Cui, W; He, Z; Luo, C; Sun, B; Wang, C; Zhang, S; Zhao, H, 2019)	0.51
"Docetaxel (DTX) was effective in the treatment of neoplasm but could only be administered intravenously with the poor oral bioavailability owing to its undesirable solubility, remarkably metabolic conversion, and other factors."	( Preparation of Deoxycholate-Modified Docetaxel-Cimetidine Complex Chitosan Nanoparticles to Improve Oral Bioavailability. Fang, T; Shen, Q; Sun, L; Xu, Y; Yang, Y, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" With the aim of improving the bioavailability of this cytotoxic agent, nanoparticles from conjugates based on the copolymer of methyl vinyl ether and maleic anhydride (poly(anhydride)) and two different types of PEG, PEG2000 (PEG2) or methoxyPEG2000 (mPEG2), were evaluated."	( Nanoparticles from Gantrez® AN-poly(ethylene glycol) conjugates as carriers for oral delivery of docetaxel. Espuelas, S; Huarte, J; Irache, JM; Larrañeta, E; Martin-Arbella, N; Ruiz-Gatón, L, 2019)	0.51
" The low bioavailability of docetaxel, however, hinders the application of oral docetaxel in the clinic."	( A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development. Beijnen, JH; de Weger, VA; Huitema, ADR; Janssen, JM; Nuijen, B; Sawicki, E; Schellens, JHM; van Hasselt, JGC; Yu, H, 2020)	0.56
", 7-day treatment) with LC478 on P-gp known to affect docetaxel bioavailability in rats."	( Effect of treatment period with LC478, a disubstituted adamantayl derivative, on P-glycoprotein inhibition: its application to increase docetaxel absorption in rats. Ahn, HC; Chae, HS; Chin, YW; Choi, YH; Chung, SJ; Han, SY; Kim, ES; Lee, K; Lu, Q; You, BH, 2020)	0.56
" Although much effort has been made in improving the bioavailability of PTX and DTX, the low bioavailability and minimal accumulation at tumor sites are still the challenges faced in PTX and DTX therapy."	( Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics. Abasi, S; Ahmadi, Z; Ashrafizadeh, M; Dehghannoudeh, G; Khanbabaei, H; Mohamadi, N; Mohammadinejad, R; Tamaddondoust, RN; Thakur, VK; Zarrabi, A, 2020)	0.56
" However, the lack of optimal bioavailability because of high toxicity, low stability, and poor solubility has limited their clinical success."	( Modeling the Effect of Composition on Formation of Aerosolized Nanoemulsion System Encapsulating Docetaxel and Curcumin Using D-Optimal Mixture Experimental Design. Abdul Rahman, MB; Abdulmalek, E; Asmawi, AA; Salim, N, 2020)	0.56
" The natural spice extract curcumin (Cur) has been discovered to improve the bioavailability of DTX."	( Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment. Cheng, Y; Hu, Y; Lin, Y; Ran, M; Wang, B; Zheng, S, 2020)	0.56
"Nanoparticle-structuring aimed at the acetic acid (A) transporter on intestinal epithelial cells and tumor cells is a new potential strategy to enhance oral bioavailability and anti-tumor efficacy."	( Acetic acid transporter-mediated, oral, multifunctional polymer liposomes for oral delivery of docetaxel. Cai, Q; Fan, S; Guo, X; Li, Z; Xu, Q; Yang, H; Yu, W; Zang, J; Zhang, J; Zhang, Z, 2021)	0.62
" The authors further explore biomaterials that have been utilized to increase the bioavailability and bioactivity of antiangiogenic factors for better antitumor responses in GBM."	( Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. Chew, SA; Ding, MH; Hasbum, A; Jr, JAA; Levy, A; Quintanilla, J, 2021)	0.62
" Nano drug delivery enables improved pharmacokinetic profile, bioavailability and therapeutic efficiency compared to the regular chemotherapeutic drugs."	( An effective strategy for development of docetaxel encapsulated gold nanoformulations for treatment of prostate cancer. Ravi Shankaran, D; Thambiraj, S; Vijayalakshmi, R, 2021)	0.62
" None of the tested CYP3A, ABCB1, ABCC2, and SLCO1B3 genotypes and diplotypes showed a significant relation with an altered bioavailability or clearance of either docetaxel or ritonavir."	( Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir. Beijnen, JH; Dorlo, TPC; Huitema, ADR; Marchetti, S; Pluim, D; van Eijk, M, 2021)	0.62
" However, the poor bioavailability and catastrophic side effects brought about limitations to clinical practice."	( Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells. Li, R; Liu, B; Liu, F; Liu, Q; Meng, F; Wang, L; Wang, Q; Wei, J; Xie, C; Yen, YT; Yu, L, 2021)	0.62
"This study investigated the efficiency and the related mechanisms of a new absorption enhancer, DL-malic acid (MA), on the oral bioavailability of docetaxel (DTX)."	( The efficiency and mechanism of a new absorption enhancer, malic acid, for enhancing the oral bioavailability of docetaxel. Cui, W; Ding, F; Guo, XH; Li, Z; Lian, X; Xing, Y, 2021)	0.62
" The other therapies like hormonal therapy, surgery, radiotherapy, and immune therapy are in use but showed many side effects like bioavailability issues, non-selectivity, pharmacokinetic-pharmacodynamic problems."	( Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. Arya, GC; Jaitak, V; Kaur, K, 2021)	0.62
" These results reveal that constructing nanocrystal-loaded micelles may be a promising way to enhance the in vivo circulation and bioavailability of rapidly metabolized drugs such as docetaxel."	( Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel. Cheng, M; Fang, Y; Feng, J; Gan, T; Jin, Y; Liu, Q; Sun, Y; Tu, L; Yue, P, 2021)	0.62
" On the contrary, ritonavir co-administration given as pre-treatment significantly enhanced oral bioavailability of both the marketed and milk-based docetaxel formulations; an even more marked increase in drug exposure was observed when ritonavir was incorporated within the docetaxel milk-based formulation."	( Enhancement of Docetaxel Absorption Using Ritonavir in an Oral Milk-Based Formulation. Karampelas, T; Macheras, P; Soulele, K; Tamvakopoulos, C, 2021)	0.62
"Targeted concurrent inhibition of intestinal drug efflux transporter P-glycoprotein (P-gp) and drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is a promising approach to improve oral bioavailability of their common substrates such as docetaxel, while avoiding side effects arising from their pan inhibitions."	( Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations. Bu, Y; Lau, JYN; Locher, KP; Nasief, NN; Nosol, K; Said, AM; Smolinski, MP; Urgaonkar, S, 2022)	0.72
" Enhancement of oral bioavailability could reduce the drug load and associated adverse effects."	( Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints and Recent Development. Chatterjee, B; Ganti, S; Pandya, M, 2022)	0.72
" Many studies have attempted to improve its bioavailability and efficiency using different nanoparticulate drug delivery systems."	( PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor. Mahmoudi, A; Malaekeh-Nikouei, B; Moosavian, SA; Shakib, Z, 2022)	0.72
" In this study, curcumin was selected as an inhibitor of P-gp and CYP450, and it was co-encapsuled in SMEs to improve the oral bioavailability of docetaxel."	( A self-microemulsion enhances oral absorption of docetaxel by inhibiting P-glycoprotein and CYP metabolism. Tong, L; Wang, G; Wu, C; Zhou, Z, 2023)	0.91
" The present research work deals with the development of an orally administrable, folate-receptor-targeted Nanostructured lipid carriers (NLCs) of DX (FA-DX-NLCs) for facilitating oral chemotherapy of lung cancer while overcoming the bioavailability and toxicity issues."	( Surface-modified nanoparticles of docetaxel for chemotherapy of lung cancer: An intravenous to oral switch. Bora, V; Khot, S; Patel, B; Patel, MM; Rawal, S, 2023)	0.91
" Further, analysis of the bioavailability of the drug in the prostate showed that DTX-LfNPs increased drug bioavailability in the prostate by two times more than the DTX."	( Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer. Jana, P; Kondapi, AK; Muj, C; Mukhopadhyay, S, 2023)	0.91
"In conclusion, DTX-LfNPs enhance the bioavailability of DTX in the prostate along with Lf-assisted improvement in inhibition of tumor metastasis and drug-associated toxicity."	( Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer. Jana, P; Kondapi, AK; Muj, C; Mukhopadhyay, S, 2023)	0.91
" Bemcentinib (BGB324), a selective orally bioavailable small molecule AXL inhibitor, synergizes with docetaxel in preclinical models."	( Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Ahn, C; Bhalla, S; Brekken, RA; Dowell, JE; Fattah, FJ; Gerber, DE; Macchiaroli, A; McCracken, N; Micklem, D; Padro, J; Pogue, M; Putnam, WC; Williams, J, 2023)	0.91

Excerpt	Relevance	Reference
" The highest dosage used (50 mg/kg/dose) was toxic in all experiments in which the 4-day treatment interval was used."	( Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere). Bissery, MC; Dykes, DJ; Harrison, SD; Waud, WR, 1995)	0.29
" The aims of these studies were to determine the optimal dosage schedule of docetaxel for use in subsequent phase II studies, and to characterise the pharmacokinetic and tolerability profiles of docetaxel."	( Early clinical studies with docetaxel. Docetaxel Investigators Group. Aapro, M; Bruno, R, 1995)	0.29
" The recommended dosage for phase II trials is 100 mg/m2 every 3 weeks which provides optimal activity with tolerable adverse effects."	( Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Schriivers D [corrected to Schrijvers, D]; Schrijvers, D; van Oosterom, AT, 1995)	0.29
" Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma."	( Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study. Bruntsch, V; Dirix, LY; Franklin, H; Kaye, SB; Le Bail, N; Pavlidis, NA; Smyth, JF; Sternberg, CN; ten Bokkel Huinink, WW; Wanders, S, 1994)	0.29
" The dose-response assays performed on asynchronous cultures during 42 hr showed clear biphasic curves with a plateau from 50 microM to 10 nM and a single sigmoid curve with a concentration inhibiting 50% of growth (IC50) of 3-6 nM observed after a 72-hr incubation."	( Interactions between docetaxel (Taxotere) and Plasmodium falciparum-infected erythrocytes. Frappier, F; Grellier, P; Guénard, D; Potier, P; Schrével, J; Sinou, V, 1994)	0.29
" Paclitaxel and docetaxel were more effective than cisplatin (4 mg/kg, same dosing regime as above) used as a reference compound."	( Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. D'Incalci, M; Giavazzi, R; Lucchini, V; Nicoletti, MI, 1994)	0.29
" The results of this trial suggest that a dosage regimen of 60 mg/m2 at 3- to 4 week intervals is appropriate in an early phase II clinical trial."	( [Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug]. Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T, 1994)	0.29
" The recommended dosage for phase II trial is 100 mg/m2 administered in 1 hour perfusion, every 21 days."	( [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials]. Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K, 1996)	0.29
" The recommended dosing regimens is 100 mg/m2 administered intravenously over one hour, with cycles repeated every three weeks."	( Docetaxel: a review of its pharmacology and clinical activity. Trudeau, ME, 1996)	0.29
"Severe docetaxel neuropathy may especially occur following treatment with cumulative dosage over 600 mg/m2; in patients treated with this dosage a moderate or severe neuropathy may not be rare."	( Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Hilkens, PH; Stoter, G; van den Bent, MJ; Vecht, CJ; Verweij, J, 1997)	0.3
" The combination was studied at six different dosing levels."	( Docetaxel in combination with doxorubicin: a phase I dose-finding study. Diéras, V, 1997)	0.3
" When cytotoxic drugs are used in combination, it is important to consider the dose-response relationships and the toxicity profiles of the agents involved."	( Future perspectives of docetaxel (Taxotere) in front-line therapy. Di Leo, A; Piccart, MJ, 1997)	0.3
" Docetaxel-induced adverse events have been shown to occur most frequently in patients with impaired liver function, and a reduction in dosage in patients with raised levels of transaminases and alkaline phosphatase is recommended to improve the tolerability of the drug in these patients."	( The taxoids: same roots, different drugs. Von Hoff, DD, 1997)	0.3
" For grade 3 or 4 hematologic toxicity, the docetaxel dosage was lowered to 75 mg/m2."	( Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. Barcos, M; Budman, DR; Cooper, MR; Johnson, JL; Peterson, BA; Petroni, GR; Schlossman, DM, 1997)	0.3
" Docetaxel pharmacokinetics and pharmacodynamics determined in Phase I and Phase II trials indicate a need to adjust the dosage for body surface area and liver function."	( Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. Bruno, R; Hille, D; Lebecq, A; Riva, A; Thomas, L, 1997)	0.3
" The dosage of docetaxel should be reduced from 100 mg/m2 to 75 mg/m2 if patients have neutropenia lasting more than one week, febrile neutropenia, or impaired liver function."	( Efficacy and safety of docetaxel in clinical trials. Fumoleau, P, 1997)	0.3
" Docetaxel dosing in the second half of darkness (19 or 23 HALO) resulted in significantly worse toxicity than its administration during the light span (3, 7, or 11 HALO)."	( Docetaxel chronopharmacology in mice. Bissery, MC; Filipski, E; François, E; Lemaigre, G; Lévi, F; Li, XM; Liu, XH; Tampellini, M; Vrignaud, P, 1998)	0.3
"The pharmacology, pharmacokinetics, clinical trials, adverse effects, and dosage and administration of docetaxel are reviewed."	( Docetaxel: a taxoid for the treatment of metastatic breast cancer. Tankanow, RM, 1998)	0.3
"The results of this study do not suggest the use of TXT at this dosage and schedule in advanced soft tissue sarcoma."	( [Phase II study of docetaxel in patients with advanced stage soft tissue sarcoma]. Amodio, A; Carpano, S; Foggi, P; Gionfra, T; Lopez, M; Manfredi, C; Paoletti, G; Rinaldi, M, )	0.13
" The drug was given at a dosage of 100 mg/m2, delivered as a 1-hour infusion once every 3 weeks."	( Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer. Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J, 1998)	0.3
" To determine the optimal dosage and the toxicities of these two agents for future trials."	( Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V, 1999)	0.3
" Grades 1 or 2 hypocalcemia and hypophosphatemia were seen at all dosage levels."	( Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V, 1999)	0.3
"5 days) and 1 to 8 (median 2) times of dosing after the initial administration."	( [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]. Furue, H; Hirabayashi, N; Kanamaru, R; Kurihara, M; Mai, M; Ota, J; Sakata, Y; Suminaga, M; Taguchi, T, 1999)	0.3
" IC50 values were obtained from dose-response curves after fitting the data to the linear quadratic equation."	( Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro. Engblom, P; Grènman, S; Kulmala, J; Rantanen, V, 1999)	0.3
" Phase II trials of a dosage of 36 mg/m2/wk in elderly patients with advanced non-small cell lung cancer are ongoing."	( Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Fossella, FV, 1999)	0.3
" During docetaxel treatment a 54-year-old man developed a sensorimotor polyneuropathy when the overall docetaxel dosage was 540 mg/m(2)."	( Docetaxel neuropathy: a distal axonopathy. Bolognesi, A; Bordogna, G; Canal, N; Fazio, R; Nemni, R; Previtali, S; Quattrini, A; Villa, E, 1999)	0.3
" Estramustine phosphate was given on a daily oral dosing schedule of 14 mg/kg; docetaxel was administered intravenously over 1 hour every 3 weeks."	( Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. Budman, D; Kreis, W, 1999)	0.3
" In the second and third courses of the chemotherapy, CBDCA and TXT were administered in the same dosage as in the initial course, but with the oral administration of UFT (600 mg/day)."	( [A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel]. Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H, 2000)	0.31
"In this multicenter, phase II trial, 33 patients with previously untreated stage IIIB (n = 8) or IV (n = 25) NSCLC received intravenous infusions of docetaxel 80 mg/m2 followed immediately by carboplatin dosed to AUC of 6 mg/ml/min (Calvert's formula) every three weeks."	( Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Belani, CP; Bonomi, P; Capozzoli, MJ; Cohen, LJ; Dobbs, T; Earhart, R; Einzig, A; Luketich, JD, 2000)	0.31
"These data stress the importance of dosing carboplatin according to renal function and age and warrant further analyses to validate this concept prospectively."	( Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. Braess, J; Friedrichsen, S; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E, 2001)	0.31
" The combination showed better antitumor efficacy than the monotherapy of either agent in either dosing regimen."	( Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001)	0.31
" Due to their low aqueous solubility, both taxanes posed difficulties to the pharmaceutical scientists with respect to the development of an intravenous dosage form."	( Progress in the development of alternative pharmaceutical formulations of taxanes. Beijnen, JH; Bouma, M; Nuijen, B; Schellens, JH, 2001)	0.31
" It is not clear however, as to why dosing by BSA was extended to the routine dosing of antineoplastic agents."	( Body surface area as a determinant of pharmacokinetics and drug dosing. Ratain, MJ; Sawyer, M, 2001)	0.31
" It was repeated every 3 weeks, as long as possible, including dosage levels of 5 scheduled steps."	( [A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001)	0.31
" Weekly calcitriol dosing is associated with minimal toxicity and permits substantial dose escalation over the daily schedule."	( Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Beer, TM; Garzotto, M; Henner, WD; Hough, KM; Lowe, BA, 2001)	0.31
" Prediction of the drug sensitivity of each patient and cell kill kinetics of the drug may improve the outcome of treatment and avoid unnecessary dosing of the drug."	( Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test. Komiyama, M; Mori, T; Ohnishi, M; Okada, H; Tsutsui, A; Yabushita, H, )	0.13
" In the second stage, which begins at the first instance of DLT, a two-parameter logistic dose-response model estimates the MTD from the DLT experience of all patients."	( Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer. Potter, DM, 2002)	0.31
" Hopefully, information from these trials will help resolve questions regarding the efficacy of various combinations and dosing schedules so that trastuzumab may be used most effectively in the treatment of HER2-overexpressing breast cancer in both the metastatic and the adjuvant settings."	( Trastuzumab/chemotherapy combinations in metastatic breast cancer. Ligibel, JA; Winer, EP, 2002)	0.31
" Administration of doxifluridine (5'-DFUR: Furtulon) (1,200 mg/day, 5 day continuous dosing followed by 2 day washout) and medroxyprogesterone acetate (MPA: Hysron H) (1,200 mg/day) was followed by chemotherapy consisting of intraarterial infusion of 100 mg of docetaxel (TXT: Taxotere), once monthly, via the left internal thoracic artery and left lateral thoracic artery."	( [One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful]. Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I, 2002)	0.31
" Adequately dosed polychemotherapy appears to be more successful than monotherapy, and, at present, the combination of anthracyclines (doxorubicin, epirubicin) and taxanes (docetaxel (Doc), paclitaxel (Pac)) might lead to a promising approach to improve the course of the metastatic disease."	( Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. Friedrichs, K; Hölzel, F; Jänicke, F, 2002)	0.31
" Treatment schedule consisted of DCT at the dosage of 50 mg/m(2) with conventional steroid premedication and GEM at the dosage of 2,000 mg/m(2)."	( Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S, 2002)	0.31
" 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD."	( A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002)	0.31
" At a docetaxel dosage of 50 mg/m2 per week, the dose-limiting events of grade 4 febrile neutropenia and grade 3 hypomagnesemia occurred."	( A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002)	0.31
" Thus, weekly scheduling of docetaxel maintains efficacy and alters the toxicity profile, and the use of weekly docetaxel will become a promising alternative to three week dosing in the treatment of advanced breast cancer once randomized controlled studies confirm these results."	( Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Bando, H; Kuroi, K; Saji, S; Toi, M, 2003)	0.32
" Carboplatin dosed to an area under the time-concentration curve (AUC) of 6 mg/ml."	( A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Agelaki, S; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kouroussis, C; Michailakis, E; Papadouris, S; Souglakos, J; Theodoropoulos, E; Tsitoura, M; Vardakis, N, )	0.13
" The first group of three patients received DCT 40 mg/m2, and in absence of DLT, DCT dosage was escalated by 10 mg/m2/cycle until DLT was reached."	( Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma. Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML, 2003)	0.32
" However, the dose recommended for the phase II trial was 50 mg/m2, because no difference in delivered dose-intesity was seen between the 50 and 60 mg/m2 dose levels, and the latter dosage was still associated with grade 3 neutropenia in most patients."	( Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma. Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML, 2003)	0.32
" The dosage of docetaxel/CPA was 40/200, 40/400, 50/400, or 60/400 mg/m(2)/day."	( Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer. Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T, 2003)	0.32
" It is important to stress the need for modification of the dosing scheme."	( Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer. Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T, 2003)	0.32
" Traditional dosing regimens with docetaxel involve doses of 60-100 mg/m(2) by infusion every 3 weeks."	( Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA, 2003)	0.32
" Because of unacceptable toxicity among the first 13 patients, dosing was reduced to docetaxel 40 mg/m2/d and irinotecan 100 mg/m2/d intravenously at 21-d intervals."	( A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT, 2002)	0.31
"To assess efficacy and optimum combination dosage of intravenous docetaxel (T), epirubicin (E) and vinorelbine (N) administered every 2 weeks and without colony stimulating factor (CSF) support in patients with metastatic breast cancer (MBC)."	( Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study. Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Modollel, A; Muñiz, I; Palacio, I; Sala, M; Vieitez, JM, 2003)	0.32
" The dosage levels of TXT and CPT-11 were as follows: level 1, 30 mg/m(2) and 50 mg/m(2); level 2, 35 and 50 mg/m(2); level 3, 40 and 50 mg/m(2); level 4, 40 and 60 mg/m(2); and level 5, 50 and 60 mg/m(2)."	( Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T, 2003)	0.32
" However, three patients at level 3 could not continue treatment without a decrease in the dosage after the second cycle."	( Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T, 2003)	0.32
" Clinical trials that include pharmacokinetic and pharmacodynamic studies may be the most efficient way to optimize the therapeutic efficacy of ifosfamide and define the dosing and scheduling."	( Antiblastic drug combinations with ifosfamide: an update. Badalamenti, G; Fulfaro, F; Gebbia, N; Russo, A; Valerio, MR, 2003)	0.32
" The purpose of this study was to evaluate the efficacy and toxicity of a modified TPFL regimen (m-TPFL) for locally advanced SCCHN, consisting of a modified dosage with docetaxel, cisplatin, 5-FU and l-leucovorin (l-LV) designed for Japanese patients."	( Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Sasaki, S; Taniguchi, M; Watanabe, A, 2003)	0.32
" No grade 3/4 hematological toxicities were manifested at any dosage level."	( Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y, 2003)	0.32
" This limitation has been overcome with intermittent dosing of calcitriol."	( Development of weekly high-dose calcitriol based therapy for prostate cancer. Beer, TM, )	0.13
"The optimal docetaxel dosage in this second-line setting is 75 mg/m(2), as it has a more favourable safety profile and on balance a similar efficacy to the 100 mg/m(2) dose."	( Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer. Brechot, JM; Breton, JL; Clouet, P; Debieuvre, D; Depierre, A; Ducolone, A; Lebeau, B; Lemarie, E; Milleron, B; Moro-Sibilot, D; Pujol, JL; Quoix, E; Vaylet, F; Vergnenegre, A; Zalcman, G, 2004)	0.32
"The purpose was to determine the optimal multifractionated (MF) dosing schedule to permit the delivery of four active agents in nonsmall cell lung cancer simultaneously in alternating doublets (docetaxel-cisplatin alternating with gemcitabine-vinorelbine)."	( Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination. Anderson, N; Coco, F; Lokich, J, 2003)	0.32
" The purpose of this study was to establish the most suitable dosing schedule to relieve severe adverse effects and improve the antitumor effects."	( Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H, 2004)	0.32
" The DOC-ADR group showed the best survival rate in the dosing groups."	( Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Higuchi, S; Matsunaga, N; Ohdo, S; Sakaguchi, H; Shin, M; Tabuchi, M; Takeuchi, A; To, H, 2004)	0.32
"Current dosing strategies for anticancer drugs result in wide interindividual pharmacokinetic variability."	( Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Armstrong, DK; Baker, SD; Garrett-Mayer, ES; Rudek, MA; Sparreboom, A; Verweij, J; Wolff, AC, 2004)	0.32
" It seems therefore safe to use the lower range of proposed doses of the weekly regimens until further data provide stronger evidence for optimal dosing in elderly patients."	( Taxanes in elderly breast cancer patients. Paridaens, R; Wildiers, H, 2004)	0.32
" These results suggest a more favorable benefit-to-risk ratio for docetaxel compared to paclitaxel when these drugs are used as single agents or in combination with other chemotherapeutic agents in an every-3-week dosing regimen."	( Preclinical pharmacology of the taxanes: implications of the differences. Gligorov, J; Lotz, JP, 2004)	0.32
" Also addressed are outstanding issues involving optimal dosing and sequencing, as well as a discussion of the relative merits of each agent in this setting."	( Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Crown, J; O'Leary, M; Ooi, WS, 2004)	0.32
" Additional phase II trials have focused on optimizing dosing and schedule schemas with the demonstration of impressive efficacy with acceptable toxicity with the biweekly administration."	( Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer. Yardley, DA, 2004)	0.32
"Weekly docetaxel at a dosage of 40 mg/m(2) is a well-tolerated treatment, which has very promising activity on the reduction of PSA in metastatic HRPC."	( A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Amiel, J; Boublil, JL; Chevallier, D; Ferrero, JM; Foa, C; Garnier, G; Lesbats, G; Peyrade, F; Ronchin, P; Tchiknavorian, X; Thezenas, S; Valenza, B, 2004)	0.32
" Depending on dosage and agent used symptoms resolve completely or not."	( [Neurotoxic effects of medications: an update]. Arné-Bès, MC, 2004)	0.32
"Nineteen patients were treated with 71 cycles of ZD9331 and docetaxel (ZD9331/docetaxel) at dose levels that encompassed dosing iterations of ZD9331 ranging from 65 to 260 mg/m(2) and docetaxel doses in the range of 50 to 75 mg/m(2)."	( A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies. Garrison, M; Jones, CB; McCreery, H; Patnaik, A; Rowinsky, EK; Schwartz, GH; Skinner, M; Takimoto, C; Tolcher, AW, 2004)	0.32
" However, further examination is needed about dosage and dosing regimen of Estramustine and Docetaxel."	( [Combination therapy with estramustine and docetaxel for hormone refractory prostate cancer]. Kanno, T; Shibasaki, N; Takeuchi, H; Taki, Y; Tsuji, Y, 2004)	0.32
" Weekly dosing of docetaxel has been investigated in an effort to reduce toxicity and has been identified as a safe and effective regimen in clinical trials."	( Practical aspects of weekly docetaxel administration schedules. Hainsworth, JD, 2004)	0.32
" Thirty-two patients with advanced refractory cancers (median age 64, 19 male) received 190 treatment courses at five dosing levels of irinotecan: 30 mg/m2 (n=6 patients), 60 (n=3), 90 (n=7), 120 (n=8) and 105 (n=8)."	( Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study. Briasoulis, E; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Rammou, D; Timotheadou, H, 2004)	0.32
" Dosing over 3 days with zosuquidar (7 doses) did not show benefit over the 1-day dosing."	( Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Andre, VA; Arquette, MA; Burgess, MF; de Alwis, DP; Fears, CL; Fracasso, PM; Gazak, RJ; Goldstein, LJ; Goodner, SA; Rader, JS; Schellens, JH; Slapak, CA; Wright, LP, 2004)	0.32
"Proapoptotic drugs such as docetaxel displayed least toxicity and highest antitumor efficacy following dosing during the circadian rest phase in mice, suggesting that cell cycle and apoptotic processes could be regulated by the circadian clock."	( Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. Cermakian, N; Filipski, E; Granda, TG; Lévi, F; Liu, XH; Sassone-Corsi, P; Smaaland, R, 2005)	0.33
" Therefore, intraperitoneal administration of docetaxel (TXT) at a dosage of 45 mg/m2 was applied."	( [A case of scirrhous carcinoma of the stomach with malignant pleural and peritoneal carcinomatosis responding to the local administration of docetaxel (TXT)]. Fujiki, H; Kadotani, Y; Kumano, T; Mitsuo, M; Morita, S; Oda, T; Sonoyama, Y; Yasuoka, R, 2004)	0.32
" A starting docetaxel dose of 30 mg/m(2) would be reasonable for future studies exploring the utility of weekly dosing in less heavily pre-treated patients."	( A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Atkinson, T; Berkenblit, A; Cannistra, SA; Krasner, CN; Matulonis, UA; Mezzetti, L; Penson, RT; Roche, M; Seiden, MV, 2004)	0.32
"Docetaxel is an active agent as first-line chemotherapy in patients with advanced breast cancer at a dosage of 100 mg/m2."	( A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer. Asaga, T; Fukuda, M; Fukuma, E; Hamaguchi, Y; Inaba, M; Ishida, K; Ishikawa, T; Ishiyama, A; Katayama, K; Shimada, H; Shimizu, S; Suda, T; Tokuda, Y, 2004)	0.32
"Docetaxel achieved good disease control with mild adverse events in first-line treatment at a dosage of 60 mg/m2."	( A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer. Asaga, T; Fukuda, M; Fukuma, E; Hamaguchi, Y; Inaba, M; Ishida, K; Ishikawa, T; Ishiyama, A; Katayama, K; Shimada, H; Shimizu, S; Suda, T; Tokuda, Y, 2004)	0.32
" The aim of this study was to determine the maximally tolerable dosage of gemcitabine and docetaxel using a weekly administration regimen."	( Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K, 2004)	0.32
" This study was designed to assess whether the application of our method to individualized dosing could decrease pharmacokinetic (PK) and pharmacodynamic (PD) variability compared with body-surface area (BSA) -based dosing."	( Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N, 2005)	0.33
"The individualized dosing method based on the total amount of urinary 6-beta-OHF after cortisol administration can decrease PK variability of docetaxel."	( Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N, 2005)	0.33
" These observations suggest a potential clinical use of combined dosing of COX-2 inhibitors and cytotoxic drugs at lower, nontoxic dose than currently used to treat advanced prostate cancer."	( Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Carey, RI; Dandekar, DS; Lokeshwar, BL; Lopez, M, 2005)	0.33
" A high rate of positive pathological responses was obtained particularly in the later period of the study with the increased dosage of the protocol regimen."	( [Preliminary results of neoadjuvant treatment of adenocarcinoma of the gastro-esophageal junction]. Bernini, M; de Manzoni, G; Gabbani, M; Giacopuzzi, S; Grandinetti, A; Guglielmi, A; Pasini, F; Pedrazzani, C; Ruzzenente, A; Tomezzoli, A, )	0.13
" At equivalent dosing levels, IT docetaxel achieved a 26-fold higher peak tumor concentration and 24-fold longer tumor exposure than IV treatment."	( An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. Boinpally, RR; Ensley, JF; Ezzat, W; Iskander, A; Lin, HS; Oliver, J; Parchment, RE; Piechocki, MP; Polin, L; Shehadeh, N; Shibuya, TY; Subramanian, G; Yoo, GH, 2005)	0.33
" Untoward side-effects were moderate, reversible and, therefore, did not require dosage to be corrected or cut down."	( [Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine]. Filatova, LV; Gershanovich, ML; Semiglazova, TIu, 2005)	0.33
" The mean dosage per course of TXT was 58."	( [Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)]. Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A, 2005)	0.33
" The major challenges on the clinical development of targeted therapy include the proper selection of patients, the identification of the optimal dosage and schedule of administration, the combinations with conventional treatments and the more appropriate therapeutic strategy."	( Therapy of breast cancer with molecular targeting agents. Gasparini, G; Longo, R; Morabito, A; Torino, F, 2005)	0.33
" ASCENT builds on phase I work showing that weekly dosing allows substantial dose-escalation of calcitriol, the natural ligand for the vitamin D receptor, and on phase II work that suggested that adding weekly high-dose 'pulse' calcitriol may enhance the activity of weekly docetaxel in patients with AIPC."	( ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. Beer, TM, 2005)	0.33
" The purpose of this study was to establish a suitable dosing schedule, based on a chronopharmacologic approach, to relieve severe adverse effects."	( Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Goto, N; Higuchi, S; Ohdo, S; Sakaguchi, H; Tabuchi, M; Takeuchi, A; To, H, 2005)	0.33
" With G-CSF support, all except 2 patients were administered as per schedule, and the TXT dosage in 2 patients was reduced."	( [Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer]. Kuramoto, K; Terao, I, 2005)	0.33
" The resulting mechanisms of cell death are likely determined by the mechanism of action of the drug, the dosing regimen used, and the genetic background of the cells within the tumor."	( Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Gillies, RJ; Gray, H; Morse, DL; Payne, CM, 2005)	0.33
" A second generation of trials are now underway which are based on the assumption that taxanes are beneficial in the adjuvant setting, and are comparing the different taxanes, dosing regimens and the addition of further agents."	( Taxanes in the treatment of early breast cancer. Ellis, PA; Ring, AE, 2005)	0.33
"Eleven patients with hormone-refractory prostate cancer were treated with escalating weekly doses of docetaxel (level I, 3 patients, 30 mg/m2; level II, 3 patients, 35 mg/m2, level III, 3 patients, 40 mg/mz; level IV, 2 patients, 45 mg/m2) associated with fixed dosage of estramustine (840 mg/day)."	( Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer. Ardito, R; Coccaro, M; Di Renzo, N; Romano, G; Tartarone, A, )	0.13
" The dosage schedule of this combination resulted in acceptable toxicities."	( A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Arquette, MA; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Lim, WT; Mortimer, JE, 2006)	0.33
"Classical isobologram analysis offers a way for analysing combined drug effects in dose-response experiments statistically."	( Statistical analysis of combined dose effects for experiments with two agents. Lehmer, A; Treiber, U; Wagenpfeil, S, 2006)	0.33
"Our package supplements the clinical software-equipment and is a tool for automatic evaluation of combined dose-response experiments in experimental oncology in the urologic clinic."	( Statistical analysis of combined dose effects for experiments with two agents. Lehmer, A; Treiber, U; Wagenpfeil, S, 2006)	0.33
" This makes precise dosing difficult to achieve clinically, which may compromise safe therapy."	( Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Fan, L; Goh, BC; Lee, HS; Lee, SC; Ong, AB; Soo, R; Sukri, N; Tham, LS; Wang, L; Yong, WP, 2006)	0.33
" The standard intermittent dosage of docetaxel is 60-100 mg/m2 every 3 weeks."	( Docetaxel-associated epiphora. Kintzel, PE; Lange, MK; Michaud, LB, 2006)	0.33
"In view of the increasing breast cancer incidence and the acceptable toxicity profile of docetaxel among Chinese patients, a dosage of 100 mg/m2 can be recommended for use among Asians."	( Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles. Chow, LW; Yip, AY, 2006)	0.33
" This study was to establish the most suitable dosing schedule to relieve severe adverse effects and improve antitumor effects by considering a chronopharmacological approach, dosing-interval and dosing-sequence to the combination chemotherapy of ADR and DOC in mice."	( [Construction of optimal combined chemotherapy of anti-tumor drugs based on chronotherapy]. To, H, 2006)	0.33
"Twenty-six patients with advanced solid tumors were treated on four dosing cohorts starting at CI-1033 (50 mg/d) + docetaxel (75 mg/m2)."	( A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP, 2006)	0.33
"It is feasible to combine the irreversible pan-erbB tyrosine kinase inhibitor CI-1033 with docetaxel on an intermittent dosing schedule in advanced cancer patients."	( A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Arun, BK; Eder, JP; Eiseman, IA; Garland, LL; Hidalgo, M; Lenehan, PF; Lovalvo, JL; Mendelson, DS; Olson, SC; Ryan, DP, 2006)	0.33
"Capecitabine/docetaxel dosing flexibility allows management of side-effects without compromising efficacy."	( Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S, 2006)	0.33
" Repeated administration of paclitaxel, but not docetaxel, decreased its area under concentration, but the effect disappeared 6h after dosing and was not sufficient to explain lower effects of paclitaxel."	( Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats. Danielová, V; Ehrlichová, M; Gut, I; Holubová, J; Horský, S; Otová, B; Simek, P; Soucek, P; Václavíková, R, 2006)	0.33
"These mechanistic models, including patient characteristics that influence drug-specific parameters, form the rationale basis for more tailored dosing of individual patients or subgroups to minimize the risk of infection and thus might contribute to a more successful therapy."	( Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J, 2006)	0.33
" In the ITT analysis, a significant dose-response relationship was observed for tumor response (P = ."	( Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. Cold, S; Groult, V; Harvey, V; Jakobsen, E; Mouridsen, H; Murawsky, M; Robinson, BA; Semiglazov, V; Voznyi, E, 2006)	0.33
" There were no other patients in whom the treatment was prolonged or dosage was reduced due to adverse reactions."	( [Examination of the safety of docetaxel/cyclophosphamide combination therapy for advanced recurrent breast cancer]. Akamatsu, H; Imazu, Y; Koshida, Y; Motegi, K; Murayama, T; Ohyama, R; Toeda, H; Toriumi, F; Yoneyama, K, 2006)	0.33
" The GEM dosage was decreased to 800 mg/m2 after the initial 21 patients because 3 patients developed interstitial lung disease (ILD)."	( Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer. Eguchi, K; Hada, E; Izumi, Y; Kawamura, M; Kobayashi, K; Koike, T; Sakaguchi, H; Yamato, Y, 2007)	0.34
" The purpose of this study was to identify the maximally tolerated dosage and characterize the pharmacokinetic disposition of oral DT combined with CSA in cats with tumors."	( Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing cats. Bailey, DB; Balkman, CE; Beaulieu, BB; Flanagan, JL; Lewis, LD; McEntee, MC; Page, RL; Rassnick, KM; Zgola, MM, )	0.13
" We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy."	( [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006)	0.33
" The cytotoxic effects of MTD and metronomic dosing were tested with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays."	( Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Bischoff, FZ; Coleman, RL; Gershenson, DM; Han, LY; Heymach, JV; Jaffe, RB; Kamat, AA; Kim, TJ; Landen, CN; Lin, YG; Lu, C; Merritt, WM; Sood, AK; Thaker, PH, 2007)	0.34
" The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion."	( [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007)	0.34
" To determine whether combination therapy produces tumor regressions, cetuximab was dosed at half-maximal efficacy with chemotherapy used at maximum tolerated dose."	( Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Bassi, R; Hadari, YR; Hicklin, DJ; Joynes, C; Steiner, P; Tonra, JR; Wang, S, 2007)	0.34
" Blood samples were obtained up to 55 hours after dosing and analyzed for irinotecan and its metabolites (SN-38, SN-38G), respectively, or docetaxel."	( Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J, 2007)	0.34
" Pharmacokinetic models capable of predicting exposure under various dosing regimens would aid the rational development of clinical protocols."	( A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL, 2007)	0.34
" This will enable us to develop and test various dosing regimens (e."	( A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Bradshaw-Pierce, EL; Eckhardt, SG; Gustafson, DL, 2007)	0.34
"Each drug, administered as a single-agent, demonstrated comparable and moderate effects on tumor growth with approximately 50 % inhibition at the end of the 3-week dosing schedule."	( Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G, 2008)	0.35
" Individual dosing of docetaxel should be based on previous chemotherapy but not on the AAG level since it has a similar influence on PD and PK docetaxel parameters."	( Clinical pharmacodynamic factors in docetaxel toxicity. Alexandre, J; Chatelut, E; Goldwasser, F; Puisset, F; Raoul, V; Roché, H; Treluyer, JM, 2007)	0.34
"We have revealed in a pre-clinical study that the combination of adriamycin (ADR) and docetaxel (DOC) in which ADR was administered 12 h after DOC injection not only significantly reduced leukopenia and toxic death but also significantly increased the antitumor effect compared with the dosing schedule without an interval between each injection used commonly in clinical practice."	( Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Ando, Y; Araki, R; Higuchi, S; Kitahara, T; Kodama, A; Ohdo, S; Sakaguchi, H; Sasaki, H; Tabuchi, M; To, H; Tomonari, M, 2008)	0.35
"When dosing intervals (0-24 h) were changed, there were no differences in survival rate among the 6, 12, and 24-h interval groups, although these groups showed significantly higher survival rate compared with the ADR/DOC group."	( Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Ando, Y; Araki, R; Higuchi, S; Kitahara, T; Kodama, A; Ohdo, S; Sakaguchi, H; Sasaki, H; Tabuchi, M; To, H; Tomonari, M, 2008)	0.35
"Twenty-five anthracycline-pretreated patients received docetaxel administered on a weekly basis, as a one-hour infusion, at various dosage levels (25, 30, 35, 40 mg/m2) depending on their baseline Karnofsky index."	( Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer. Harbeck, N; Kates, R; Mallmann, P; Nawroth, F; Ohlinger, R; Pantke, E; Thomas, A; Valter, M; Warm, M, 2007)	0.34
" The cumulative dose per patient was largest for a weekly docetaxel dosage of 35 mg/m2 and almost as large for 30 mg/m2."	( Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer. Harbeck, N; Kates, R; Mallmann, P; Nawroth, F; Ohlinger, R; Pantke, E; Thomas, A; Valter, M; Warm, M, 2007)	0.34
" efficacy/cumulative dosage delivered, our results support weekly administration of docetaxel at dosages of 30-35 mg/m2 in metastatic breast cancer."	( Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer. Harbeck, N; Kates, R; Mallmann, P; Nawroth, F; Ohlinger, R; Pantke, E; Thomas, A; Valter, M; Warm, M, 2007)	0.34
"Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing."	( A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008)	0.35
" Dosage and scheduling of the taxane drug is not clearly defined and we await results of the next generation of studies to determine the optimal use of taxanes in early breast cancer."	( Taxanes for adjuvant treatment of early breast cancer. Ferguson, T; Ghersi, D; Nowak, AK; Vagg, R; Wilcken, N, 2007)	0.34
"Weekly dosage of docetaxel combined with cisplatin and 5-fluororacil is an effective regimen for AGC with only mild toxic reactions and good patient tolerance."	( [Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer]. Ye, S; Zhang, AM, 2007)	0.34
"First-pass metabolism is a common cause of incomplete and variable absolute bioavailability for an orally dosed drug."	( Gut instincts: CYP3A4 and intestinal drug metabolism. Thummel, KE, 2007)	0.34
" Moreover, many trials conducted to evaluate the optimal taxane dosing and schedule."	( Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Radaideh, SM; Sledge, GW, 2008)	0.35
" Although select patients may benefit from treatment, the overall risk:benefit ratio is unfavorable, and other dosing regimens and therapeutic options should be explored in this setting."	( Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP, 2008)	0.35
"These studies provide a rationale for intermittent dosing of EGFR TKIs with chemotherapy in order to enhance cytotoxicity."	( Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B, 2007)	0.34
"2-CADO pre-treatment followed by Docetaxel at subclinical dosage reduced the viability of either PC3 or LNCaP while it did not enhance Docetaxel-induced cytotoxicity in adherent non-neoplastic HECV."	( 2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells. Bellezza, I; Bracarda, S; Conte, C; Culig, Z; Minelli, A; Tucci, A, 2008)	0.35
" Three treatment cohorts were assessed, using different dosing regimens."	( Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T, 2008)	0.35
" The dose of carboplatin was determined by a measured glomerular filtration rate (GFR), ensuring accurate dosing in all categories of BMI and the dose of taxane was not capped."	( Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA, 2008)	0.35
"Although no maximum tolerated dose was reached in cycle 1 with 35 mg/m(2) docetaxel, repetitive dosing proved intolerable in a substantial number of patients; thus, the recommended phase II dose of weekly docetaxel is 30 mg/m(2) when combined with 150 mg of daily erlotinib."	( A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M, 2008)	0.35
" Each course consisted of capecitabine at a dosage of 1,800 mg/body/day for 2 weeks and docetaxel at a dosage of 60 mg/body (day 8 only) followed by withdrawal for 1 week."	( [A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy]. Hachisuka, Y; Hatano, H; Johira, H; Kamei, Y; Kawata, N; Kimura, M; Miyata, N; Ohmori, K; Umeoka, T; Uomoto, M; Watanabe, R; Yunoki, S, 2008)	0.35
" Docetaxel was dissolved in an isotonic saline to a final 1 liter solution and was administered in a 1 h dosage of 25, 35, 45 and 60 mg/m(2) to determine the maximum tolerated dose (MTD)."	( Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Fujimura, T; Funaki, H; Fushida, S; Kayahara, M; Kinami, S; Kinoshita, J; Ninomiya, I; Nishimura, G; Ohta, T; Yagi, Y, 2008)	0.35
"The dosing schedule of docetaxel may affect its clinical activity and toxicity profile."	( Biweekly docetaxel-containing chemotherapy may be the optimal schedule. Cai, Y; Hong, X; Hu, X; Li, J; Ou, Z; Shen, Z; Wang, Z; Yang, X; Zhao, X, 2008)	0.35
" In addition to standard threeweekly dosing regimens, alternative schedules of administration of taxanes and gemcitabine doublets (weekly, twoweekly) might deserve further investigation due to their potential usefulness in reducing pharmacological toxicity while maintaining or increasing dose-intensity and clinical efficacy."	( Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. Carlini, P; Cognetti, F; De Laurentiis, M; Fabi, A; Felici, A; Ferretti, G; Graziano, V; Introna, M; Metro, G; Nuzzo, C; Papaldo, P; Pellegrini, D; Russillo, M; Vici, P, )	0.13
" A number of preclinical and early clinical studies have evaluated the feasibility, duration, and appropriate dosing schedule(s) for taxane-trastuzumab combinations in HER-2-positive metastatic breast cancer."	( Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Blackwell, K; Bullock, K, 2008)	0.35
" At the end of the 3-week dosing schedule, single-agent treatment induced a tumor regression of 59%, 49% and 75% for sunitinib, docetaxel 10mg/kg, and docetaxel 30 mg/kg, respectively."	( Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cumashi, A; Iacobelli, S; Lattanzio, R; Natoli, C; Piantelli, M; Rossi, C; Tinari, N, 2008)	0.35
" Nab-paclitaxel at submaximum-tolerated dosage was significantly more effective than polysorbate-based docetaxel at its maximum-tolerated dosage in these three HER2-negative tumors."	( Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Desai, NP; Gradishar, WJ; Hwang, LY; Soon-Shiong, P; Trieu, V; Wu, R, 2008)	0.35
" Docetaxel may exert antiangiogenic effects if dosed so plasma levels are maintained at low nanomolar concentrations over a prolonged time."	( Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Bradshaw-Pierce, EL; Gustafson, DL; Raben, D; Steinhauer, CA, 2008)	0.35
"Based on existing evidence, clinicians should choose a taxane-based regimen for their patients, according to clinical activity, toxicity profile, pharmacokinetics, and a dosing schedule that best meets the therapeutic needs and convenience."	( Paclitaxel and docetaxel in the treatment of breast cancer. Georgoulias, V; Mavroudis, D; Saloustros, E, 2008)	0.35
" The recommended phase II dosing is docetaxel 75 mg/m(2) on day 1, lenalidomide 25 mg on days 1-14, and pegfilgrastim 6 mg on day 2, given every 3 weeks."	( Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Bako, J; Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Horvath, N; Krishnamurthi, S; Nock, C; Remick, SC; Sanborn, SL, 2009)	0.35
" Targeted anti-angiogenic therapies have shown encouraging results in patients with metastatic localizations, and underline the need to identify target patients early through cellular markers (mTOR or EGFR overexpression) as well as the uselessness of PSA dosage to monitor efficacy."	( [Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer]. Lebret, T; Méjean, A; Timsit, MO, 2008)	0.35
" Recent analyses show that capecitabine/docetaxel dosing flexibility for managing side effects does not compromise efficacy, and define this combination regimen as an important treatment option for its efficacy, tolerability and cost-effectiveness."	( Capecitabine and docetaxel combination for the treatment of breast cancer. Leonard, RC; Morishita, M, 2008)	0.35
" The relevance of the interface model for dosage adjustment is illustrated by numerous simulations."	( An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. Barbolosi, D; Frances, N; Freyer, G; Iliadis, A; Meille, C, 2008)	0.35
" The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research."	( The role of capecitabine in the management of tumors of the digestive system. Gennatas, C; Gennatas, S; Michalaki, V, 2009)	0.35
"This study assesses the pharmacokinetics, biodistribution and efficacy of ginsenoside Rh2 as a single agent administered in a novel oral dosage formulation."	( Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C, 2009)	0.35
"A novel oral dosage formulation of Rh2 has been described."	( Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C, 2009)	0.35
"These results suggest that the combination of ixabepilone and mitoxantrone is feasible and active in CRPC and requires dosing with pegfilgrastim."	( Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2009)	0.35
" To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam."	( Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Carrasquillo, J; Curley, T; Delacruz, A; Divgi, CR; Gignac, GA; Heller, G; Hong, C; Jia, X; Kelly, WK; Larson, S; Morris, MJ; O'Donoghue, J; Pandit-Taskar, N; Rathkopf, D; Scher, HI; Schwartz, L; Slovin, S; Solit, D; Stephenson, RD, 2009)	0.35
" Maximum-tolerated dose was not reached, because full doses of both agents were well tolerated, even using an every-6-week dosing schedule of (153)Sm-EDTMP."	( Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Carrasquillo, J; Curley, T; Delacruz, A; Divgi, CR; Gignac, GA; Heller, G; Hong, C; Jia, X; Kelly, WK; Larson, S; Morris, MJ; O'Donoghue, J; Pandit-Taskar, N; Rathkopf, D; Scher, HI; Schwartz, L; Slovin, S; Solit, D; Stephenson, RD, 2009)	0.35
" Further advantages of low-dose CP were its convenient oral administration, dosing schedule, low cost, and low-toxicity profile."	( Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. de Riese, W; Filleur, S; Haynes, A; Klatte, T; Nelius, T, 2010)	0.36
" The purpose of this study was to establish a suitable dosing schedule to reduce adverse effects and improve the antitumour effects."	( Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. Higuchi, S; Ieiri, I; Kinoshita, T; Kodama, A; To, H, 2009)	0.35
" Cisplatin concentrations in the plasma and kidney were higher in the simultaneous dosing group than the sequential dosing groups."	( Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. Higuchi, S; Ieiri, I; Kinoshita, T; Kodama, A; To, H, 2009)	0.35
"Two dosing cycles consisting of weekly docetaxel and monthly (153)Sm-lexidronam were well tolerated and feasible in this CRPC population."	( Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. Johnson, MM; Jones, D; Logothetis, CJ; Mathew, P; Tu, SM; Wong, FC, 2009)	0.35
" Intermittent dosing of lonafarnib (5 days on then 5 days off) coadministered with docetaxel produced similar regressions in hormone-refractory 22Rv1 tumors."	( Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. Bishop, WR; Hsieh, Y; Kirschmeier, P; Liu, G; Long, BJ; Marrinan, CH; Taylor, SA, 2009)	0.35
"This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer."	( Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I, 2009)	0.35
"Weekly dosing of combination of irinotecan and docetaxel is active against MBC."	( N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Anderson, DM; Bernath, AM; Gamini, SS; Hillman, DW; Niedringhaus, R; Northfelt, DW; Palmieri, F; Perez, EA; Salim, M; Stella, PJ; Tan, WW, 2010)	0.36
" Further evaluation of different scheduling and dosing of PI-88 and docetaxel may be warranted to optimise efficacy with a more manageable safety profile."	( Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Begbie, S; Boyce, A; de Souza, P; Harvie, R; Khasraw, M; Lim, V; Marx, G; McCowatt, S; Parnis, F; Pavlakis, N; Underhill, C, 2010)	0.36
"This study was aimed to propose a novel dosing schedule of docetaxel based on alpha(1)-acid glycoprotein (AGP)as an index."	( [Proposal of a novel dosing schedule of docetaxel by using alpha1-acid glycoprotein as an index]. Minami, H; Ozawa, K; Sato, H, 2009)	0.35
" Target plasma concentrations were correctly predicted by our previously described dosing nomogram."	( Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y, 2010)	0.36
" Once the MTD was reached the schedule of PLD was changed to days 1 and 15 to explore an alternative and potentially more manageable dosing schedule."	( Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Aparicio, A; El-Khoueiry, A; Garcia, AA; Gitlitz, BJ; Groshen, S; Iqbal, S; Lenz, HJ; Pinski, J; Quinn, DI; Tsao-Wei, DD, 2011)	0.37
"Thirty-two patients with unresectable stage IIIA/B NSCLC received irinotecan (30 mg/m) and carboplatin dosed to a target area under the concentration curve of 2, each administered weekly for 7 weeks."	( Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR, 2010)	0.36
" Similarly, docetaxel has been investigated for 3-weekly versus weekly schedule, reporting equivalent efficacy and improved side effect profile for weekly dosing with regards myelosuppression."	( Scheduling of taxanes: a review. Twelves, C; Woodward, EJ, 2010)	0.36
" The aim of this study was to identify cellular processes in mouse heart tissue affected by different ADR/DOC dosing protocols using a toxicoproteomic approach."	( A toxicoproteomic study on cardioprotective effects of pre-administration of docetaxel in a mouse model of adriamycin-induced cardiotoxicity. Ichibangase, T; Imai, K; Kishikawa, N; Kuroda, N; Nakashima, K; Ohyama, K; To, H; Tomonari, M, 2010)	0.36
" In 24 patients, the mean Cmax and AUC erlotinib values increased with dose and following cumulative dosing (days 7 and 8 vs."	( Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y, 2011)	0.37
" Dosing for phase II trials was docetaxel 35 mg/m² and erlotinib 50 mg."	( Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y, 2011)	0.37
"The clinical dosage formulation of Paclitaxel and Docetaxel, Taxol and Taxotere, while having high efficacy, can cause serious side effects due to the adjuvant used."	( Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Chien, S; Feng, SS; Gan, CW, 2010)	0.36
" Although some patients may benefit from the treatment, other dosing regimens and novel taxanes such as Nab-paclitaxel should be explored in this setting."	( Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Kaley, K; Penney, R; Saif, MW; Syrigos, K, 2010)	0.36
" For Docetaxel and 5-FU, a linear correlation between this sensitizing effect and the ascorbate dosage is observed."	( Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Aigner, A; Czubayko, F; Frömberg, A; Gutsch, D; Schulze, D; Vollbracht, C; Weiss, G, 2011)	0.37
"Population pharmacokinetic (PK) analyses have been successfully incorporated into drug dosing optimization; however, these analyses necessitate relatively large patient cohorts that many clinical trials do not have the luxury of affording."	( Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis. Gustafson, DL; Hudachek, SF, 2011)	0.37
"This study was conducted to determine the optimal dosage of the docetaxel-capecitabine-cisplatin (DXP) regimen and to evaluate its efficacy and safety in patients with advanced gastric cancer."	( Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH, 2011)	0.37
" We first performed a dosing experiment of CTCE-9908 in the PyMT mouse model, testing 25, 50 and 100 mg/kg versus the scrambled peptide in groups of 8-16 mice."	( CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Aguilar-Mahecha, A; Alsawafi, Y; Basik, M; Buchanan, M; Gaboury, L; Hassan, S; Jahan, K; Mourskaia, AA; Muller, WJ; Salvucci, O; Siegel, PM, 2011)	0.37
"59 primary M0 breast cancer patients received pre-operative sequential dose-dense epirubicin and cyclophosphamide followed by docetaxel (19 patients at dosage 100 mg/m(2), 40 patients at 75 mg/m(2))."	( Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer. Grosse-Onnebrink, E; Harbeck, N; Hoopmann, M; Kates, R; Mallmann, P; Stoff-Khalili, M; Thomas, A; Warm, M, 2010)	0.36
" Hand-foot syndrome occurred in 12/19 patients treated at the higher docetaxel dosage but only 1/40 of the remaining patients."	( Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer. Grosse-Onnebrink, E; Harbeck, N; Hoopmann, M; Kates, R; Mallmann, P; Stoff-Khalili, M; Thomas, A; Warm, M, 2010)	0.36
" The purpose of this study was to evaluate the effect of PK-guided [area under the plasma concentration versus time curve (AUC) targeted], individualized docetaxel dosing on interindividual variability in exposure."	( Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. de Bruijn, P; Engels, FK; Loos, WJ; Mathijssen, RH; Mathot, RA; van der Bol, JM; Verweij, J, 2011)	0.37
" PK-guided dosing also decreased the interindividual variability of percentage decrease in white blood cell and absolute neutrophil counts by approximately 50%."	( Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. de Bruijn, P; Engels, FK; Loos, WJ; Mathijssen, RH; Mathot, RA; van der Bol, JM; Verweij, J, 2011)	0.37
" All in all, this new NSC design provides a convenient mean to set up a clinically more appealing weekly or longer dosing cycle for siRNA therapy, which addresses a significant unmet need for prostate cancer treatment and is potentially useful for other chronic disease conditions as well."	( Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Wong, HL; Xue, HY, 2011)	0.37
" We administered a dosage of 50mg/day for four-week cycles, followed by a two-week rest per cycle, until we reached a total of eight cycles or up to clinical progression or intolerable toxicity."	( [Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel]. Alberola, V; Casinello, J; Gasent, JM; Grande, E; Laforga, JB; Provencia, M, 2011)	0.37
" Treatment durations and dosing were derived from randomized controlled trials, FDA labeling, and National Comprehensive Cancer Network guidelines."	( Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB, 2011)	0.37
" Unlike trials with continuous daily dosing of AT-101, no cases of small bowel obstruction were reported."	( Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA, 2011)	0.37
"Single or combination chemotherapy with paclitaxel, docetaxel, carboplatin, and trastuzumab was administered to 9 baboons at a mean (SD) gestational age of 117 (26) days (paclitaxel, 100 mg/m2 [n = 2]; docetaxel, 100 mg/m2 [n = 2]; paclitaxel, 175 mg/m2 with carboplatin, area under the curve of 6 at standard dosage [n = 2] and 50% dosage [n = 1]; docetaxel, 75 mg/m2 with carboplatin, area under the curve 6 [n = 1]; and docetaxel, 75 mg/m2 with trastuzumab, 8 mg/kg [n = 1])."	( Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Amant, F; Beijnen, J; Calsteren, KV; Chai, DC; de Bruijn, E; De Catte, L; de Hoon, J; Demarsin, S; Devlieger, R; Heyns, L; Van Bree, R; Verbesselt, R, 2010)	0.36
"The objective of this study was to evaluate the tolerability, to establish a dosing regimen, and to evaluate the efficacy of intravesical docetaxel (DTX) formulations in a mouse model of bladder cancer."	( In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer. Brooks, DE; Burt, HM; Chafeeva, I; Gleave, ME; Heller, L; Heller, M; Matsui, Y; Mugabe, C; So, AI; Zeisser-Labouèbe, M, 2011)	0.37
" Sensory NCI-CTC scores were higher in patients receiving higher cumulative chemotherapy dosage (z = -2."	( The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. Beck, SL; Cohen, JA; Lavoie Smith, EM; Pett, MA, 2011)	0.37
"We revealed that pre-treatment with docetaxel (DOC) 12 h before adriamycin (ADR) administration significantly reduced ADR-induced toxic death compared with the simultaneous dosing schedule that was commonly used in previous studies."	( Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity. Kurose, H; Mishima, T; Nishida, M; Sasaki, H; To, H; Tomonari, M, 2011)	0.37
" Patients were randomized to 1 of 4 dosing cohorts: 1) 30 mg/m², 100 mg; 2) 36 mg/m², 100 mg; 3) 30 mg/m², 150 mg; or 4) 36 mg/m², 150 mg of DTX intravenously weekly, LNF orally twice daily, respectively."	( Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Bender, L; Chanel-Vos, C; Escuin, D; Fanucchi, MP; Gal, A; Giannakakou, P; Harvey, RD; Kauh, J; Khuri, FR; Kutner, M; Marcus, A; Pan, L; Ramalingam, SS; Saba, N; Shin, DM, 2011)	0.37
" Animals received a 7-day continuous infusion of YM155, 2 mg/kg, and/or three bolus doses of docetaxel, 20 mg/kg, according to three dosing schedules: YM155 administered concomitantly with docetaxel, before docetaxel, and after docetaxel."	( YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Hatakeyama, S; Kinoyama, I; Kita, A; Koutoku, H; Matsuhisa, A; Nakahara, T; Nakano, K; Sasamata, M; Shishido, T; Takeuchi, M; Yamanaka, K, 2011)	0.37
" Data on molecular-genetic characteristics of tumor may be used to individualize choice of drugs, dosage and to lower risk of toxicity."	( [Frequency of expression of markers predictive of sensitivity to cytostatics in skin melanoma]. Ievleva, AG; Imianitov, EN; Moiseenko, VM; Protsenko, SA; Zhabina, AS, 2010)	0.36
"In this phase I study successive patient cohorts received docetaxel 60 or 75mg/m(2) every 3weeks in combination with chronic daily dosing of SU-014813."	( Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Battista, A; Beuselinck, B; Brega, N; Courtney, R; de Jonge, MJ; Dumez, H; Kitzen, JJ; Schöffski, P; Verweij, J, 2011)	0.37
" The present study addressed whether changes in the chemotherapy dosing schedule affect the development, further worsening, or circumvention of drug resistance in chemosensitive and chemoresistant ovarian cancer."	( Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Allen, C; Badame, RM; De Souza, R; Piquette-Miller, M; Zahedi, P, 2011)	0.37
" Controlled release of DTX with a dosage suitable for the treatment of diabetic retinopathy has been achieved for 35 days."	( On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device. Burt, HM; Chiao, M; Jackson, JK; Pirmoradi, FN, 2011)	0.37
" For 12 weeks they were treated with neoadjuvant docetaxel and ketoconazole, with dosing based on phase I data."	( A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. Holzbeierlein, JM; Nisbet, AA; Reed, GA; Thrasher, JB; VanVeldhuizen, PJ; Womble, PR, 2011)	0.37
"A dose escalation schedule was designed consisting of four dose levels with a standard dosage of docetaxel (75 mg/m(2) 3-weekly)."	( A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH, 2011)	0.37
" Adjustment for docetaxel dosage and period per cycle was subject to investigator's judgment."	( Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. Hongo, F; Iwata, T; Kamoi, K; Kawauchi, A; Miki, T; Okihara, K; Takaha, N; Takeuchi, I; Ueda, T; Yamada, T; Yano, K, 2011)	0.37
"For use in chronic oral chemotherapeutic regimens, the potent anticancer drug docetaxel needs a solid oral dosage form."	( Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Beijnen, JH; Huitema, AD; Koolen, SL; Moes, JJ; Nuijen, B; Schellens, JH, 2011)	0.37
" The first 2 patients developed a dose-limiting toxicity (neutropenic infection), prompting a mandatory dose reduction and PK evaluation of both everolimus and docetaxel for patients enrolled in subsequent dosing cohorts."	( A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Booser, D; Brewster, A; Cristofanilli, M; Ensor, J; Giordano, SH; Gladish, G; Gonzalez-Angulo, AM; Hortobagyi, GN; Moore, J; Moulder, S; Murray, JL; Rivera, E; Tran, HT, 2012)	0.38
" If the present rat data could be expressed to humans, the alterations in docetaxel absorption and metabolism should be considered in designing a dosage regimen for cancer patients with PCM state after cysteine supplement."	( Effects of cysteine on the pharmacokinetics of docetaxel in rats with protein-calorie malnutrition. Choi, YH; Kim, YG; Lee, MG; Yoon, I, 2012)	0.38
" All the patients received study medication rG-CSF at a dosage of 5 μg/kg per day (Sicor Biotech UAB, Teva Group) from day 2 of each cycle and continued for minimum 5 days or until absolute neutrophil count reached ≥1."	( An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients. Characiejus, D; Juozaitytė, E; Liutkauskienė, S; Šeštakauskas, K; Sveikata, A; Tamošaitytė, L, 2011)	0.37
" Thus, we hypothesized that BH3-mimetic drugs that antagonize Bcl-2 family proteins may exert a greater efficacy when dosed metronomically."	( Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z, 2012)	0.38
" was administered on days 1, 8, 15, and erlotinib 150 mg was dosed orally on days 2-7, 9-14, 16-28 of each 28-day cycle."	( Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Bufill, JA; Chiorean, EG; Coleman, N; Currie, C; Johnston, EL; Loehrer, PJ; Picus, J; Ramasubbaiah, R; Tong, Y; Yu, M, 2012)	0.38
" The physicochemical and pharmacokinetic properties of NOSC-modified DTX liposomes (NDLs) were evaluated compared with the conventional DTX liposomes (DLs) and commercial dosage form of DTX, Taxotere(®)."	( N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics. Qu, G; Wu, X; Yin, L; Zhang, C, 2012)	0.38
" A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient's therapeutic needs and quality of life."	( Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. Bae, JW; Kim, WY; Lee, JB; Seo, JH; Son, GS; Woo, SU, )	0.13
" Scheduling of docetaxel before selumetinib was more beneficial than when selumetinib was dosed before docetaxel and demonstrated a pro-apoptotic phenotype."	( The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW, 2012)	0.38
" The antitumor activity, different dosing sequences, and dosing regimens of TH-302 in combination with commonly used conventional chemotherapeutics were investigated in human tumor xenograft models."	( TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y, 2012)	0.38
" Simultaneous administration of TH-302 and chemotherapeutics increased toxicity versus schedules with dosing separations."	( TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y, 2012)	0.38
"In the current study, gemcitabine-docetaxel combination therapy at this dosage and schedule was found to be well tolerated and marginally effective, which could be considered as salvage therapy for patients with recurrent or refractory high-grade osteosarcoma."	( Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y, 2012)	0.38
"Consistent with previously published efficacy results, these data suggest that 150 mg/m(2) qw 3/4 may represent the most clinically efficacious nab-paclitaxel dosing regimen for patients with no previous chemotherapy for MBC."	( Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Iglesias, J; Krasnojon, D; Makhson, AN; Manikhas, GM; McGuire, JR, 2012)	0.38
" The DTX dose-response and proliferation was measured by MTT and colony assays, respectively."	( In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. Beretov, J; Chang, L; Cozzi, PJ; Graham, PH; Hao, J; Hung, TT; Kearsley, JH; Khatri, A; Li, Y; Madigan, MC; Power, CA; Xiao, W, 2012)	0.38
" over two different dosing schedules with equivalent dose intensity in patients with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment."	( Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. Berardi, R; Bleuse, JP; Cappuzzo, F; de Wit, R; Dogliotti, L; Jannuzzo, MG; Mariani, M; Meulenbeld, HJ; Petroccione, A; Raymond, E; Santoro, A; Sternberg, CN; Tagawa, ST; Vinci, EM; Vitali, G, 2013)	0.39
" Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC)."	( Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)	0.38
" Ninety-three patients received the same chemotherapy regimen except for the fixed vinorelbine (20 mg/m(2)) dosage and consolidation therapy with docetaxel (60 mg/m(2), every 3 weeks)."	( Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. Goto, K; Horinouchi, H; Mori, K; Noda, K; Sekine, I; Sumi, M; Tamura, T, 2013)	0.39
"Patients with advanced solid tumors received three weekly AVE1642 dosed at 6 mg/kg, chosen following previous study, with 75 (cohort A) or 100 mg/m(2) (B) docetaxel, 1250 mg/m(2) gemcitabine/100 mg erlotinib (C1), or 60 mg/m(2) doxorubicin (D1)."	( Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A, 2013)	0.39
" Intetumumab serum concentrations increased with repeated dosing and did not reach steady-state."	( A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M, 2013)	0.39
"Cbz at a dosage of 25mg/m(2) intravenously every 3 wk combined with 5mg of oral prednisone twice a day."	( Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M, 2013)	0.39
" The prolonged duration of Docetaxel in plasma when dosed with PRINT formulations subsequently led to increased tumor exposure of Docetaxel from 0 to 168h (~53% higher for PRINT-Doc-80×320 and ~76% higher for PRINT-Doc-200×200 particles)."	( Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Bridges, AS; Chu, KS; DeSimone, JM; Enlow, EM; Hasan, W; Kuijer, JL; Luft, JC; Napier, ME; Rawal, S; Walsh, MD; Zamboni, WC, 2013)	0.39
"Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule."	( A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Chiorean, EG; Dipaola, RS; Jung, DT; Kroll, S; Kurtoglu, M; Lampidis, TJ; Langmuir, VK; Papadopoulos, K; Raez, LE; Ricart, AD; Rocha Lima, CM; Rosenblatt, J; Schlesselman, JJ; Stein, MN; Tolba, K, 2013)	0.39
" Larger studies with more frequent dosing of zoledronic acid are needed to assess these complex interactions more thoroughly."	( Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study. Coleman, RE; Cross, SS; Evans, A; Freeman, JV; Hatton, MQ; Holen, I; Ingram, CE; Jolley, IJ; Mori, S; Syddall, SP; Wilson, C; Winter, MC, 2013)	0.39
" Luminescence returned to baseline by 24-48 hours after drug injection and was reinducible over two additional rounds of drug dosing in pxr(+/+) mice."	( Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice. Chen, J; Forman, BM; Gu, L; Kane, SE; Synold, TW, 2013)	0.39
" Currently, taxane dosing is based primarily on body surface area, ignoring other factors that are known to dictate variability in pharmacokinetics or outcome."	( Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Hertz, DL; Krens, SD; McLeod, HL, 2013)	0.39
" Uses of such models may include interpretation of preclinical toxicology studies, selection of first in man dosing regimens, and PK/PD model development."	( Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. Harasym, T; Liboiron, B; Mayer, LD; McNeil, SE; Skoczen, S; Stern, ST; Tardi, P; Xie, S; Zou, P, 2013)	0.39
" Pharmacokinetic results indicated that patients with more severe hepatic dysfunction may have been underdosed based on our conservative dosing strategy."	( Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. Booser, DJ; Eckmann, K; Esparza-Guerra, L; Green, MC; Hortobagyi, GN; Kawedia, J; Madden, TL; Michaud, LB; Rivera, E; Valero, V, 2014)	0.4
"7 %) experienced grade 3 skin toxicity events attributable to docetaxel, a significantly higher rate than previously reported for docetaxel dosed at 75-100 mg/m(2)."	( Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Berger, M; Layman, R; Lustberg, M; Mrozek, E; Olson, E; Poi, MJ; Ramaswamy, B; Shapiro, CL; Wesolowski, R, 2013)	0.39
" Therefore our aim was to explore the short- and long-term cognitive effects of different dosing schedules of the taxane docetaxel (DTX) on laboratory rodents."	( The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Fardell, JE; Johnston, IN; Vardy, J, 2013)	0.39
" Taken together, D-SNEDDS could be a potential candidate for an oral dosage form of DCT with enhanced antitumor activity and reduced toxicity."	( Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Choi, HG; Kim, DH; Kim, DW; Kim, JH; Kim, JK; Kim, JO; Marasini, N; Oh, YK; Ramasamy, T; Seo, YG; Yong, CS, 2013)	0.39
" Grade 4 neutropenia was revealed, but the treatment could be continued by G-CSF or by down dosing the anticancer agents."	( [An 84-year-old man with highly advanced gastric cancer showing good response after chemotherapy with docetaxel, cisplatin and S-1 combination therapy]. Fukumoto, M; Irei, Y; Maruyama, S; Matsuki, A; Nakagawa, S; Nashimoto, A; Nomura, T; Takii, Y; Tsuchiya, Y; Yabusaki, H, 2013)	0.39
" There was no relation between dosage and age (p=0."	( Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM, 2013)	0.39
" Intestinal damage after repeated dosing of docetaxel (20 mg/kg) for 3 weeks was more severe at 14 hours after light on (HALO) than at 2 HALO."	( Involvement of Wee1 in the circadian rhythm-dependent intestinal damage induced by docetaxel. Fujimura, A; Ishikawa-Kobayashi, E; Kusama, M; Obi-Ioka, Y; Ushijima, K, 2013)	0.39
"Oncologists limited the dosing of chemotherapy because of CIPN in a significant proportion of paclitaxel recipients, most frequently in those who received a weekly regimen."	( Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Sammel, MD; Speck, RM; Stineman, MG, 2013)	0.39
"These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim."	( Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011)	0.37
"A total of 30 cases were selected and randomly divided into 5 groups: three HHPG-19K groups of different dosage (60 μg/kg/day, 100 μg/kg/day, 200 μg/kg/day), positive control group (Filgrastim, namely G-CSF5 μg/kg/day) and negative control group."	( Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. Chen, ZL; Han, BH; Jiang, LY; Lu, F; Yan, B; Zhang, W, 2013)	0.39
" There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference."	( Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. Chen, ZL; Han, BH; Jiang, LY; Lu, F; Yan, B; Zhang, W, 2013)	0.39
" Besides, dosage at 100 μ g/kg is the most safe."	( Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. Chen, ZL; Han, BH; Jiang, LY; Lu, F; Yan, B; Zhang, W, 2013)	0.39
"This study examined the impact of variable docetaxel (DTX) chemotherapy dosing on brain DTX exposure via analyses of neural morphology and changes in cognition."	( The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Allen, C; De Souza, R; Fardell, JE; Henderson, J; Johnston, I; Piquette-Miller, M; Vardy, J; Zhang, J, 2014)	0.4
"Post-treatment behavioral testing demonstrated impaired NOR in mice treated with either dosing schedule relative to controls."	( The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Allen, C; De Souza, R; Fardell, JE; Henderson, J; Johnston, I; Piquette-Miller, M; Vardy, J; Zhang, J, 2014)	0.4
" Additional large randomized studies are needed to optimize the schedule and dosage of combination therapy with docetaxel and cisplatin in high-risk patients with unresectable NSCLC."	( Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer. Cho, YJ; Choi, JY; Hwang, YS; Jeong, YY; Kang, JH; Kim, HC; Kim, HG; Kim, MG; Kim, MJ; Kim, SH; Lee, GW; Lee, JD, 2013)	0.39
" Given this background, it is troubling that limited information is available for dosing chemotherapy agents in obese patients."	( Dosing considerations for obese patients receiving cancer chemotherapeutic agents. Hall, RG; Jean, GW; Shah, S; Sigler, M, 2013)	0.39
" Hepatic clearance of docetaxel was enhanced in vitro and in vivo at dosage of 120 and 180 mg kg(-1), and CYP3A activity was up-regulated by measuring the formation rate of 1-hydroxymidazolam."	( Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2. Chen, X; Deng, S; Fan, A; Gao, W; Li, C; Li, N; Liu, Q; Wang, C; Wen, X; Zhang, Q; Zhang, W; Zhang, Y; Zhao, D; Zhao, J, 2014)	0.4
" Dose-response curves were constructed, and the combination index (CI) for drug interaction was calculated."	( Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression. Adams, DJ; Grace, L; Jia, J; Murphy, SK; Nixon, AB; Secord, AA; Teoh, D, 2014)	0.4
" Full body surface areas-based dosing appears to be tolerated as well in obese as in lean women."	( Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women. Carroll, JP; Cheng, ME; Fay, M; Martin, JH; Nguyen, L; Pillay, PS; Protani, MM; Saleem, M; Walpole, E, 2014)	0.4
" 18/49 HNSCC qualified for FLAVINO-based dose-response analyses, and Sim significantly suppressed CF in 18/18 primary HNSCC."	( Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Aigner, A; Boehm, A; Dietz, A; Mozet, C; Stoehr, M; Wichmann, G, 2014)	0.4
" Dose-response curve analysis of the mitotic index assay with an antimitotic drug (docetaxel) on DropArray is presented that shows an effective dosage compared to previous established results similar to those obtained with conventional microtiter plates."	( Miniaturization of mitotic index cell-based assay using "wall-less" plate technology. Kim, N; Le Guezennec, X; Nor, L; Phong, M, 2014)	0.4
" Although we had a small number of patients, our findings suggest that both dose concentration and total docetaxel dose may be important in the treatment of CRPC and q2w dosing is an option in patients intolerant of a higher dose concentration."	( Efficacy and Toxicity of Every 2 Weeks Docetaxel Regimen in Comparison With Weekly or Every 3 Weeks in Metastatic Prostate Cancer: A Retrospective Analysis. Malhotra, A; Poiesz, BJ; Rosenbaum, P; Welch, D, 2016)	0.43
" Phostaxel has always shown better efficacy than Taxotere(®) in various xenograft trials at the same dosage and administration schedule against the tumor cell lines tested."	( Preclinical evaluation of efficacy and stability of docetaxel micelle-encapsulated by a tripodal cyclotriphosphazene amphiphile. Chae, SW; Cui, JX; Jun, YJ; Lee, HJ; Park, JH; Sohn, YS, 2014)	0.4
" Therefore, overall results suggest that thermosensitive nanomicelles could be a potential dosage form for improvement of the bioavailability and chemotherapeutic profile of DCT."	( The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles. Choi, HG; Choi, JY; Kim, DW; Kim, JH; Kim, JO; Ramasamy, T; Yong, CS, 2014)	0.4
" Because tasisulam is highly albumin-bound, patients in the tumor-specific confirmation arms were dosed targeting specific albumin-corrected exposure ranges (AUCalb) identified during dose-escalation (3,500 hμg/mL [75th percentile] for docetaxel, temozolomide, and cisplatin; 4,000 hμg/mL for gemcitabine and erlotinib)."	( An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD, 2015)	0.42
"To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC)."	( Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN, 2014)	0.4
" The dosing commenced using an accelerated titration design and was followed by a modified 3 + 3 Fibonacci schema to determine maximally tolerated dose (MTD)."	( Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Anderson, G; Charles, J; Gallegos, NS; Hart, J; Kousba, A; Mahalingam, D; Malik, L; Mita, AC; Nemunaitis, JJ; Rogers, JM; Sankhala, K; Sarantopoulos, J; Senzer, NN; Weitman, S, 2014)	0.4
" Despite years of research, the optimal dosing regimen (weekly vs 3-weekly) and optimal dose is still controversial, as is the value of pharmacological personalization of taxane dosing."	( Metabolism of the taxanes including nab-paclitaxel. Joerger, M, 2015)	0.42
" The latter includes the ongoing debate on the most active and safe regimen (paclitaxel, docetaxel, nab-paclitaxel), the recommended initial dose (cabazitaxel) and pharmacological dosing individualization."	( Metabolism of the taxanes including nab-paclitaxel. Joerger, M, 2015)	0.42
"The purpose of this study is to synthesize a novel galactosylated cholesterol derivative, cholesterol-diethenyl decanedioate-lactitol (CHS-DD-LA) through lipase-catalyzed esterification in non-aqueous and to evaluate the preparation, pharmacokinetics and biodistribution of docetaxel (DOC) liposomes modified with CHS-DD-LA (G-DOC-L), which may actively gather at the liver compared with the conventional DOC liposomes (DOC-L) and commercial dosage form of DOC injection (DOC-i)."	( Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase. Chen, J; Chen, YC; Cheng, Y; Luo, LH; Nie, H; Tong, D; Zheng, PJ, 2016)	0.43
" Among all the single and combination dosing regimens of free drugs and conjugates, the macromolecular combination therapy showed significantly prolonged mice survival in vivo."	( Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Kopeček, J; Yang, J; Zhang, R; Zhou, Y, 2015)	0.42
"The purpose of this study was to assess whether an intercalated dosing schedule of erlotinib and docetaxel could avoid possible negative interactions and optimize the benefit obtained as second-line therapy in non-small-cell lung cancer (NSCLC) patients."	( Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial. Aparisi, F; Esquerdo, G; García-Sánchez, J; Garde, J; Giner, V; Juan, Ó; López, A; Muñoz-Langa, J; Sánchez-Hernández, A, 2015)	0.42
" All of our results indicated that an intercalated dosing schedule of erlotinib and docetaxel could be more efficient than erlotinib treatment alone."	( Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial. Aparisi, F; Esquerdo, G; García-Sánchez, J; Garde, J; Giner, V; Juan, Ó; López, A; Muñoz-Langa, J; Sánchez-Hernández, A, 2015)	0.42
" Cox proportional hazard regression showed that age ≥65 years, high VSR, abnormal serum alkaline phosphatase, and >10% reduction of initial dosage were significant predictors of shorter time between starting docetaxel and death, and that high VMR, obesity, and weekly regimens were significant predictors of longer survival after docetaxel."	( Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. Chaftari, P; Cruz Carreras, MT; Dalal, S; Gonzalez, C; Liu, X; Merriman, K; Tu, SM; Viets-Upchurch, J; Wu, W; Yeung, SC, 2015)	0.42
"Obese and overweight patients may benefit more from weekly docetaxel regimens using the reference dosage of 35 mg/m2 without empirical dosage reduction."	( Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. Chaftari, P; Cruz Carreras, MT; Dalal, S; Gonzalez, C; Liu, X; Merriman, K; Tu, SM; Viets-Upchurch, J; Wu, W; Yeung, SC, 2015)	0.42
"Intermittent dosing of inhibitors of the PI3K/AKT/mTOR network offers the potential to maximize the therapeutic margin."	( Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cheng, J; D'Cruz, C; Davies, BR; Dudley, P; Yates, JW, 2015)	0.42
"A mathematical model of pharmacokinetics, pharmacodynamics and anti-tumor effect was constructed based upon experimental data from dosing regimens that give constant and transient inhibition of the AKT pathway."	( Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cheng, J; D'Cruz, C; Davies, BR; Dudley, P; Yates, JW, 2015)	0.42
"Continuous and intermittent dosing of AZD5363 inhibited growth of BT474c xenografts and caused dose- and time-dependent inhibition of AKT substrate phosphorylation."	( Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cheng, J; D'Cruz, C; Davies, BR; Dudley, P; Yates, JW, 2015)	0.42
"Equivalent anti-tumor activity to continuous dosing can be achieved at modestly increased intermittent doses of AZD5363."	( Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cheng, J; D'Cruz, C; Davies, BR; Dudley, P; Yates, JW, 2015)	0.42
" Although small-molecule microarrays are a promising platform for miniaturized screening, it has been a challenge to use them to obtain quantitative dose-response curves in vitro, especially for lipophilic compounds."	( Quantitative dose-response curves from subcellular lipid multilayer microarrays. Chadwick, BP; Darrow, EM; Davidson, MW; Kusi-Appiah, AE; Lenhert, S; Lowry, TW; Wilson, KA, 2015)	0.42
" During HIPEC in Colliseum technique Oxaliplatin was given in a dosage of 200 mg/m2 and Docetaxel in a dosage of 80 mg/m2."	( Systemic Chemotherapy using FLOT - Regimen Combined with Cytoreductive Surgery plus HIPEC for Treatment of Peritoneal Metastasized Gastric Cancer. . Hotopp, T; Müller, H; Tofeili, A; Wutke, K, 2014)	0.4
" The AUC0-inf after microdosing was 3640 ± 1150 ng h L(-1), while that after therapeutic dosing adjusted to 100 mg/patient was 2230 ± 757 µg h L(-1)."	( A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Fujita, K; Ishida, H; Kaneta, T; Kawara, K; Kusuhara, H; Maeda, K; Sasaki, Y; Sugiyama, Y; Yokoyama, T; Yoshino, E, 2015)	0.42
" Still, the optimal dosing regimen (weekly vs 3 weekly) and optimal dose of the taxanes are controversial, as is the value of pharmacological personalization of taxane dosing."	( Treatment regimens of classical and newer taxanes. Joerger, M, 2016)	0.43
" In this article, it is demonstrated that these two tumor-targeted drug delivery mechanisms are interrelated and dosage dependent."	( Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles. Bradshaw, M; Galabura, Y; Ho, D; House, MJ; Iyer, KS; Lim, LY; Luzinov, I; Norret, M; Singh, R; Smith, NM; St Pierre, TG; Woodward, RC, 2016)	0.43
" As a result, dosing recommendations have changed from high dosage loading every 3 weeks to lower dosage loading weekly."	( Quantification of Docetaxel in Serum Using Turbulent Flow Liquid Chromatography Electrospray Tandem Mass Spectrometry (TFC-HPLC-ESI-MS/MS). Clarke, WA; Crutchfield, CA; Marzinke, MA, 2016)	0.43
" We carried out the first prospective study of a personalized dosage regimen for cancer patients with liver dysfunction treated with docetaxel."	( Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. Chan, D; Chuah, B; Goh, BC; Lee, SC; Soe, MY; Soo, RA; Syn, NL; Tan, SH; Wang, L; Wong, AL; Yong, WP, 2016)	0.43
"This current MBMA identified docetaxel dose-response relationships for both neutropenia and ORR, an effect of age on ORR, and Japanese study effects on both neutropenia and OS."	( Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer. Cha, E; Green, M; Jin, J; Stroh, M; Wada, R; Zhang, N, 2016)	0.43
" We have developed a mathematical model to optimize drug dosing regimens and to redesign the dose intensification-dose escalation process, using densified cycles of combined anticancer drugs."	( Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy. Barbolosi, D; Ciccolini, J; Freyer, G; Iliadis, A; Meille, C, 2016)	0.43
" Dose densification was guided by a model of neutrophil kinetics, able to optimize docetaxel plus epirubicin dosing with respect to pre-defined acceptable levels of hematological toxicity while ensuring maximal efficacy."	( Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. Barbolosi, D; Freyer, G; Guitton, J; Hénin, E; Iliadis, A; Meille, C; You, B, 2016)	0.43
" The investigators claim the method of preparation of therapeutic nanosuspension, optimized composition of the formulation and dosage regimen for the clinical studies to effectively treat gastroesophageal and breast cancers."	( Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1). Adams, DJ; Kulhari, H; Pooja, D; Sistla, R, 2016)	0.43
" No significant differences were noted between dosing strategies."	( A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP, 2016)	0.43
" Of the 48 breast cancer patients who commenced new 3-weekly docetaxel dosage regimens during the study period, 6 (12."	( [A Retrospective Analysis of Epiphora Due to Docetaxel]. Kawara, H; Kawashima, Y; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2016)	0.43
"The American Society of Clinical Oncology provides clinical practice guidelines for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer."	( Myelosuppression by chemotherapy in obese patients with gynecological cancers. Kamimura, K; Matsumoto, Y; Moriyama, M; Saijo, Y; Zhou, Q, 2016)	0.43
" However, no recommended steroid dosage for a weekly docetaxel regimen has been established to date."	( Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Han, HJ; Kang, RY; Kim, DW; Lee, JY; Lee, SH; Lee, YJ; Yoo, KS, 2017)	0.46
"Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy."	( Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. Anderson, H; Bengtsson, NO; Bergh, J; Brandberg, Y; Carlsson, L; Egle, D; Fornander, T; Foukakis, T; Gnant, M; Greil, R; Hellström, M; Johansson, H; Karlsson, E; Loibl, S; Malmström, P; Mlineritsch, B; Möbus, V; Schmatloch, S; Singer, CF; Steger, G; Untch, M; von Minckwitz, G; Wallberg, B, 2016)	0.43
"4% for total length values, at 4 μM) as compared to DTX at the clinical dosage 4x10-2 μM (26."	( Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent. Batista de Carvalho, AL; Costa, FM; Diniz, C; Marques, MP; Medeiros, PS; Ribeiro, VP; Sousa, JB, 2016)	0.43
" This analysis of pertuzumab aimed to (1) compare its pharmacokinetics (PK) in patients with EBC versus advanced cancers, (2) to further evaluate PK drug-drug interactions (DDIs) when given in combination with trastuzumab, and (3) to assess the relationship between exposure and efficacy to assess the clinical dosing regimen in the EBC patients."	( Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Benyunes, MC; Garg, A; Jin, JY; Li, H; Lum, BL; McNally, V; Nijem, I; Quartino, AL; Viganò, L; Wada, DR, 2017)	0.46
" Medication costs were calculated according to published pricing benchmarks factored by dosing and duration of therapy as stated in the prescribing information for each agent."	( Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. Corman, S; Drea, E; Flannery, K; Gao, X; Hudspeth, L; Miao, R; Xue, M, 2017)	0.46
" However, a high dosage of chemotherapy drugs or photothermal agents may cause series side effects."	( Novel Approach of Using Near-Infrared Responsive PEGylated Gold Nanorod Coated Poly(l-lactide) Microneedles to Enhance the Antitumor Efficiency of Docetaxel-Loaded MPEG-PDLLA Micelles for Treating an A431 Tumor. Cao, Y; Dong, M; Hao, Y; Jia, Y; Peng, J; Qian, Z; Zhang, T, 2017)	0.46
" Twelve patients received weekly dosing at 60 to 100 mg/m²."	( Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. Mahdi, H; Maurer, K; Michener, C; Rose, PG, 2017)	0.46
" We sought to identify genomic loci that influence chemotherapy-induced hematotoxicity by dosing Diversity Outbred mice with one of three chemotherapy drugs; doxorubicin, cyclophosphamide or docetaxel."	( Genetic background influences susceptibility to chemotherapy-induced hematotoxicity. Churchill, GA; Gatti, DM; Goodwin, NC; Lammert, F; Weber, SN, 2018)	0.48
"The taxane drugs paclitaxel and docetaxel, widely used on cancer chemotherapy, are currently dosed mainly based on body-surface area."	( Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel. Andriguetti, NB; Antunes, MV; Linden, R; Perassolo, MS; Raymundo, S; Suyenaga, ES; Verza, SG, 2017)	0.46
" The dosage and duration of biosimilar were lower than lenograstim (4."	( Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients. Alcácera, MA; Andrés, R; Frutos Pérez-Surio, A; Puértolas, I; Salvador, MDT, 2018)	0.48
" PAG can self-assemble into micelles as amphiphilic block copolymers, which exhibits an excellent loading ability for the co-delivery of docetaxel (DTX) and MMP-9 shRNA with adjustable dosing ratios."	( Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA. Ding, Y; Ho, RJY; Kang, Y; Lan, J; Lu, L; Yang, J; Zhang, T; Zhang, Y; Zhao, Y, 2018)	0.48
" PD-L1 subgroups suggested positive dose-response relationship between PD-L1 expression levels with survival benefits."	( Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Aguiar, P; Haaland, B; Lopes, G; Tan, PS, 2018)	0.48
" There is a positive dose-response relationship between PD-L1 expression and survival benefits, and little evidence of survival differences between nivolumab, pembrolizumab and atezolizumab."	( Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Aguiar, P; Haaland, B; Lopes, G; Tan, PS, 2018)	0.48
" Moreover, there is no uniform standard for dosage and course for docetaxel treatment."	( [Progress in study on the treatment of gastric cancer with docetaxel]. Du, H; Jiao, Z; Ren, Y; Wang, K; Wang, Z; Zhang, G, 2018)	0.48
" Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function."	( Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review . Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T, 2018)	0.48
" The docetaxel dosing with trastuzumab requires further study."	( Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. Auvinen, P; Canney, P; Fraser, J; Granstam-Björneklett, H; Halonen, P; Harvey, VJ; Huovinen, R; Huttunen, T; Joensuu, H; Johansson, O; Kellokumpu-Lehtinen, PL; Lindman, H; Lundgren, L; Neven, P; Nyandoto, P; Ritchie, D; Sailas, L; Tanner, M; Turpeenniemi-Hujanen, T; Utriainen, M; Villman, KK; Wildiers, H; Yachnin, J, 2018)	0.48
"To assess the impact of relative dosing intensity (RDI) on the outcomes of breast cancer patients referred for adjuvant anthracycline-taxane chemotherapy."	( Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. Abdel-Rahman, O, 2019)	0.51
"Treatment with BIND-014 at a dosage of 60 mg/m2 was given intravenously on day 1 of 21-day cycles in combination with prednisone until disease progression or unacceptable toxic effects occurred."	( Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. Alva, A; Anderson, J; Autio, KA; Dittamore, R; Dreicer, R; Garcia, JA; Graf, RP; Hart, LL; Milowsky, MI; Morris, MJ; Posadas, EM; Ryan, CJ; Scher, HI; Schreiber, NA; Summa, JM; Youssoufian, H, 2018)	0.48
"Many anti-cancer drugs are difficult to formulate into an oral dosage form because they are both poorly water-soluble and show poor permeability, the latter often as a result of being an intestinal efflux pump substrate."	( Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Bohr, A; Grohganz, H; Harmankaya, N; Löbmann, K; Nascimento, TL; Rades, T; Wang, Y; Weisser, JJ, 2019)	0.51
"Older patients with metastatic castration-resistant prostate cancer (mCRPC) may be more prone to chemotherapy-induced hematological toxicity, but tailored docetaxel dosing guidelines in older patients are lacking because of conflicting data."	( Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Doremalen, JGC, 2019)	0.51
"This study included patients with mCRPC treated with docetaxel between January 2006 and January 2016 at the Netherlands Cancer Institute and Medical Center Slotervaart for whom dosing and hematological toxicity data were available from electronic patient records."	( Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. Beijnen, JH; Bergman, AM; Crombag, MBS; de Vries Schultink, AHM; Huitema, ADR; Otten, HM; Schellens, JHM; van Doremalen, JGC, 2019)	0.51
" ENZ was routinely started as a dose of 160 mg per day; the dosage was reduced in some patients due to side effects."	( Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. Hasegawa, Y; Kawahara, T; Kumano, Y; Matsubara, N; Miyoshi, Y; Uemura, H; Yasui, M, 2019)	0.51
" The aim of this study is to examine the relationship of the dosage of cisplatin that causes nephrotoxicity and back ground factors of patients using information about the dose of cisplatin actually administered to patients."	( Evaluating dose of cisplatin responsible for causing nephrotoxicity. Higuchi, K; Yanagawa, T, 2019)	0.51
"Intermittent dosing of erlotinib plus docetaxel is clinically feasible in phase I part but did not significantly improve ORR in phase II part."	( Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L). Asai, K; Chiba, Y; Hayashi, H; Kasai, T; Kawaguchi, T; Kijima, T; Kimura, T; Kogure, Y; Nakagawa, K; Nakanishi, Y; Niwa, T; Oguri, T; Ono, A; Tanaka, H; Watanabe, K; Yamamoto, N; Yano, S; Yoshimura, N; Yoshioka, H, 2019)	0.51
" While considering the standard AA dosage (1000 mg) as the main analysis, we also examined the potential impact of the low-dose AA (250 mg) strategy."	( Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. Chiang, CL; Choi, HCW; Lam, TC; So, TH, 2020)	0.56
" The low-dose AA (250 mg) strategy is potentially cost-effective when it generates equivalent efficacy as the standard dosage (1000 mg)."	( Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective. Chiang, CL; Choi, HCW; Lam, TC; So, TH, 2020)	0.56
" However, the current guidelines fail to recommend an optimal dosing schedule of pegfilgrastim along with the DCF regimen to prevent FN."	( Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study. Dohi, O; Fujiwara, H; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Okayama, T; Shiozaki, A; Takagi, T; Teramukai, S; Uchiyama, K; Yasuda, T; Yoshida, N, 2019)	0.51
" A low dosage of loaded DTX in FA-CD@PP-CpG can promote infiltration of CTLs to improve efficacy of anti-PD-L1 antibody (aPD-L1), suppress MDSCs, and effectively polarize MDSCs toward M1 phenotype to reduce tumor burden, further to enhance the antitumor efficacy."	( Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers. Chen, L; Dong, C; Han, Y; Hu, X; Liang, S; Lin, Y; Liu, J; Lu, Y; Shi, S; Wang, C; Yao, T; Zhou, L, 2019)	0.51
" Deterministic, probabilistic sensitivity analyses and a scenario analysis examined parameter uncertainty and accounted for drug wastage in dosage and cost calculations."	( A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Ali, AA; Alqhtani, H; Balkrishnan, R; de Lima Lopes, G; Diaby, V; Ko, Y; Palacio, S; van Boemmel-Wegmann, S; Wang, CY, 2020)	0.56
" The drug effect score (DES) was calculated from the dose-response of each drug for comparison among drugs or samples."	( Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia. Goto, H; Goto, S; Hamanoue, S; Inukai, T; Ito, M; Iwasaki, F; Keino, D; Kumamoto, T; Miyagawa, N; Nagai, J; Sakurai, Y; Shiomi, M; Yokosuka, T; Yoshino, Y, 2020)	0.56
" In dose-escalation trials, the maximum tolerated doses for two different dosing regimens were established and dose-limiting toxicities (DLTs) were recorded."	( Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir. Beijnen, JH; de Weger, VA; Dorlo, TPC; Huitema, ADR; Janssen, JM; Marchetti, S; Nuijen, B; Schellens, JHM; Stuurman, RE; Yu, H, 2020)	0.56
"Docetaxel (DTX) is a widely used anti-tumour drug, and its dosage is solely determined by body surface area (BSA)."	( Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study. Liang, G; Lu, J; Shen, B; Sun, N; Yang, D; Zhang, X; Zhang, Y; Zhu, H; Zhu, J, 2020)	0.56
"A total of 209 eligible patients who provided consent were enrolled and randomised into two groups to receive the BSA- and PK-guided dosage adjustments of DTX-based chemotherapy (3 weeks per cycle)."	( Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study. Liang, G; Lu, J; Shen, B; Sun, N; Yang, D; Zhang, X; Zhang, Y; Zhu, H; Zhu, J, 2020)	0.56
"The PK-guided dosage adjustment of DTX could significantly increase the proportion of patients within the therapeutic window, decrease the incidence of neutropenia and increase the DCR and the 3-year survival rate."	( Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study. Liang, G; Lu, J; Shen, B; Sun, N; Yang, D; Zhang, X; Zhang, Y; Zhu, H; Zhu, J, 2020)	0.56
" This work had permitted to show that all the tested products complied with specifications in terms of dosage and purity."	( Comparative analysis of docetaxel: physical and chemical characterisation of Taxotère® and generics. Audrey, S; Bernard, D; Eloïse, DC; François, L; Gérard, P; Guillaume, LG; Jérôme, C; Maxime, A; Muriel, P; Pétronille, R; Suzette, D; Sylvie, S; Thomas, F; Victoire, V, 2020)	0.56
" Taxanes (paclitaxel and docetaxel) have unwanted pharmacokinetic profiles when they are given in their current dosage forms."	( Current Development of Oral Taxane Formulations: A Review. Chowdhury, N; Singh, M, 2020)	0.56
"Statistically significant differences were found between the different docetaxel formulations in the cumulative per-cycle incidence of: dosage change, anemia, hypersensitivity reactions and anaphylaxis, neuropathy, palmoplantar and dermal toxicity, ungual toxicity and facial edema."	( Observational study of clinical toxicity with different formulations of docetaxel in breast cancer patients. Aldaz-Pastor, A; Burgos-San José, A; Garrido-Siles, M; González-Haba-Peña, E; Mangues-Bafalluy, I; Martínez-Bautista, MJ, 2020)	0.56
"Estimated glomerular filtration rate (eGFR) is commonly used to calculate carboplatin doses and capping the eGFR may be used to reduce the risk of excessive dosing and toxicity."	( Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP). Coe, F; Ekholm, M; Horsley, L; Howell, SJ; Wang, X, 2020)	0.56
"Prior to docetaxel chemotherapy, incomplete dosing of steroid premedication is common."	( A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Clemons, M; Daigle, K; Fergusson, D; Hilton, J; Hsu, T; Hutton, B; Moledina, N; Pond, G; Stober, C; Vandermeer, L, 2021)	0.62
" Fixed dosing with oral dexamethasone 8 mg should be the preferred standard of care."	( A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Clemons, M; Daigle, K; Fergusson, D; Hilton, J; Hsu, T; Hutton, B; Moledina, N; Pond, G; Stober, C; Vandermeer, L, 2021)	0.62
" For drugs where neutropenia is dose limiting, neutrophil counts might be used for monitoring drug effect and for dosing optimisation."	( Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients. Aarons, L; Lombard, A; Mistry, H; Ogungbenro, K, 2021)	0.62
" Once the association has been established, dosing optimisation was performed for patients with severe toxicities (neutropenia) without compromising drug efficacy (overall survival)."	( Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients. Aarons, L; Lombard, A; Mistry, H; Ogungbenro, K, 2021)	0.62
"Results of this Phase Ib trial indicate that PG-11047 can be safely administered to patients in combination with bevacizumab, erlotinib, cisplatin, and 5-FU on the once weekly dosing schedule described and may provide therapeutic benefit."	( A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH, 2021)	0.62
" The latter includes the ongoing debate on the most effective and safe regimen, the recommended initial dose, and pharmacological dosing individualization."	( Role of TDM-based dose adjustments for taxane anticancer drugs. Joerger, M; Kloft, C; Muth, M; Ojara, FW, 2021)	0.62
" Optimal control analysis shows that an increasing dose titration protocol, a very common clinical dosing process, can achieve tumor stabilization for a wide range of potential initial tumor compositions and volumes."	( Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. Brown, J; Cunningham, J; Gatenby, R; Peeters, R; Staňková, K; Thuijsman, F; Viossat, Y, 2020)	0.56
" In part 1, dose-escalation using a standard 3 + 3 design was performed in two dosing schedules (every week (QW) and every 3 weeks (Q3W))."	( First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. De Souza, P; Dees, CE; Gangadhar, T; Kefford, R; Markman, B; Piha-Paul, SA; Schuster, S; Smith, C; Thein, KZ; Zamboni, WC, 2021)	0.62
"Chemotherapy requires careful dosing and monitoring and is associated with numerous adverse events."	( Impact of Clinical Pharmacy Services on Patient Management in the Chemotherapy Infusion Clinics: A 5-Year Study at a Comprehensive Cancer Center. Dalbah, MI; Jaddoua, SM; Khalil, HZ; Mashni, OK; Nazer, LH; Rumman, AT; Tuffaha, HW, 2022)	0.72
"We used an electronic query of the electronic medical record followed up with a manual review of patient charts to ask whether we could find a correlation between steroid premedication dosing and the incidence or severity of HSRs with the first taxane dose."	( Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions. Biedermann, S; Colevas, AD; He, Z; Lansinger, OM, 2021)	0.62
" Besides, the dosing schedule is also limited."	( Probing the new strategy for the oral formulations of taxanes: changing the method with the situation. He, ZG; Sun, J; Tian, CT; Wang, HL, 2021)	0.62
" Weekly administration of nab-paclitaxel at a lower dosage provided better tolerance."	( Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. He, F; Li, G; Li, Q; Liu, J; Shen, X; Wang, Z, 2022)	0.72
" Plinabulin's same-day dosing compared with pegfilgrastim's next-day dosing offers distinct advantages, including reducing use of health care services."	( Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial. Adamchuk, H; Blayney, DW; Chen, M; Du, L; Ginn, G; Huang, L; Kirtbaya, DV; Mohanlal, R; Ogenstad, S; Zhang, Q, 2022)	0.72
" The OBI, which consists of a main pump unit and infusion set, is a drug delivery device designed to be attached to the patient's body, with a timer-controlled dosing function."	( Evaluation of a novel medical device for pegfilgrastim administration. Aruga, T; Doihara, H; Hara, Y; Ishida, T; Kaneko, K; Ohtake, T; Saji, S; Taira, T; Takeshita, T; Tsurutani, J; Tsuyuki, S; Uehara, K; Yamaguchi, Y; Yamashita, T; Yanagita, Y, 2022)	0.72
" Docetaxel (DTX), a poorly water-soluble drug, is commercially available only as injectable dosage forms, and thus many publications studied the development of oral DTX formulations."	( Design and Evaluation of Two-Step Biorelevant Dissolution Methods for Docetaxel Oral Formulations. Dong, X; Shah, B, 2022)	0.72
"Oral administration of chemotherapy agents, such as docetaxel (DTX), is expected to reduce side effects significantly and increase dosing frequency."	( Long chain triglyceride-lipid formulation promotes the oral absorption of the lipidic prodrugs through coincident intestinal behaviors. Guo, CL; Guo, JJ; He, ZG; Miao, YF; Sun, J; Tian, CT; Wang, HL; Ye, Q; Zhang, MY, 2022)	0.72
" Further, the benefits of using low concentrations of DTX combined with GNPs extended for over 72 h, allowing for less frequency in dosing when translating to the clinic."	( Enhancing nanoparticle accumulation in two dimensional, three dimensional, and xenograft mouse cancer cell models in the presence of docetaxel. Alexander, A; Barta, I; Beckham, W; Bromma, K; Chithrani, DB; Dos Santos, N; Krishnan, S, 2022)	0.72
" In addition, LBM, TBW, and a fixed dose were compared with BSA as dosing parameters for dose individualization of docetaxel."	( Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity. Detert Oude Weme, SEH; Hoge, RHL; Jacobs, MS; Jansman, FGA; Mathôt, RAA; Roorda, L; van Berlo-van de Laar, IRF; van Erp, NP; van Herpen, CML; Vervenne, WL, 2022)	0.72
" Blood samples were collected up to 180 minutes after dosing to analyze docetaxel concentrations and determine individual pharmacokinetic parameters."	( Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity. Detert Oude Weme, SEH; Hoge, RHL; Jacobs, MS; Jansman, FGA; Mathôt, RAA; Roorda, L; van Berlo-van de Laar, IRF; van Erp, NP; van Herpen, CML; Vervenne, WL, 2022)	0.72
" The mean absolute percentage error and mean error of simulated dosing based on LBM and fixed dosing were not significantly different from those of BSA."	( Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity. Detert Oude Weme, SEH; Hoge, RHL; Jacobs, MS; Jansman, FGA; Mathôt, RAA; Roorda, L; van Berlo-van de Laar, IRF; van Erp, NP; van Herpen, CML; Vervenne, WL, 2022)	0.72
" Therefore, dose individualization of docetaxel based on LBM, TBW, or fixed dosing cannot be recommended over BSA-based dosing."	( Lean Body Mass and Total Body Weight Versus Body Surface Area as a Determinant of Docetaxel Pharmacokinetics and Toxicity. Detert Oude Weme, SEH; Hoge, RHL; Jacobs, MS; Jansman, FGA; Mathôt, RAA; Roorda, L; van Berlo-van de Laar, IRF; van Erp, NP; van Herpen, CML; Vervenne, WL, 2022)	0.72
" Both S100A8/A9 expression was transiently or time-dependently elevated in four tissues within 48 h after dosing of the three anticancer agents under toxicity-inducing conditions."	( Inflammatory markers S100A8/A9 and metabolic alteration for evaluating signs of early phase toxicity of anticancer agent treatment. Fujimura, Y; Kumazoe, M; Miura, D; Morikawa-Ichinose, T; Onda, H; Tachibana, H, 2022)	0.72
" Multivariate logistic regression analysis also suggested that lower DEX dosage was a singular risk factor for all-grade OM incidence."	( Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer. Oshino, T; Saito, Y; Sugawara, M; Takekuma, Y; Takeshita, T, 2023)	0.91
" It is unclear whether under- or overexposure occurs in pregnant cancer patients and thus also whether adjustments in dosing regimens are required."	( Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs. Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC, 2023)	0.91
" Systemic therapies were dosed according to local practice guidelines."	( Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Aerts, J; Akerley, W; Andric, Z; Berghmans, T; Cobo, M; Delmonte, A; Eaton, M; Gerber, DE; Greil, R; Havel, L; Iqbal, M; Kalmadi, S; Kloecker, G; Kotecha, R; Langer, C; Leal, T; Milanowski, J; Panikkar, R; Petruzelka, L; Pless, M; Ramlau, R; Rolfo, C; Roubec, J; Ward, J; Zhang, L, 2023)	0.91
" Notably, mPEG-CMC-DTX PMs demonstrated a superior antitumor efficacy and low systemic toxicity due to the elevated tolerance dosage (even at 40 mg/kg DTX)."	( Design of carboxymethylcellulose-conjugated polymeric prodrug micelles for enhanced in vivo performance of docetaxel. Gao, S; Gou, J; He, H; Liu, B; Liu, H; Liu, Y; Liu, Z; Lv, R; Tang, X; Yang, L; Yin, T; Zhang, Y; Zhao, L, 2023)	0.91
"Overview of the existing literature regarding approval, dosage and new combination options for metastatic castration-resistant prostate cancer (mCRPC)."	( [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?] Thomas, C, 2023)	0.91
" Therapy adherence for taxanes can be significantly improved by dosage adjustments."	( [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?] Thomas, C, 2023)	0.91

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
photosensitizing agent	A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
antimalarial	A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
tetracyclic diterpenoid	A diterpenoid with a tetracyclic skeleton.
secondary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing one hydrogen and one organyl group. Secondary alpha-hydroxy ketones are also known as acyloins, and are formally derived from reductive coupling of two carboxylic acid groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Docetaxel Action Pathway	7	5

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	0.0052	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	0.0022	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.0164	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	25.6795	0.0002	21.2231	8,912.5098	AID743035; AID743053; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	0.0841	0.0133	26.9810	70.7614	AID1346978
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	0.0348	0.0010	22.6508	76.6163	AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	4.3649	0.0123	7.9835	43.2770	AID1645841
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	10.6822	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	0.0806	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	0.5828	0.0015	30.6073	15,848.9004	AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	1.6784	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	17.7828	0.0054	28.0263	1,258.9301	AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	7.0722	0.0002	29.3054	16,493.5996	AID743069; AID743075; AID743078; AID743080; AID743091
67.9K protein	Vaccinia virus	Potency	31.6228	0.0001	8.4406	100.0000	AID720580
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	13.6257	0.0010	19.4141	70.9645	AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	0.0085	0.0237	23.2282	63.5986	AID743223
caspase-3	Homo sapiens (human)	Potency	0.0841	0.0133	26.9810	70.7614	AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	53.0804	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	16.7855	0.0016	28.0151	77.1139	AID1259385
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	10.0000	0.1000	9.1916	31.6228	AID1346983
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	0.0337	0.0003	23.4451	159.6830	AID743065; AID743067
Interferon beta	Homo sapiens (human)	Potency	0.0091	0.0033	9.1582	39.8107	AID1347407; AID1347411
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.0045	0.0023	19.5956	74.0614	AID651631; AID720552
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	11.2202	0.0096	10.5250	35.4813	AID1479145
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	33.4915	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	33.4915	0.0119	12.2221	68.7989	AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	41.0000	0.1100	7.1903	10.0000	AID1473738
Serum paraoxonase/arylesterase 1	Homo sapiens (human)	Ki	291.0000	9.0000	9.0000	9.0000	AID1801808
Kinesin-like protein KIF11	Homo sapiens (human)	IC50 (µMol)	0.0014	0.0001	1.4057	10.0000	AID1799370; AID1799371; AID1799372; AID1799373; AID1799374; AID1799375; AID1799376; AID1799377
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)	IC50 (µMol)	5.0119	0.0370	4.3307	7.9433	AID1426753
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of plasma lipoprotein oxidation	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
cholesterol metabolic process	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
response to toxic substance	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
positive regulation of cholesterol efflux	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
carboxylic acid catabolic process	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
organophosphate catabolic process	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
phosphatidylcholine metabolic process	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
lactone catabolic process	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
mitotic cell cycle	Kinesin-like protein KIF11	Homo sapiens (human)
microtubule-based movement	Kinesin-like protein KIF11	Homo sapiens (human)
spindle organization	Kinesin-like protein KIF11	Homo sapiens (human)
mitotic spindle organization	Kinesin-like protein KIF11	Homo sapiens (human)
mitotic centrosome separation	Kinesin-like protein KIF11	Homo sapiens (human)
regulation of mitotic centrosome separation	Kinesin-like protein KIF11	Homo sapiens (human)
cell division	Kinesin-like protein KIF11	Homo sapiens (human)
mitotic spindle assembly	Kinesin-like protein KIF11	Homo sapiens (human)
spindle elongation	Kinesin-like protein KIF11	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
positive regulation of interleukin-10 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
detection of muramyl dipeptide	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of stress-activated MAPK cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of JNK cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
temperature homeostasis	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
pattern recognition receptor signaling pathway	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
innate immune response in mucosa	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
adaptive immune response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of dendritic cell antigen processing and presentation	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of T cell mediated immunity	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of cytokine production involved in immune response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of dendritic cell cytokine production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-positive bacteria	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of type 2 immune response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulin	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
phagocytosis	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
defense response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
JNK cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
response to nutrient	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
detection of biotic stimulus	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of macrophage cytokine production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
detection of bacterium	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
maintenance of gastrointestinal epithelium	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
regulation of appetite	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
response to muramyl dipeptide	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
detection of muramyl dipeptide	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of type II interferon production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of interleukin-12 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of interleukin-18 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of interleukin-2 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of tumor necrosis factor production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of interleukin-12 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of interleukin-17 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of interleukin-6 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of interleukin-8 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
toll-like receptor 2 signaling pathway	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathway	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
response to endoplasmic reticulum stress	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
intracellular signal transduction	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
intestinal stem cell homeostasis	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
defense response to bacterium	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
response to exogenous dsRNA	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of MAPK cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
innate immune response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of Notch signaling pathway	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of gamma-delta T cell activation	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
host-mediated regulation of intestinal microbiota composition	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
regulation of inflammatory response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of phagocytosis	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of B cell activation	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
stress-activated MAPK cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
establishment of localization in cell	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of macrophage cytokine production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
ERK1 and ERK2 cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cellular response to lipopolysaccharide	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cellular response to peptidoglycan	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cellular response to muramyl dipeptide	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cellular response to organic cyclic compound	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 production	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
regulation of neutrophil chemotaxis	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
xenophagy	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
antibacterial innate immune response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory response	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of mitophagy	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of protein K63-linked ubiquitination	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
positive regulation of xenophagy	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
negative regulation of macrophage apoptotic process	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
aryldialkylphosphatase activity	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
arylesterase activity	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
calcium ion binding	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
phospholipid binding	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
protein homodimerization activity	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
acyl-L-homoserine-lactone lactonohydrolase activity	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
microtubule motor activity	Kinesin-like protein KIF11	Homo sapiens (human)
protein binding	Kinesin-like protein KIF11	Homo sapiens (human)
ATP binding	Kinesin-like protein KIF11	Homo sapiens (human)
microtubule binding	Kinesin-like protein KIF11	Homo sapiens (human)
protein kinase binding	Kinesin-like protein KIF11	Homo sapiens (human)
plus-end-directed microtubule motor activity	Kinesin-like protein KIF11	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
actin binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
protein binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
ATP binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
enzyme binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
protein kinase binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
Hsp70 protein binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
muramyl dipeptide binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
pattern recognition receptor activity	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
peptidoglycan binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
ubiquitin binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
ADP binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
protein-containing complex binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
CARD domain binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
Hsp90 protein binding	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular region	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
extracellular space	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
endoplasmic reticulum membrane	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
extracellular exosome	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
blood microparticle	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
high-density lipoprotein particle	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
spherical high-density lipoprotein particle	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
extracellular space	Serum paraoxonase/arylesterase 1	Homo sapiens (human)
spindle pole	Kinesin-like protein KIF11	Homo sapiens (human)
spindle microtubule	Kinesin-like protein KIF11	Homo sapiens (human)
spindle	Kinesin-like protein KIF11	Homo sapiens (human)
cytosol	Kinesin-like protein KIF11	Homo sapiens (human)
microtubule	Kinesin-like protein KIF11	Homo sapiens (human)
membrane	Kinesin-like protein KIF11	Homo sapiens (human)
mitotic spindle	Kinesin-like protein KIF11	Homo sapiens (human)
kinesin complex	Kinesin-like protein KIF11	Homo sapiens (human)
protein-containing complex	Kinesin-like protein KIF11	Homo sapiens (human)
nucleus	Kinesin-like protein KIF11	Homo sapiens (human)
mitotic spindle	Kinesin-like protein KIF11	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
cytosol	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
plasma membrane	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
extrinsic component of plasma membrane	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cytoplasm	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
mitochondrion	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
Golgi apparatus	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cytosol	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cytoskeleton	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
plasma membrane	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
cell surface	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
basolateral plasma membrane	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
vesicle	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
phagocytic vesicle	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
protein-containing complex	Nucleotide-binding oligomerization domain-containing protein 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1546454	Inhibition of NFkappaB p65 transcriptional activity in human PC3 cells at GI50 by sandwich ELISA
AID1569098	Induction of bovine brain tubulin polymerization at 10 uM measured at time interval of 1 mins for 20 mins by spectrophotometric analysis
AID1765196	Resistance index, ratio of IC50 for human A549/Taxol cells to IC50 for human A549 cells	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1504292	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1504301	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human Hep2 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1760631	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1876678	Effect on cell stiffness in human 22Rv1 cells assessed as increase in young's modulus at 1 nM measured after 1 hr by topography based scanning ion-conductance microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1711506	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential.
AID1572738	Cytostatic activity against human Capan1 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1760632	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1287726	Total clearance in Sprague-Dawley rat plasma	2016	European journal of medicinal chemistry, May-04, Volume: 113	Differential metabolism of 3FDT and docetaxel in RLMs, rats, and HLMs.
AID1473727	Resistance index, ratio of IC50 for human DU145-TxR cells to IC50 for human DU145 cells	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1569087	Resistance index, ratio of IC50 for human PC3-TxR cells to IC50 for human PC3 cells
AID1693074	Anticancer activity against human T84 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism.
AID1760629	Antiproliferative activity against human DND41 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1876704	Antitumor activity against human DU-145 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 24.8 mg/kg, ip measured upto 30 days	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1594646	Antiproliferative activity against human NCI-H460 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1474044	AUC in human at 60 to 100 mg/m2, iv via infusion for 1 hr every 3 weeks measured after 1 hr	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1504282	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human MDA-MB-231 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1508806	Antimigratory activity against MYOF-knockout human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin.
AID1406311	Resistance factor, ratio of IC50 for human paclitaxl resistant A549 cells to IC50 for human A549 cells	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1504272	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human HeLa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1876752	Chronic toxicity in rat assessed as hair loss administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1504274	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human MCF7 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1666224	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1502933	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Berchemiosides A-C, 2-Acetoxy-ω-phenylpentaene Fatty Acid Triglycosides from the Unripe Fruits of Berchemia berchemiifolia.
AID1404490	Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1688850	Cytotoxicity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
AID1762230	Antiproliferative activity against Docetaxel-resistant human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1404166	Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1471133	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1876707	Antitumor activity against human DU-145 cells xenografted in BALB/c nude mouse assessed as reduction in tumor growth index at 12.4 mg/kg, ip measured upto 30 days (Rvb = 799 +/- 121.8 %)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1471155	Inhibition of Erk2 phosphorylation in human PC3 cells at 2 nM after 24 hrs by Western blot method relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1262042	Cytotoxicity against human PC3 cells assessed as cell viability at 100 nM after 72 hrs by tryphan blue staining-based microscopy (Rvb = 95 to 98 %)	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
AID1594330	Antitumor activity activity against human A549 cells xenografted in Balb/c nude mouse assessed as tumor volume at 10 mg/kg, iv dosed as QW x 3 weeks regime relative to untreated control	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.
AID1504303	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human SiHa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1473725	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1272834	Inhibition of microtubule-stimulated N-terminal MKLP-2 (56 to 505 residues) ATPase activity isolated from human hepatocellular carcinoma cells by pyruvate kinase/lactate dehydrogenase enzyme linked assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1504308	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human Hep2 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1423577	Cytotoxicity against human KB cells by MTT assay	2018	Journal of natural products, 11-26, Volume: 81, Issue:11	Metabolomics-Driven Discovery of Meroterpenoids from a Mussel-Derived Penicillium ubiquetum.
AID1876675	Selectivity ratio of CC50 for cytotoxicity against human PC-3 cells to CC50 for cytotoxicity against human 22Rv1 cells	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1272838	Induction of of sheep brain microtubule disassembly by UV spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1876775	Chronic toxicity in rat assessed as change in relative heart mass administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1813522	Cytotoxicity against human 22Rv1 cells expressing PMSA measured using MTT assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1546450	Antiproliferative activity human PC3 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay
AID1546449	Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay
AID1476601	Toxicity in SCID mouse xenografted with human CAL51 cells assessed as loss in body weight at 5 mg/kg, iv administered every 4 days for 16 days relative to control	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
AID1504278	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human Hep2 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1691481	MRT (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv measured up to 72 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1691491	Drug uptake in BALB/c nude mouse xenografted with human HCT-116 cells assessed as drug level in heart at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1404167	Cytotoxicity against human A2780AD cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1267187	Displacement of [3H]-vinblastine from biotinylated porcine tubulin after 15 mins by competitive binding assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID1497068	Antiproliferative activity against docetaxel-sensitive human LNCAP cells after 3 days by WST-1 assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1594650	Antiproliferative activity against human Z138 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1691496	Drug uptake in BALB/c nude mouse xenografted with human HCT-116 cells assessed as drug level in tumour at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1575482	Antiproliferative activity against human Calu1 cells after 72 hrs by MTT assay	2019	Journal of natural products, 01-25, Volume: 82, Issue:1	Antiproliferative Cardenolides from the Aerial Parts of Pergularia tomentosa.
AID1876689	Antitumor activity against human 22Rv1 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered daily for 5 days and measured at day 34 relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1594645	Antiproliferative activity against human HCT116 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1404499	Resistance index, ratio of IC50 for vinblastine-resistant human SKVLB1 cells to IC50 for human SKOV3 cells	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1876698	Toxicity in Balb/c nude mouse xenografted with human 22Rv1 cells assessed as animal death at 10 mg/kg, ip measured upto 30 days	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1813523	Cytotoxicity against human PC-3 cells not expressing PMSA measured using MTT assay	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
AID1504275	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human MDA-MB-231 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1760627	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1876773	Chronic toxicity in rat assessed as increase in relative mass of liver administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1473707	Inhibition of tubulin polymerization in human WM164 cells assessed as increase in cytoplasmic soluble tubulin levels at 100 nM after 18 hrs using DAPI by immunofluorescence-based confocal microscopic method	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1543670	Antiproliferative activity against human SK-MEL-19 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
AID1562551	In vivo inhibition of GLS1 in tumor of human NCI-H1703 cells xenografted in SCID mouse assessed as change in aspartate level at 7.5 mg/kg, iv administered once per week for 21 days measured 24 hrs post-last dose relative to control	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1569757	Antitumor activity against human 22Rv1 cells xenografted in NMRI mouse assessed as inhibition of tumor growth by measuring T/C value at 15 mg/kg, iv administered on day 7 and 14 and measured on day 14	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1876782	Chronic toxicity in rat assessed as decrease in relative mass of testes administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1497066	Antiproliferative activity against human DU145/DTX cells after 3 days by WST-1 assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1394815	Inhibition of porcine brain tubulin polymerization assessed as tubulin polymerization level by measuring arbitary units at 3 uM by fluorescence analysis	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
AID1404498	Cytotoxicity against vinblastine-resistant human SKVLB1 cells after 72 to 120 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1504294	Antiproliferative activity in HEK293 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1267186	Displacement of [3H]-paclitaxel from biotinylated porcine tubulin after 25 mins by competitive binding assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID1404487	Binding affinity to P-gp in human SKVLB1 cells assessed as increase in [3H]vinblastine accumulation at 40 uM after 1 hr by liquid scintillation counting method	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1691493	Drug uptake in BALB/c nude mouse xenografted with human HCT-116 cells assessed as drug level in spleen at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1473726	Cytotoxicity against human DU145-TxR cells after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1876677	Induction of ROS generation in human PC-3 cells at 800 mV holding potential measured after 1 hr by patch clamp amplifier based optical inverted microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1272837	Growth inhibition of human KB cells after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1471131	Cytotoxicity against 3D cultures of human PC3 cells assessed as size of tissue-like structure at 2 nM administered once every alternative day for 10 days measured on post last dose by matrigel based microscopic method relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1569768	Antitumor activity against human 22Rv1 cells xenografted in NMRI mouse assessed as reduction of tumor volume at 15 mg/kg, ip administered on day 7 and 14 and measured on day 20	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1471134	Drug uptake in patient plasma at 20 mg/m2, iv administered for 1 hr as infusion measured 72 hrs post dose	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1762231	Resistance index, ratio of IC50 for antiproliferative activity against human DU145/DTX cells to IC50 for antiproliferative activity against human DU145 cells	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1546451	Antiproliferative activity human 22Rv1 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay
AID1625521	Antitumor activity against human PC3M-lluc-C6 cells xenografted in athymic Balb/c mouse assessed as decrease in tumor burden by measuring photon intensity at 15 mg/kg, ip measured on day 9 by bioluminescence method (Rvb = 6.501 x 10'9 photons/s/cm2)	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1471160	Induction of apoptosis in human PC3 cells assessed as Bcl2 level at 2 nM after 24 hrs by Western blot method relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1471141	Potentiation of 3 nM docetaxel-induced cytotoxicity against human PC3 cells assessed as decrease in cell viability at 50 nM after 72 hrs by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1504277	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human KB cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1504298	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human MDA-MB-231 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1471143	Induction of apoptosis in human PC3 cells at 2 nM after 72 hrs by propidium iodide staining based fluorescence microscopy (Rvb = 1.9 +/- 0.8%)	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1471142	Potentiation of 2 nM docetaxel-induced cytotoxicity against human RWPE1 cells assessed as decrease in cell viability at 50 nM after 72 hrs by by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1569765	Antitumor activity against human 22Rv1 cells xenografted in NMRI mouse assessed as tumor volume doubling time at 15 mg/kg, ip administered on day 7 and 14 (Rvb = 2.7 day)	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1887346	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
AID1504302	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human HeLa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1406304	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1497063	Antiproliferative activity against human PC3/DTX cells after 3 days by WST-1 assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1876778	Chronic toxicity in rat assessed as increase in relative spleen mass administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1594643	Antiproliferative activity against human Capan1 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1762226	Antiproliferative activity against androgen-insensitive human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1404491	Cytotoxicity against human Hey/Tx100 cells after 72 to 120 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1504267	Cytotoxic activity in human DU145 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1760625	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1473705	Inhibition of tubulin polymerization in human WM164 cells assessed as fragmentation of microtubules at 100 nM after 18 hrs using DAPI by immunofluorescence-based confocal microscopic method	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1562546	In vivo inhibition of GLS1 in tumor of human NCI-H1703 cells xenografted in SCID mouse assessed as change in glutamine level at 7.5 mg/kg, iv administered once per week for 21 days measured 4 hrs post-last dose relative to control	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1714647	Covalent modification of GAB-buffer assembled microtubule (unknown origin) assessed as effect on nucleotide binding affinity at E-site by measuring ratio of GTP concentration to tubulin concentration incubated for 30 mins in presence or absence of 1 mM GT	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Zampanolide Binding to Tubulin Indicates Cross-Talk of Taxane Site with Colchicine and Nucleotide Sites.
AID1543692	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
AID1876676	Induction of ROS generation in human 22Rv1 cells at 800 mV holding potential measured after 1 hr by patch clamp amplifier based optical inverted microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1562547	In vivo inhibition of GLS1 in tumor of human NCI-H1703 cells xenografted in SCID mouse assessed as change in glutamine level at 7.5 mg/kg, iv administered once per week for 21 days measured 24 hrs post-last dose relative to control	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1471137	Induction of apoptosis in human PC3 cells assessed as morphological changes by propidium iodide staining based fluorescence microscopy	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1272839	Growth inhibition of human KB cells at 10 uM after 72 hrs by MTS assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1887350	Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured upto 72 hrs by clonogenic assay
AID1473706	Inhibition of tubulin polymerization in human WM164 cells assessed as decrease in polymeric tubulin filaments at 100 nM after 18 hrs using DAPI by immunofluorescence-based confocal microscopic method	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1497064	Resistance index, ratio of IC50 for human PC3/DTX cells to IC50 for docetaxel-sensitive human PC3 cells	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1691495	Drug uptake in BALB/c nude mouse xenografted with human HCT-116 cells assessed as drug level in kidney at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1693072	Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism.
AID1625456	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1569100	Effect on microtubule network in human WM164 cells assessed as formation of dense and aggregated bundles of microtubules at 100 nM after 18 hrs by DAPI staining based fluorescence confocal microscopic method
AID1497065	Antiproliferative activity against docetaxel-sensitive human DU145 cells after 3 days by WST-1 assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1691443	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1471151	Inhibition of Akt phosphorylation in human PC3 cells at 2 nM after 24 hrs by Western blot method relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1711507	Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential.
AID1287727	Apparent volume of distribution in Sprague-Dawley rat	2016	European journal of medicinal chemistry, May-04, Volume: 113	Differential metabolism of 3FDT and docetaxel in RLMs, rats, and HLMs.
AID1711505	Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential.
AID1887349	Cytotoxicity against human WPMY-1 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
AID1446664	Cytotoxicity against human MRC5 cells assessed as mortality at 1 ug/ml relative to control	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Aedes aegypti Larvicidal Sesquiterpene Alkaloids from Maytenus oblongata.
AID1691479	AUC (0 to t) in Sprague-Dawley rat at 5 mg/kg, iv measured up to 72 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1569089	Antiproliferative activity against human DU145-TxR cells
AID1423578	Cytotoxicity against human MCF7 cells by MTT assay	2018	Journal of natural products, 11-26, Volume: 81, Issue:11	Metabolomics-Driven Discovery of Meroterpenoids from a Mussel-Derived Penicillium ubiquetum.
AID1876706	Antitumor activity against human DU-145 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 12.4 mg/kg, ip measured upto 30 days	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1594649	Antiproliferative activity against human K562 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1569085	Antiproliferative activity against human PC3 cells
AID1421575	Antitumor activity against human HCT116 cells xenografted in BALB/c nu/nu mouse assessed as tumor growth inhibition at 5 mg/kg, iv administered every other day for 14 days measured 24 hrs post last dose relative to control	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59.
AID1691472	Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as disordered myocardial fiber in heart at 5 mg/kg, ip administered once for every 7 days for 14 days by H and E staining based assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1300287	Antitumor activity against human A2780 cells xenografted in nude mouse harboring wild type p53 assessed as tumor growth inhibition at 40 mg/kg, po once weekly for 15 days relative to control	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
AID1572741	Cytostatic activity against human DND41 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1625458	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1569767	Antitumor activity against human 22Rv1 cells xenografted in NMRI mouse assessed as tumor volume quadrupling time at 15 mg/kg, ip administered on day 7 and 14 (Rvb = 6.2 day)	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1876785	Chronic toxicity in Soviet Chinchilla rabbit assessed as animal death administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed one week post first injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1876783	Chronic toxicity in rat assessed as increase in relative mass of adrenal gland administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1546455	Inhibition of NFkappaB p65 transcriptional activity in human 22Rv1 cells at GI50 by sandwich ELISA
AID1765199	Cytotoxicity against human KB/VCR cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1691478	Toxicity in ip dosed Kunming mouse measured for 14 days	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1406308	Resistance factor, ratio of IC50 for human MCF7/ADR cells to IC50 for human MCF7 cells	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1551625	Toxicity in CB17 SCID mouse xenografted with human CAL51 cells assessed as body weight loss at 5 mg/kg, iv q4d and measured up to 31 days relative to control	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
AID1404496	Resistance index, ratio of IC50 for human HEY/EpoB8 cells to IC50 for human HEY cells	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1762229	Antiproliferative activity against androgen-insensitive human DU-145 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1876729	Acute toxicity in iv dosed ICR mouse assessed as lethal dose	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1457460	Antitumor activity against human 22Rv1 cells xenografted in CD-1 Foxn1 nude mouse assessed as median tumor growth delay time at 32 umol/kg, ip once in every two weeks after 100 to 120 days	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy.
AID1404170	Resistance index, ratio of IC50 for human Hela-beta3 cells to IC50 for human HeLa cells	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1471140	Cytotoxicity against human RWPE1 cells at 5 to 10 nM after 72 hrs by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1504297	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human MCF7 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1432725	Antitumor activity against human NCI-H460 cells xenografted in nude mouse assessed as tumor growth inhibition at 10 mg/kg, iv administered every 2 days for 21 days relative to vehicle-treated control	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1765194	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1762227	Antiproliferative activity against Docetaxel-resistant human PC-3 cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1504285	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human Hep2 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1691444	Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1760630	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1504307	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human KB cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1404168	Resistance index, ratio of IC50 for human A2780AD cells to IC50 for human A2780 cells	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1476605	Antiproliferative activity against human CAL51 cells xenografted in SCID mouse assessed as tumor growth inhibition at 5 mg/kg, iv administered every 4 days for 16 days	2017	Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21	The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
AID1287725	AUC (0 to infinity) in Sprague-Dawley rat	2016	European journal of medicinal chemistry, May-04, Volume: 113	Differential metabolism of 3FDT and docetaxel in RLMs, rats, and HLMs.
AID1876764	Chronic toxicity in rat assessed as change in alkaline phosphatase level at 15.6 g/Kg, iv administered as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1876779	Chronic toxicity in rat assessed as increase in relative brain mass administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1575479	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2019	Journal of natural products, 01-25, Volume: 82, Issue:1	Antiproliferative Cardenolides from the Aerial Parts of Pergularia tomentosa.
AID1404495	Resistance index, ratio of IC50 for human HEY/Ixab80 cells to IC50 for human HEY cells	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1575480	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2019	Journal of natural products, 01-25, Volume: 82, Issue:1	Antiproliferative Cardenolides from the Aerial Parts of Pergularia tomentosa.
AID1504304	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human MCF7 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1714648	Covalent modification of GAB-buffer assembled microtubule (unknown origin) assessed as effect on nucleotide binding affinity at E-site by measuring ratio of GDP concentration to microtubule concentration incubated for 30 mins in presence or absence of 1 m	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Zampanolide Binding to Tubulin Indicates Cross-Talk of Taxane Site with Colchicine and Nucleotide Sites.
AID1562548	In vivo inhibition of GLS1 in tumor of human NCI-H1703 cells xenografted in SCID mouse assessed as change in glutamate level at 7.5 mg/kg, iv administered once per week for 21 days measured 4 hrs post-last dose relative to control	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1406662	Inhibition of tubulin (unknown origin) polymerization assessed as polymerized tubulin level at 5 to 25 uM by fluorescence assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors.
AID1471135	Drug uptake in cancer patient plasma at 35 mg/m2, iv administered once every week via infusion measured on day 8 by HPLC-TMS	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1876708	Toxicity in BALB/c nude mouse xenografted with human DU-145 cells assessed as animal death at 12.4 to 24.8 mg/kg, ip measured on day 8	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1431178	Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
AID1551626	Antitumor activity against human CAL51 cells xenografted in CB17 SCID mouse assessed as tumor growth inhibition at 5 mg/kg, iv q4d and measured twice per week up to 31 days by caliper method relative to control	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
AID1504281	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human MCF7 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1691492	Drug uptake in BALB/c nude mouse xenografted with human HCT-116 cells assessed as drug level in liver at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1625459	Cytotoxicity against human RWPE1 cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1918745	Cytotoxicity against docetaxel-resistant human PC-3 cells assessed as reduction in cell viability at 0.5 to 64 uM pretreated with tariquidar for 1 hrs followed by compound addition and measured after 48 hrs by MTT assay
AID1765200	Resistance index, ratio of IC50 for human KB/VCR cells to IC50 for human KB cells	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1504270	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1625520	Antitumor activity against human PC3M-lluc-C6 cells xenografted in athymic Balb/c mouse assessed as decrease in tumor burden by measuring photon intensity at 15 mg/kg, ip measured on day 18 by bioluminescence method (Rvb = 2.332 x 10'10 photons/s/cm2)	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1666222	Antiproliferative activity against human LN229 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1546453	Inhibition of NFkappaB p65 nuclear translocation in human 22Rv1 cells at GI50 by DAPI staining based immunofluorescence assay
AID1846764	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth by MTT assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1876758	Chronic toxicity in rat assessed as reduction in getting up frequency at 15.16 mg/kg, iv administered as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1594647	Antiproliferative activity against human DND41 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1404494	Resistance index, ratio of IC50 for human HEY/Tx100 cells to IC50 for human HEY cells	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1691473	Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as inflammatory cell invasion in heart at 5 mg/kg, ip administered once for every 7 days for 14 days by H and E staining based assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1666226	Antiproliferative activity against human DND41 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1431177	Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay	2017	Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2	Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
AID1625454	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1569761	Toxicity in NMRI mouse xenografted with human 22Rv1 cells assessed as survival rate at 15 mg/kg, ip administered on day 7 and 14 and measured on day 49	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1762232	Antiproliferative activity against androgen-insensitive human LNCaP cells assessed as reduction in cell viability incubated for 3 days by WST-1 assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1594338	Toxicity in human A549 cells xenografted Balb/c nude mouse assessed as body weight change weight at 10 mg/kg, iv dosed on day 0, 7 and 14 (Rvb = 6.96%)	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.
AID1711508	Cytotoxicity against human L-132 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential.
AID1406306	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1504284	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human KB cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1691445	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1691483	Apparent volume of distribution in Sprague-Dawley rat at 5 mg/kg, iv measured up to 72 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1404165	Inhibition of flutax-2 binding to calf brain microtubule paclitaxel binding site incubated for 10 mins measured after 20 mins by fluorescence polarization method	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1876685	Chronic toxicity in rat assessed as increase in creatinine concentration at 15.6 g/Kg, iv administered as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1404164	Cytotoxicity against human Hela-beta3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1887347	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay
AID1404486	Inhibition of [3H]2-m-AzTax binding to P-gp in human SKVLB1 cell plasma membranes at 40 uM treated for 30 mins followed by UV irradiation for 10 mins by fluorographic method relative to control	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1876687	Aqueous solubility of compound	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1406310	Cytotoxicity against human paclitaxl resistant A549 cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1504300	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human KB cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1569763	Toxicity in NMRI mouse xenografted with human 22Rv1 cells assessed as body weight loss at 15 mg/kg, ip administered on day 7 and 14 and measured on day 49	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1572739	Cytostatic activity against human HAP1 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1432731	Toxicity in nude mouse xenografted with human NCI-H460 cells assessed as decrease in body weight at 10 mg/kg, iv administered every 2 days for 21 days	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
AID1569086	Antiproliferative activity against human PC3-TxR cells
AID1569769	Antitumor activity against human 22Rv1 cells xenografted in NMRI mouse assessed as reduction of tumor volume at 15 mg/kg, ip administered on day 7 and 14 and measured on day 10	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1569823	Antitumor activity against human 22Rv1 cells xenografted in NMRI mouse assessed as inhibition of tumor growth by measuring T/C value at 15 mg/kg, iv administered on day 7 and 14 and measured on day 49	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
AID1473724	Resistance index, ratio of IC50 for human PC3-TxR cells to IC50 for human PC3 cells	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1693073	Anticancer activity against human SW-620 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism.
AID1504305	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human MDA-MB-231 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1504263	Cytotoxic activity in human HeLa cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1504271	Cytotoxic activity in HEK293 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1625455	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1594334	Antitumor activity activity against human A549 cells xenografted in Balb/c nude mouse assessed as tumor weight at 10 mg/kg, iv dosed as QW x 3 weeks regime (Rvb = 0.596 +/- 0.042 g)	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.
AID1504291	Antiproliferative activity in human KB cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1876674	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1896545	Toxicity in mouse xenografted with human LNCaP cells assessed as change in body weight at 10 mg/kg,ip administrated upto 35 days for every 5 days	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1504295	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human HeLa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1471136	Induction of apoptosis in human LNCAP cells assessed as morphological changes by propidium iodide staining based fluorescence microscopy	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1381594	Inhibition of tubulin (unknown origin) polymerization assessed as tubulin assembly rate by fluorescence assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.
AID1572740	Cytostatic activity against human NCI-H460 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1287724	AUC (0 to t) in Sprague-Dawley rat	2016	European journal of medicinal chemistry, May-04, Volume: 113	Differential metabolism of 3FDT and docetaxel in RLMs, rats, and HLMs.
AID1504306	Selectivity index, ratio of antiproliferative IC50 for HEK293 cells to antiproliferative IC50 for human DU145 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1691442	Cytotoxicity against human SW-620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1406303	Cytotoxicity against human KB/VCR cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1625516	Antitumor activity against human PC3M-lluc-C6 cells xenografted in athymic Balb/c mouse assessed as tumor growth inhibition at 15 mg/kg, ip administered every 2 days measured on day 18	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1666225	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1569090	Resistance index, ratio of IC50 for human DU145-TxR cells to IC50 for human DU145 cells
AID1760628	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1474045	Drug concentration at steady state in human at 60 to 100 mg/m2, iv via infusion for 1 hr every 3 weeks measured after 1 hr	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1404489	Inhibition of [3H]2-m-AzTax binding to P-gp in human SKVLB1 cell plasma membranes assessed as residual [3H]2-m-AzTax binding at 40 uM treated for 30 mins followed by UV irradiation measured after 10 mins by fluorographic method relative to control	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1691494	Drug uptake in BALB/c nude mouse xenografted with human HCT-116 cells assessed as drug level in lung at 5 mg/kg, iv measured up to 24 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1272836	Inhibition of sheep brain tubulin polymerization by UV spectrophotometric analysis	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1691456	Antitumour activity against human HCT-116 cells xenografted in BALB/c nude mouse assessed as tumour growth inhibition at 5 mg/kg, ip administered once for every 7 days for 14 days relative to control	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1457459	Antitumor activity against human 22Rv1 cells xenografted in CD-1 Foxn1 nude mouse assessed as tumor stasis at 32 umol/kg, ip once in every two weeks after 100 to 120 days	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy.
AID1471146	Cytotoxicity against human PC3 cells assessed as cell viability at 2 nM after 72 hrs by trypan blue exclusion assay relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1272832	Inhibition of N-terminal MKLP2 (56 to 505 residues) ATPase basal activity isolated from human hepatocellular carcinoma cells by pyruvate kinase/lactate dehydrogenase enzyme linked assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1546448	Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay
AID1691482	Half life in Sprague-Dawley rat at 5 mg/kg, iv measured up to 72 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1404493	Cytotoxicity against human Hey/EpoB8 cells after 72 to 120 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1876705	Antitumor activity against human DU-145 cells xenografted in BALB/c nude mouse assessed as reduction in tumor growth index at 24.8 mg/kg, ip measured upto 30 days (Rvb = 799 +/- 121.8 %)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1760626	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1504290	Antiproliferative activity in human DU145 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1763570	Cytotoxicity against human DU-145 cells	2021	Bioorganic & medicinal chemistry letters, 07-01, Volume: 43	Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents.
AID1504276	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human DU145 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1404169	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.
AID1406307	Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1876776	Chronic toxicity in rat assessed as increase in relative lung mass administered intravenously as pluronic F127 formulation for 4 intervals of 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1575483	Antiproliferative activity against human U251MG cells after 72 hrs by MTT assay	2019	Journal of natural products, 01-25, Volume: 82, Issue:1	Antiproliferative Cardenolides from the Aerial Parts of Pergularia tomentosa.
AID1562550	In vivo inhibition of GLS1 in tumor of human NCI-H1703 cells xenografted in SCID mouse assessed as change in aspartate level at 7.5 mg/kg, iv administered once per week for 21 days measured 4 hrs post-last dose relative to control	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1666223	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1691466	Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as concentrated nucleus in liver at 5 mg/kg, ip administered once for every 7 days for 14 days by H and E staining based assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1896539	Toxicity in mouse assessed as reduction in body weight at 20 mg/kg,ip measured for 21 days by every 3 days	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1572744	Cytostatic activity against human Z138 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1404497	Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1473722	Cytotoxicity against human PC3 cells after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1876759	Chronic toxicity in rat assessed as neurological disorder administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1762228	Resistance index, ratio of IC50 for antiproliferative activity against human PC-3/DTX cells to IC50 for antiproliferative activity against human PC-3 cells	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	An amide mimic of desTHPdactylolide: Total synthesis and antiproliferative evaluation.
AID1876671	Chronic toxicity in rat assessed as increase in relative kidney weight administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1504265	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1896540	Toxicity in mouse assessed as reduction in body weight at 40 mg/kg,ip measured upto 21 days for every 3 days	2022	Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22	Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
AID1765195	Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1688851	Cytotoxicity against human DU-145 cells over expressing CYP1B1 assessed as reduction in cell viability after 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
AID1691484	Apparent clearance in Sprague-Dawley rat at 5 mg/kg, iv measured up to 72 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1569088	Antiproliferative activity against human DU145 cells
AID1504269	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1666229	Antiproliferative activity against human Z138 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1572737	Cytostatic activity against human hTERT-RPE1 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1546452	Inhibition of NFkappaB p65 nuclear translocation in human PC3 cells at GI50 by DAPI staining based immunofluorescence assay
AID1404484	Inhibition of [3H]2-m-AzTax binding to bovine brain beta-tubulin at 20 uM treated for 30 mins followed by UV irradiation for 10 mins by fluorographic method relative to control	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1426753	Inhibition of MDP-induced human NOD2 signaling expressed in HEK-Blue cells preincubated for 3 hrs followed by MDP-stimulation for 20 hrs by spectrophotometry based SEAP reporter gene assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis.
AID1471153	Inhibition of Erk1 phosphorylation in human PC3 cells at 2 nM after 24 hrs by Western blot method relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1504280	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human SiHa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1562560	Antitumor activity against human NCI-H1703 cells xenografted in SCID mouse assessed as tumor growth inhibition at 7.5 mg/kg, iv administered once per week for 21 days measured post-last dose by caliper method	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1876673	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1688852	Selectivity ratio of IC50 for cytotoxicity against human DU-145 cells over expressing CYP1B1 to cytotoxicity against human DU-145 cells	2020	European journal of medicinal chemistry, Mar-01, Volume: 189	Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
AID1728101	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
AID1236551	Antitumor activity against human H460 cells xenografted in athymic nu/nu mouse assessed as tumor regression at 10 mg/kg/day, po administered for 24 days	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1691467	Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as necrosis in liver at 5 mg/kg, ip administered once for every 7 days for 14 days by H and E staining based assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1504293	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1497067	Resistance index, ratio of IC50 for human DU145/DTX cells to IC50 for docetaxel-sensitive human DU145 cells	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1575481	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	2019	Journal of natural products, 01-25, Volume: 82, Issue:1	Antiproliferative Cardenolides from the Aerial Parts of Pergularia tomentosa.
AID1594648	Antiproliferative activity against human HL60 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1474046	Ratio of drug concentration at steady state in human at 60 to 100 mg/m2, iv via infusion for 1 hr every 3 weeks measured after 1 hr to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1504273	Selectivity index, ratio of cytotoxic CC50 for African green monkey Vero cells to cytotoxic CC50 for human SiHa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1406309	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1876767	Chronic toxicity in rat assessed as change in erythrocytes in blood administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1504287	Antiproliferative activity in human SiHa cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1267181	Displacement of [3H]-colchicine from biotinylated porcine tubulin after 2 hrs by competitive binding assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID1272833	Inhibition of N-terminal MKLP2 (56 to 505 residues) ATPase basal activity isolated from human hepatocellular carcinoma cells up to 100 uM by pyruvate kinase/lactate dehydrogenase enzyme linked assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1691461	Toxicity in BALB/c nude mouse xenografted with human HCT-116 cells assessed as reduction in body weight at 5 mg/kg, ip administered once for every 7 days for 14 days relative to control	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1457461	Toxicity in CD-1 Foxn1 nude mouse xenografted with human 22Rv1 cells assessed as change in body weight at 32 umol/kg, ip once in every two weeks after 100 to 120 days	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy.
AID1504283	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human DU145 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1876780	Chronic toxicity in rat assessed as increase in relative mass of stomach administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1404485	Inhibition of [3H]2-m-AzTax binding to chicken erythrocyte beta-tubulin 4 at 20 uM treated for 30 mins followed by UV irradiation for 10 mins by fluorographic method relative to control	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1421579	Toxicity in BALB/c nu/nu mouse xenografted with human HCT116 cells assessed as spleen index at 5 mg/kg, iv administered every other day for 14 days measured 24 hrs post last dose (Rvb = 0.41 +/- 0.08%)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59.
AID1287723	Metabolic stability in human liver microsomes assessed as compound remaining after 60 mins	2016	European journal of medicinal chemistry, May-04, Volume: 113	Differential metabolism of 3FDT and docetaxel in RLMs, rats, and HLMs.
AID1625460	Induction of morphological changes in human PC3 cells assessed as formation of massive cytoplasmic vacuoles at 1 uM after 12 hrs by confocal microscopic analysis	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1876770	Chronic toxicity in rat assessed as change in volume of excreted urine administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1471132	Cytotoxicity against human LNCAP cells assessed as decrease in cell viability after 72 hrs by trypan blue exclusion assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1497062	Antiproliferative activity against docetaxel-sensitive human PC3 cells after 3 days by WST-1 assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Optimized synthesis and antiproliferative activity of desTHPdactylolides.
AID1666227	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1328431	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	2016	Journal of natural products, 09-23, Volume: 79, Issue:9	Cytotoxic Ceanothane- and Lupane-Type Triterpenoids from the Roots of Ziziphus jujuba.
AID1572742	Cytostatic activity against human HL60 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1504286	Antiproliferative activity in human HeLa cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1318676	Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	neo-Clerodane diterpenoids from Scutellaria barbata mediated inhibition of P-glycoprotein in MCF-7/ADR cells.
AID1504296	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human SiHa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1504299	Selectivity index, ratio of antiproliferative IC50 for African green monkey Vero cells to antiproliferative IC50 for human DU145 cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1691480	AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv measured up to 72 hrs by LC-MS/MS analysis	2020	European journal of medicinal chemistry, May-01, Volume: 193	Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
AID1711504	Cytotoxicity against human A-549 cells assessed as reduction in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Design, synthesis and biological evaluation of 1,3,6-trisubstituted β-carboline derivatives for cytotoxic and anti-leishmanial potential.
AID1404492	Cytotoxicity against human Hey/Ixab80 cells after 72 to 120 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
AID1625457	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1471150	Cytotoxicity against human PC3 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
AID1272835	Inhibition of microtubule-stimulated N-terminal MKLP-2 (56 to 505 residues) ATPase activity isolated from human hepatocellular carcinoma cells up to 100 uM by pyruvate kinase/lactate dehydrogenase enzyme linked assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1562549	In vivo inhibition of GLS1 in tumor of human NCI-H1703 cells xenografted in SCID mouse assessed as change in glutamate level at 7.5 mg/kg, iv administered once per week for 21 days measured 24 hrs post-last dose relative to control	2019	Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
AID1876757	Chronic toxicity in rat assessed as reduction in grooming frequency at 15.16 mg/kg, iv administered as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1625453	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1594644	Antiproliferative activity against human HAP1 cells	2019	Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12	Xylo-C-nucleosides with a pyrrolo[2,1-f][1,2,4]triazin-4-amine heterocyclic base: Synthesis and antiproliferative properties.
AID1569099	Effect on microtubule network in human WM164 cells assessed as induction of polymerization at 100 nM after 18 hrs by DAPI staining based fluorescence confocal microscopic method
AID1572743	Cytostatic activity against human K562 cells	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives.
AID1504289	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1625519	Toxicity in athymic Balb/c mouse assessed as body weight loss at 15 mg/kg, ip administered every 2 days for 18 days	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.
AID1504264	Cytotoxic activity in human SiHa cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1876680	Effect on cell stiffness in human PC-3 cells assessed as increase in young's modulus at 1 nM measured after 1 hr by topography based scanning ion-conductance microscopic analysis	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1666228	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by IncuCyte live-cell imaging assay	2020	ACS medicinal chemistry letters, Aug-13, Volume: 11, Issue:8	Synthesis and Antitumor Activity of C-7-Alkynylated and Arylated Pyrrolotriazine C-Ribonucleosides.
AID1504268	Cytotoxic activity in human KB cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1452457	Inhibition of tubulin (unknown origin) polymerization by fluorescence assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
AID1760633	Antiproliferative activity against human Z138 cells assessed as inhibition of cell proliferation measured after 72 hrs by by real time imaging analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
AID1504288	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1504266	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1876781	Chronic toxicity in rat assessed as increase in relative mass of pancreas administered intravenously as pluronic F127 formulation at 4 intervals for 21 days and observed 3 weeks post last injection relative to control	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
AID1504279	Selectivity index, ratio of cytotoxic CC50 for HEK293 cells to cytotoxic CC50 for human HeLa cells	2017	Journal of natural products, 11-22, Volume: 80, Issue:11	Lupane-Type Triterpenes of Phoradendron vernicosum.
AID1765198	Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	2021	Bioorganic & medicinal chemistry, 07-01, Volume: 41	Synthesis and biological evaluation of novel cabazitaxel analogues.
AID1473723	Cytotoxicity against human PC3-TxR cells after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4	Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
AID1454745	Cytotoxicity against human 1A9 cells	2018	Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1406305	Resistance factor, ratio of IC50 for human KB/VCR cells to IC50 for human KB cells	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Synthesis and biological evaluation of novel larotaxel analogues.
AID1799373	Wild-type 3x biaryl selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1801808	Paraoxonase Activity Assay from Article 10.1111/cbdd.12746: \\Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.\\	2016	Chemical biology & drug design, Aug, Volume: 88, Issue:2	Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.
AID1799374	HCT116-D130V not selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1799376	HCT116-D130V IC95 biaryl selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1799372	Wild-type IC95 biaryl selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1799375	HCT116-D130V IC50 biaryl selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1799371	Wild-type IC50 biaryl selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1799370	Wild-type HCT116 from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
AID1799377	HCT116-D130V 3x biary selected from Article 10.1038/nchembio.2007.34: \\ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.\\	2007	Nature chemical biology, Nov, Volume: 3, Issue:11	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	625 (5.40)	18.2507
2000's	3498 (30.24)	29.6817
2010's	5764 (49.84)	24.3611
2020's	1679 (14.52)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3,216 (26.56%)	5.53%
Reviews	1,483 (12.25%)	6.00%
Case Studies	1,050 (8.67%)	4.05%
Observational	87 (0.72%)	0.25%
Other	6,274 (51.81%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
acetylcarnitine Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.	4.43	2	2	O-acylcarnitine	human metabolite
phosphoserine Phosphoserine: The phosphoric acid ester of serine.	2.21	1	0	non-proteinogenic alpha-amino acid; O-phosphoamino acid; serine derivative	human metabolite
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	3.63	3	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	2.08	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
ethylene glycol Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.	2.17	1	0	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin
acetic acid Acetic Acid: Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed). acetic acid : A simple monocarboxylic acid containing two carbons.	4.46	4	1	monocarboxylic acid	antimicrobial food preservative; Daphnia magna metabolite; food acidity regulator; protic solvent
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	2.43	2	0	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
adenine [no description available]	6.46	7	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ammonium hydroxide azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.	4.99	2	1	azane; gas molecular entity; mononuclear parent hydride	EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant
betaine glycine betaine : The amino acid betaine derived from glycine.	3.23	1	0	amino-acid betaine; glycine derivative	fundamental metabolite
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	2.03	1	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
carbamates [no description available]	4.5	7	0	amino-acid anion
carnitine [no description available]	3.42	1	1	amino-acid betaine	human metabolite; mouse metabolite
methane Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).	6.21	9	1	alkane; gas molecular entity; mononuclear parent hydride; one-carbon compound	bacterial metabolite; fossil fuel; greenhouse gas
choline [no description available]	3.8	10	0	cholines	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter; nutrient; plant metabolite; Saccharomyces cerevisiae metabolite
aconitic acid Aconitic Acid: A tricarboxylic acid with the formula (COOH)-CH2-C(COOH)=CH-COOH.. aconitic acid : A tricarboxylic acid that is prop-1-ene substituted by carboxy groups at positions 1, 2 and 3.	2.15	1	0	tricarboxylic acid
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	4.61	1	1	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	3.6	2	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
coumarin 2H-chromen-2-one: coumarin derivative	2.07	1	0	coumarins	fluorescent dye; human metabolite; plant metabolite
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	8.54	19	5	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
phloroglucinol Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.	2.02	1	0	benzenetriol; phenolic donor	algal metabolite
3-hydroxybutyric acid 3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.. 3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.	2.52	2	0	(omega-1)-hydroxy fatty acid; 3-hydroxy monocarboxylic acid; hydroxybutyric acid	human metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	3.23	1	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
n(1)-methylnicotinamide N(1)-methylnicotinamide: RN given refers to parent cpd. 1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.	2.15	1	0	pyridinium ion	algal metabolite; anti-inflammatory agent; human urinary metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
methylmalonic acid Methylmalonic Acid: A malonic acid derivative which is a vital intermediate in the metabolism of fat and protein. Abnormalities in methylmalonic acid metabolism lead to methylmalonic aciduria. This metabolic disease is attributed to a block in the enzymatic conversion of methylmalonyl CoA to succinyl CoA.. methylmalonic acid : A dicarboxylic acid that is malonic acid in which one of the methylene hydrogens is substituted by a methyl group.	3.42	1	1	C4-dicarboxylic acid	human metabolite
malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group.	2.31	1	0	2-hydroxydicarboxylic acid; C4-dicarboxylic acid	food acidity regulator; fundamental metabolite
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	3.23	1	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
cytosine [no description available]	2.44	2	0	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	5.67	70	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	3.24	6	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	3.43	1	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
glycine [no description available]	2.48	2	0	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	7.13	15	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
dalteparin Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)	5.98	7	4
histamine [no description available]	5.25	3	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	4.61	1	1	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
hydroquinone [no description available]	2.1	1	0	benzenediol; hydroquinones	antioxidant; carcinogenic agent; cofactor; Escherichia coli metabolite; human xenobiotic metabolite; mouse metabolite; skin lightening agent
iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..	2.57	2	0	diatomic iodine	nutrient
thioctic acid Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.	4.9	7	1	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector
racemethionine Racemethionine: A preparation of METHIONINE that includes a mixture of D-methionine and L-methionine isomers.	2.41	1	0	alpha-amino acid; amino acid zwitterion; sulfur-containing amino acid	algal metabolite; Daphnia magna metabolite; Escherichia coli metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	3.58	8	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.03	1	0	cyclitol; hexol
melatonin [no description available]	3.82	9	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	11.67	21	7	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	3.59	2	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	4.61	1	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
nitrites Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)	4.61	1	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite
oxamic acid Oxamic Acid: Amino-substituted glyoxylic acid derivative.. oxamic acid : A dicarboxylic acid monoamide resulting from the formal condensation of one of the carboxy groups of oxalic acid with ammonia.	2.21	1	0	dicarboxylic acid monoamide	Escherichia coli metabolite
triphosphoric acid triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure	2.57	2	0	acyclic phosphorus acid anhydride; phosphorus oxoacid
phosphorylcholine Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.	3.84	2	1	phosphocholines	allergen; epitope; hapten; human metabolite; mouse metabolite
propylene glycol Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.	4.61	1	1	glycol; propane-1,2-diols	allergen; human xenobiotic metabolite; mouse metabolite; protic solvent
propionic acid propionic acid : A short-chain saturated fatty acid comprising ethane attached to the carbon of a carboxy group.	3.53	1	1	saturated fatty acid; short-chain fatty acid	antifungal drug
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	3.61	2	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyridine azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.	2.15	1	0	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	4.75	3	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2.25	1	0	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
thiosulfates Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.. thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.	5.19	3	1	divalent inorganic anion; sulfur oxide; sulfur oxoanion	human metabolite
sarcosine cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis	2.08	1	0	N-alkylglycine zwitterion; N-alkylglycine; N-methyl-amino acid; N-methylglycines	Escherichia coli metabolite; glycine receptor agonist; glycine transporter 1 inhibitor; human metabolite; mouse metabolite
spermine [no description available]	4.19	3	1	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
sulfur dioxide Sulfur Dioxide: A highly toxic, colorless, nonflammable gas. It is used as a pharmaceutical aid and antioxidant. It is also an environmental air pollutant.	4.61	1	1	sulfur oxide	Escherichia coli metabolite; food bleaching agent; refrigerant
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	3.66	2	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thymine [no description available]	3.27	1	0	pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	9.81	20	4	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	4.56	5	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
pk 11195 PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine	2.45	2	0	aromatic amide; isoquinolines; monocarboxylic acid amide; monochlorobenzenes	antineoplastic agent
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.08	1	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.83	3	0	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
pd 173074 [no description available]	2.08	1	0	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	2.63	2	0	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
phenytoin [no description available]	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
5-(n,n-hexamethylene)amiloride 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity. 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.	2.13	1	0	aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines	antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker
hydroxyindoleacetic acid (5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.	3.4	1	1	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.08	1	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
abt 702 [no description available]	2.08	1	0	bipyridines
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	3.23	1	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	3.61	2	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	3.61	2	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	3.23	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
alaproclate alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer	3.23	1	0	alpha-amino acid ester
albendazole [no description available]	3.61	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	3.61	2	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	4.31	5	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin alfuzosin: structure given in first source	3.23	1	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	3.23	1	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	3.23	1	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.08	1	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	4.07	2	0	triamino-1,3,5-triazine
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	3.23	1	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
ambenonium ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.	3.23	1	0	quaternary ammonium ion	EC 3.1.1.8 (cholinesterase) inhibitor
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	3.61	2	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	7.17	6	3	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.08	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.23	1	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	3.89	3	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	5.09	7	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.08	1	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	3.61	2	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.53	2	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	3.85	3	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	3.61	2	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.08	1	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	8.18	12	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	2.08	1	0	anthracenes	antipsoriatic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	4.13	3	1	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.15	4	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.08	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	3.61	2	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	3.61	2	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
baclofen [no description available]	3.61	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bendazac bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.	3.23	1	0	indazoles; monocarboxylic acid	non-steroidal anti-inflammatory drug; radical scavenger
bendroflumethiazide Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.	3.23	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	3.61	2	0	1-benzofurans; aromatic ketone	uricosuric drug
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	2.08	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
benzothiazide benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.	4.61	1	1	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
berberine [no description available]	2.6	1	0	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
betaxolol [no description available]	3.23	1	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bethanechol Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	3.23	1	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	11.78	41	9	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.	2.08	1	0	biphenyls; imidazoles
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	3.23	1	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	3.61	2	0	diarylmethane
bisbenzimidazole Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.	2.02	1	0	bibenzimidazole; N-methylpiperazine	anthelminthic drug; fluorochrome
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	3.23	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bromopride bromopride: RN given refers to parent cpd; structure	2.08	1	0	benzamides
bronopol [no description available]	2.08	1	0	nitro compound
bumetanide [no description available]	3.61	2	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	4.16	2	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
busulfan [no description available]	4.13	4	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
secbutabarbital secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital	3.23	1	0	barbiturates
caffeine [no description available]	3.61	2	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	5.16	14	0	aromatic ether; nitrile; polyether; tertiary amino compound
beta-glycerophosphoric acid beta-glycerophosphoric acid: plays role in mineralization of bone in vitro. glycerol 2-phosphate : A glycerol monophosphate having the phosphate group at the 2-position.	2.1	1	0	glycerol monophosphate	Escherichia coli metabolite; plant metabolite
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	5.08	2	1	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	3.87	3	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbinoxamine carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.	3.23	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carisoprodol Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.	3.23	1	0	carbamate ester	muscle relaxant
carmofur [no description available]	2	1	0	organohalogen compound; pyrimidines
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.74	3	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.08	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
carvedilol [no description available]	5.53	4	1	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
celecoxib [no description available]	13.07	38	17	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	5.75	3	2	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.08	1	0	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	3.87	3	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	3.23	1	0	diarylmethane
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	3.61	2	0	benzodiazepine
chlormezanone Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.	3.23	1	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	4.94	10	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorothiazide Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.	3.23	1	0	benzothiadiazine	antihypertensive agent; diuretic
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	3.61	2	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	3.61	2	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	3.61	2	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	3.61	2	0	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	3.61	2	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
ci 994 tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.	2.02	1	0	acetamides; benzamides; substituted aniline	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
cifenline [no description available]	2.08	1	0	diarylmethane
ciclopirox [no description available]	2.08	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.08	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	3.92	3	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	5.78	6	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofibrate [no description available]	2.08	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	5.64	5	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	3.88	3	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.08	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clobazam Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.	2.08	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.08	1	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	3.61	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	3.61	2	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	3.61	2	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	3.23	1	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	3.23	1	0	clonidine; imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide [no description available]	2.08	1	0	sulfonamide
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	3.23	1	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
clotrimazole [no description available]	3.23	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cyclobenzaprine cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.	3.23	1	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
cyclofenil Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.	3.23	1	0	organic molecular entity
cycloleucine Cycloleucine: An amino acid formed by cyclization of leucine. It has cytostatic, immunosuppressive and antineoplastic activities.. 1-aminocyclopentanecarboxylic acid : A non-proteinogenic alpha-amino acid that is cyclopentane substituted at position 1 by amino and carboxy groups.	3	1	0	non-proteinogenic alpha-amino acid	EC 2.5.1.6 (methionine adenosyltransferase) inhibitor
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
cystamine [no description available]	2.41	1	0	organic disulfide; primary amino compound	EC 2.3.2.13 (protein-glutamine gamma-glutamyltransferase) inhibitor
indibulin indibulin: Tubulin Modulator/Antineoplastic Agent; structure in first source	2.11	1	0
dapi DAPI: RN given refers to parent cpd.	2.05	1	0	indoles	fluorochrome
dapsone [no description available]	3.85	3	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
decanoic acid decanoate : A fatty acid anion 10:0 that is the conjugate base of decanoic acid.. decanoic acid : A C10, straight-chain saturated fatty acid.	2.08	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; anti-inflammatory agent; antibacterial agent; human metabolite; plant metabolite; volatile oil component
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.23	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	3.61	2	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	3.23	1	0	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	3.61	2	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	3.61	2	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	4.15	4	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	3.23	1	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
dicyclomine Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	3.23	1	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	3.58	2	0	pentacarboxylic acid	copper chelator
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	3.23	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
3,3'-diindolylmethane 3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist	2.99	4	0	indoles	antineoplastic agent; P450 inhibitor
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	3.23	1	0	dithiol; primary alcohol	chelator
dimethoate Dimethoate: An organothiophosphorus cholinesterase inhibitor that is used as a systemic and contact insecticide.. dimethoate : A monocarboxylic acid amide that is N-methylacetamide in which one of the hydrogens of the methyl group attached to the carbonyl moiety is replaced by a (dimethoxyphosphorothioyl)sulfanediyl group.	3.41	1	1	monocarboxylic acid amide; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	6.51	5	3	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
benzophenone benzophenone : The simplest member of the class of benzophenones, being formaldehyde in which both hydrogens are replaced by phenyl groups.	2.03	1	0	benzophenones	photosensitizing agent; plant metabolite
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	3.61	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	3.61	2	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	4.45	6	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	3.68	2	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.08	1	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	3.61	2	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	3.23	1	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	3.23	1	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	3.61	2	0	dibenzooxepine; tertiary amino compound	antidepressant
doxylamine Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.	3.23	1	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.	3.23	1	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	3.23	1	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
ebastine [no description available]	2.08	1	0	organic molecular entity
edrophonium Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	3.23	1	0	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
emodin Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.. emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.	2.6	1	0	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.08	1	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	5.81	6	1
estazolam Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.	3.23	1	0	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	3.85	3	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ether Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.	2.61	2	0	ether; volatile organic compound	inhalation anaesthetic; non-polar solvent; refrigerant
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	3.61	2	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	8.29	9	4	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	3.23	1	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810 [no description available]	3.61	2	0	2-aminopurines; acetate ester	antiviral drug; prodrug
famotidine Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.	2.06	1	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	3.23	1	0	carbamate ester	anticonvulsant; neuroprotective agent
4-biphenylylacetic acid biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.	2.08	1	0	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	3.61	2	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	3.91	3	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	3.23	1	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fenoprofen Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.	3.23	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fipexide fipexide: regulates dopaminergic systems at macromolecular level	3.23	1	0	benzodioxoles
flavoxate Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.	3.23	1	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	3.23	1	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.08	1	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	5.31	3	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	3.9	3	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
fluphenazine [no description available]	3.23	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	3.61	2	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	3.61	2	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	27.73	1,480	577	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	3.61	2	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurazepam Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.	3.23	1	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	3.23	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	4.6	7	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
fomepizole Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.	3.23	1	0	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	3.23	1	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	4.09	4	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
fusaric acid Fusaric Acid: A picolinic acid derivative isolated from various Fusarium species. It has been proposed for a variety of therapeutic applications but is primarily used as a research tool. Its mechanisms of action are poorly understood. It probably inhibits DOPAMINE BETA-HYDROXYLASE, the enzyme that converts dopamine to norepinephrine. It may also have other actions, including the inhibition of cell proliferation and DNA synthesis.	2.08	1	0	aromatic carboxylic acid; pyridines
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	4.74	3	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gemfibrozil [no description available]	3.61	2	0	aromatic ether	antilipemic drug
glafenine Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.	3.23	1	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.08	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	3.61	2	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	3.61	2	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glutaral Glutaral: One of the protein CROSS-LINKING REAGENTS that is used as a disinfectant for sterilization of heat-sensitive equipment and as a laboratory reagent, especially as a fixative.. glutaraldehyde : A dialdehyde comprised of pentane with aldehyde functions at C-1 and C-5.	2.5	2	0	dialdehyde	cross-linking reagent; disinfectant; fixative
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	3.87	3	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester [no description available]	3.23	1	0	benzenes
gossypol Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.	8.63	15	7
granisetron [no description available]	3.23	1	0	aromatic amide; indazoles
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	3.23	1	0	methoxybenzenes
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	3.23	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	3.61	2	0	acetamides
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	3.71	2	0	carboxamidine; guanidines; one-carbon compound
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	2.08	1	0	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
ha14-1 ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia	2.02	1	0	1-benzopyran
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	3.61	2	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.	2.13	1	0	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor
ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.	2.49	2	0	phenanthridines	fluorochrome; intercalator
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	3.23	1	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	3.61	2	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	3.61	2	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	3.71	2	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	10.19	11	5	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	3.23	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	3.85	3	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	3.23	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	3.93	3	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	16.55	89	35	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	3.61	2	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	3.61	2	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	3.61	2	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1	0
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	4.42	6	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.08	1	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
ioversol [no description available]	3.23	1	0	amidobenzoic acid
ioxaglate Ioxaglic Acid: A low-osmolar, ionic contrast medium used in various radiographic procedures.. ioxaglic acid : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an acetyl(methyl)amino group at the 5-position.	2	1	0	benzenedicarboxamide; benzoic acids; organoiodine compound	radioopaque medium
iproniazid [no description available]	3.61	2	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	3.61	2	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	3.23	1	0	benzenes
isoflurane Isoflurane: A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.	6.67	3	1	organofluorine compound	inhalation anaesthetic
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.61	2	0	carbohydrazide	antitubercular agent; drug allergen
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	3.53	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isoxsuprine Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.	3.23	1	0	alkylbenzene
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	3.61	2	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	3.61	2	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	5.8	3	1	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.08	1	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	13.28	35	15	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	3.23	1	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	3.23	1	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
ketotifen Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.	4.34	2	2	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	3.23	1	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	3.61	2	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	3.61	2	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
lauric acid dodecanoic acid : A straight-chain, twelve-carbon medium-chain saturated fatty acid with strong bactericidal properties; the main fatty acid in coconut oil and palm kernel oil.	2.05	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; antibacterial agent; plant metabolite
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	3.89	3	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	9.35	21	1	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lg 100268 LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source	2.08	1	0
lofepramine Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.	2.08	1	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	3.23	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lomustine [no description available]	3.92	3	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	5.73	3	1	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	3.61	2	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	3.23	1	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	3.23	1	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
loxapine Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.	3.23	1	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	3.7	9	0	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	3.61	2	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	3.93	3	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	3.23	1	0	primary aliphatic amine
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	3.23	1	0	nitrogen mustard; organochlorine compound	alkylating agent
meclizine Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.	3.23	1	0	diarylmethane
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	3.23	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	3.61	2	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
memantine [no description available]	5.53	2	1	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
mepenzolate mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure	3.23	1	0	diarylmethane
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	3.23	1	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	3.23	1	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	3.23	1	0	organic molecular entity
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	3.23	1	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
mesoridazine Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.	3.23	1	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	3.23	1	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	8.47	20	2	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	5.53	2	1	benzenes; diarylmethane; ketone; tertiary amino compound
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	3.23	1	0	sulfonamide; thiadiazoles
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	3.23	1	0	aromatic ether; carbamate ester; secondary alcohol
methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.	3.23	1	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
methyclothiazide Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)	3.23	1	0	benzothiadiazine
nocodazole [no description available]	3.96	13	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
methyl salicylate methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990. methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.	4.61	1	1	benzoate ester; methyl ester; salicylates	flavouring agent; insect attractant; metabolite
methyl methanesulfonate [no description available]	2.13	1	0	methanesulfonate ester	alkylating agent; apoptosis inducer; carcinogenic agent; genotoxin; mutagen
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	4.99	2	1	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	3.86	3	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	3.23	1	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	3.61	2	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	3.61	2	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	3.23	1	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	3.61	2	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	9.27	12	3	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midodrine Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.	3.23	1	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
milrinone [no description available]	3.23	1	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	4.8	3	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	3.61	2	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	3.56	2	0	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	21.14	188	86	dihydroxyanthraquinone	analgesic; antineoplastic agent
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.08	1	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
modafinil Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.	7.82	4	3	monocarboxylic acid amide; sulfoxide
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	3.23	1	0	monoterpenoid
entinostat [no description available]	2.5	2	0	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.08	1	0	acetamides; benzamides	anti-arrhythmia drug
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	3.23	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nadolol [no description available]	3.61	2	0	tetralins
naftopidil [no description available]	2.17	1	0	piperazines
nalidixic acid [no description available]	3.61	2	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
naratriptan naratriptan: structure given in first source	3.23	1	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	3.61	2	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.08	1	0	benzoxazocine; tertiary amino compound
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.08	1	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	3.87	3	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nialamide Nialamide: An MAO inhibitor that is used as an antidepressive agent.	3.23	1	0	organonitrogen compound; organooxygen compound
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	3.95	3	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	4.05	4	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilutamide [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	3.61	2	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	3.61	2	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	3.61	2	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.08	1	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.08	1	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	5.27	3	1	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nizatidine [no description available]	3.23	1	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	3.23	1	0	isoquinolines	dopamine uptake inhibitor
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	3.61	2	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	3.61	2	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.	2.97	4	0	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor
o(6)-benzylguanine O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity	2.02	1	0
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	5.27	3	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
olprinone olprinone: RN refers to HCl; structure given in first source	2.08	1	0	bipyridines
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	4.09	4	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	6.4	4	1	carbazoles
orphenadrine Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.	3.23	1	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxonic acid Oxonic Acid: Antagonist of urate oxidase.	19.53	277	84	1,3,5-triazines; monocarboxylic acid
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	3.61	2	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	3.23	1	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	3.9	3	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.23	1	0	aminobenzoic acid; phenols	antitubercular agent
quinone benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included).	2.1	1	0	1,4-benzoquinones	cofactor; human xenobiotic metabolite; mouse metabolite
pamidronate [no description available]	4.06	4	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	6.13	4	2	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	3.61	2	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.42	2	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	3.61	2	0	1,3-oxazoles	central nervous system stimulant
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	3.61	2	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.23	1	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	3.93	3	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	3.23	1	0	piperidines	cardiovascular drug
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	3.61	2	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.08	1	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	5.48	4	1	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	3.23	1	0	aromatic amine
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	3.23	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	3.23	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
phloretin [no description available]	2.1	1	0	dihydrochalcones	antineoplastic agent; plant metabolite
moxonidine moxonidine: structure given in first source	2.1	1	0	organohalogen compound; pyrimidines
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	3.61	2	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	3.89	3	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.08	1	0	organonitrogen compound; organooxygen compound
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.08	1	0	N-arylpiperazine
polythiazide [no description available]	3.23	1	0	benzothiadiazine
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.04	1	0	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
duodote duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents	3.23	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
ono 1078 pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist	2.08	1	0	chromones
pyranoprofen pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source	2.08	1	0	pyridochromene
praziquantel azinox: Russian drug	3.61	2	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	3.89	3	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	3.9	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	3.61	2	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	3.86	3	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	3.61	2	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	5.11	5	0	benzamides; hydrazines	antineoplastic agent
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	3.61	2	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	3.61	2	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	3.61	2	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	3.61	2	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propantheline Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.	3.23	1	0	xanthenes
propidium Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.	2.76	3	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	5.52	4	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	3.61	2	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protoporphyrin ix protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685. protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.	2.54	2	0
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	3.23	1	0	carbotricyclic compound	antidepressant
pyridostigmine [no description available]	3.23	1	0	pyridinium ion
pyrimethamine Maloprim: contains above 2 cpds	3.23	1	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134 quazepam: structure given in first source	3.23	1	0	benzodiazepine
quetiapine [no description available]	3.23	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	3.23	1	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one [no description available]	2.08	1	0	indoles
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	3.23	1	0	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
ranitidine [no description available]	2.08	1	0	aralkylamine
opc 12759 rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase	2.11	1	0	secondary carboxamide
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	3.89	3	0	benzothiazoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	3.23	1	0	alkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	3.61	2	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	3.23	1	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib [no description available]	2.08	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
rolipram [no description available]	2.11	1	0	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
ropinirole [no description available]	3.23	1	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
salicylsalicylic acid salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.	3.23	1	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
sb 206553 SB 206553: a high-affinity 5-HT(2C/2B) antagonist; structure given in first source	2.08	1	0	pyrroloindole
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.08	1	0	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.08	1	0	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
secobarbital Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.	3.23	1	0	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
sibutramine sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride	3.23	1	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	3.61	2	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sk&f 86002 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase	2.08	1	0	imidazoles
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	6.59	5	1	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	3.61	2	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
stearic acid octadecanoic acid : A C18 straight-chain saturated fatty acid component of many animal and vegetable lipids. As well as in the diet, it is used in hardening soaps, softening plastics and in making cosmetics, candles and plastics.	3.41	6	0	long-chain fatty acid; saturated fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; human metabolite; plant metabolite
imatinib [no description available]	3.89	3	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
streptonigrin [no description available]	2.08	1	0	pyridines; quinolone	antimicrobial agent; antineoplastic agent
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	6.2	9	1	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.	3.23	1	0	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	3.23	1	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.08	1	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfanitran [no description available]	2.08	1	0	sulfonamide
sulfaphenazole Sulfaphenazole: A sulfonilamide anti-infective agent.. sulfaphenazole : A sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent.	2.31	1	0	primary amino compound; pyrazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial drug; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor; P450 inhibitor
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	3.89	3	0
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	3.23	1	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.08	1	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
sulforaphane sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.	2.84	3	0	isothiocyanate; sulfoxide	antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available]	3.23	1	0	alkylbenzene
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	3.61	2	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	6.45	5	1	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine [no description available]	2.08	1	0	stilbenoid
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.08	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.08	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
1,4-bis(2-(3,5-dichloropyridyloxy))benzene 1,4-bis(2-(3,5-dichloropyridyloxy))benzene: potent phenobarbital-like inducer of microsomal monooxygenase activity; structure given in first source	2.08	1	0
tegafur [no description available]	19.75	300	88	organohalogen compound; pyrimidines
temazepam Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.	3.23	1	0	benzodiazepine
temozolomide [no description available]	8.97	12	4	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	3.61	2	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	3.61	2	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.47	2	0	diarylmethane
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	13.32	30	13	phthalimides; piperidones
thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate	3.23	1	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	3.23	1	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	9.44	13	4	aziridines
thonzylamine thonzylamine: major descriptor (72-84); file-maintained to PYRIMIDINES	2.31	1	0	methoxybenzenes
tiapride [no description available]	2.08	1	0	benzamides
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	3.87	3	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	2.08	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	3.61	2	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	3.23	1	0	N-acyl-amino acid
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	3.61	2	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
nikethamide Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)	2.08	1	0	pyridinecarboxamide
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	3.23	1	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	3.61	2	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolmetin Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.	3.23	1	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
tolnaftate [no description available]	2.08	1	0	monothiocarbamic ester	antifungal drug
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	3.23	1	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	3.23	1	0	amino acid
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	3.61	2	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	3.61	2	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	3.23	1	0	triazolobenzodiazepine	sedative
trifluoperazine [no description available]	3.23	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trihexyphenidyl Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.	3.23	1	0	amine
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	3.23	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethobenzamide trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.	3.23	1	0	benzamides; tertiary amino compound	antiemetic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	3.61	2	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	3.23	1	0
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	3.23	1	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	3.89	3	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
thenoyltrifluoroacetone Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.	2.08	1	0
tyramine [no description available]	3.23	1	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.23	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
undecylenic acid undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.	2.08	1	0	undecenoic acid	antifungal drug; plant metabolite
urapidil [no description available]	2.08	1	0	piperazines
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	3.61	2	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vigabatrin [no description available]	3.61	2	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
pirinixic acid pirinixic acid: structure	2.08	1	0	aryl sulfide; organochlorine compound; pyrimidines
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	3.93	3	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	3.61	2	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	3.23	1	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	3.61	2	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.08	1	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
cortisone acetate Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.	3.23	1	0	corticosteroid hormone
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	14.22	41	17	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	15.84	66	23	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
estriol hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone. chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.	2.06	1	0	16alpha-hydroxy steroid; 17beta-hydroxy steroid; 3-hydroxy steroid	estrogen; human metabolite; human xenobiotic metabolite; mouse metabolite
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	3.61	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	3.23	1	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	3.23	1	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
thymidine [no description available]	2.05	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	9.99	30	8	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
triethylenemelamine Triethylenemelamine: Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.	2.11	1	0	1,3,5-triazines	alkylating agent; insect sterilant
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	3.63	2	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	3.23	1	0	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
carbachol Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	1.98	1	0	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	4.52	2	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
prednisolone acetate prednisolone acetate: RN given refers to cpd with locant for acetate group in position 21 & (11 beta)-isomer	3.27	1	0	corticosteroid hormone
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	3.61	2	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
cysteine [no description available]	3.23	1	0	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	22.75	293	153	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	3.23	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
oxandrolone Oxandrolone: A synthetic hormone with anabolic and androgenic properties.	3.23	1	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid; oxa-steroid	anabolic agent; androgen
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	3.21	1	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	3.23	1	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	3.23	1	0	pilocarpine	antiglaucoma drug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	3.61	2	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.08	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
cantharidin Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.. cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.	2.1	1	0	cyclic dicarboxylic anhydride; monoterpenoid	EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; herbicide
alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.	2.11	1	0	alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid	EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	7.21	5	3	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	3.61	2	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.79	3	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	7	4	2	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	4.43	6	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
vincristine [no description available]	4.63	7	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	3.23	1	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2.17	1	0	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.08	1	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	2.08	1	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
9,10-dimethyl-1,2-benzanthracene 9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.	3.19	5	0	ortho-fused polycyclic arene; tetraphenes	carcinogenic agent
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	3.61	2	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
methyltestosterone Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent
tetrabenazine 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.	3.23	1	0	benzoquinolizine; cyclic ketone; tertiary amino compound
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	3.61	2	0	kanamycins	bacterial metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.02	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
galactose galactopyranose : The pyranose form of galactose.	2.95	4	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	7.98	9	3	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.08	1	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	3.69	2	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
phenylethyl alcohol Phenylethyl Alcohol: An antimicrobial, antiseptic, and disinfectant that is used also as an aromatic essence and preservative in pharmaceutics and perfumery.. 2-phenylethanol : A primary alcohol that is ethanol substituted by a phenyl group at position 2.	2.57	2	0	benzenes; primary alcohol	Aspergillus metabolite; fragrance; plant growth retardant; plant metabolite; Saccharomyces cerevisiae metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.76	3	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	3.23	1	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
acetylcholine chloride acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.	3.23	1	0	quaternary ammonium salt
phlorhizin [no description available]	2.1	1	0	aryl beta-D-glucoside; dihydrochalcones; monosaccharide derivative	antioxidant; plant metabolite
mepazine mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.	3.23	1	0	phenothiazines
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	3.23	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	3.81	2	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
calcium acetate calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.	3.23	1	0	calcium salt	chelator
lactose Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form.. beta-lactose : The beta-anomer of lactose.	2.06	1	0	lactose
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	4.54	3	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
1,2-dipalmitoylphosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.	3	4	0
phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.	2.41	2	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid	algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	6.52	18	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
mebanazine mebanazine: RN given refers to parent cpd without isomeric designation; structure	3.23	1	0	benzenes
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	3.23	1	0	penicillin	antibacterial agent; antibacterial drug
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.07	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
ficusin Ficusin: A naturally occurring furocoumarin, found in PSORALEA. After photoactivation with UV radiation, it binds DNA via single and double-stranded cross-linking.. psoralen : The simplest member of the class of psoralens that is 7H-furo[3,2-g]chromene having a keto group at position 7. It has been found in plants like Psoralea corylifolia and Ficus salicifolia.	3.4	2	0	psoralens	plant metabolite
chloroform Chloroform: A commonly used laboratory solvent. It was previously used as an anesthetic, but was banned from use in the U.S. due to its suspected carcinogenicity.. chloroform : A one-carbon compound that is methane in which three of the hydrogens are replaced by chlorines.	2.69	3	0	chloromethanes; one-carbon compound	carcinogenic agent; central nervous system drug; inhalation anaesthetic; non-polar solvent; refrigerant
triamcinolone diacetate triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone	2.08	1	0	corticosteroid hormone
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	3.23	1	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	3.23	1	0	aromatic ketone
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	3.23	1	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	3.61	2	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	6.93	12	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	3.59	2	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	2.21	1	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.	2.46	2	0	amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	5.1	2	1	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
medroxyprogesterone acetate [no description available]	3.41	7	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	6.2	6	2	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	2.47	2	0	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	3.48	1	1	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
isoleucine Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.	2.96	1	0	aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	5.86	6	1	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
ethylene Plastipore: high density polyethylene sponge biocompatible material; used as posts in dental bridges	4.61	1	1	alkene; gas molecular entity	plant hormone; refrigerant
acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.	1.99	1	0	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent
tert-butyl alcohol tert-Butyl Alcohol: An isomer of butanol that contains a tertiary butyl group that consists of three methyl groups, each separately attached to a central (tertiary) carbon.. tert-butanol : A tertiary alcohol alcohol that is isobutane substituted by a hydroxy group at position 2.	2.13	1	0	tertiary alcohol	human xenobiotic metabolite
perflutren Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.	3.23	1	0	fluoroalkane; fluorocarbon
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
fluoxymesterone Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.	3.23	1	0	11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid	anabolic agent; antineoplastic agent
methsuximide methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation	3.23	1	0	organic molecular entity
tromethamine Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)	3.23	1	0	primary amino compound; triol	buffer
isoprene isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.	2.6	1	0	alkadiene; hemiterpene; volatile organic compound	plant metabolite
trichloroethylene Trichloroethylene: A highly volatile inhalation anesthetic used mainly in short surgical procedures where light anesthesia with good analgesia is required. It is also used as an industrial solvent. Prolonged exposure to high concentrations of the vapor can lead to cardiotoxicity and neurological impairment.. triol : A chemical compound containing three hydroxy groups.	2	1	0	chloroethenes	inhalation anaesthetic; mouse metabolite
acrylic acid acrylic acid: RN given refers to parent cpd. acrylic acid : A alpha,beta-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.	2.17	1	0	alpha,beta-unsaturated monocarboxylic acid	metabolite
dichloroacetic acid [no description available]	4.8	2	1	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
taurocholic acid Taurocholic Acid: The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.. taurocholate : An organosulfonate oxoanion that is the conjugate base of taurocholic acid.. taurocholic acid : A bile acid taurine conjugate of cholic acid that usually occurs as the sodium salt of bile in mammals.	2.49	2	0	amino sulfonic acid; bile acid taurine conjugate	human metabolite
rhodamine b rhodamine B: RN & N1 from 9th CI Form Index; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7973; TETRAETHYLRHODAMINE was see RHODAMINES 1975-93; use RHODAMINES to search TETRAETHYLRHODAMINE 1975-93. rhodamine B : An organic chloride salt having N-[9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethylethanaminium as the counterion. An amphoteric dye commonly used as a fluorochrome.	2.84	3	0	organic chloride salt; xanthene dye	fluorescent probe; fluorochrome; histological dye
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	8.82	18	6	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.53	2	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
brompheniramine Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	3.23	1	0	penicillin allergen; penicillin
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	3.23	1	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
penicillanic acid Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.	2.15	1	0	penicillanic acids
n-vinyl-2-pyrrolidinone N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source	4.16	3	1	pyrrolidin-2-ones
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	3.23	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylpropion Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.	3.23	1	0	aromatic ketone; tertiary amine	appetite depressant
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	5.95	4	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
quinoline [no description available]	2.1	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines
dilactide dilactide: structure given in first source	2.94	3	0	dioxanes
styrene oxide styrene oxide: structure. styrene oxide : An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group.	2.03	1	0	epoxide	human xenobiotic metabolite
butyl methacrylate [no description available]	2.25	1	0	enoate ester
trehalose alpha,alpha-trehalose : A trehalose in which both glucose residues have alpha-configuration at the anomeric carbon.	2.17	1	0	trehalose	Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
quinuclidines Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.	2.46	2	0	quinuclidines; saturated organic heterobicyclic parent
benzonatate benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.	3.23	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
n-methyldiethanolamine [no description available]	2.1	1	0
caprolactam Caprolactam: Cyclic amide of caproic acid used in manufacture of synthetic fibers of the polyamide type. Can cause local irritation.. epsilon-caprolactam : A member of the class of caprolactams that is azepane substituted by an oxo group at position 2.	5.28	3	1	caprolactams	human blood serum metabolite
allyl alcohol allyl alcohol: structure. allylic alcohol : An alcohol where the hydroxy group is attached to a saturated carbon atom adjacent to a double bond (R groups may be H, organyl, etc.).. allyl alcohol : A propenol in which the C=C bond connects C-2 and C-3. It is has been found in garlic (Allium sativum). Formerly used as a herbicide for the control of various grass and weed seeds.	2.04	1	0	primary allylic alcohol; propenol	antibacterial agent; fungicide; herbicide; insecticide; plant metabolite
succinic anhydride [no description available]	2.17	1	0	cyclic dicarboxylic anhydride; tetrahydrofurandione
maleic anhydride Maleic Anhydrides: Used in copolymerization reactions, in the Diels-Alder(diene)synthesis, in the preparation of resins, pharmaceuticals and agricultural chemicals. It is a powerful irritant and causes burns.. maleic anhydride : A cyclic dicarboxylic anhydride that is the cyclic anhydride of maleic acid.	2.21	1	0	cyclic dicarboxylic anhydride; furans	allergen
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	14.73	58	24	pyrrole; secondary amine
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	7.71	15	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
isopropyl myristate isopropyl myristate: used for microemulsions; structure	4.61	1	1	fatty acid ester
octylamine octylamine: RN given refers to 1-octylamine. octan-1-amine : An 8-carbon primary aliphatic amine.	2.03	1	0	primary aliphatic amine	metabolite
carbitol carbitol: used as lubricating oil & in braking fluid, structure. diethylene glycol monoethyl ether : A primary alcohol that is ethanol substituted by a 2-ethoxyethoxy group at position 2.	2.48	2	0	diether; glycol ether; hydroxypolyether; primary alcohol	protic solvent
methylergonovine Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)	3.23	1	0	ergoline alkaloid
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.08	1	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
diethylhexyl phthalate Diethylhexyl Phthalate: An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.. bis(2-ethylhexyl) phthalate : A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.	2	1	0	diester; phthalate ester	androstane receptor agonist; apoptosis inhibitor; plasticiser
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.83	3	0	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
meglumine Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.	2.63	2	0	hexosamine; secondary amino compound
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	3.23	1	0	quinolines
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.08	1	0	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
ethyl acetate ethyl acetate : The acetate ester formed between acetic acid and ethanol.	2.06	1	0	acetate ester; ethyl ester; volatile organic compound	EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor; metabolite; polar aprotic solvent; Saccharomyces cerevisiae metabolite
hexanoic acid hexanoic acid : A C6, straight-chain saturated fatty acid.	2.31	1	0	medium-chain fatty acid; straight-chain saturated fatty acid	human metabolite; plant metabolite
20-alpha-dihydroprogesterone 20-alpha-Dihydroprogesterone: A biologically active 20-alpha-reduced metabolite of PROGESTERONE. It is converted from progesterone to 20-alpha-hydroxypregn-4-en-3-one by the 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE in the CORPUS LUTEUM and the PLACENTA.	2.05	1	0	20-hydroxypregn-4-en-3-one	human metabolite; mouse metabolite
2-chloroadenosine 5-chloroformycin A: structure given in first source	2.04	1	0	purine nucleoside
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	3.23	1	0	penicillin allergen; penicillin	antibacterial drug
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	3.23	1	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	3.24	5	0	catechin	antioxidant; plant metabolite
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	22.07	288	101	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	3.89	4	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	8.29	16	6	indazole
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	5.05	2	1	1,3-benzoxazoles; mancude organic heterobicyclic parent
adamantane Adamantane: A tricyclo bridged hydrocarbon.	2.25	1	0	adamantanes; polycyclic alkane
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	4.16	3	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.1	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	3.33	6	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	11.17	53	5	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	11.75	27	10	diazine; pyrazines	Daphnia magna metabolite
calcium gluconate [no description available]	3.43	1	1	calcium salt	nutraceutical
ephedrine Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.	3.23	1	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
hydrazine diamine : Any polyamine that contains two amino groups.	2.86	3	0	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
hemicholinium 3 Hemicholinium 3: A potent inhibitor of the high affinity uptake system for CHOLINE. It has less effect on the low affinity uptake system. Since choline is one of the components of ACETYLCHOLINE, treatment with hemicholinium can deplete acetylcholine from cholinergic terminals. Hemicholinium 3 is commonly used as a research tool in animal and in vitro experiments.	2.05	1	0
evans blue Evans Blue: An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.. Evans blue : An organic sodium salt that is the tetrasodium salt of 6,6'-{(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis[diazene-2,1-diyl]}bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate). It is sometimes used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.	2.07	1	0	organic sodium salt	fluorochrome; histological dye; sodium channel blocker; teratogenic agent
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	3.61	2	0	mixture	bronchodilator agent; cardiotonic drug
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	9.43	18	3	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	3.61	2	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
nandrolone decanoate Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.	3.23	1	0	steroid ester
aminoimidazole carboxamide Aminoimidazole Carboxamide: An imidazole derivative which is a metabolite of the antineoplastic agents BIC and DIC. By itself, or as the ribonucleotide, it is used as a condensation agent in the preparation of nucleosides and nucleotides. Compounded with orotic acid, it is used to treat liver diseases.. 5-aminoimidazole-4-carboxamide : An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.	2.21	1	0	aminoimidazole; monocarboxylic acid amide	mouse metabolite
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.08	1	0	hydrochloride	antineoplastic agent
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.08	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
cyproterone acetate [no description available]	3.04	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin
lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.	3.82	2	0	bile acid; C24-steroid; monohydroxy-5beta-cholanic acid	geroprotector; human metabolite; mouse metabolite
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.03	1	0	imidazolidine-2,4-dione
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	3.23	1	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	2.15	1	0	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	3.58	2	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
glycocholic acid Glycocholic Acid: The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed.. glycocholic acid : A bile acid glycine conjugate having cholic acid as the bile acid component.. glycocholate : A cholanic acid conjugate anion that is the conjugate base of glycocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	2.21	1	0	bile acid glycine conjugate	human metabolite
nuciferine nuciferine: CNS depressant; glutamic acid antagonist; RN given refers to (R)-isomer; structure	2.25	1	0
rhein [no description available]	2.31	1	0	dihydroxyanthraquinone
berbamine [no description available]	2.11	1	0	phenylpropanoid
cepharanthine cepharanthine: isoquinoline alkaloid from tubers of STEPHANIA; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. cepharanthine : A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.	2.06	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
imperatorin imperatorin: tumor necrosis factor antagonist; furanocoumarin from West African medicinal plant Clausena anisata; structure in Negwer, 5th ed, #3005. imperatorin : A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 8. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor.	2.15	1	0	psoralens	EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.08	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
thymoquinone thymoquinone: constituent of cedarwood; can cause dermatitis; structure. thymoquinone : A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity.	3.11	4	0	1,4-benzoquinones	adjuvant; anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; cardioprotective agent; plant metabolite
carvacrol carvacrol : A phenol that is a natural monoterpene derivative of cymene. An inhibitor of bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).	2.6	1	0	botanical anti-fungal agent; p-menthane monoterpenoid; phenols	agrochemical; antimicrobial agent; flavouring agent; TRPA1 channel agonist; volatile oil component
caprolactone hexano-6-lactone : A epsilon-lactone that is oxepane substituted by an oxo group at position 2.	2.41	1	0	epsilon-lactone
4-hydroxybutyric acid 4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.	3.23	1	0	4-hydroxy monocarboxylic acid; hydroxybutyric acid	general anaesthetic; GHB receptor agonist; neurotoxin; sedative
oxetane oxetane: structure. oxetane : A saturated organic heteromonocyclic parent that is a four-membered ring comprising of three carbon atoms and an oxygen atom.	2.01	1	0	oxetanes; saturated organic heteromonocyclic parent
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	4.58	4	1
oleanolic acid [no description available]	4	3	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	3.23	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
elemene elemene: a sclerosing and antineoplastic agent isolated from Curcuma wenyujin & Rhizoma zedoariae; beta- and delta- elemene are also available	2.1	1	0
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	6.44	7	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
hesperidin Hesperidin: A flavanone glycoside found in CITRUS fruit peels.. hesperidin : A disaccharide derivative that consists of hesperetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.	2.17	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; dihydroxyflavanone; disaccharide derivative; flavanone glycoside; monomethoxyflavanone; rutinoside	mutagen
medroxyprogesterone [no description available]	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.05	1	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	3.61	2	0	diarylmethane
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.78	3	0	C-nitro compound; imidazoles	antitubercular agent
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	3.23	1	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
aminoacetonitrile Aminoacetonitrile: Cyanomethylamine.	2.15	1	0
levocarnitine (R)-carnitine : The (R)-enantiomer of carnitine.	3.23	1	0	carnitine	antilipemic drug; nootropic agent; nutraceutical; Saccharomyces cerevisiae metabolite; water-soluble vitamin (role)
maleimide [no description available]	2.17	1	0	dicarboximide; maleimides	EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
muscone muscone: structure in first source	4.61	1	1
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.48	2	0	dialdehyde	biomarker
poldine poldine: major descriptor (66-86); on-line search BENZILATES (66-86); INDEX MEDICUS search POLDINE (66-86); RN given refers to parent cpd	3.45	1	1	diarylmethane
sulfanilylurea sulfanilylurea: antimicrobial agent; structure	3.23	1	0	benzenes; sulfonamide
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.08	1	0	isothiocyanate	insecticide
hematoporphyrin Hematoporphyrins: Iron-free derivatives of heme with 4 methyl groups, 2 hydroxyethyl groups and 2 propionic acid groups attached to the pyrrole rings. Some of these PHOTOSENSITIZING AGENTS are used in the PHOTOTHERAPY of malignant NEOPLASMS.. hematoporphyrin : A dicarboxylic acid that is protoporphyrin in which the vinyl groups at positions 7 and 12 are replaced by 1-hydroxyethyl groups.	2.41	1	0
tristearin tristearoylglycerol : A triglyceride that is glycerol in which all three hydroxy groups have been formally esterified with stearic acid.	2.51	2	0	triacylglycerol 54:0	Caenorhabditis elegans metabolite; plant metabolite
glycerylphosphorylcholine Glycerylphosphorylcholine: A component of PHOSPHATIDYLCHOLINES or LECITHINS, in which the two hydroxy groups of GLYCEROL are esterified with fatty acids. (From Stedman, 26th ed)	2.03	1	0	glycerophosphocholine
formestane [no description available]	2.08	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lactulose [no description available]	3.23	1	0	glycosylfructose	gastrointestinal drug; laxative
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.02	1	0	flavonols; monohydroxyflavone
succinimide succinimide: RN given refers to parent cpd. succinimide : A dicarboximide that is pyrrolidine which is substituted by oxo groups at positions 2 and 5.	2.04	1	0	dicarboximide; pyrrolidinone
megestrol acetate [no description available]	3.4	2	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
triphenylphosphine triphenylphosphine: RN given refers to parent cpd. triphenylphosphine : A member of the class of tertiary phosphines that is phosphane in which the three hydrogens are replaced by phenyl groups.	2.58	2	0	benzenes; tertiary phosphine	NMR chemical shift reference compound; reducing agent
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	3.02	4	0	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
pamabrom [no description available]	3.23	1	0
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	4.5	3	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
c.i. 42510 Rosaniline Dyes: Compounds that contain the triphenylmethane aniline structure found in rosaniline. Many of them have a characteristic magenta color and are used as COLORING AGENTS.. basic fuchsin : A four-component mixture of chemically related dyes comprising pararosanilin, rosanilin, magenta II and new fuchsin in varying amounts. rosanilin : A hydrochloride that is the monohydrochloride of 4-[(4-aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline. One of the major constituents of Basic fuchsin, together with pararosanilin, magenta II and new fuchsin.	6.72	3	3
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	6.18	5	2	cyclic ketone; erythromycin
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	3.94	2	1	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
methylnitrosourea Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.	3.83	3	0	N-nitrosoureas	alkylating agent; carcinogenic agent; mutagen; teratogenic agent
2-fluoroadenine 2-fluoroadenine : An organofluorine compound that is adenine in which the hydrogen at position 2 (the carbon between the two nitrogens of the pyrimidine ring) is replaced by a fluorine.	2.11	1	0	organofluorine compound; purines	antineoplastic agent
hydroxychloroquine sulfate [no description available]	2.49	2	0
ethylnitrosourea Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.	2.01	1	0	N-nitrosoureas	alkylating agent; carcinogenic agent; genotoxin; mutagen
2,3-dimethylmaleic anhydride [no description available]	2.21	1	0	butenolide
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	3.61	2	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
hydroxyethyl methacrylate hydroxyethyl methacrylate: many of cited refs are for gel which refers to polymeric form of above cpd: POLYHYDROXYETHYL METHACRYLATE. 2-hydroxyethyl methacrylate : An enoate ester that is the monomethacryloyl derivative of ethylene glycol.	2.13	1	0	enoate ester	allergen; polymerisation monomer
diphenoxylate Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.	3.23	1	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
deoxycytidine [no description available]	26.96	1,058	452	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	3.48	1	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
ethambutol hydrochloride ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.	2.08	1	0	hydrochloride	antitubercular agent
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	3.23	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
durapatite Durapatite: The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.. hydroxylapatite : A phosphate mineral with the formula Ca5(PO4)3(OH).	2.05	1	0
cupric sulfide copper(II) sulfide : A copper sulfide in which the metal is in the +2 oxidation state.	2.21	1	0
arsenic trioxide Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.	3.58	2	0
antimycin a [no description available]	2.08	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	4.54	2	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	8.69	71	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
tocopherols [no description available]	2.11	1	0
pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.	2.08	1	0	aliphatic nitrile
1,2-epoxyhexane [no description available]	4.61	1	1
selenomethionine [no description available]	2.11	1	0	selenoamino acid; selenomethionines	plant metabolite
ibufenac ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.	3.23	1	0	monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug
metylperon metylperon: RN given refers to parent cpd	2.08	1	0	aromatic ketone
methyl tert-butyl ether methyl tert-butyl ether: used to dissolve gallstones; gasoline additive. methyl tert-butyl ether : An ether having methyl and tert-butyl as the two alkyl components.	2.11	1	0	ether	fuel additive; metabolite; non-polar solvent
metaxalone [no description available]	3.23	1	0	aromatic ether
spectinomycin Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.	3.23	1	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
stearylamine stearylamine: RN given refers to parent cpd. octadecan-1-amine : An 18-carbon primary aliphatic amine.	2.49	2	0	primary aliphatic amine	film-forming compound
paraquat Paraquat: A poisonous dipyridilium compound used as contact herbicide. Contact with concentrated solutions causes irritation of the skin, cracking and shedding of the nails, and delayed healing of cuts and wounds.. paraquat : An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.	2.1	1	0	organic cation	geroprotector; herbicide
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	3.61	2	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
amiloride hydrochloride, anhydrous amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride	diuretic; sodium channel blocker
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	3.63	2	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
diallyl trisulfide [no description available]	2.13	1	0	organic trisulfide	anti-inflammatory agent; antilipemic drug; antineoplastic agent; antioxidant; antiprotozoal drug; apoptosis inducer; estrogen receptor antagonist; insecticide; platelet aggregation inhibitor; vasodilator agent
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	3.23	1	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
phenethyl isothiocyanate phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.	2.05	1	0	isothiocyanate	antineoplastic agent; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; metabolite
fluorescein Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.	2.45	2	0	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
dexbrompheniramine dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	brompheniramine	anti-allergic agent; H1-receptor antagonist
fucose Fucose: A six-member ring deoxysugar with the chemical formula C6H12O5. It lacks a hydroxyl group on the carbon at position 6 of the molecule.. L-fucopyranose : The pyranose form of L-fucose.. fucose : Any deoxygalactose that is deoxygenated at the 6-position.	2.07	1	0	fucopyranose; L-fucose	Escherichia coli metabolite; mouse metabolite
acadesine [no description available]	2.08	1	0	1-ribosylimidazolecarboxamide; aminoimidazole; nucleoside analogue	antineoplastic agent; platelet aggregation inhibitor
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	3.61	2	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	8.81	26	7	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	3.61	2	0	dichlorobenzene; penicillin	antibacterial drug
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2.55	2	0	fluorescein isothiocyanate
megestrol Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	2.31	1	0	2-phenylcyclopropan-1-amine
streptomycin [no description available]	3.23	1	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
cladribine [no description available]	4.58	4	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
carbenicillin Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.	3.23	1	0	penicillin allergen; penicillin	antibacterial drug
metocurine metocurine: from Chinese herb Cyclea hainanensis Mrr	2.08	1	0	isoquinolines
clomacran clomacran: RN given refers to parent cpd; structure	3.23	1	0	acridines
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	3.53	2	0	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
methenamine hippurate methenamine hippurate: both parts of molecule contribute to its antibacterial action	3.23	1	0	N-acylglycine
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	3.23	1	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
enbucrilate Enbucrilate: A tissue adhesive that is applied as a monomer to moist tissue and polymerizes to form a bond. It is slowly biodegradable and used in all kinds of surgery, including dental.	2.8	3	0	alpha,beta-unsaturated monocarboxylic acid; nitrile
etidronate disodium etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.	2.08	1	0	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator
lutetium Lutetium: An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.	5.87	6	1	d-block element atom; lanthanoid atom
manganese Manganese: A trace element with atomic symbol Mn, atomic number 25, and atomic weight 54.94. It is concentrated in cell mitochondria, mostly in the pituitary gland, liver, pancreas, kidney, and bone, influences the synthesis of mucopolysaccharides, stimulates hepatic synthesis of cholesterol and fatty acids, and is a cofactor in many enzymes, including arginase and alkaline phosphatase in the liver. (From AMA Drug Evaluations Annual 1992, p2035). manganese(4+) : A manganese cation that is monoatomic and has a formal charge of +4.	2.31	1	0	elemental manganese; manganese group element atom	Escherichia coli metabolite; micronutrient
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.13	1	0	metal allergen; nickel group element atom; platinum group metal atom
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	16.44	75	32	elemental platinum; nickel group element atom; platinum group metal atom
rhodium Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.	2.1	1	0	cobalt group element atom
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	5.37	3	1	copper group element atom; elemental silver	Escherichia coli metabolite
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.49	2	0	manganese group element atom
thulium Thulium: An element of the rare earth family of metals. It has the atomic symbol Tm, atomic number 69, and atomic weight 168.93.	4.61	1	1	f-block element atom; lanthanoid atom
titanium Titanium: A dark-gray, metallic element of widespread distribution but occurring in small amounts with atomic number, 22, atomic weight, 47.867 and symbol, Ti; specific gravity, 4.5; used for fixation of fractures.	6.6	8	1	titanium group element atom
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	3.02	4	0	f-block element atom; lanthanoid atom
gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.	6.82	29	0	copper group element atom; elemental gold
uranium Uranium: A radioactive element of the actinide series of metals. It has an atomic symbol U, atomic number 92, and atomic weight 238.03. U-235 is used as the fissionable fuel in nuclear weapons and as fuel in nuclear power reactors.	4.61	1	1	actinoid atom; f-block element atom; monoatomic uranium
yttrium Yttrium: An element of the rare earth family of metals. It has the atomic symbol Y, atomic number 39, and atomic weight 88.91. In conjunction with other rare earths, yttrium is used as a phosphor in television receivers and is a component of the yttrium-aluminum garnet (YAG) lasers.	2.01	1	0	d-block element atom; rare earth metal atom; scandium group element atom
zirconium Zirconium: A rather rare metallic element with atomic number 40, atomic weight 91.224, and symbol Zr.	2.11	1	0	titanium group element atom
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.08	1	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
magnesium sulfate Magnesium Sulfate: A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083). magnesium sulfate : A magnesium salt having sulfate as the counterion.	5.29	3	1	magnesium salt; metal sulfate; organic magnesium salt	anaesthetic; analgesic; anti-arrhythmia drug; anticonvulsant; calcium channel blocker; cardiovascular drug; fertilizer; tocolytic agent
galactosamine 2-amino-2-deoxy-D-galactopyranose : The pyranose form of D-galactosamine.. D-galactosamine : The D-stereoisomer of galactosamine.	2.15	1	0	D-galactosamine; primary amino compound	toxin
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	21.34	276	82	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
zinc sulfate Zinc Sulfate: A compound given in the treatment of conditions associated with zinc deficiency such as acrodermatitis enteropathica. Externally, zinc sulfate is used as an astringent in lotions and eye drops. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995). zinc sulfate : A metal sulfate compound having zinc(2+) as the counterion.	2.08	1	0	metal sulfate; zinc molecular entity	fertilizer
tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.	3.09	4	0	calcium phosphate
sodium thiosulfate sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.	5.94	4	1	inorganic sodium salt	antidote to cyanide poisoning; antifungal drug; nephroprotective agent
calcium sulfate Calcium Sulfate: A calcium salt that is used for a variety of purposes including: building materials, as a desiccant, in dentistry as an impression material, cast, or die, and in medicine for immobilizing casts and as a tablet excipient. It exists in various forms and states of hydration. Plaster of Paris is a mixture of powdered and heat-treated gypsum.	2.15	1	0	calcium salt; inorganic calcium salt
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	1.99	1	0	dihydrogen
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	3.84	3	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
chlorine Chlorine: An element with atomic symbol Cl, atomic number 17, and atomic weight 35, and member of the halogen family.	2.15	1	0	diatomic chlorine; gas molecular entity	bleaching agent
glycerol 1-stearate glycerol 1-stearate: isolated from the young fronds of the bracken fern Pteridium aquilinum; structure in first source. rac-1-monostearoylglycerol : A rac-1-monoacylglycerol composed of equal amounts of 3-stearoyl-sn-glycerol and 1-stearoyl-sn-glycerol.. 1-monostearoylglycerol : A 1-monoglyceride that has stearoyl as the acyl group.	2.51	2	0	1-acylglycerol 18:0; rac-1-monoacylglycerol	algal metabolite; Caenorhabditis elegans metabolite
galactose aldohexose : A hexose with a (potential) aldehyde group at one end.	5.36	3	1
poloxalene Poloxalene: A copolymer of polyethylene and polypropylene ether glycol. It is a non-ionic polyol surface-active agent used medically as a fecal softener and in cattle for prevention of bloat.. pluronic : A triblock copolymer composed of a central hydrophobic chain of poly(propylene oxide) flanked by two hydrophilic chains of poly(ethylene oxide).	3.19	5	0	epoxide
ozone Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.	4.61	1	1	elemental molecule; gas molecular entity; reactive oxygen species; triatomic oxygen	antiseptic drug; disinfectant; electrophilic reagent; greenhouse gas; mutagen; oxidising agent; tracer
sodium selenite disodium selenite : An inorganic sodium salt composed of sodium and selenite ions in a 2:1 ratio.	2.06	1	0	inorganic sodium salt; selenite salt	nutraceutical
trolamine salicylate Arthritis: Acute or chronic inflammation of JOINTS.	2.08	1	0
clodronic acid Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.	4.38	3	0	1,1-bis(phosphonic acid); one-carbon compound; organochlorine compound	antineoplastic agent; bone density conservation agent
mafenide acetate [no description available]	2.08	1	0	carboxylic acid
titanium dioxide titanium dioxide: used medically as protectant against externally caused irritation & sunlight; high concentrations of dust may cause irritation to respiratory tract; RN given refers to titanium oxide (TiO2); structure. titanium dioxide : A titanium oxide with the formula TiO2. A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.	2.11	1	0	titanium oxides	food colouring
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	2.08	1	0	anthraquinone
myrmicacin myrmicacin: found in secretions of South American leaf-cutting ant; inhibitor for mitotic progression after metaphase. 3-hydroxydecanoic acid : A medium-chain fatty acid that is decanoic acid substituted at position 3 by a hydroxy group.	2.08	1	0	3-hydroxy fatty acid; medium-chain fatty acid	antimitotic; Escherichia coli metabolite
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	3.23	1	0	selegiline; terminal acetylenic compound	geroprotector
selegiline hydrochloride, (r)-isomer [no description available]	2.08	1	0	hydrochloride; terminal acetylenic compound	antiparkinson drug; dopaminergic agent; EC 1.4.3.4 (monoamine oxidase) inhibitor
clemastine Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	3.23	1	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
thiamphenicol [no description available]	2.08	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
pancuronium bromide pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.	2.08	1	0	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	3.23	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
cromolyn sodium Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.. disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid.	1.99	1	0	organic sodium salt	anti-asthmatic drug; drug allergen
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	2.08	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
gold tetrachloride, acid gold tetrachloride, acid: used in root canal therapy; RN given refers to (SP-4-1)	2.11	1	0
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	3.61	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
fenclozic acid fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd	3.23	1	0
laxagetten 4,4'-diacetoxydiphenylpyridylemethane [no description available]	3.23	1	0
iodine [no description available]	2.1	1	0	halide anion; monoatomic iodine	human metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	7.16	10	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
razoxane Razoxane: An antimitotic agent with immunosuppressive properties.	2.01	1	0	N-alkylpiperazine
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	4.37	3	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
phosphotyrosine Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.. O(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.	2.01	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid; O(4)-phosphotyrosine	Escherichia coli metabolite; immunogen
alclofenac alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.	3.23	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	3.65	2	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	5.42	5	1	benzenes; phenyl acetates
acetylacetone acetylacetone : A beta-diketone that is pentane in which the hydrogens at positions 2 and 4 are replaced by oxo groups.	2.6	1	0	beta-diketone
triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections.	2	1	0	11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
oxyphenisatin [no description available]	3.23	1	0	indoles
fludrocortisone Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.	3.23	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	3.23	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.25	1	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
pyrene pyrene: structure in Merck Index, 9th ed, #7746. pyrene : An ortho- and peri-fused polycyclic arene consisting of four fused benzene rings, resulting in a flat aromatic system.	2.13	1	0	ortho- and peri-fused polycyclic arene	fluorescent probe; persistent organic pollutant
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.08	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
transferrin Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.	4.13	14	0
alkenes [no description available]	2.1	1	0
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	3.32	6	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	3.23	1	0	chlorphenamine
glucaric acid Glucaric Acid: A sugar acid derived from D-glucose in which both the aldehydic carbon atom and the carbon atom bearing the primary hydroxyl group are oxidized to carboxylic acid groups.. D-glucaric acid : The D-enantiomer of glucaric acid.. glucaric acid : A hexaric acid derived by oxidation of sugar such as glucose with nitric acid.	3.44	1	1	glucaric acid	antineoplastic agent
alovudine [no description available]	5.27	6	2	pyrimidine 2',3'-dideoxyribonucleoside
adenylyl imidodiphosphate Adenylyl Imidodiphosphate: 5'-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation.	2.13	1	0	adenosine 5'-phosphate
clometacin clometacin: structure	3.23	1	0	N-acylindole
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	3.23	1	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.71	3	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	3.61	2	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	3.61	2	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.08	1	0	tryptamines
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	3.61	2	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	3.61	2	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	3.23	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
vidarabine phosphate Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.	3.12	1	0
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	3.23	1	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	4.09	4	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
feprazone Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)	2.08	1	0	organic molecular entity
pirprofen pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure	3.23	1	0	pyrroline
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.08	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	30.15	2,649	738	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	17.58	134	21	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
substance p [no description available]	2.11	1	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	3.23	1	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
penbutolol Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.	3.23	1	0	ethanolamines
ribavirin Rebetron: Rebetron is tradename	3.89	3	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
lentinan [no description available]	2.08	1	0
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	3.61	2	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
phorbol 12,13-dibutyrate Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems.	1.98	1	0	butyrate ester; phorbol ester; tertiary alpha-hydroxy ketone
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	3.23	1	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
ticrynafen Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.	3.23	1	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
n-(2-hydroxypropyl)methacrylamide Duxon: RN given refers to unlabeled cpd	3.61	8	0
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	3.23	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	4.07	4	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
lonidamine lonidamine: structure. lonidamine : A member of the class of indazoles that is 1H-indazole that is substituted at positions 1 and 3 by 2,4-dichlorobenzyl and carboxy groups, respectively.	2.08	1	0	dichlorobenzene; indazoles; monocarboxylic acid	antineoplastic agent; antispermatogenic agent; EC 2.7.1.1 (hexokinase) inhibitor; geroprotector
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
vecuronium vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.	3.23	1	0	acetate ester; androstane; quaternary ammonium ion	drug allergen; muscle relaxant; neuromuscular agent; nicotinic antagonist
benoxaprofen benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.	3.23	1	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
exifone [no description available]	3.23	1	0	benzophenones
decamethrin decamethrin: pyrethroid insecticide; RN given refers to cpd without isomeric designation; structure	2.15	1	0	aromatic ether; cyclopropanecarboxylate ester; nitrile; organobromine compound	agrochemical; antifeedant; calcium channel agonist; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; pyrethroid ester insecticide
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.17	1	0	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
mefloquine (-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	3.23	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
vindesine Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).	11.47	16	8	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.95	3	0	benzamides; carboxylic ester
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	3.23	1	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
acarbose [no description available]	3.61	2	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	3.23	1	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	23.11	532	233	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
lorcainide [no description available]	2.08	1	0	acetamides
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	5.68	5	1	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
eniluracil eniluracil: structure in first source; inactivates dihydropyrimidine dehydrogenase	5.81	2	1	pyrimidone
propiconazole Orbit: Bony cavity that holds the eyeball and its associated tissues and appendages.	2.44	2	0	conazole fungicide; cyclic ketal; dichlorobenzene; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic
2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone: structure given in first source	2.17	1	0
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	3.64	2	0	penicillin allergen; penicillin	antibacterial drug
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	3.57	2	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	3.61	2	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	3.23	1	0	cephalosporin	antibacterial drug
staurosporine [no description available]	4.7	7	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
foscarnet sodium trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.08	1	0	one-carbon compound; organic sodium salt	antiviral drug
atracurium Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.	3.23	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
atracurium besylate atracurium besylate : The bisbenzenesulfonate salt of atracurium.	2.08	1	0	organosulfonate salt; quaternary ammonium salt	muscle relaxant; nicotinic antagonist
nicorandil Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.	2.08	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
pergolide Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	3.23	1	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	2.08	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.	1.98	1	0	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.61	2	0	cephalosporin	antibacterial drug
talniflumate talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma	2.08	1	0	benzofurans
fenoldopam mesylate [no description available]	2.08	1	0	benzazepine
iso-sulfan blue iso-sulfan blue: 2,5-disulfobenzylidene-isomer of sulfan blue; RN given refers to Na salt; structure in first source	6.72	3	3
buserelin Buserelin: A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.	2.11	1	0	oligopeptide
fialuridine [no description available]	3.23	1	0
amonafide xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor	3.09	1	0	isoquinolines
pimonidazole pimonidazole: structure given in first source	2.11	1	0
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.61	2	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	2.49	2	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	3.23	1	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	3.23	1	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate [no description available]	3.23	1	0	organic molecular entity
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	3.85	3	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	4.84	5	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.08	1	0	aminopyridine
tolrestat tolrestat: RN & structure given in first source	3.23	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.08	1	0	aromatic ketone
stepronin [no description available]	2.08	1	0	N-acyl-amino acid
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	5.44	10	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.08	1	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.08	1	0	dimethoxybenzene
balsalazide balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.	3.23	1	0
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	3.23	1	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	3.61	2	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
atomoxetine hydrochloride Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.	2.08	1	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	3.23	1	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	3.61	2	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
alpidem [no description available]	3.23	1	0	imidazoles
raloxifene hydrochloride Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.	2.88	3	0	hydrochloride	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
gepirone gepirone: RN given refers to parent cpd; structure given in first source	3.27	1	0	N-arylpiperazine
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	5.05	4	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
itraconazole Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.	4.42	4	1	aromatic ether; conazole antifungal drug; cyclic ketal; dichlorobenzene; dioxolane; N-arylpiperazine; triazole antifungal drug; triazoles	EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; Hedgehog signaling pathway inhibitor; P450 inhibitor
nitrogenase stabilizing-protective protein, bacteria [no description available]	2.21	1	0	N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide	androgen antagonist; antineoplastic agent
fosphenytoin fosphenytoin: structure given in first & second source	3.23	1	0	imidazolidine-2,4-dione
pravadoline [no description available]	2.08	1	0
salmeterol xinafoate Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	2.08	1	0	naphthoic acid
ranolazine Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.	3.23	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	5.23	3	1	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.83	3	0	imidazoquinoline	antineoplastic agent; interferon inducer
fadrozole Fadrozole: A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.	2	1	0	imidazopyridine
esmolol methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.	3.23	1	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
sertindole sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.	2.08	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.23	1	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
aromasil [no description available]	4.91	6	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
sparfloxacin [no description available]	2.08	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	3.89	3	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
niguldipine [no description available]	2.08	1	0	diarylmethane
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	3.87	3	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	3.92	3	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	3.23	1	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	14.63	70	12	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
eliprodil 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.	2.08	1	0	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	3.61	2	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine hydrochloride [no description available]	2.08	1	0	hydrochloride; organofluorine compound	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral drug; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; immunosuppressive agent; radiosensitizing agent
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	25.83	838	314	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide ibutilide: RN & structure in first source; RN refers to the fumarate salt	3.23	1	0	benzenes; organic amino compound
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	3.61	2	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	3.23	1	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
atorvastatin calcium anhydrous [no description available]	2.08	1	0	organic calcium salt
atorvastatin [no description available]	3.59	2	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	3.61	2	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
duloxetine hydrochloride Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.	2.83	3	0	duloxetine hydrochloride	antidepressant
duloxetine [no description available]	3.23	1	0	duloxetine
irinotecan [no description available]	21.58	275	86	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	3.61	2	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	5.15	5	0
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	3.23	1	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	3.61	2	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
3-iodobenzylguanidine 3-Iodobenzylguanidine: A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.	2.11	1	0	organoiodine compound
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.08	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	3.61	2	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tasosartan tasosartan: angiotensin II antagonist; structure given in first source	3.23	1	0	biphenyls
tiludronic acid tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source	3.23	1	0	organochlorine compound
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	3.23	1	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	22.59	341	175	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	4.18	4	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
vanadates Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.. vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.	2.07	1	0	trivalent inorganic anion; vanadium oxoanion	EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
acridine orange Acridine Orange: A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.. acridine orange : Fluorescent dye useful for cell cycle determination. It is cell-permeable, and interacts with DNA and RNA by intercalation or electrostatic attractions respectively.. acridine orange free base : A member of the class of aminoacridines that is acridine carrying two dimethylamino substituents at positions 3 and 6. The hydrochloride salt is the fluorescent dye 'acridine orange', used for cell cycle determination.	2.1	1	0	aminoacridines; aromatic amine; tertiary amino compound	fluorochrome; histological dye
paroxetine hydrochloride paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.	2.08	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
bupropion hydrochloride [no description available]	2.08	1	0	aromatic ketone
halofuginone [no description available]	2.03	1	0	quinazolines
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.08	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	3.23	1	0
verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride.	2.08	1	0
cefprozil [no description available]	3.23	1	0	cephalosporin; semisynthetic derivative	antibacterial drug
doxazosin mesylate Cardura: Trade name in United States.	2.08	1	0	methanesulfonate salt	geroprotector
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	4.11	4	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	4.95	6	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	4.96	6	0	D-glucopyranose	epitope; mouse metabolite
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.08	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
bupivacaine hydrochloride bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride; racemate	adrenergic antagonist; amphiphile; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; local anaesthetic
fenofibric acid fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.	3.23	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	4.11	15	0	organic bromide salt	colorimetric reagent; dye
betulinic acid [no description available]	4.34	5	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
calanolide a calanolide A: NSC 661122 and costatolide are isomers; a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum (Clusiaceae); structure in first source. (+)-calanolide A : An organic heterotetracyclic compound that is 11,12-dihydro-2H,6H,10H-dipyrano[2,3-f:2',3'-h]chromen-2-one substituted by a hydroxy group at position 12, methyl groups at positions 6, 6, 10 and 11 and a propyl group at position 4 (the 10R,11S,12S stereoisomer). Isolated from Calophyllum lanigerum var austrocoriaceum and Calophyllum brasiliense, it exhibits potent activity against HIV-1 reverse transcriptase.	3.27	1	0	cyclic ether; delta-lactone; organic heterotetracyclic compound; secondary alcohol	HIV-1 reverse transcriptase inhibitor; plant metabolite
arctigenin arctigenin: precursor to catechols; in many plants	2.15	1	0	lignan
baicalin [no description available]	5.03	2	1	dihydroxyflavone; glucosiduronic acid; glycosyloxyflavone; monosaccharide derivative	antiatherosclerotic agent; antibacterial agent; anticoronaviral agent; antineoplastic agent; antioxidant; cardioprotective agent; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; ferroptosis inhibitor; neuroprotective agent; non-steroidal anti-inflammatory drug; plant metabolite; prodrug
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	4.71	8	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	3.61	2	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	4.09	2	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.04	4	0	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
fluorexon fluorexon: structure	2.96	4	0	xanthene dye	fluorochrome
cholesteryl succinate cholesteryl succinate: RN given refers to (3beta)-isomer. cholesteryl hemisuccinate : A dicarboxylic acid monoester resulting from the formal condensation of the hydroxy group of cholesterol with one of the carboxy groups of succinic acid. A detergent that is often used to replace cholesterol in protein crystallography, biochemical studies of proteins, and pharmacology.	2.78	3	0	cholestane ester; dicarboxylic acid monoester; hemisuccinate	detergent
aica ribonucleotide AICA ribonucleotide: purine precursor that has antineoplastic activity. AICA ribonucleotide : A 1-(phosphoribosyl)imidazolecarboxamide that is acadesine in which the hydroxy group at the 5' position has been converted to its monophosphate derivative.	2.21	1	0	1-(phosphoribosyl)imidazolecarboxamide; aminoimidazole	cardiovascular drug; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
aconitic anhydride aconitic anhydride: RN refers to (cis)-isomer; structure given in first source	2.15	1	0
lissamine rhodamine b lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt	3.13	5	0
ticlopidine hydrochloride [no description available]	2.08	1	0	hydrochloride
epirubicin hydrochloride [no description available]	2.08	1	0
glutathione disulfide Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.	4.37	1	1	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
baccatin iii [no description available]	2.95	4	0	acetate ester; benzoate ester; tetracyclic diterpenoid	plant metabolite
hypusine hypusine: N-terminal amino alcohol deriv of Lys occurring in bovine brain & in the urine of children with familial hyperlysinemia; minor descriptor (75-82); online & Index Medicus search LYSINE/AA (75-82). hypusine : An L-lysine derivative that is L-lysine bearing a (2R)-4-amino-2-hydroxybutyl substituent at position N(6).	3.13	1	0
histamine phosphate histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.	3.23	1	0	phosphate salt	histamine agonist
tetraiodothyroacetic acid tetraiodothyroacetic acid: RN given refers to parent cpd; structure. 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'.	2.13	1	0	2-halophenol; aromatic ether; iodophenol; monocarboxylic acid	apoptosis inducer; human metabolite; thyroid hormone
tilbroquinol [no description available]	3.23	1	0	organohalogen compound; quinolines
2,2'-dithiodiethanesulfonic acid [no description available]	4.34	1	1
bendamustine [no description available]	3.61	2	0	benzimidazoles
imirestat imirestat: structure given in first source	2.03	1	0
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	3.23	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
trofosfamide trofosfamide: cyclophosphamide analog; structure	3.43	1	1	ifosfamides
caroverine caroverine: structure	2.08	1	0	quinoxaline derivative
ebrotidine ebrotidine: an H2-receptor antagonist and gastric mucosa protector	3.23	1	0	sulfonamide
cgs 9343b [no description available]	2.08	1	0	benzimidazoles
emitefur Emitefur: structure given in first source	4	2	0
pazufloxacin [no description available]	2.08	1	0	quinolines
repaglinide [no description available]	3.61	2	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	5.41	6	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
2-methoxyestradiol 2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2.	7.07	13	1	17beta-hydroxy steroid; 3-hydroxy steroid	angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite
naphthalimides Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.	3.51	2	0
porphine porphine: structure given in first source	2.11	1	0
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	10.16	28	3	1,2,3-triazole
apaflurane [no description available]	2.03	1	0
isoimperatorin isoimperatorin: tumor necrosis factor antagonist isolated from Glehniae root. isoimperatorin : A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 5. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor.	2.15	1	0	psoralens	EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite
isocoumarins Isocoumarins: Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule.. isocoumarin : The simplest member of the class of isocoumarins that is 1H-isochromene which is substituted by an oxo group at position 1.	2.02	1	0	isocoumarins
isobutyramide [no description available]	2	1	0	carboximidic acid
miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.08	1	0
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	13.15	45	14	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	4.47	3	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	16.62	84	27	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.08	1	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source	2.08	1	0	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
1-triacontanol 1-triacontanol: constituent of Apocynum venetum leaf & Cirsium segetum. triacontan-1-ol : An ultra-long-chain primary fatty alcohol that is triacontane in which one of the terminal methyl hydrogens is replaced by a hydroxy group.	2.1	1	0	fatty alcohol 30:0; ultra-long-chain primary fatty alcohol
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	3.23	1	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
isaxonine isaxonine: promotes nerve growth	3.23	1	0	aminopyrimidine
nebivolol 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.	3.23	1	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798 [no description available]	3.61	2	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
dapoxetine [no description available]	4.61	1	1	naphthalenes
hp 873 iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.	3.61	2	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	3.23	1	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
loxapine succinate [no description available]	2.08	1	0	succinate salt	geroprotector
tocophersolan tocophersolan: RN given refers to parent cpd	6.5	52	0	tocol
fenoxypropazine [no description available]	3.23	1	0	aromatic ether
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	6.03	4	1	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	2.08	1	0	organonitrogen compound; organooxygen compound
uroxatral [no description available]	2.08	1	0	hydrochloride
aceclofenac [no description available]	3.61	2	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
nitrefazole [no description available]	3.23	1	0	imidazoles
alacepril [no description available]	2.08	1	0	dipeptide; thioacetate ester	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
thiocolchicoside [no description available]	2.08	1	0	glycoside
ubenimex ubenimex: growth inhibitor	3.86	2	1
7-hydroxystaurosporine [no description available]	3.09	1	0
hesperetin [no description available]	2.17	1	0	3'-hydroxyflavanones; 4'-methoxyflavanones; monomethoxyflavanone; trihydroxyflavanone	antineoplastic agent; antioxidant; plant metabolite
honokiol [no description available]	2.03	1	0	biphenyls
betulin betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.	2.15	1	0	diol; pentacyclic triterpenoid	analgesic; anti-inflammatory agent; antineoplastic agent; antiviral agent; metabolite
nobiletin nobiletin : A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.	2.11	1	0	methoxyflavone	antineoplastic agent; plant metabolite
9-aminocamptothecin [no description available]	3.08	1	0	pyranoindolizinoquinoline
suksdorfin suksdorfin: from the fruit of Lomatium sukdorfi; structure given in first source	3.27	1	0
picropodophyllin picropodophyllin: isolated from American May apple (Podophyllum); inhibits IGF-I autophosphorylation without interfering with tyrosine kinase activity. picropodophyllotoxin : An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents.	3.53	1	1	furonaphthodioxole; lignan; organic heterotetracyclic compound	antineoplastic agent; insulin-like growth factor receptor 1 antagonist; plant metabolite; tyrosine kinase inhibitor
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	3.61	2	0	carbapenems
fr 109615 cispentacin: structure given in first source; isolated from Bacillus cereus	3	1	0
magnoflorine magnoflorine: opium alkaloid having the aporphine configuration; RN given refers to parent cpd(S)-isomer; structure. (S)-magnoflorine : An aporphine alkaloid that is (S)-corytuberine in which the nitrogen has been quaternised by an additional methyl group.	2.6	1	0	aporphine alkaloid; quaternary ammonium ion	plant metabolite
calpeptin [no description available]	2.11	1	0	amino acid amide
corilagin corilagin: isolated from Geranii herba. corilagin : An ellagitannin with a hexahydroxydiphenoyl group bridging over the 3-O and 6-O of the glucose core.	2.41	1	0	ellagitannin; gallate ester	antihypertensive agent; antioxidant; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; non-steroidal anti-inflammatory drug
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	3.23	1	0	hydroxy-1,2-naphthoquinone
5-aminofluorescein 5-aminofluorescein: used to determine progesterone in human serum or plasma. 5-aminofluorescein : A primary amino compound that is fluorescein carrying an amino substituent at C-5. Building block/intermediate for the synthesis of the fluorescent dye flourescein; also used to produce N-(fluorescein-5-yl)maleamic acid.	2.11	1	0	primary amino compound
rivastigmine [no description available]	3.23	1	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan [no description available]	3.23	1	0	carbazoles
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	3.23	1	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	3.61	2	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
tamiflu [no description available]	2.08	1	0	phosphate salt
bexarotene [no description available]	6.91	6	2	benzoic acids; naphthalenes; retinoid	antineoplastic agent
s20098 [no description available]	2.08	1	0	acetamides
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
adriamycinol doxorubicinol : A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.	2.03	1	0	aminoglycoside; anthracycline antibiotic; aromatic ether; deoxy hexoside; p-quinones; phenols; polyol; tetracenequinones	cardiotoxic agent; drug metabolite
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.08	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	3.89	3	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
cholest-5-ene-3,4-diol cholest-5-ene-3,4-diol: RN given refers to (3beta,4beta)-isomer	3.5	1	1
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	5.79	3	1	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fibrinogen Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.	4.33	4	1	iditol	fungal metabolite
moexipril [no description available]	3.23	1	0	peptide
equol Equol: A non-steroidal ESTROGEN generated when soybean products are metabolized by certain bacteria in the intestines.	2.21	1	0	hydroxyisoflavans
homocysteine Homocysteine: A thiol-containing amino acid formed by a demethylation of METHIONINE.. homocysteine : A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain.. L-homocysteine : A homocysteine that has L configuration.	3.42	1	1	amino acid zwitterion; homocysteine; serine family amino acid	fundamental metabolite; mouse metabolite
gliquidone gliquidone: structure; RN given refers to parent cpd	2.08	1	0	isoquinolines
lupenone lupenone: structure in first source	2.15	1	0	triterpenoid	metabolite
mci 9038 [no description available]	4.16	2	0	peptide
lopinavir [no description available]	5.31	3	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
uzarigenin [no description available]	2.21	1	0
firefly luciferin Firefly Luciferin: A benzothaizole which is oxidized by LUCIFERASES, FIREFLY to cause emission of light (LUMINESCENCE).. Photinus luciferin : A 1,3-thiazolemonocarboxylic acid consisting of 3,5-dihydrothiophene-4-carboxylic acid having a 6-hydroxybenzothiazol-2-yl group at the 2-position.	2.05	1	0	1,3-thiazolemonocarboxylic acid; benzothiazoles; imidothioate	luciferin
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	4.39	4	1	D-glucuronic acid	algal metabolite
10-hydroxycamptothecin [no description available]	2.48	2	0	pyranoindolizinoquinoline
4-hydroxycyclophosphamide 4-hydroxycyclophosphamide: primary activation metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation. 4-hydroxycyclophosphamide : A phosphorodiamide that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide having two 2-chloroethyl groups attached to the exocyclic nitrogen.	2.02	1	0	nitrogen mustard; organochlorine compound; phosphorodiamide	alkylating agent; metabolite
nimbolide nimbolide: isolated from Nigerian medicinal plant Azadirachta indica; RN given refers to 4alpha,5alpha,6alpha,7alpha,15beta,17alpha-isomer; structure given in first source	2.41	1	0
coumarin 6 coumarin 6: structure in first source	4.24	16	0	7-aminocoumarins	fluorochrome
isophosphamide mustard isophosphamide mustard: antitumor metabolite of ifosfamide; palifosfamide-tris is a salt with tris; structure in first source	2.07	1	0	phosphorodiamide
arctiin arctiin: from fruits of Arctium lappa L; RN given refers to (3R-trans)-isomer; RN for cpd without isomeric designation not avail 12/92	2.15	1	0	glycoside; lignan
obovatol obovatol: antineoplastic agent from Magnolis obovata; structure given in first source	2.05	1	0
moxifloxacin hydrochloride moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.	2.08	1	0	hydrochloride	antibacterial drug
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.31	1	0	methyladenosine
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	2.9	3	0	cobalt group element atom; metal allergen	micronutrient
p-methoxy-n-methylphenethylamine p-Methoxy-N-methylphenethylamine: A potent mast cell degranulator. It is involved in histamine release.. N,O-dimethyltyramine : A secondary amino compound that is tyramine in which the hydrogen of the phenolic hydroxy group has been replaced by a methyl group.	2.02	1	0	aromatic ether; secondary amino compound	metabolite
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	4.79	5	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mafosfamide mafosfamide: RN given refers to cis-(+-)-isomer	2.02	1	0
uftoral UFT(R) drug: a drug containing tegafur and uracil; a biochemical modulator of 5-fluorouracil; used for postoperative chemotherapy of colon cancer; reported to cause severe liver injury; do not confuse with 1-UFT protocol	4.32	4	1
yttrium radioisotopes Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.	2.05	1	0
mizoribine [no description available]	2.08	1	0	imidazoles	anticoronaviral agent
arginyl-glycyl-aspartic acid arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system	4.02	12	0	oligopeptide
vitamin b 6 Vitamin B 6: VITAMIN B 6 refers to several PICOLINES (especially PYRIDOXINE; PYRIDOXAL; & PYRIDOXAMINE) that are efficiently converted by the body to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, and aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into PYRIDOXAMINE phosphate. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). Most of vitamin B6 is eventually degraded to PYRIDOXIC ACID and excreted in the urine.	2.05	1	0
cremophor el cremophor EL: solvent for Althesin & Propanidid implicated as possible cause of similar adverse effects polyethoxylated castor oil; RN given refers to cpd with unknown MF; see also records for cremophor & cremophor A	4.63	8	0
sr141716 [no description available]	2.08	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	3.61	2	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
1,n(6)-ethenoadenine 1,N(6)-ethenoadenine: biologically active fluorescent derivatives of this cpd potentially valuable in studies concerning interactions between adenine cpds & various enzymes for which they serve as substrates or co-factors; structure	4.61	1	1	imidazo[2,1-i]purine	mutagen
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	2.77	3	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
vinpocetine [no description available]	2.08	1	0
pyridinoline pyridinoline: 3-hydroxypyridinium derivative collagen crosslink; structure	4.4	1	1	organonitrogen compound; organooxygen compound
thiamethoxam Thiamethoxam: A nitro-oxazine and thiazole derivative that is used as a broad spectrum neonicotinoid insecticide.. thiamethoxam : An oxadiazane that is tetrahydro-N-nitro-4H-1,3,5-oxadiazin-4-imine bearing (2-chloro-1,3-thiazol-5-yl)methyl and methyl substituents at positions 3 and 5 respectively.	4.61	1	1	1,3-thiazoles; 2-nitroguanidine derivative; organochlorine compound; oxadiazane	antifeedant; carcinogenic agent; environmental contaminant; neonicotinoid insectide; xenobiotic
s-ethyl glutathione [no description available]	2.08	1	0	oligopeptide
racecadotril racecadotril: parenterally active enkephalinase inhibitor	2.08	1	0	N-acyl-amino acid
dimyristoylphosphatidylglycerol [no description available]	2.17	1	0
saikosaponin d [no description available]	2.6	1	0
perindopril Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline	3.23	1	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
procyanidin Proanthocyanidins: Dimers and oligomers of flavan-3-ol units (CATECHIN analogs) linked mainly through C4 to C8 bonds to leucoanthocyanidins. They are structurally similar to ANTHOCYANINS but are the result of a different fork in biosynthetic pathways.	4.92	2	1	proanthocyanidin
1-hydroxymethylmidazolam 1-hydroxymethylmidazolam: metabolite of midazolam. 1-hydroxymidazolam : An imidazobenzodiazepine that is midazolam in which one of the hydrogens of the methyl group is substituted by a hydroxy group. It is the major metabolite of the anesthetic, midazolam.	2.1	1	0	aromatic primary alcohol; imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	drug metabolite; human blood serum metabolite; human urinary metabolite
deguelin deguelin: a natural product from Mundulea sericea; RN refers to (7aS-cis)-isomer; structure given in first source. deguelin : A rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.	2.53	2	0	aromatic ether; diether; organic heteropentacyclic compound; rotenones	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; antiviral agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; mitochondrial NADH:ubiquinone reductase inhibitor; plant metabolite
1,9-dideoxyforskolin [no description available]	1.98	1	0	acetate ester; labdane diterpenoid; organic heterotricyclic compound	plant metabolite
fingolimod hydrochloride Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).	2.15	1	0	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
triptolide [no description available]	2.57	2	0	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
parthenolide [no description available]	2.73	3	0	germacranolide
tesmilifene [no description available]	2.05	1	0	diarylmethane
ecteinascidin 743 [no description available]	9.19	10	3	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
kt 6149 KW 2149: derivative of mitomycin C; structure in first source	3.09	1	0
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	4.79	2	1
tadalafil [no description available]	3.61	2	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
selenomethylselenocysteine selenomethylselenocysteine: RN given refers to parent cpd	2.03	1	0	non-proteinogenic alpha-amino acid; selenocysteines	antineoplastic agent; human metabolite
paliperidone 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.	3.23	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol
nitisinone [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; cyclohexanones; mesotrione	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix [no description available]	2.08	1	0	azaheterocycle sulfate salt; organoammonium sulfate salt	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
marimastat marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary. marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.	4.03	2	0	hydroxamic acid; secondary carboxamide	antineoplastic agent; matrix metalloproteinase inhibitor
cynaropicrin cynaropicrin: structure given in first source; RN given for ((3aR-(3aalpha,4alpha,6aalpha,8beta,9aalpha,9bbeta)))-isomer	2.08	1	0	sesquiterpene lactone
clofarabine [no description available]	3.61	2	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
sr 48692 SR 48692: structure in first source; a neurotensin receptor-1 antagonist	2.08	1	0	N-acyl-amino acid
cucurbitacins [no description available]	3.21	1	0	11-oxo steroid
ginsenoside rh2 ginsenoside Rh2: from leaves of Panax ginseng C; structure given in first source. (20S)-ginsenoside Rh2 : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.46	2	0	12beta-hydroxy steroid; 20-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; bone density conservation agent; cardioprotective agent; hepatoprotective agent; plant metabolite
iodofiltic acid iodofiltic acid: labeled with 123 I for myocardial imaging; RN given refers to unlabeled, non-isomeric cpd	3.4	1	1
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	4.08	5	0
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	3.61	2	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib [no description available]	3.61	2	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
xymedon xymedon: nitrogen-containing heterocyclic compound; Russian patent; antiatherogenic; used for treatment of burns; used on varicose ulcer	2.15	1	0
rhenium-186 hedp rhenium-186 HEDP: used as a complement to analgesic therapy in patients with painful disseminated bone metastases	5.34	4	3
4-aminophenyl alpha-d-mannopyranoside p-aminophenyl alpha-D-mannoside : An alpha-D-mannoside having 4-aminophenyl as the anomeric substituent.	2.11	1	0	alpha-D-mannoside; substituted aniline
celastrol [no description available]	2.76	2	0	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
procyanidin b2 procyanidin B2 : A proanthocyanidin consisting of two molecules of (-)-epicatechin joined by a bond between positions 4 and 8' in a beta-configuration. Procyanidin B2 can be found in Cinchona pubescens (Chinchona, in the rind, bark and cortex), in Cinnamomum verum (Ceylon cinnamon, in the rind, bark and cortex), in Crataegus monogyna (Common hawthorn, in the flower and blossom), in Uncaria guianensis (Cat's claw, in the root), in Vitis vinifera (Common grape vine, in the leaf), in Litchi chinensis (litchi, in the pericarp), in the apple, in Ecdysanthera utilis and in red wine.	2.31	1	0	biflavonoid; hydroxyflavan; polyphenol; proanthocyanidin	antioxidant; metabolite
betulonic acid betulonic acid: isolated from Rush javanica; strucure in first source	2.15	1	0	triterpenoid	anticoronaviral agent
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	4.61	1	1	nitrogen oxoacid
fullerene c60 Fullerenes: A polyhedral CARBON structure composed of around 60-80 carbon atoms in pentagon and hexagon configuration. They are named after Buckminster Fuller because of structural resemblance to geodesic domes. Fullerenes can be made in high temperature such as arc discharge in an inert atmosphere.. fullerene : A compound composed solely of an even number of carbon atoms, which form a cage-like fused-ring polycyclic system with twelve five-membered rings and the rest six-membered rings. The term has been broadened to include any closed cage structure consisting entirely of three-coordinate carbon atoms.	3.22	5	0	fullerene	geroprotector
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	13.08	35	10	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	3.23	1	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663 [no description available]	4.87	2	1	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	2.15	1	0	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
gefitinib [no description available]	18.97	133	43	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
bay x 1005 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;	2.08	1	0
vadimezan vadimezan : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.	6.71	3	2	monocarboxylic acid; xanthones	antineoplastic agent
27-hydroxycholesterol (25R)-cholest-5-ene-3beta,26-diol : A 26-hydroxycholesterol in which the 25-position has R-configuration.	2.13	1	0	26-hydroxycholesterol	apoptosis inducer; human metabolite; mouse metabolite; neuroprotective agent
swertisin swertisin: from Wilbrandia ebracteata; structure in first source. swertisin : A flavone C-glycoside that is 7-O-methylapigenin in which the hydrogen at position 6 has been replaced by a beta-D-glucosyl residue.	2.15	1	0	dihydroxyflavone; flavone C-glycoside; monomethoxyflavone; monosaccharide derivative; polyphenol	adenosine A1 receptor antagonist; anti-inflammatory agent; antioxidant; hypoglycemic agent; plant metabolite
desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.	3.61	2	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
garenoxacin garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.	2.07	1	0	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
solutol hs 15 Solutol HS 15: multidrug resistance modification agent in tumor cells; polyoxyethylene esters of 12-hydroxystearic acid; previous RN 105109-85-1	2.53	2	0	aliphatic alcohol
desvenlafaxine O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.	3.23	1	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
gyki 53655 GYKI 53655: an AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) receptor antagonist	2.08	1	0
methotrexate [no description available]	17.19	100	37	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
sdz 880-431 SDZ 880-431: structure given in first source; inhibits the action of lipopolysaccharides on neutrophils	1.98	1	0
4'-deoxydoxorubicinol 4'-deoxydoxorubicinol: structure given in first source	2.03	1	0
tamsulosin [no description available]	3.23	1	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
rufinamide rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source	3.23	1	0	aromatic amide; heteroarene
sulbactam [no description available]	2.08	1	0	penicillanic acids
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	3.61	2	0	biphenyls
ym 529 YM 529: inhibits osteoclastic bone resorption; structure given in first source	2.02	1	0
dexpanthenol dexpanthenol: The alcohol of pantothenic acid	3.23	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
fosamprenavir fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.	3.23	1	0	sulfonamide	prodrug
osw 1 OSW 1: RN given for the (3beta,16beta)-isomer	2.41	1	0
abiraterone [no description available]	19.34	193	25	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
alpha-conotoxin imi [no description available]	2.17	1	0
ml-3000 [no description available]	2.08	1	0
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	3.61	2	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
calcium borate calcium borate: RN given refers to cpd with MF CaB4O7	4.61	1	1
cd 437 CD 437: selective for retinoic acid receptors gamma. CD437 : A naphthoic acid that is 6-phenylnaphthylene-2-carboxyic acid in which the phenyl substituent has been substituted at positions 3 and 4 by adamant-1-yl and hydroxy groups, respectively. It acts as a selective agonist of retinoic acid receptor (RAR)gamma and induces cell cycle arrest and apoptosis in various cancer cells.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid; phenols	apoptosis inducer; retinoic acid receptor gamma agonist
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	2.03	1	0	beta-lactam antibiotic allergen; beta-lactam
escitalopram Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.	3.23	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.	2.08	1	0
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	4.96	2	1	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel [no description available]	2.03	1	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
perifosine [no description available]	3.87	2	1	ammonium betaine; phospholipid	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
irofulven irofulven: structure in first source	2.43	2	0	cyclohexenones
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	3.23	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
lonafarnib lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.	4.11	3	1	4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
tariquidar [no description available]	5.82	2	2	benzamides
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	5.27	3	1	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	3.61	2	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	3.23	1	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
gamma-glutamylglutamine gamma-glutamylglutamine: RN given refers to all (L)-isomer. gamma-Glu-Gln : A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of glutamine	2.07	1	0	dipeptide	human metabolite
dx 8951 [no description available]	3.09	1	0	pyranoindolizinoquinoline
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	3.87	3	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
conivaptan conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).	3.23	1	0	benzazepine	aquaretic; vasopressin receptor antagonist
mk 767 5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide: an antihyperlipidemic agent that also functions as an insulin sensitizer, PPARalpha agonist, and PPARgamma agonist; structure in first source	2.08	1	0
3-hydroxyhexanoic acid 3-hydroxyhexanoic acid: abnormal metabolite in urine & serum of diabetic ketoacidotic patients	2.17	1	0	3-hydroxy monocarboxylic acid
sabarubicin sabarubicin: structure given in first source	2.15	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	3.23	1	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
pralnacasan pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source	3.23	1	0
cyc 682 sapacitabine: structure in first source. sapacitabine : A nucleoside analogue resulting from the formal condensation of the carboxy group of hexadecanoic acid with the amino group of CNDAC. It is the prodrug of CNDAC and is currently in clinical development for the treatment of acute myeloid leukemia (AML).	2.03	1	0	nitrile; nucleoside analogue; secondary carboxamide	antimetabolite; antineoplastic agent; DNA synthesis inhibitor; prodrug
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	3.23	1	0	dihydropyridine
solifenacin [no description available]	3.23	1	0	isoquinolines
dexmethylphenidate dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.	3.23	1	0	methyl phenyl(piperidin-2-yl)acetate	adrenergic agent
bazedoxifene acetate [no description available]	2.08	1	0
10-deacetylbaccatine iii 10-deacetylbaccatine III: structure given in first source	3.13	5	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid
schizandrin a schizandrin A: the major lignan, 2-9%, of Schisandra plant; has hepatoprotective, antioxidant, and antineoplastic activities	2.15	1	0
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.08	1	0	morpholines
10-deacetyltaxol 10-deacetyltaxol: alkaloid from Taxus wallichiana, structure given in first source	2.45	2	0
atractylenolide iii atractylenolide III: from Atractylodes macrocephala Koidz; structure in first source	2.21	1	0	naphthofuran	metabolite
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	3.94	3	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
canertinib dihydrochloride [no description available]	2.39	2	0
canertinib [no description available]	3.84	2	1	monochlorobenzenes; morpholines; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
cinacalcet cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.	3.23	1	0	(trifluoromethyl)benzenes; naphthalenes; secondary amino compound	calcimimetic; P450 inhibitor
birb 796 [no description available]	2.08	1	0	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
gemcabene [no description available]	2.08	1	0
lubiprostone [no description available]	3.23	1	0
telbivudine [no description available]	3.61	2	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
jte 522 tiracoxib: The combined administration of tiracoxib with probucol significantly inhibited the tumor growth. The angiogenesis was markedly reduced; no further information available 1/31/2001. tilmacoxib : A member of the class of 1,3-oxazoles that is that is 1,3-oxazole which is substituted at positions 2, 4 and 5 by methyl, cyclohexyl, and 3-fluoro-4-sulfamoylphenyl groups, respectively.	2.01	1	0	1,3-oxazoles; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor
tipifarnib [no description available]	5.77	6	1	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
gadolinium oxide gadolinium oxide: RN given refers to cpd with MF of Gd2-O3	2.6	1	0
atrasentan Atrasentan: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.	10.47	13	4	pyrrolidines
singlet oxygen Singlet Oxygen: An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages.	2.08	1	0	chalcogen; monoatomic oxygen; nonmetal atom	macronutrient
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.47	2	0	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
carbodiimides Carbodiimides: Compounds with the general formula RN=C=NR, where R is a hydrocarbyl group.. methanediimine : A carbodiimide in which both nitrogens are unsubstituted.	2.15	1	0	carbodiimide
oxypeucadanin oxypeucadanin: furanocoumarin from W. Afr. medicinal plant Clausena anisata; RN given refers to cpd without isomeric designation. oxypeucedanin : A furanocoumarin that is 7H-furo[3,2-g][1]benzopyran-7-one substituted by a [(2S)-3,3-dimethyloxiran-2-yl]methoxy group at position 4.	2.57	2	0	psoralens
ceanothic acid ceanothic acid: isolated from Ceanothus americanus; structure in first source	2.13	1	0
methylselenic acid methylseleninic acid : An organoselenium compound that is seleninic acid in which the hydrogen attached to selenium is replaced by a methyl group.	2.96	4	0	one-carbon compound; organoselenium compound	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor; human xenobiotic metabolite
n,n-dimethyl-n-hexadecyl-1-octadecylammonium N,N-dimethyl-N-hexadecyl-1-octadecylammonium: cationic lipid; RN given refers to chloride	2.6	1	0
n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid: used for (111)Indium labeling of monoclonal antibodies; structure in J Chem Soc (Perkin 1) 1992:1173-8; RN given refers to ((1alpha(S*),2beta)-(+-))-isomer	2.05	1	0
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	3.73	2	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	3.23	1	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
anacardic acid anacardic acid: isolated from Anacardium occidentale; monophenol monooxygenase inhibitor. anacardic acid : A hydroxybenzoic acid that is salicylic acid substituted by a pentadecyl group at position 6. It is a major component of cashew nut shell liquid and exhibits an extensive range of bioactivities.	2.58	2	0	hydroxy monocarboxylic acid; hydroxybenzoic acid	anti-inflammatory agent; antibacterial agent; anticoronaviral agent; apoptosis inducer; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; neuroprotective agent; plant metabolite
aminopterin Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.	7.49	6	1	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen
17 alpha-hydroxyprogesterone caproate 17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.	3.23	1	0	corticosteroid hormone
varenicline Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.	3.23	1	0
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	3	4	0	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
fiduxosin fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source	3.23	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	5.25	3	1
anemodeanin a anemodeanin A: RN given refers to (3beta)-isomer; from Anemone raddeana Regel; structure given in first source	2.21	1	0
7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid [no description available]	5.32	2	2	prostanoid
sb 203580 [no description available]	2.08	1	0	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.11	1	0	indoles; maleimides
enzastaurin [no description available]	4.79	2	1	indoles; maleimides
erlotinib [no description available]	5.15	7	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
erlotinib hydrochloride [no description available]	19.67	146	62	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
cilengitide Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells	3.47	1	1	oligopeptide
piboserod Serotonin 5-HT4 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT4 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN RECEPTOR AGONISTS.	2.08	1	0
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	3.54	2	0	divalent inorganic anion; phosphite ion
l 163191 [no description available]	2.08	1	0
bd 1047 N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity	2.08	1	0	primary amine
etravirine [no description available]	3.23	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
troleandomycin Troleandomycin: A macrolide antibiotic that is similar to ERYTHROMYCIN.. troleandomycin : A semi-synthetic macrolide antibiotic obtained by acetylation of the three free hydroxy groups of oleandomycin. Troleandomycin is only found in individuals that have taken the drug.	2.02	1	0	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic
dronedarone Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.	3.89	3	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea [no description available]	3.13	1	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	3.61	2	0	indanes
lapatinib [no description available]	14.34	42	8	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	3.64	2	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
dofequidar dofequidar: structure given in first source	3.81	2	1
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	3.61	2	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.08	1	0
tbc-11251 sitaxsentan: endothelin A receptor antagonist; structure in first source	3.61	2	0	benzodioxoles
tolvaptan [no description available]	3.61	2	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sorafenib [no description available]	11.66	24	7	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	10.22	11	6	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	0	aminoquinoline
regadenoson [no description available]	3.23	1	0	purine nucleoside
sr 142806 [no description available]	2.08	1	0
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	3.61	2	0	N-acyl-amino acid
phenoxodiol phenoxodiol: a synthetic derivative of DAIDZEIN	2.02	1	0
demecolcine Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.. (-)-demecolcine : A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.	1.98	1	0	alkaloid; secondary amino compound	antineoplastic agent; microtubule-destabilising agent
cholic acid Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.	2.52	2	0	12alpha-hydroxy steroid; 3alpha-hydroxy steroid; 7alpha-hydroxy steroid; bile acid; C24-steroid; trihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
deoxycholic acid Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.	3.06	4	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human blood serum metabolite
cortisone [no description available]	2.03	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mouse metabolite
gossypol acetic acid [no description available]	8.27	10	7
exaltolide exaltolide: synthetic musk odor; structure	2.1	1	0	macrolide
epinastine dexamethasone acetate: RN given refers to (11beta,16alpha)-isomer	2.17	1	0	corticosteroid hormone
vincaleukoblastine [no description available]	4.15	4	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
n-acetylcolchinol N-acetylcolchinol: structure	2.02	1	0
vincristine sulfate [no description available]	2.08	1	0	organic sulfate salt	antineoplastic agent; geroprotector
nsc 74859 NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.	2.58	2	0	amidobenzoic acid; monohydroxybenzoic acid; tosylate ester	STAT3 inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.15	1	0
benzarone benzarone: antihemorrhagic agent; structure	3.23	1	0	1-benzofurans
nsc 83265 3-tritylthio-L-alanine: RN & NM given refers to (L)-isomer	2.05	1	0	benzenoid aromatic compound
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	19.91	164	73	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
metribolone Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.	3	1	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid	androgen
noscapine Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.. (-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.	2.82	3	0	aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound	antineoplastic agent; antitussive; apoptosis inducer; plant metabolite
homoharringtonine Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.	3.64	2	0	alkaloid ester; enol ether; organic heteropentacyclic compound; tertiary alcohol	anticoronaviral agent; antineoplastic agent; apoptosis inducer; protein synthesis inhibitor
elesclomol [no description available]	2.08	1	0	carbohydrazide; thiocarbonyl compound	antineoplastic agent; apoptosis inducer
u-104 SLC-0111: a carbonic anhydrase inhibitor; structure in first source	2.6	1	0
wortmannin [no description available]	2.98	4	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
menogaril Menogaril: A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors.	3.09	1	0
anthricin anthricin: antitumor constituent from Anthriscus sylvestris (L.) Hoffm; structure in first source. deoxypodophyllotoxin : A member of the class of furonaphthodioxoles that is (5R,5aR,8aR)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one substituted at position 5 by a 3,4,5-trimethoxyphenyl group.	2.13	1	0	furonaphthodioxole; gamma-lactone; lignan; methoxybenzenes	antineoplastic agent; apoptosis inducer; plant metabolite
annonacin annonacin: linear polyketide isolated from extracts of the stembark of Annona densicoma; structure given in first source	2.25	1	0
o-(chloroacetylcarbamoyl)fumagillol O-(Chloroacetylcarbamoyl)fumagillol: Semisynthetic analog of fumagillin (a cyclohexane-sesquiterpene antibiotic isolated from ASPERGILLUS FUMIGATUS) that inhibits angiogenesis.. O-(chloroacetylcarbamoyl)fumagillol : A carbamate ester that is fumagillol in which the hydroxy group has been converted to the corresponding N-(chloroacetyl)carbamate derivative.	2.42	2	0	carbamate ester; organochlorine compound; semisynthetic derivative; sesquiterpenoid; spiro-epoxide	angiogenesis inhibitor; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; methionine aminopeptidase 2 inhibitor; retinoic acid receptor alpha antagonist
nsc 663284 NSC 663284: structure in first source	2.08	1	0	quinolone
pomolic acid pomolic acid: from Rosa woodsii & Hyptis capitata; structure in first source	2.21	1	0	triterpenoid	metabolite
bortezomib [no description available]	12.34	37	10	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	10.56	29	8	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
bardoxolone methyl methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source	2.08	1	0	cyclohexenones
fluorocholine fluorocholine: a radiopharmaceutical agent	2.51	2	0
n,n-dimethyl-n-(18f)fluoromethyl-2-hydroxyethylammonium [no description available]	2.11	1	0
nsc 23766 [no description available]	2.08	1	0	aminopyrimidine; aminoquinoline; primary amino compound; secondary amino compound; tertiary amino compound	antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist
permanganate [no description available]	4.61	1	1	manganese oxoacid
carboplatin [no description available]	24.58	674	248
glycogen glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.	2.17	1	0
n-acetylneuraminic acid N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.	2.6	1	0	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
elastin [no description available]	2.17	1	0	oligopeptide
carnosine polaprezinc: stimulates bone growth	3.45	1	1	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent
mevalonic acid Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.	2.47	2	0	3,5-dihydroxy-3-methylpentanoic acid
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.23	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
allose [no description available]	2.1	1	0	allopyranose; D-allose	antioxidant
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	3.61	2	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
dehydroascorbic acid Dehydroascorbic Acid: The reversibly oxidized form of ascorbic acid. It is the lactone of 2,3-DIKETOGULONIC ACID and has antiscorbutic activity in man on oral ingestion.. L-dehydroascorbate : An organic anion and the conjugate base of L-dehydroascorbic acid, arising from deprotonation of the acidic C2-position.. L-dehydroascorbic acid : Dehydroascorbic acid having the L-configuration.	2.06	1	0	dehydroascorbic acid; vitamin C	coenzyme; mouse metabolite
strychnine Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.	2.21	1	0	monoterpenoid indole alkaloid; organic heteroheptacyclic compound	avicide; cholinergic antagonist; glycine receptor antagonist; neurotransmitter agent; rodenticide
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	3.93	3	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	3.61	2	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	3.65	2	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	3.23	1	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.08	1	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.61	2	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.	3.23	1	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
hyperforin hyperforin: a prenylated acylphloroglucinol derivative; antibiotic component of novoimanine; psychoactive agent in St. John's wort; Russian; structure;. hyperforin : A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.	2.02	1	0
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	3.23	1	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
perindopril erbumine [no description available]	2.08	1	0	addition compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol [no description available]	3.61	2	0	piperidines
mometasone furoate Mometasone Furoate: A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.	2.06	1	0	11beta-hydroxy steroid; 2-furoate ester; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; organochlorine compound; steroid ester	anti-allergic agent; anti-inflammatory drug
metyrosine alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.	3.23	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent
linezolid [no description available]	3.61	2	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
Calactin [no description available]	2.21	1	0	cardenolide glycoside
vicenin ii vicenin: isolated from the leaves of the Indian plant Ocimum sanctum were tested for their radioprotective effect in mice. isovitexin 8-C-beta-glucoside : A C-glycosyl compound that is isovitexin in which the hydrogen at position 8 is replaced by a beta-D-glucosyl residue.	3.6	2	0	C-glycosyl compound; trihydroxyflavone	metabolite
cyclopamine [no description available]	3.17	5	0	piperidines	glioma-associated oncogene inhibitor
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2.78	3	0
clindamycin phosphate [no description available]	3.23	1	0
cromakalim [no description available]	3.27	1	0	1-benzopyran
pemirolast potassium salt [no description available]	2.08	1	0
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	3.61	2	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
tolterodine [no description available]	3.23	1	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
doxorubicin hydrochloride [no description available]	2.55	2	0	anthracycline
ao 128 AO 128: alpha-glucosidase inhibitor; structure given in first source	2.08	1	0	organic molecular entity
loteprednol etabonate Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; etabonate ester; organochlorine compound; steroid acid ester; steroid ester	anti-inflammatory drug
darifenacin darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.	3.23	1	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	4.44	20	0	cyclodextrin
maleic acid maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.	2.21	1	0	butenedioic acid	algal metabolite; mouse metabolite; plant metabolite
acetyl coenzyme a Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.	2.17	1	0	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	3.23	5	0	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	7.41	14	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
farnesol Farnesol: A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). (2-trans,6-trans)-farnesol : The (2-trans,6-trans)-stereoisomer of farnesol.. farnesol : A farnesane sesquiterpenoid that is dodeca-2,6,10-triene substituted by methyl groups at positions 3, 7 and 11 and a hydroxy group at position 1.	2.06	1	0	farnesol	plant metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	6.35	10	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	3.57	2	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	3.25	5	0	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	3.61	2	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	2.31	1	0	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	3.23	1	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	2.83	3	0	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	3.15	5	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	3.23	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.08	1	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	3.23	1	0
brivudine brivudine: anti-herpes agent	2.21	1	0
lycopene [no description available]	3.92	2	1	acyclic carotene	antioxidant; plant metabolite
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	3.23	1	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	3.61	2	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
cefoxitin Tn antigen: immediate precursor in biosynthesis of Thomsen-Friedenreich (T) antigen; present in about 90% of human carcinoma tissue; proposed as universal carcinoma marker. O-(N-acetyl-alpha-D-galactosaminyl)-L-serine : A non-proteinogenic L-amino acid that is N-acetyl-alpha-D-galactosamine linked via an alpha glycosidic bond to the O at position 3 of L-serine.	2.31	1	0	L-serine derivative; non-proteinogenic L-alpha-amino acid	tumour antigen
desoxyepothilone b desoxyepothilone B: microtubule-targeted antitumor agent; lacking the epoxide of epothilone B; may be equiv to epothilone D. epothilone D : An epithilone that is epithilone C in which the hydrogen at position 13 of the oxacyclohexadec-13-ene-2,6-dione macrocycle has been replaced by a methyl group.	3.42	1	1	epothilone	microtubule-stabilising agent
gw 3965 GW 3965: a liver X receptor ligand	2.08	1	0	diarylmethane
epothilone b [no description available]	7.05	14	1	epothilone; epoxide	antineoplastic agent; apoptosis inducer; microtubule-stabilising agent
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.05	1	0
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	2.08	1	0	aromatic amide
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.03	1	0	prostaglandins D	human metabolite; mouse metabolite
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	2.74	3	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
octreotide [no description available]	3.23	1	0
epothilone a Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).	13.3	38	8	epothilone; epoxide	antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator
eptifibatide [no description available]	3.23	1	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.08	1	0
purvalanol b purvalanol B: protein kinase inhibitor; structure in first source	2.08	1	0	purvalanol	protein kinase inhibitor
y-700 [no description available]	2.08	1	0
repsox RepSox: inhibits TGF-beta signaling; structure in first source appears to be incorrect	2.08	1	0	pyrazolopyridine
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	3.14	1	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.	3.94	3	0	phenols; tertiary amino compound	antineoplastic agent; estrogen receptor antagonist; metabolite
carbon-11 acetate carbon-11 acetate: a tracer of myocardial oxygen consumption	3.45	1	1
aclarubicin Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.	2	1	0	aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion	antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
decitabine [no description available]	4.54	7	0	2'-deoxyribonucleoside
teniposide [no description available]	3.61	2	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	2.03	1	0	carbohydrate derivative; nucleobase-containing molecular entity
valrubicin [no description available]	3.92	3	0	anthracycline; trifluoroacetamide
ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration.	2.31	1	0	cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	4.28	5	0	actinomycin	mutagen
bevirimat bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.	3.27	1	0	dicarboxylic acid monoester; monocarboxylic acid; pentacyclic triterpenoid	HIV-1 maturation inhibitor; metabolite
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	6.59	8	2	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.23	1	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
posaconazole [no description available]	3.61	2	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
rubitecan rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.	2.73	3	0	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	3.23	1	0	antibiotic antifungal drug; echinocandin	antiinfective agent
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	2.21	1	0	hydroxy-1,4-naphthoquinone
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide [no description available]	2.08	1	0	tropane alkaloid
3-epi-betulinic acid [no description available]	2.15	1	0
riboflavin vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).	3.71	2	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
2,3-bis(bromomethyl)quinoxaline-1,4-dioxide conoidin A: inhibits the peroxiredoxin TgPrx11; structure in first source	4.61	1	1
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	3.23	1	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
sodium acetate, anhydrous Sodium Acetate: The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.	2.17	1	0	organic sodium salt	NMR chemical shift reference compound
arsenic trioxide Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.	3.23	1	0	arsenic oxide	antineoplastic agent; insecticide
zn(ii)-phthalocyanine [no description available]	2.51	2	0	metallophthalocyanine; zinc tetrapyrrole	fluorochrome
dipyrone Dipyrone: A drug that has analgesic, anti-inflammatory, and antipyretic properties. It is the sodium sulfonate of AMINOPYRINE.. metamizole sodium : An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic.	2	1	0	organic sodium salt	anti-inflammatory agent; antipyretic; antirheumatic drug; cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug; prodrug
thiacremonone thiacremonone: results suggest that a sulfurocompound from garlic inhibited colon cancer cell growth through induction of apoptotic cell death by modulating of NF-kappaB; structure in first source	2.05	1	0	secondary alpha-hydroxy ketone
bromochloroacetic acid Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.. bromochloroacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by bromine while a second is replaced by chlorine. A low-melting (27.5-31.5degreeC), hygroscopic crystalline solid, it can be formed during the disinfection (by chlorination) of water that contains bromide ions and organic matter, so can occur in drinking water as a byproduct of the disinfection process.	6.62	10	2	2-bromocarboxylic acid; monocarboxylic acid; organochlorine compound
sr 90107 fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.	3.23	1	0
meglumine iodipamide [no description available]	3.23	1	0	organoammonium salt	radioopaque medium
cinnamaldehyde 3-phenylprop-2-enal : A member of the class of cinnamaldehydes that is prop-2-enal in which a hydrogen at position 3 has been replaced by a phenyl group. The configuration of the double bond is not specified; the name "cinnamaldehyde" is widely used to refer to the E (trans) isomer.. (E)-cinnamaldehyde : The E (trans) stereoisomer of cinnamaldehyde, the parent of the class of cinnamaldehydes.	2.6	1	0	3-phenylprop-2-enal; cinnamaldehydes	antifungal agent; EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor; flavouring agent; hypoglycemic agent; plant metabolite; sensitiser; vasodilator agent
trans-4-coumaric acid hydroxycinnamic acid : Any member of the class of cinnamic acids carrying one or more hydroxy substituents.. trans-4-coumaric acid : The trans-isomer of 4-coumaric acid.. 4-coumaric acid : A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.	2.63	2	0	4-coumaric acid	food component; mouse metabolite; plant metabolite
glycosides [no description available]	3.87	3	0
isomethyleugenol Methylation: Addition of methyl groups. In histo-chemistry methylation is used to esterify carboxyl groups and remove sulfate groups by treating tissue sections with hot methanol in the presence of hydrochloric acid. (From Stedman, 25th ed)	3.49	7	0	isomethyleugenol
piplartine piplartine: Antineoplastic Agent, Phytogenic; alkaloid from Piper; structure in first source	2.54	2	0	cinnamamides; dicarboximide
piperine piperine : A N-acylpiperidine that is piperidine substituted by a (1E,3E)-1-(1,3-benzodioxol-5-yl)-5-oxopenta-1,3-dien-5-yl group at the nitrogen atom. It is an alkaloid isolated from the plant Piper nigrum.	3.04	4	0	benzodioxoles; N-acylpiperidine; piperidine alkaloid; tertiary carboxamide	food component; human blood serum metabolite; NF-kappaB inhibitor; plant metabolite
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	4.91	10	0	stilbene
thyrotropin-releasing hormone PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.	3.23	1	0	peptide hormone; tripeptide	human metabolite
picibanil Picibanil: A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.	2.7	3	0	penicillinate anion
cannabidiol Cannabidiol: Compound isolated from Cannabis sativa extract.. cannabidiol : An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.	2.55	2	0	olefinic compound; phytocannabinoid; resorcinols	antimicrobial agent; plant metabolite
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	3.61	2	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
s 1033 [no description available]	3.61	2	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
trilostane trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
bucillamine [no description available]	2	1	0	organic molecular entity
leuprolide acetate leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.08	1	0	acetate salt	antineoplastic agent; gonadotropin releasing hormone agonist
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	8.87	14	5	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
diethylstilbestrol dipropionate diethylstilbestrol dipropionate: RN given refers to parent cpd	2.02	1	0
fludarabine [no description available]	3.53	2	0	purine nucleoside
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	3.61	2	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
nsc 4347 NSC 4347: structure in first source	2.13	1	0
sesquiterpenes [no description available]	3.92	12	0
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	3.23	1	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	3.89	3	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
1-methyltryptophan 1-methyltryptophan: an immunomodulator. 1-methyltryptophan : A tryptophan derivative that is tryptophan carrying a single methyl substituent at position 1 on the indole.	3.48	1	1	indolyl carboxylic acid
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	2.08	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
rg108 RG108: DNA methyltransferase inhibitor; structure in first source	2.08	1	0	indolyl carboxylic acid
pyrantel Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.	3.23	1	0	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug
stf 083010 [no description available]	2.08	1	0
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide [no description available]	2.08	1	0	naphthalenecarboxamide
7-benzyloxy-4-trifluoromethylcoumarin 7-benzyloxy-4-trifluoromethylcoumarin: a substrate for CYP3A4	2.1	1	0
thiothixene [no description available]	3.23	1	0	N-methylpiperazine	anticoronaviral agent
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	3.61	2	0	zopiclone	central nervous system depressant; sedative
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	9.37	35	3	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
cct018159 CCT018159: structure in first source. CCT-018159 : A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively.	2.08	1	0	benzodioxine; pyrazoles; resorcinols	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
secinh3 SecinH3: a small molecule antagonist of cytohesins; structure in first source	2.08	1	0	triazoles
jk184 JK184: structure in first source	2.08	1	0
benztropine Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	3.23	1	0	diarylmethane
thiohydantoins Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups.	5.92	8	0
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	3.61	2	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.08	1	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	9.79	14	8	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
terbinafine [no description available]	3.23	1	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2.08	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.08	1	0	isoquinolines
fatostatin fatostatin: inhibits activation of SREBP; structure in first source	2.11	1	0	thiazoles
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.23	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
thiobarbituric acid thiobarbituric acid: RN given refers to parent cpd. 2-thiobarbituric acid : A barbiturate, the structure of which is that of barbituric acid in which the oxygen at C-2 is replaced by sulfur.	2.11	1	0	barbiturates	allergen; reagent
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.78	3	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
D-fructopyranose [no description available]	2	1	0	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
ferric ferrocyanide ferric ferrocyanide: antidote to thallium poisoning; RN given refers to Fe(+3)[3:4] salt; structure	2.31	1	0
succimer Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.	3.23	1	0	dicarboxylic acid; dithiol; sulfur-containing carboxylic acid	chelator
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	3.23	1	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
streptozocin [no description available]	3.23	1	0
tamoxifen citrate [no description available]	2.08	1	0	citrate salt	angiogenesis inhibitor; anticoronaviral agent
tamoxifen [no description available]	14.91	65	14	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
nadp [no description available]	2.13	1	0
hc-067047 HC-067047: a TRPA1 antagonist; structure in first source	2.08	1	0
bi-78d3 [no description available]	2.08	1	0	aryl sulfide
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.23	1	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
stattic [no description available]	2.6	1	0	1-benzothiophenes; C-nitro compound; sulfone	antineoplastic agent; radiosensitizing agent; STAT3 inhibitor
gsk 3787 [no description available]	2.08	1	0
p5091 P5091: inhibits ubiquitin-specific protease 7; structure in first source	2.21	1	0
cancidas [no description available]	3.23	1	0
sirtinol [no description available]	2.08	1	0	aldimine; benzamides; naphthols	anti-inflammatory agent; EC 3.5.1.98 (histone deacetylase) inhibitor; Sir2 inhibitor
methyl-thiohydantoin-tryptophan methyl-thiohydantoin-tryptophan: structure in first source	2.08	1	0	organonitrogen compound; organooxygen compound
2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester [no description available]	2.08	1	0	monocarboxylic acid
k 858 K 858: an Eg5 inhibitor and antineoplastic agent; structure in first source	2.11	1	0	benzenes
1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane [no description available]	2.08	1	0
importazole importazole: an importin-8 inhibitor; structure in first source	2.15	1	0	quinazolines
4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide [no description available]	2.08	1	0	sulfonamide
monastrol monastrol: stops mitosis by fostering formation of monopolar spindles; structure in first source. (S)-monastrol : An ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate that has S configuration.. monastrol : A racemate comprising equimolar amounts of R- and S-monastrol.. ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate : A member of the class of thioureas that is 3,4-dihydropyrimidine-2(1)-thione substituted by a 3-hydroxyphenyl group at position 4, an ethoxycarbonyl group at position 5, and a methyl group at position 6.	2.13	1	0	enoate ester; ethyl ester; phenols; racemate; thioureas	antileishmanial agent; antimitotic; antineoplastic agent; EC 3.5.1.5 (urease) inhibitor
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.08	1	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	3.23	1	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	2.48	2	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	3.59	2	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
aplaviroc aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source	3.23	1	0
thiamine disulfide thiamine disulfide: structure	2.21	1	0	aminopyrimidine; formamides; homoallylic alcohol; organic disulfide
hmr 3647 [no description available]	3.61	2	0
latoconazole latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source	2.08	1	0	conazole antifungal drug; imidazole antifungal drug
maraviroc [no description available]	3.61	2	0	tropane alkaloid
LSM-1318 [no description available]	2.08	1	0	oxa-steroid
toremifene citrate [no description available]	2.08	1	0	stilbenoid	anticoronaviral agent
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	4.07	4	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
2'-deoxy-2'-methylenecytidine [no description available]	2.01	1	0
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.44	2	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
rwj 67657 RWJ 67657: inhibits p38 mitogen-activated protein kinase; structure in first source	2.08	1	0
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	3.61	2	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
3,7,11,15-tetramethyl-1,2,3-hexadecanetriol 3,7,11,15-tetramethyl-1,2,3-hexadecanetriol: structure in first source. phytantriol : A triol that consists of 3,7,11,15-tetramethylhexadecane bearing three hydroxy substituents at positions 1, 2 and 3.	2.49	2	0	triol
6-methyl-2-(phenylethynyl)pyridine 6-methyl-2-(phenylethynyl)pyridine: an mGlu5 antagonist. 2-methyl-6-(phenylethynyl)pyridine : A methylpyridine that coinsists of 2-methylp[yridine bearing an additional phenylethynyl group at position 6. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.	2.08	1	0	acetylenic compound; methylpyridines	anxiolytic drug; metabotropic glutamate receptor antagonist
bms 387032 N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide: a CDK2 inhibitor with antineoplastic activity; structure in first source. N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of piperidine-4-carboxylic acid with the amino group of 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine. It is an ATP-competitive inhibitor of CDK2, CDK7 and CDK9 kinases and exhibits anti-cancer properties.	2.08	1	0	1,3-oxazoles; 1,3-thiazoles; organic sulfide; piperidinecarboxamide; secondary carboxamide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
cobaltous chloride cobaltous chloride: RN given refers to unlabeled cpd; RN in Chemline for cobalt trichloride: 10241-04-0; RN for 60-labeled cpd: 14543-09-0; RN for 57-labeled cpd: 164113-89-1; RN for 58-labeled cpd: 29377-09-1; structure. cobalt dichloride : A cobalt salt in which the cobalt metal is in the +2 oxidation state and the counter-anion is chloride. It is used as an indicator for water in desiccants.	2.13	1	0	cobalt salt; inorganic chloride	allergen; calcium channel blocker; sensitiser; two-colour indicator
nitrogen dioxide Nitrogen Dioxide: Nitrogen oxide (NO2). A highly poisonous gas. Exposure produces inflammation of lungs that may only cause slight pain or pass unnoticed, but resulting edema several days later may cause death. (From Merck, 11th ed) It is a major atmospheric pollutant that is able to absorb UV light that does not reach the earth's surface.	4.61	1	1	nitrogen oxide
dermatan sulfate Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.	3.23	1	0	amino disaccharide; glycosylgalactose derivative; iduronic acids; oligosaccharide sulfate
dolasetron [no description available]	3.23	1	0	indolyl carboxylic acid
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.08	1	0	steroid	estrogen
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	3.61	2	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	3.61	2	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
amrubicin amrubicin: structure in first source; a 9-amino-anthracycline antibiotic. amrubicin : A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol.	5.07	3	1	anthracycline antibiotic; methyl ketone; primary amino compound; quinone; tetracenes	antineoplastic agent; prodrug; topoisomerase II inhibitor
rtki cpd RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors	2.46	2	0
2'-cyano-2'-deoxyarabinofuranosylcytosine 2'-cyano-2'-deoxyarabinofuranosylcytosine: structure given in first source; RN given is for mono HCl	2.03	1	0
e 7010 E 7010: inhibits tubulin polymerization; structure given in first source	4.9	2	1	sulfonamide
cystine [no description available]	2.31	1	0
ly335979 [no description available]	4.38	2	2	carbopolycyclic compound
fospropofol [no description available]	3.23	1	0	alkylbenzene
tandutinib [no description available]	2.08	1	0	aromatic ether; N-arylpiperazine; N-carbamoylpiperazine; phenylureas; piperidines; quinazolines; tertiary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
vx-745 [no description available]	2.08	1	0	aryl sulfide; dichlorobenzene; difluorobenzene; pyrimidopyridazine	anti-inflammatory drug; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
corlanor ivabradine hydrochloride : A hydrochloride obtained by combining ivabradine with one molar equivalent of hydrochloric acid. Used to treat patients with angina who have intolerance to beta blockers and/or heart failure.	2.08	1	0	hydrochloride	cardiotonic drug
azilect [no description available]	2.08	1	0
rasagiline [no description available]	3.23	1	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	9.73	14	3	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
zd 6474 CH 331: structure in first source	12.07	23	10	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
salinomycin salinomycin: from Streptomyces albus; RN given refers to parent cpd; structure	3.24	5	0	polyketide; spiroketal	animal growth promotant; potassium ionophore
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	3.34	6	0
compound 968 compound 968: a glutaminase inhibitor. 5-[3-bromo-4-(dimethylamino)phenyl]-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one : A partially hydrogenated benzophenanthridine carrying an oxo group at C-4, geminal methyl groups at C-2 and a 3-bromo-4-(dimethylamino)phenyl group at C-5.	2.08	1	0	benzophenanthridine	EC 3.5.1.2 (glutaminase) inhibitor
sb-224289 SB 224289 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.	2.08	1	0	1,2,4-oxadiazole; azaspiro compound; benzamides; organic heterotetracyclic compound	serotonergic antagonist
gw 7647 GW 7647: a PPAR-alpha agonist; structure in first source. GW 7647 : A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.	2.08	1	0	aryl sulfide; monocarboxylic acid; ureas	PPARalpha agonist
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	4.11	3	1	organic sodium salt	detergent; protein denaturant
mtt formazan MTT formazan: a blue MEM-insoluble mitochondrial byproduct; used to determine viability of cells with active mitochondrial dehydrogenase enzymes	2.46	2	0
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.08	1	0	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine [no description available]	2.08	1	0	imidazoles
zinc protoporphyrin ix [no description available]	2.1	1	0
N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine [no description available]	2.08	1	0	aromatic amine; tertiary amino compound
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester [no description available]	2.08	1	0	isoquinolines
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	5.43	7	2
sch 79797 [no description available]	2.08	1	0	quinazolines
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	3.61	2	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.74	3	0	long-chain fatty acid
icodextrin Icodextrin: A glucan that is structurally related to maltodextrin, with more than 85% of its molecules having molecular weights between 1640 and 45 000 Daltons (Da), and a weight-average molecular weight of about 20 000 Da; it is used in dialysis fluids as an alternative to glucose-based solutions, and to reduce adhesions after gynecological or abdominal surgery. It has also been used as a vehicle for drugs given via the peritoneal cavity.	2	1	0
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	2.08	1	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	3.15	5	0	organic cation; xanthene dye	fluorochrome
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	3.61	2	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
myelin basic protein Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.	2.05	1	0
1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one [no description available]	2.08	1	0	monobactam
imd 0354 N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source	2.08	1	0	benzamides
ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine.	2.08	1	0	carbazoles; monocarboxylic acid amide; organochlorine compound
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	3.7	9	0	sphing-4-enine	human metabolite; mouse metabolite
quercetin [no description available]	5.11	12	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	4.74	3	2	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	4.81	7	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
formononetin [no description available]	2.41	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	4.13	4	0	trihydroxyflavone	antineoplastic agent; metabolite
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.86	3	0	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	13.61	36	17	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
daphnetin [no description available]	2.6	1	0	hydroxycoumarin
alprostadil [no description available]	2.73	3	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	5.46	4	1	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	6.5	7	2	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	3.38	1	1	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol [no description available]	2.17	1	0	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
gamma-linolenic acid gamma-Linolenic Acid: An omega-6 fatty acid produced in the body as the delta 6-desaturase metabolite of linoleic acid. It is converted to dihomo-gamma-linolenic acid, a biosynthetic precursor of monoenoic prostaglandins such as PGE1. (From Merck Index, 11th ed). gamma-linolenic acid : A C18, omega-6 acid fatty acid comprising a linolenic acid having cis- double bonds at positions 6, 9 and 12.	2.02	1	0	linolenic acid; omega-6 fatty acid	human metabolite; mouse metabolite; plant metabolite
genistein [no description available]	4.35	7	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.23	1	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	3.61	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
oxymetholone Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.	3.61	2	0
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	3.61	2	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	3.69	2	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.	3.23	1	0	isoquinolines
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	maleate salt	anti-allergic agent
dexchlorpheniramine maleate [no description available]	2.08	1	0	organic molecular entity
hemabate carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.	3.23	1	0
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	3.61	2	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	3.92	3	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol [no description available]	3.23	1	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
cucurbitacin b [no description available]	2.46	2	0	cucurbitacin; secondary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
esculetin esculetin: used in filters for absorption of ultraviolet light; structure. esculetin : A hydroxycoumarin that is umbelliferone in which the hydrogen at position 6 is substituted by a hydroxy group. It is used in filters for absorption of ultraviolet light.	2.6	1	0	hydroxycoumarin	antioxidant; plant metabolite; ultraviolet filter
zearalenone Zearalenone: (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione. One of a group of compounds known under the general designation of resorcylic acid lactones. Cis, trans, dextro and levo forms have been isolated from the fungus Gibberella zeae (formerly Fusarium graminearum). They have estrogenic activity, cause toxicity in livestock as feed contaminant, and have been used as anabolic or estrogen substitutes.. zearalenone : A macrolide comprising a fourteen-membered lactone fused to 1,3-dihydroxybenzene; a potent estrogenic metabolite produced by some Giberella species.	2.11	1	0	macrolide; resorcinols	fungal metabolite; mycoestrogen
baicalein [no description available]	5.61	4	1	trihydroxyflavone	angiogenesis inhibitor; anti-inflammatory agent; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 4.1.1.17 (ornithine decarboxylase) inhibitor; ferroptosis inhibitor; geroprotector; hormone antagonist; plant metabolite; prostaglandin antagonist; radical scavenger
chrysin chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.	2.58	2	0	7-hydroxyflavonol; dihydroxyflavone	anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite
diosmin [no description available]	3.39	1	1	dihydroxyflavanone; disaccharide derivative; glycosyloxyflavone; monomethoxyflavone; rutinoside	anti-inflammatory agent; antioxidant
fisetin [no description available]	2.02	1	0	3'-hydroxyflavonoid; 7-hydroxyflavonol; tetrahydroxyflavone	anti-inflammatory agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; metabolite; plant metabolite
morin morin: a light yellowish pigment found in the wood of old fustic (Chlorophora tinctoria). morin : A pentahydroxyflavone that is 7-hydroxyflavonol bearing three additional hydroxy substituents at positions 2' 4' and 5.	2.06	1	0	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent
myricetin [no description available]	2.63	2	0	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
tricin tricin: from Spartina cynosuroides and other plants; structure	2.21	1	0	3'-methoxyflavones; dimethoxyflavone; trihydroxyflavone	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; metabolite
daidzein [no description available]	2.21	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite
pterostilbene [no description available]	2.1	1	0	diether; methoxybenzenes; stilbenol	anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; hypoglycemic agent; neuroprotective agent; neurotransmitter; plant metabolite; radical scavenger
caffeic acid phenethyl ester phenethyl caffeate : An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.	2.57	2	0	alkyl caffeate ester	anti-inflammatory agent; antibacterial agent; antineoplastic agent; antioxidant; antiviral agent; immunomodulator; metabolite; neuroprotective agent
maytansine Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.	11.53	16	5	alpha-amino acid ester; carbamate ester; epoxide; maytansinoid; organic heterotetracyclic compound; organochlorine compound	antimicrobial agent; antimitotic; antineoplastic agent; plant metabolite; tubulin modulator
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	3.51	2	0	homodetic cyclic peptide
l 660,711 [no description available]	2.08	1	0	quinolines
picromycin picromycin: structure. pikromycin : A macrolide antibiotic that is biosynthesised by Streptomyces venezuelae.	2.15	1	0	enone; macrolide antibiotic; monosaccharide derivative	bacterial metabolite
cerulenin Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.	2.02	1	0	epoxide; monocarboxylic acid amide	antifungal agent; antiinfective agent; antilipemic drug; antimetabolite; antimicrobial agent; fatty acid synthesis inhibitor
lafutidine lafutidine: structure given in first source	2.06	1	0	organic molecular entity
quercetin-3-o-sophoroside quercetin-3-O-sophoroside: structure given in first source. quercetin 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside : A quercetin O-glucoside that is quercetin attached to a beta-D-sophorosyl residue at position 3 via a glycosidic linkage.	2.15	1	0	sophoroside; tetrahydroxyflavone	antioxidant; plant metabolite
travoprost Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.	2.08	1	0	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist
tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.	2.52	2	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
7432 s Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.	3.23	1	0	cephalosporin; dicarboxylic acid	antibacterial drug
tocotrienol, delta delta-tocotrienol : A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2 and 8 and a farnesyl chain at position 2.	2.6	1	0	tocotrienol; vitamin E	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bone density conservation agent; NF-kappaB inhibitor; plant metabolite; radiation protective agent; Saccharomyces cerevisiae metabolite
imipenem [no description available]	2.08	1	0	carbapenems
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	2.08	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	5.26	3	1	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.	2.08	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
epoprostenol [no description available]	3.23	1	0	prostaglandins I	mouse metabolite
indocyanine green [no description available]	3.23	1	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
dinoprost tromethamine [no description available]	2.08	1	0	organic molecular entity
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	3.23	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
pitavastatin pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.	3.23	1	0	cyclopropanes; dihydroxy monocarboxylic acid; monofluorobenzenes; quinolines; statin (synthetic)	antioxidant
rosuvastatin calcium S 4522: structure in first source	2.08	1	0	N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine; organic calcium salt	anti-inflammatory agent; cardioprotective agent; CETP inhibitor
terbinafine hydrochloride terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.	2.08	1	0	allylamine antifungal drug; hydrochloride	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor
ethamolin monoethanolamine oleate: used for treatment of pyogenic granuloma	3.23	1	0	long-chain fatty acid
alatrofloxacin mesylate [no description available]	3.23	1	0
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.1	1	0	4-hydroxynon-2-enal; 4-hydroxynonenal
1-monooleoyl-rac-glycerol Peceol: lipid excipient containing readily dispersible mixture of mono- & diglycerides of oleic acid. 1-oleoylglycerol : A 1-monoglyceride where the acyl group is oleoyl.. monooleoylglycerol : A monoglyceride in which the acyl group is oleoyl with the position of acylation unspecified.	2.21	1	0	1-acylglycerol 18:1; monooleoylglycerol	plant metabolite
menaquinone 6 menaquinone 6: RN given refers to (all-E)-isomer	4.95	2	1
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	3.47	7	0	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
codeine [no description available]	3.23	1	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	3.61	2	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
phenylephrine hydrochloride Nose: A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.. phenylephrine hydrochloride : A hydrochloride that is the monohydrochloride salt of phenylephrine.	2.1	1	0	hydrochloride
natamycin [no description available]	2.08	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	3.94	3	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
estropipate estropipate: used therapeutically in menopausal patients	3.23	1	0	piperazinium salt; steroid sulfate
granisetron Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.. granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.	2.03	1	0	aromatic amide; indazoles
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	3.23	1	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	3.61	2	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	3.23	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nabilone nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure	3.23	1	0
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.08	1	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	3.61	2	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	3.23	1	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
oxymorphone Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)	3.23	1	0	morphinane alkaloid
vitamin k 1 Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.	3.23	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
proscillaridin Proscillaridin: A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill).	2.25	1	0	organic molecular entity
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	10.9	35	8	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	3.85	3	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
trospium chloride trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.	3.23	1	0
gamma-cyclodextrin gamma-cyclodextrin : A cycloamylose composed of eight alpha-(1->4) linked D-glucopyranose units.	2.11	1	0	cyclodextrin
menaquinone 7 menaquinone-7 : A menaquinone whose side-chain contains seven isoprene units in an all-trans-configutation.	4.61	1	1	menaquinone	bone density conservation agent; cofactor; Escherichia coli metabolite; human blood serum metabolite; Mycoplasma genitalium metabolite
brefeldin a [no description available]	2.44	2	0	macrolide antibiotic	Penicillium metabolite
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	8.56	13	4	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fenretinide Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.	2.73	3	0	monocarboxylic acid amide; retinoid	antineoplastic agent; antioxidant
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.23	1	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
demycarosylturimycin h [no description available]	2.08	1	0
ter 199 [no description available]	2.08	1	0
acipimox acipimox: lipolysis inhibitor	2.08	1	0	pyrazinecarboxylic acid
arachidonylcyclopropylamide arachidonylcyclopropylamide: a potent and selective agonist of neuronal cannabinoid receptor; structure in first source	2.08	1	0
atosiban [no description available]	2.08	1	0	oligopeptide
benzphetamine Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.	3.23	1	0	amphetamines; tertiary amine	adrenergic uptake inhibitor; appetite depressant; dopamine uptake inhibitor; sympathomimetic agent
bimatoprost Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.08	1	0	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent
deamino arginine vasopressin Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.	4.11	4	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
dexmedetomidine [no description available]	3.23	1	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
herbimycin herbimycin: herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source. herbimycin : A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.	2.01	1	0	1,4-benzoquinones; lactam; macrocycle	antimicrobial agent; apoptosis inducer; herbicide; Hsp90 inhibitor; tyrosine kinase inhibitor
fr 173657 FR 173657: structure given in first source	2.31	1	0
fr 190997 FR 190997: structure given in first source	2.31	1	0
goserelin Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.	10.85	16	9	organic molecular entity
15-deoxy-delta(12,14)-prostaglandin j2 15-deoxy-delta(12,14)-prostaglandin J2: 15-deoxy-PGJ2 is also available; check for double bonds (indicated by delta) at 12 and 14 positions. 15-deoxy-Delta(12,14)-prostaglandin J2 : A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions.	2.03	1	0	prostaglandins J	electrophilic reagent; insulin-sensitizing drug; metabolite
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
ly 320135 LY 320135: cannabinoid receptor antagonist; structure in first source	2.08	1	0	benzofurans
lysophosphatidic acid lysophosphatidic acid: RN given refers to parent cpd. 1-oleoyl-sn-glycerol 3-phosphate : A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.. lysophosphatidic acid : A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class.	2.05	1	0	1-acyl-sn-glycerol 3-phosphate
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	3.23	1	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	3.61	2	0	phenylalanine derivative
pd 166285 [no description available]	2.08	1	0
vinorelbine [no description available]	3.23	1	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
onapristone onapristone: induces vaginal bleeding and luteal regression in monkeys; structure given in first source; progesterone antagonist	2.07	1	0
silodosin silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source	3.23	1	0	indolecarboxamide
kn 62 KN 62: inhibitor of Ca/calmodulin-dependent protein kinase II	2.08	1	0	piperazines
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.46	2	0
1,2-oleoylphosphatidylcholine 1,2-oleoylphosphatidylcholine: RN given refers to (Z,Z)-isomer. dioleoyl phosphatidylcholine : A phosphatidylcholine in which the phosphatidyl acyl groups are both oleoyl.	2.06	1	0	phosphatidylcholine(1+)
icaritin icaritin: structure in first source	2.41	1	0
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	3.23	1	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
ag-490 [no description available]	2.05	1	0	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
semaxinib semaxanib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is replaced by a 3,5-dimethylpyrrol-2-yl group.	2.52	2	0	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	4.98	4	2
su 11248 [no description available]	14.12	44	19	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
palbociclib [no description available]	3.39	6	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
jnj-7706621 [no description available]	2.08	1	0	sulfonamide
fosbretabulin [no description available]	2.15	1	0	stilbenoid
fosbretabulin fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source	2.01	1	0
4-nerolidylcatechol 4-nerolidylcatechol: scavenges peroxyl radicals; inhibits Fe(II)-dependent DNA damage; isolated from Pothomorphe; structure in first source	2.6	1	0	sesquiterpenoid
hemiasterlin hemiasterlin: structure in first source	3.43	1	1
lead Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.	4.61	1	1	carbon group element atom; elemental lead; metal atom	neurotoxin
sulindac sulfide sulindac sulfide: sulfated analog of indomethacin & inhibitor of prostaglandin synthesis in vitro; RN given refers to cpd without isomeric designation; structure given in first source. sulindac sulfide : An aryl sulfide that is a metabolite of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity.	2.06	1	0	aryl sulfide; monocarboxylic acid; organofluorine compound	antineoplastic agent; apoptosis inducer; non-steroidal anti-inflammatory drug
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.98	1	0	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	3.61	2	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine: structure given in first source. 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine : The cationic form of a C3 cyanine dye having 1,3-diethyl-5,6-dichloroindoleinine units at each end.	2.1	1	0	cyanine dye; indolium ion	fluorochrome
molsidomine [no description available]	2.08	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
flavokawain b flavokawain B: from Piper methysticum Forst (Kava Kava) roots; structure in first source. flavokawain B : A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities.	2.07	1	0	chalcones; dimethoxybenzene; phenols	anti-inflammatory agent; antileishmanial agent; antineoplastic agent; apoptosis inducer; metabolite
levorphanol Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	3.23	1	0	morphinane alkaloid
strontium Strontium: An element of the alkaline earth family of metals. It has the atomic symbol Sr, atomic number 38, and atomic weight 87.62.	4.99	2	1	alkaline earth metal atom
bismuth Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.	2.17	1	0	metal atom; pnictogen
arsenic Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)	6	4	1	metalloid atom; pnictogen	micronutrient
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	3.62	2	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	3.23	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	3.61	2	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	2.11	1	0	phenanthrenes
cefixime [no description available]	3.61	2	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	3.61	2	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	3.23	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	3.61	2	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
verteporfin (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.	3.23	1	0
batimastat batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor. batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.	2.41	2	0	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	3.61	2	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.	2.03	1	0	chalcogen; nonmetal atom	macronutrient
glyceryl behenate 1-behenoylglycerol : A fatty acid ester resulting from the formal condensation of the hydroxy group at position-1 of glycerol with the carboxy group of docosanoic acid.	2.66	2	0	1-monoglyceride; fatty acid ester	antineoplastic agent; plant metabolite
geldanamycin [no description available]	2.78	3	0
zimeldine Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)	3.23	1	0	styrenes
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.08	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.58	2	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
trientine hydrochloride [no description available]	3.23	1	0
scirpusin a scirpusin A: from the rhizome of Scirpus fluviatilis and Xinjiang wine grape; structure in first soource	2.15	1	0
n-methylscopolamine bromide scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.	3.23	1	0
dimyristoylphosphatidylcholine 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).	2.08	1	0	1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester	antigen; mouse metabolite
cisplatin [no description available]	2.08	1	0	diamminedichloroplatinum	antineoplastic agent; apoptosis inducer; cross-linking reagent; ferroptosis inducer; genotoxin; mutagen; nephrotoxin; photosensitizing agent
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	2.41	1	0	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
bleomycin [no description available]	3.23	1	0	bleomycin	antineoplastic agent; metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	3.67	9	0	cysteinium	fundamental metabolite
silicon Silicon: A trace element that constitutes about 27.6% of the earth's crust in the form of SILICON DIOXIDE. It does not occur free in nature. Silicon has the atomic symbol Si, atomic number 14, and atomic weight [28.084; 28.086].	2.11	1	0	carbon group element atom; metalloid atom; nonmetal atom
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	5.37	3	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	3.61	2	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
bergamottin bergamottin: constituent of bergamot oil; structure given in first source	2.15	1	0	furanocoumarin	metabolite
sulindac sulfone sulindac sulfone: inhibits K-ras-dependent cyclooxygenase-2; sulfated analog of indomethacin;; CP248 is an antineoplastic agent that fosters microtubule depolymerization; structure in first source. sulindac sulfone : A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor.	9.04	11	8	monocarboxylic acid; organofluorine compound; sulfone	apoptosis inducer; cyclooxygenase 2 inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	3.23	1	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
sarcodictyin a sarcodictyin A: structure in first source	2.69	3	0
phytochlorin phytochlorin: RN given refers to (2S-trans)-isomer; structure given in the first source	2.88	3	0
cefuroxime [no description available]	3.23	1	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	3.23	1	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.23	1	0	cephalosporin; oxime O-ether	antibacterial drug
pafuramidine pafuramidine: a prodrug of furamidine	3.23	1	0
ceftazidime [no description available]	3.23	1	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	3.61	2	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
strontium radioisotopes Strontium Radioisotopes: Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.	5.97	4	1
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	5.71	5	1	gamma-amino acid	anticonvulsant; calcium channel blocker
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	3.61	2	0	peptide
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	3.23	1	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
isocoumarin nm-3 isocoumarin NM-3: a synthetic derivative of cytogenin; structure in first source	2.02	1	0
vx680 [no description available]	2.76	3	0	N-arylpiperazine
n-acetylsphingosine N-acetylsphingosine: inhibits phospholipase D. N-acetylsphingosine : A N-acylsphingosine that has an acetamido group at position 2.	2.06	1	0	N-acylsphingosine
famotidine [no description available]	3.61	2	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
n-caproylsphingosine N-(hexanoyl)sphing-4-enine : An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen.	2.11	1	0	N-acylsphingosine
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	3.22	5	0	cyanine dye; organic iodide salt	fluorochrome
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	3.23	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	3.23	1	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
1,2-dielaidoylphosphatidylethanolamine 1,2-dielaidoylphosphatidylethanolamine: RN given refers to (E,E)-isomer; member of a class of cationic lipid formulations called cytofectins	2.03	1	0
ammonium sulfate Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.. ammonium sulfate : An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.	2.54	2	0	ammonium salt; inorganic sulfate salt	fertilizer
12-o-undecadienoylphorbol-13-acetate 12-O-undecadienoylphorbol-13-acetate: from fruit & stems of Ostodes paniculata; structure given in first source	2.17	1	0
cci 15641 [no description available]	2.08	1	0	cephalosporin
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.25	1	0	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
selenium Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.	3.59	7	0	chalcogen; nonmetal atom	micronutrient
selenocysteine Selenocysteine: A naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes. The genes for glutathione peroxidase and formate dehydrogenase contain the TGA codon, which codes for this amino acid.. selenocysteine : An alpha-amino acid that consists of alanine where one of the methyl hydrogens is substituted with a seleno group.	2.03	1	0
methaneselenol methaneselenol: RN given refers to (75)Se-labeled cpd. methylselenol : An organoselenium compound that is a selenium analogue of methanol, comprising a methyl group covalently bound to a selenol group.	2.11	1	0
radium Radium: A radioactive element of the alkaline earth series of metals. It has the atomic symbol Ra and atomic number 88. Radium is the product of the disintegration of URANIUM and is present in pitchblende and all ores containing uranium. It is used clinically as a source of beta and gamma-rays in radiotherapy, particularly BRACHYTHERAPY.	14.66	47	7	alkaline earth metal atom
cefpodoxime [no description available]	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	3.56	2	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
(3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid Fluvastatin: An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.. (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which both chiral centres have S configuration.. fluvastatin : A racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin. An HMG-CoA reductase inhibitor, it is used (often as the corresponding sodium salt) to reduce triglycerides and LDL-cholesterol, and increase HDL-chloesterol, in the treatment of hyperlipidaemia.	2.07	1	0	(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
tenofovir disoproxil fumarate tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.	2.08	1	0	fumarate salt	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
d 4476 [no description available]	2.08	1	0	imidazoles
cyc 116 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine: an aurora kinase inhibitor; structure in first source	2.08	1	0
bay 19-8004 BAY 19-8004: a PDE4 inhibitor; structure in first source	2.08	1	0
dexbrompheniramine maleate dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	brompheniramine maleate	anti-allergic agent; H1-receptor antagonist
rifaximin [no description available]	3.61	2	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.1	1	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
rhizoxin rhizoxin: from Rhizopus chinensis; causal agent of rice seedling blight; structure given in first source. rhizoxin : An macrolide antibiotic isolated from the pathogenic plant fungus Rhizopus microsporus. It also exhibits antitumour and antimitotic activity.	4.46	1	1	1,3-oxazoles; epoxide; macrolide antibiotic	antimitotic; antineoplastic agent; metabolite
1,2-dioleoyloxy-3-(trimethylammonium)propane 1,2-dioleoyloxy-3-(trimethylammonium)propane: fluorescent probe for phospholipids; RN & structure given in first source	2.52	2	0
plastochromanol 8 plastochromanol 8: has antiproliferative activity against 3T3-L1 cells and anti-adipogenic activity; structure; plastochromanol 3 is gamma-tocotrienol	2.79	3	0
thermozymocidin thermozymocidin: a serine palmitoyltransferase inhibitor; FTY720 is an analog	2.1	1	0	alpha-amino fatty acid; hydroxy monocarboxylic acid; non-proteinogenic alpha-amino acid; sphingoid	antifungal agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor; fungal metabolite; immunosuppressive agent
2,3,5,4'-tetrahydroxystilbene 2-o-glucopyranoside 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside: isolated from dried root tubers of Polygonum multiflorum; structure in first source	2.31	1	0
5'-oleoyl cytarabine elaidic acid-cytarabine: a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine	2.05	1	0	pyrimidine nucleoside
e 3330 E 3330: structure given in first source; MW 378.47	2.15	1	0
krn 5500 KRN 5500: a derivative of spicamycin with a wide range of antitumor activity against human cancer cell lines; structure given in first source	3.09	1	0
curdione curdione: from Curcuma wenyujin; structure in first source	2.31	1	0	germacrane sesquiterpenoid
everolimus [no description available]	10.77	21	6	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
laq824 LAQ824: Histone deacetylase inhibitor	2.01	1	0
ixabepilone [no description available]	11.54	18	6	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
axitinib [no description available]	6.99	6	4	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
laniquidar laniquidar: structure in first source	5	3	1
oc 144-093 OC 144-093: inhibits P-glycoprotein-mediated drug resistance; structure in first source	3.41	1	1
pai 039 tiplaxtinin: inhibitor of plasminogen activator inhibitor-1	2.08	1	0	indole-3-acetic acids
belotecan belotecan: structure in first source	2.25	1	0	pyranoindolizinoquinoline
tanespimycin CP 127374: analog of herbimycin A	4.98	8	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.08	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
ceftizoxime [no description available]	3.23	1	0	cephalosporin	antibacterial drug
1-methyl-d-lysergic acid butanolamide [no description available]	3.23	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
beta-escin [no description available]	2.87	3	0
fluphenazine [no description available]	2.08	1	0
gw2974 GW2974: quinazoline derivative, which is able to block the activation of both the EGFR and erbB2	2.08	1	0	pyridopyrimidine
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	3.61	2	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
ispinesib [no description available]	4.91	4	2	benzamides
peplomycin Peplomycin: An antineoplastic agent derived from BLEOMYCIN.	2.25	1	0	glycopeptide
6 beta-hydroxycortisol 6 beta-hydroxycortisol: RN given refers to the (6beta,11beta)-isomer; see also record for 6 alpha-hydrocortisol. 6beta-hydroxycortisol : A C21-steroid that is cortisol bearing an additional hydroxy substituent at the 6beta-position. In humans, it is produced as a metabolite of cortisol by cytochrome p450-3A4 (CYP3A4, an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds) and can be used to detect moderate and potent CYP3A4 inhibition in vivo.	3.41	1	1	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; 6beta-hydroxy steroid; C21-steroid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	human metabolite; mammalian metabolite; probe
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	2.75	3	0	gadolinium coordination entity	MRI contrast agent
dantrolene [no description available]	3.23	1	0
roxithromycin (E)-roxithromycin : A major geometrical isomer of roxithromycin.	2.08	1	0	roxithromycin	environmental contaminant; xenobiotic
inecalcitol [no description available]	3.48	1	1
cefdinir [no description available]	3.61	2	0	cephalosporin; ketoxime	antibacterial drug
etonogestrel [no description available]	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin
bisoprolol, fumarate (1:1) salt [no description available]	2.08	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.08	1	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
edatrexate edatrexate: structure given in first source	5.95	5	0	glutamic acid derivative
etoposide phosphate [no description available]	2.08	1	0	furonaphthodioxole
ciclesonide ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis	2.08	1	0	organic molecular entity
perfosfamide [no description available]	2.02	1	0
rpr 109881a RPR 109881A: a semisynthetic taxoid compound that has a similar mechanism of action to docetaxel	3.1	1	0
larotaxel larotaxel: has antineoplastic activity	2.17	1	0
temsirolimus [no description available]	3.89	3	0	macrolide lactam
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	3.61	2	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
soblidotin soblidotin: a dolastatin 10 derivative; RN refers to (2S-(1(1R(R),2S),2R(1S,2S)))-isomer; structure given in first source. soblidotin : A tetrapeptide derivative of dolastatin 10. It is an inhibitor of tubulin polymerization which exhibits potent antitumor activity.	2.42	2	0	tetrapeptide	antineoplastic agent; apoptosis inducer; microtubule-destabilising agent
eleutherobin eleutherobin: structure in first source	2.41	2	0
bay 12-9566 Bay 12-9566: an angiogenesis inhibitor with matrix metalloproteinase inhibitory activity	3.11	1	0	biphenyls; organochlorine compound
beta-elemene beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.	2.5	2	0	beta-elemene	antineoplastic agent
ac 7700 AC 7700: a vascular disrupting agent; structure in first source	7.01	4	3
idn 5109 IDN 5109: structure in first source	3.5	2	0
tekturna [no description available]	2.08	1	0	fumarate salt	antihypertensive agent
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.46	2	0	aminobenzoic acid
laulimalide laulimalide: isolated from Cacospongia mycofijiensis; structure in first source. laulimalide : A macrolide with formula C30H42O7 that is isolated from the marine sponges, Cacospongia mycofijiensis and Hyattella sp.	2.73	3	0	carboxylic ester; epoxide; macrolide; secondary alcohol; secondary allylic alcohol	animal metabolite; antimitotic; antineoplastic agent; marine metabolite; microtubule-stabilising agent
bms184476 [no description available]	3.14	1	0
lu 208075 ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension	3.23	1	0	diarylmethane
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	3.61	2	0	substituted aniline
vildagliptin [no description available]	2.08	1	0	amino acid amide
fesoterodine fesoterodine: a muscarinic antagonist for treatment of overactive bladder	3.23	1	0	diarylmethane
abt-510 NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt: has antiangiogenic and antineoplastic activity; structure in first source	2.94	1	0
talabostat talabostat: an antineoplastic agent; structure in first source	3.43	1	1
tesetaxel tesetaxel: structure in first source	2.01	1	0
mac321 MAC321: antineoplastic agent, phytogenic; structure in first source	2.42	2	0
hti-286 HTI-286: a synthetic analog of the tripeptide hemiasterlin; structure in first source	3.43	1	1
belinostat [no description available]	2.03	1	0	hydroxamic acid; olefinic compound; sulfonamide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostat Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.	5.31	4	1	cinnamamides; hydroxamic acid; methylindole; secondary amino compound	angiogenesis modulating agent; antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42 HDAC-42: structure in first source	2.08	1	0	amidobenzoic acid
staurosporine staurosporinium : Conjugate acid of staurosporine.	3.09	1	0	ammonium ion derivative
galbanic acid [no description available]	2.25	1	0	terpene lactone
bufalin bufalin: cardiotonic; powerful anesthetic & one of the active constituents of the Chinese drug ch'an su(senso); in Japan prepared from skin of Bufo bufo garfarizans; RN given refers to (3beta,5beta)-isomer. bufalin : A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo.	2.41	1	0	14beta-hydroxy steroid; 3beta-hydroxy steroid	animal metabolite; anti-inflammatory agent; antineoplastic agent; cardiotonic drug
1,25-dihydroxyergocalciferol 1,25-dihydroxyergocalciferol: RN given refers to (3beta,5Z,7E,22E)-isomer. 1alpha,25-dihydroxyvitamin D2 : A hydroxycalciol that is vitamin D2 bearing additional hydroxy substituents at positions 1alpha and 25.	2.03	1	0	hydroxycalciol; seco-ergostane; vitamin D	bone density conservation agent; human xenobiotic metabolite; nutraceutical
hypericum Hypericum: Genus of perennial plants in the family CLUSIACEAE (sometimes classified as Hypericaceae). Herbal and homeopathic preparations are used for depression, neuralgias, and a variety of other conditions. Hypericum contains flavonoids; GLYCOSIDES; mucilage, TANNINS; volatile oils (OILS, ESSENTIAL), hypericin and hyperforin.. 6-formamidopenicillanic acid : A penicillanic acid having a (6R)-formamido substituent.	4.37	4	1	penicillanic acids
taxane taxane: produced by Taxomyces andreanae	16.35	130	12	diterpene; terpenoid fundamental parent
sl 327 SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.	2.15	1	0
[4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone [no description available]	2.08	1	0	benzamides; N-acylpiperidine
sgd 301-76 [no description available]	2.08	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt	antiinfective agent
fluvoxamine maleate [no description available]	2.08	1	0	(trifluoromethyl)benzenes
formazans Formazans: Colored azo compounds formed by the reduction of tetrazolium salts. Employing this reaction, oxidoreductase activity can be determined quantitatively in tissue sections by allowing the enzymes to act on their specific substrates in the presence of tetrazolium salts.	2.46	2	0
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.08	1	0
s 1743 Esomeprazole: The S-isomer of omeprazole.. esomeprazole : A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.	2.41	1	0	magnesium salt	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	3.23	1	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-aminopyridine-2-carboxaldehyde thiosemicarbazone: a neuroprotective agent; structure given in first source	2.6	1	0
st 1481 ST 1481: structure in first source	2.05	1	0
dexlansoprazole Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.	3.61	2	0	benzimidazoles; sulfoxide
gemifloxacin mesylate gemifloxacin mesylate : The mesylate salt of gemifloxacin.	2.08	1	0	methanesulfonate salt	antimicrobial agent; topoisomerase IV inhibitor
fosinopril [no description available]	3.23	1	0
armodafinil armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.	3.23	1	0	2-[(diphenylmethyl)sulfinyl]acetamide	central nervous system stimulant; eugeroic
s-allylmercaptocysteine S-allylmercaptocysteine: a potent inhibitor of cell proliferation	2.04	1	0
iniparib [no description available]	2.08	1	0	carbonyl compound; organohalogen compound
orteronel orteronel: non-steroidal 17,20-lyase inhibitor; structure in first source	6.5	3	3
mk 0752 [no description available]	2.08	1	0
gw 501516 GW 501516: a selective PPARdelta agonist; structure in first source. GW 501516 : An aromatic ether that is phenoxyacetic acid in which the phenyl group is substituted at position 2 by a methyl group and at position 4 by a (1,3-thiazol-5-ylmethyl)sulfanediyl group, and in which the 1,3-thiazolyl group is substituted at positions 2 and 4 by p-trifluoromethylphenyl and methyl groups, respectively.	2.08	1	0	1,3-thiazoles; aromatic ether; aryl sulfide; monocarboxylic acid; organofluorine compound	carcinogenic agent; PPARbeta/delta agonist
av 412 [no description available]	2.08	1	0
ag-041r AG-041R: structure in first source	2.08	1	0
telatinib [no description available]	2.08	1	0
edotecarin [no description available]	2.03	1	0
dolastatin 10 dolastatin 10: from mollusk Dolabella auricularia; contains four amino acids, dolavaline, dolaisoleucine, dolaproine, valine and the primary amine dolaphenine; deo-dolastatin 10 is a new dolastatin 10 chiral derivative with MW of 784. dolastatin 10 : A tetrapeptide that is isolated from the sea hare Dolabella auricularia. It is a potent anticancer agent which inhibits tubulin polymerization.	3.1	1	0	1,3-thiazoles; tetrapeptide	animal metabolite; antineoplastic agent; apoptosis inducer; marine metabolite; microtubule-destabilising agent
ggti 298 GGTI 298: inhibits geranylgeranyltransferase-I; structure in first source	2.07	1	0	leucine derivative
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.08	1	0
apricoxib apricoxib: a COX-2 inhibitor; structure in first source	4.41	1	1
spc-839 SPC-839: an inhibitor of activator protein 1; structure in first source	2.08	1	0
abiraterone acetate Abiraterone Acetate: An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.. abiraterone acetate : A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.	18.07	125	24	pyridines; sterol ester	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor; prodrug
lenvatinib lenvatinib : A member of the class of quinolines that is the carboxamide of 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxylic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine.	2.08	1	0	aromatic amide; aromatic ether; cyclopropanes; monocarboxylic acid amide; monochlorobenzenes; phenylureas; quinolines	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist; orphan drug; vascular endothelial growth factor receptor antagonist
andarine [no description available]	2.08	1	0	acetamides; anilide
gw843682x [no description available]	2.08	1	0	(trifluoromethyl)benzenes
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.53	2	0	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
cp 4126 CP 4126: the elaidic acid ester of gemcitabine	2.05	1	0	pyrimidine 2'-deoxyribonucleoside
midostaurin midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.	2.08	1	0	benzamides; gamma-lactam; indolocarbazole; organic heterooctacyclic compound	antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
bromotetrandrine bromotetrandrine: structure in first source	2.05	1	0
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	3.23	1	0	oligopeptide
tapentadol Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.	3.61	2	0	alkylbenzene
ag 14361 [no description available]	2.08	1	0	benzimidazoles
sb 265610 [no description available]	2.08	1	0
pr-104a PR-104A: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; PR-104A is the corresponding alcohol of PR104	4.37	1	1
px-866 PX-866: inhibitor of phosphoinositide-3-kinase signaling with antitumor activity; structure in first source. PX-866 : An organic heterotetracyclic compound that is obtained from wortmanin via aminolysis of its furan ring by diallyl amine.	6.01	3	3	acetate ester; delta-lactone; organic heterotetracyclic compound; tertiary amino compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
gambogic acid gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer	3.36	6	0	pyranoxanthones	metabolite
pentagastrin Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.	3.23	1	0	organic molecular entity
cabazitaxel cabazitaxel: an antineoplastic agent; structure in first source. cabazitaxel : A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.	20.46	251	37	tetracyclic diterpenoid	antineoplastic agent; microtubule-stabilising agent
fr 148083 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB.	2.08	1	0	aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone	antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.52	2	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
sc 236 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide: SC58236 = SC236 re email from Harris, Ray	2.93	1	0
osi 930 OSI 930: inhibits both receptor tyrosine kinase Kit and kinase insert domain receptor; structure in first source	2.08	1	0	aromatic amide
ki 20227 [no description available]	2.08	1	0
cefditoren cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
scio-469 SCIO-469: a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor for potential oral therapy for inflammatory disorders; in phase lib clinical trials for rheumatoid arthritis 4/2004. talmapimod : An indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties.	2.08	1	0	aromatic amide; aromatic ketone; chloroindole; dicarboxylic acid diamide; indolecarboxamide; monofluorobenzenes; N-acylpiperazine; N-alkylpiperazine	antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
ssr 69071 SSR 69071: structure in first source	2.08	1	0	pyridopyrimidine
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.08	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
lipid a Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).	1.98	1	0	dodecanoate ester; lipid A; tetradecanoate ester	Escherichia coli metabolite
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.08	1	0	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
sb 210313 [no description available]	2.08	1	0
gw 4064 [no description available]	2.08	1	0	stilbenoid
zd 6126 [no description available]	2.02	1	0
idn 5390 IDN 5390: structure in first source	2.21	1	0
mart-1 antigen MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.	2.21	1	0
sb t-1214 [no description available]	2.17	1	0
sa 4503 [no description available]	2.08	1	0
ic 87114 IC 87114: structure in first source	2.08	1	0	6-aminopurines; biaryl; quinazolines	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zibotentan ZD4054: a potent endothelin receptor A antagonist that inhibits ovarian carcinoma cell proliferation	6.96	4	2	phenylpyridine
tivozanib N-(2-chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea: KNR-951 is the HCl, monohydrate salt; an antineoplastic agent; structure in first source	2.08	1	0	aromatic ether
hki 272 [no description available]	2.49	2	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
nb 506 NB 506: an indolocarbazole antitumor agent; structure given in first source; a DNA topoisomerase I inhibitor	3.09	1	0
adh-1 pepide ADH-1 pepide: a cyclic pentapeptide and N-cadherin antagonist targeting cancer vascularization	3.33	1	0
casopitant [no description available]	4.37	1	1	piperidines
ginsenoside rg3 ginsenoside Rg3: from Red ginseng; inhibits lung metastasis of tumor cells; structure given in first source. (20S)-ginsenoside Rg3 : A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.78	3	0	ginsenoside; glycoside; tetracyclic triterpenoid	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; plant metabolite
motexafin gadolinium [no description available]	3.82	2	1
sorbitan monooleate [no description available]	5.06	2	1	fatty acid ester
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.49	2	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
bibr 1532 [no description available]	2.08	1	0
n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide [no description available]	2.08	1	0
rucaparib AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source	5.17	3	1	azepinoindole; caprolactams; organofluorine compound; secondary amino compound	antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cediranib [no description available]	5.92	4	2	aromatic ether
gw0742 GW 610742: structure in first source	2.08	1	0	monocarboxylic acid
pasireotide pasireotide : A six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease.	3.56	1	1	homodetic cyclic peptide; peptide hormone	antineoplastic agent
zeolites [no description available]	2.1	1	0
pitolisant pitolisant: functions as both inverse agonist and antagonist of histamine H3 receptors; structure in first source	4.61	1	1	organochlorine compound
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	3.84	2	1	beta-carbolines
npi 2358 NPI 2358: antineoplastic; structure in first source. plinabulin : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione substituted by benzylidene and (5-tert-butyl-1H-imidazol-4-yl)methylidene groups at positions 3 and 6, respectively. It is a vascular disrupting agent and a microtubule destabalising agent which was in clinical trials (now discontinued) for the treatment of non-small cell lung cancer.	5.94	4	2	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent
bay 41-8543 BAY 41-8543: structure in first source	2.08	1	0	pyrazolopyridine
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.08	1	0	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
sb 525334 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline: a TGF-betaR kinase inhibitor	2.08	1	0	quinoxaline derivative
way-362450 [no description available]	2.08	1	0	indoles
masitinib [no description available]	2.08	1	0	1,3-thiazoles; benzamides; N-alkylpiperazine; pyridines	antineoplastic agent; antirheumatic drug; tyrosine kinase inhibitor
bx795 BX795: structure in first source	2.54	2	0	ureas
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	8	13	3	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	5.42	7	2	organic cation
azd 6244 AZD 6244: a MEK inhibitor	11.79	22	9	benzimidazoles; bromobenzenes; hydroxamic acid ester; monochlorobenzenes; organofluorine compound; secondary amino compound	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
phenobarbital sodium 2-(phosphonomethyl)pentanedioic acid: an N-acetylated alpha-linked acidic dipeptidase (NAALADase) antagonist	2.41	1	0
prasugrel hydrochloride Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.	3.59	2	0
1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea: structure in first source	2.08	1	0
bibw 2992 [no description available]	11.23	16	3	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide : A member of the class of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-carboxylic acid with the amino group of 3-cyanoaniline.	2.08	1	0	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
artenimol artenimol: derivative of antimalarial drug artemisinin (quinghaosu)	2.61	2	0
ar c155858 AR C155858: an MCT1 inhibitor; structure in first source	2.08	1	0
arisugacin arisugacin: isolated from Penicillium sp. FO-4259; structure given in first source. arisugacin A : An organic heterotetracyclic compound that is 4a,12a-dihydroxy-4,4,6a,12b-tetramethyl-4a,6,6a,12,12a,12b-hexahydro-4H,11H-benzo[f]pyrano[4,3-b]chromene-1,11(5H)-dione substituted by 3,4-dimethoxyphenyl group at position 9 (the 4aR,6aR,12aS,12bS steroisomer). Isolated from the culture broth of Penicillium, it acts as a selective inhibitor of acetylcholinesterase.	3.27	1	0	aromatic ether; delta-lactone; enone; organic heterotetracyclic compound; tertiary alcohol	antimicrobial agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; metabolite; Penicillium metabolite
edoxaban edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.	2.21	1	0	chloropyridine; monocarboxylic acid amide; tertiary amino compound; thiazolopyridine	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor; platelet aggregation inhibitor
sotrastaurin sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source. sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients.	2.11	1	0	indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines	anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent
aee 788 AEE 788: structure in first source	2.46	2	0	6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist; trypanocidal drug
saracatinib [no description available]	2.08	1	0	aromatic ether; benzodioxoles; diether; N-methylpiperazine; organochlorine compound; oxanes; quinazolines; secondary amino compound	anticoronaviral agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; radiosensitizing agent
sd-208 [no description available]	2.08	1	0
7-aminoactinomycin d 7-aminoactinomycin D: staining reagent used in flow cytometry	2.31	1	0
vx 702 VX 702: a p38 MAP kinase inhibitor	2.08	1	0	phenylpyridine
ngr peptide [no description available]	3	4	0
tak 385 relugolix: structure in first source	3.99	1	1
betulone [no description available]	2.15	1	0	triterpenoid	metabolite
volasertib BI 6727: a polo-like kinase inhibitor with broad antitumor activity; structure in first source	2.08	1	0
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	2.08	1	0	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
amg 009 AMG 009: an anti-inflammatory agent; structure in first source	2.08	1	0
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.41	1	0
vinflunine vinflunine: inhibits tubulin assembly; structure in first source. vinflunine : An organic heteropentacyclic compound and an organic heterotetracyclic compound that is vinorelbine in which the tetrahydropyridine moiety of the heterotetracyclic part of the molecule has been redced to the corresponding piperidine, and in which the ethyl group attached to this ring has been replaced by a 1,1-difluoroethyl group.	12.17	16	11	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; semisynthetic derivative; vinca alkaloid	antineoplastic agent
cefotaxime sodium [no description available]	2.08	1	0	organic sodium salt
1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one: from Curcuma longa; structure in first source	2.63	2	0	diarylheptanoid
baci-im [no description available]	3.23	1	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
cypate Cypate: a fluorescent dye; structure in first source	2.21	1	0
tafamidis tafamidis: may be effective in treating transthyretin amyloid polyneuropathy. tafamidis : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis.	2.41	1	0	1,3-benzoxazoles; dichlorobenzene; monocarboxylic acid	central nervous system drug
azd 7762 [no description available]	2.08	1	0	aromatic amide; thiophenes
krp-203 [no description available]	2.08	1	0
mk 0354 [no description available]	2.08	1	0
regorafenib [no description available]	2.52	2	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; monofluorobenzenes; phenylureas; pyridinecarboxamide	antineoplastic agent; hepatotoxic agent; tyrosine kinase inhibitor
acetyl-11-ketoboswellic acid acetyl-11-ketoboswellic acid: a 5-lipoxygenase inhibitor; structure given in first source	2.58	2	0	triterpenoid
3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene 3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene: has antineoplastic activity; structure in first source	2.6	1	0	3-hydroxy steroid	androgen
acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester [no description available]	2.08	1	0	pyrroloquinoline
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [no description available]	2.08	1	0	methoxybenzenes; substituted aniline
erastin erastin: an antineoplastic agent; structure in first source. erastin : A member of the class of quinazolines that is quinazolin-4(3H)-one in which the hydrogens at positions 2 and 3 are replaced by 1-{4-[(4-chlorophenoxy)acetyl]piperazin-1-yl}ethyl and 2-ethoxyphenyl groups, respectively. It is an inhibitor of voltage-dependent anion-selective channels (VDAC2 and VDAC3) and a potent ferroptosis inducer.	2.31	1	0	aromatic ether; diether; monochlorobenzenes; N-acylpiperazine; N-alkylpiperazine; quinazolines; tertiary carboxamide	antineoplastic agent; ferroptosis inducer; voltage-dependent anion channel inhibitor
abt-737 [no description available]	2.99	4	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
brivanib [no description available]	2.08	1	0	aromatic ether; diether; fluoroindole; pyrrolotriazine; secondary alcohol	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; drug metabolite; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
icg 001 [no description available]	2.08	1	0	peptide
bms 477118 [no description available]	3.23	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
mp470 [no description available]	3.01	4	0	N-arylpiperazine
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	3.23	1	0	nystatins
pirarubicin [no description available]	6.16	11	3	anthracycline
nu 7441 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source	2.55	2	0	dibenzothiophenes
at 7519 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide : A member of the class of pryrazoles that is 4-amino-1H-pyrazole-3-carboxylic acid in which the primary amino group has been acylated by a 2,6-dichlorobenzoyl group and in which the carboxylic acid has been converted into a carboxamide by formal condensation with the primary amino group of 4-aminopiperidine.	2.08	1	0	dichlorobenzene; piperidines; pyrazoles; secondary carboxamide	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
peloruside a peloruside A: Antibiotics, Antineoplastic from the sponge Mycale; structure in first source. peloruside A : A macrolide that is a novel secondary metabolite isolated from a New Zealand marine sponge, Mycale hentscheli.	3.03	4	0
er-086526 eribulin: a halichondrin B derivative that suppresses microtubule growth and acts as an antimitotic agent; structure in first source. eribulin : A fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mechanism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage	5.43	4	1	cyclic ketal; cyclic ketone; macrocycle; polycyclic ether; polyether; primary amino compound	antineoplastic agent; microtubule-destabilising agent
bi 2536 [no description available]	2.08	1	0
nutlin-3a nutlin 3: an MDM2 antagonist; structure in first source	2.49	2	0	stilbenoid
danusertib [no description available]	3.87	2	1	piperazines
zampanolide zampanolide: structure in first source	2.61	2	0
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide [no description available]	2.08	1	0	benzamides
pr-104 PR-104: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; structure in first source	4.37	1	1
N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide [no description available]	2.08	1	0	benzamides
nvp-aew541 [no description available]	3.27	1	0
abt 869 [no description available]	2.08	1	0	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
arq 197 [no description available]	3.56	1	1	indoles
ridaforolimus [no description available]	3.21	1	0	macrolide lactam
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.08	1	0	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
ac 261066 [no description available]	2.08	1	0
monomethyl auristatin e [no description available]	2.98	3	0
carfilzomib [no description available]	2.51	2	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
gw9508 GW9508: structure in first source	2.08	1	0	aromatic amine
jnj 26854165 [no description available]	2.08	1	0
pf 573228 6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one: structure in first source	2.08	1	0	quinolines
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.08	1	0
milnacipran [no description available]	3.23	1	0	acetamides
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.08	1	0	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
crizotinib Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.. crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)	9.31	16	7	3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine	antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile [no description available]	2.08	1	0	benzimidazoles
4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide Vx-11e: ERK1-2 inhibitor	2.08	1	0	aromatic amide; heteroarene
osi 906 [no description available]	2.08	1	0	cyclobutanes; quinolines
ly2334737 LY2334737: an orally available prodrug of gemcitabine for treatment of patients with advanced solid tumors	3.48	1	1
ly2109761 [no description available]	2.08	1	0
chir-265 [no description available]	2.08	1	0	aromatic ether
motesanib [no description available]	2.08	1	0	pyridinecarboxamide
az-628 AZ-628: a multikinase inhibitor; structure in first source	2.08	1	0	benzamides
darinaparsin darinaparsin: cytotoxic compound	2.11	1	0	peptide
trametinib [no description available]	5.58	5	1	acetamides; aromatic amine; cyclopropanes; organofluorine compound; organoiodine compound; pyridopyrimidine; ring assembly	anticoronaviral agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
pf-562,271 [no description available]	2.08	1	0	indoles
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	8.16	11	6
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	1.98	1	0	benzoxazole
veliparib [no description available]	2.49	2	0	benzimidazoles	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
perferryl iron [no description available]	2.6	1	0
ku-0060648 [no description available]	2.08	1	0	dibenzothiophenes
sepharose agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.	4.68	4	0
indocyanine green Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.	3.31	5	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
scopolamine hydrobromide [no description available]	3.23	1	0
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	3.22	5	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
th 302 TH 302: an hypoxia-activated prodrug of bromo-isophosphoramide mustard; an antineoplastic agent	2.78	3	0
palomid 529 [no description available]	2.48	2	0
tubulysin b [no description available]	2.17	1	0	butyrate ester
2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid alphitolic acid: from the aerial parts of Gouania longipetala; structure in first source. 2alpha,3beta-dihydroxy-20(29)-lupen-28-oic acid : A pentacyclic triterpenoid that is betulinic acid carrying an additional alpha-hydroxy group at position 2. It has been isolated from Breynia fruticosa.	2.13	1	0	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
roburic acid roburic acid : A tetracyclic triterpenoid with formula C30H40O2 that is isolated from the roots of Gentiana dahurica and Gentiana macrophylla.	2.41	1	0	monocarboxylic acid; olefinic compound; tetracyclic triterpenoid	plant metabolite
acid phosphatase Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.	5.28	4	1
discodermolide discodermolide: a lactone-bearing polyhydroxylated alkatetraene from the marine sponge Discodermia dissoluta; microtubule-stabilizing agent like taxol	4.23	5	0
rabeprazole sodium [no description available]	2.08	1	0	organic sodium salt
jaw [no description available]	2.08	1	0	indolecarboxamide
tosedostat [no description available]	2.08	1	0	carboxylic ester; hydroxamic acid; secondary carboxamide
mdv 3100 [no description available]	19.96	198	40	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
ku 60019 [no description available]	2.08	1	0
gsk 461364 GSK 461364: an antineoplastic agent that inhibits polo-like kinase 1	2.53	2	0	(trifluoromethyl)benzenes
n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide: a MEK inhibitor; structure in first source	2.08	1	0
nvp-tae684 [no description available]	2.08	1	0	piperidines
vtx-2337 [no description available]	2.31	1	0
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	3.92	12	0
4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide: structure in first source	2.08	1	0
gsk 269962a [no description available]	2.08	1	0
pf-00562271 [no description available]	2.1	1	0
bivalirudin bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.	3.61	2	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
somatostatin [no description available]	2.08	1	0	heterodetic cyclic peptide; peptide hormone
enfuvirtide Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.	3.23	1	0
cecropin b protein, insecta cecropin B protein, Insecta: from cecropia moth, Hyalophora cecropia; small basic protein; has potent antibacterial activity against E coli & other Gram-negative bacteria; also found in a variety of other insects; structure given in first source; also prevents development of malarial oocysts in mosquito vector	2.1	1	0
ganirelix [no description available]	3.23	1	0	polypeptide
abarelix abarelix: RN & structure in first source. abarelix : A polypeptide compound composed of ten natural and non-natural amino acid resiudes in a linear sequence.	3.12	1	0	polypeptide	antineoplastic agent; hormone antagonist
gastrins Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.	2.46	2	0
glucagon Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.	4.61	1	1	peptide hormone
big gastrin big gastrin: isolated from Zollinger-Ellison syndrome gastrinomas & hog antral mucosa; have encountered tetratricontapeptide & nonadecapeptide gastrin; big-big gastrin significantly higher in patients with duodenal ulcers; big gastrin refers gastrin which has a longer peptide chain than the normal heptadecapeptide gastrin	2.02	1	0
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	3.56	1	1
teriparatide [no description available]	3.23	1	0	polypeptide
salmon calcitonin [no description available]	3.23	1	0	heterodetic cyclic peptide; peptide hormone; polypeptide	bone density conservation agent; metabolite
irl 1620 sovateltide: a potent, specific ligand for the endothelin-B receptor	3.53	1	1
oligonucleotides [no description available]	8.08	12	5
ly-146032 [no description available]	3.61	2	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
liraglutide [no description available]	2.25	1	0	lipopeptide; polypeptide	glucagon-like peptide-1 receptor agonist; neuroprotective agent
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt	4.29	5	0	polypeptide
tigapotide tigapotide: a synthetic peptide corresponding to amino acids 31-45 of PSP94 (prostate secretory protein) that inhibits matrix metalloproteinase-9 secretion	2.11	1	0
exenatide [no description available]	3.23	1	0
ctce-9908 CTCE-9908: antineoplastic; a small peptide CXCR4 antagonist	2.52	2	0
warfarin sodium warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.	2.08	1	0
cellulose DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.	4.61	1	1	glycoside
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	4.34	3	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	3.82	10	0	1,2-diacyl-sn-glycero-3-phosphocholine
a-83-01 A-83-01: an ALK-5 inhibitor; structure in first source	2.08	1	0
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [no description available]	2.08	1	0	indoles
vx-770 ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.	2.08	1	0	aromatic amide; monocarboxylic acid amide; phenols; quinolone	CFTR potentiator; orphan drug
buparlisib NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source	2.08	1	0	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
azd 1480 [no description available]	2.08	1	0
pevonedistat pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.	4.04	2	1	cyclopentanols; indanes; pyrrolopyrimidine; secondary amino compound; sulfamidate	antineoplastic agent; apoptosis inducer
fedratinib fedratinib: a selective small-molecule inhibitor of JAK2	2.08	1	0	sulfonamide
gsk690693 [no description available]	2.08	1	0	1,2,5-oxadiazole; acetylenic compound; aromatic amine; aromatic ether; imidazopyridine; piperidines; primary amino compound; tertiary alcohol	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
cnf 2024 [no description available]	2.08	1	0	2-aminopurines; aromatic ether; organochlorine compound; pyridines	antineoplastic agent; Hsp90 inhibitor
ku 0063794 Ku 0063794: an mTOR inhibitor; structure in first source	2.57	2	0	benzyl alcohols; monomethoxybenzene; morpholines; pyridopyrimidine; tertiary amino compound	antineoplastic agent; mTOR inhibitor
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene: has antineoplastic activity; also inhibits Fms-like tyrosine kinase-3; structure in first source	2.1	1	0
azd 7545 AZD 7545: an anilide tertiary carbinol; a pyruvate dehydrogenase kinase 2 inhibitor. AZD7545 : A sulfone that is benzene substituted by [4-(dimethylcarbamoyl)phenyl]sulfonyl, chloro and [(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]amino groups at positions 1, 3 and 4, respectively. It is a potent and non-ATP-competitive inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2) with IC50 of 6.4 nM and exhibits glucose-lowering activity. Also inhibits PDHK1 at higher levels (IC50 = 36.8 nM).	2.08	1	0	benzamides; monochlorobenzenes; organofluorine compound; secondary carboxamide; sulfone; tertiary alcohol; tertiary carboxamide	EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor; hypoglycemic agent
nutlin-3b [no description available]	2.08	1	0	Nutlin; piperazinone	anticoronaviral agent
pravastatin sodium pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.08	1	0	organic sodium salt; statin (semi-synthetic)	anticholesteremic drug
alendronate sodium [no description available]	2.08	1	0
sphingosine kinase [no description available]	3.7	9	0
pf 04217903 [no description available]	2.08	1	0	quinolines
gdc 0941 pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.	2.53	2	0	indazoles; morpholines; piperazines; sulfonamide; thienopyrimidine	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
sm 164 SM 164: a bivalent Smac mimetic with antineoplastic activity; structure in first source	2.08	1	0	benzenes; organic heterobicyclic compound; secondary carboxamide; triazoles	antineoplastic agent; apoptosis inducer; radiosensitizing agent
sl 80.0750 [no description available]	2.08	1	0
calpain Calpain: Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4.	2.53	2	0
idarubicinol idarubicinol: RN given refers to (7S-(7alpha,9alpha,9(R*))-isomer	3.39	1	1	anthracycline
sapogenins Sapogenins: The aglucon moiety of a saponin molecule. It may be triterpenoid or steroid, usually spirostan, in nature.	2.08	1	0
chitosan [no description available]	8.53	60	1
icotinib [no description available]	2.52	2	0
ph 797804 PH 797804: an NSAID; structure in first source. PH 797804 : A member of the class of benzamides obtained by formal condensation of the carboxy group of 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1-yl}-4-methylbenzoic acid with the amino group of methylamine.	2.08	1	0	aromatic ether; benzamides; organobromine compound; organofluorine compound; pyridone	anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
pha 408 PHA 408: an IKK-2 antagonist; structure in first source	2.08	1	0
technetium tc 99m sestamibi Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.	4.67	3	2
gsk 1016790a GSK1016790A : A tertiary carboxamide that is piperazine in which one of the amino groups has undergone condensation with the carboxy group of N-[(2,4-dichlorophenyl)sulfonyl]-L-serine, while the other has undergone condensation with the carboxy group of N-(1-benzothiophen-2-ylcarbonyl)-L-leucine. It is a cell-permeable, potent and selective agonist of the TRPV4 (transient receptor potential vanilloid 4) channel.	2.08	1	0	1-benzothiophenes; aromatic primary alcohol; dichlorobenzene; N-acylpiperazine; sulfonamide; tertiary carboxamide	TRPV4 agonist
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	7.55	8	2	organosulfonic acid
bucladesine Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.	1.98	1	0	3',5'-cyclic purine nucleotide
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.08	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
sodium lactate Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.	3.23	1	0	lactate salt; organic sodium salt	food acidity regulator; food preservative
piperacillin sodium [no description available]	2.08	1	0	organic sodium salt
sodium iothalamate [no description available]	3.23	1	0
oxacillin sodium [no description available]	2.08	1	0	organic sodium salt
cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.	2.08	1	0	organic sodium salt
xk 469 XK 469: structure in first source	2.03	1	0
azlocillin sodium [no description available]	2.08	1	0	organic sodium salt
chiniofon Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.	2.08	1	0
arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.	5.32	5	0
olaparib [no description available]	5.77	6	1	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
thiostrepton Thiostrepton: One of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders.. thiostrepton : A heterodetic cyclic peptide, in which the cyclisation step involves a formal lactonisation between the carboxy group of a quinaldic acid-based residue and a secondary alcohol. An antibiotic that inhibits bacterial protein synthesis. Also acts as an antitumor agent.	2.49	2	0
srt1720 [no description available]	2.08	1	0
plx 4720 PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source	2.08	1	0	aromatic ketone; difluorobenzene; organochlorine compound; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
cx 4945 [no description available]	2.08	1	0
cudc 101 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source	2.58	2	0
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	3.41	1	0	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
mln 8237 MLN 8237: an aurora kinase A inhibitor	4.72	6	1	benzazepine
tenovin-6 tenovin-6 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(dimethylamino)pentanoic acid with the aromatic amino group of N-[(4-aminophenyl)carbamothioyl]-4-tert-butylbenzamide.	2.1	1	0	monocarboxylic acid amide; tertiary amino compound; thioureas	antineoplastic agent; p53 activator; Sir2 inhibitor
lde225 sonidegib: specific Smoothened/Smo antagonist. sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.	4.83	2	1	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist
gdc 0449 HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity	5.11	3	1	benzamides; monochlorobenzenes; pyridines; sulfone	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent
sgx 523 [no description available]	2.08	1	0	aryl sulfide; biaryl; pyrazoles; quinolines; triazolopyridazine	c-Met tyrosine kinase inhibitor; nephrotoxic agent
bms 754807 BMS 754807: an IGR-1R kinase inhibitor; structure in first source	2.06	1	0	pyrazoles; pyridines; pyrrolidines; pyrrolotriazine	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	2.08	1	0	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	2.53	2	0	imidazoles
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	2.08	1	0	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
ponatinib [no description available]	2.08	1	0	(trifluoromethyl)benzenes; acetylenic compound; benzamides; imidazopyridazine; N-methylpiperazine	antineoplastic agent; tyrosine kinase inhibitor
amg 900 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine: a pan-aurora kinase inhibitor; structure in first source	2.08	1	0
mk-1775 adavosertib: a Wee1 kinase inhibitor; structure in first source	2.08	1	0	piperazines
apalutamide [no description available]	5.92	8	0
bag956 BAG956: an imidazo[4,5-c]quinoline; dual PI3K/PDK-1 inhibitor, used in antileukemic therapies	2.08	1	0
quizartinib [no description available]	2.08	1	0	benzoimidazothiazole; isoxazoles; morpholines; phenylureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; necroptosis inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester CAY10603: a HDAC6 inhibitor	2.08	1	0	carbamate ester
tak 733 [no description available]	2.08	1	0
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	4.8	2	1	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	3.23	5	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
sns 314 SNS 314: an aurora kinase inhibitor; structure in first source	2.08	1	0	ureas
jzl 184 JZL 184: inhibits monoacylglycerol lipase; structure in first source	2.08	1	0	benzodioxoles
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene [no description available]	2.1	1	0	BODIPY compound
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide: a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source. momelotinib : A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.	2.08	1	0	aminopyrimidine; benzamides; morpholines; nitrile; secondary amino compound; tertiary amino compound	anti-anaemic agent; antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
dcc-2036 rebastinib: an inhibitor of Tie2 tyrosine kinase receptor and antineoplastic agent	2.08	1	0	organofluorine compound; phenylureas; pyrazoles; pyridinecarboxamide; quinolines	tyrosine kinase inhibitor
trelstar Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.	6.33	4	2
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	3.23	1	0	oligopeptide	antineoplastic agent; GnRH antagonist
deslorelin deslorelin: Ovuplant is tradename for a short-term-release implant containing deslorelin acetate; RN given refers to D-isomer; RN for cpd without isomeric designation not avail 12/90	2.05	1	0	oligopeptide
cabozantinib cabozantinib: a multikinase inhibitor. cabozantinib : A dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer.	6.31	5	2	aromatic ether; dicarboxylic acid diamide; organofluorine compound; quinolines	antineoplastic agent; tyrosine kinase inhibitor
defactinib [no description available]	2.17	1	0
N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide [no description available]	2.08	1	0	benzamides
incb-018424 [no description available]	2.55	2	0	nitrile; pyrazoles; pyrrolopyrimidine	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mannans [no description available]	2.07	1	0
bix 01294 [no description available]	2.08	1	0	piperidines
pexidartinib pexidartinib: inhibits both CSF1R and c-kit receptor tyrosine kinase; structure in first source. pexidartinib : A pyrrolopyridine that is 5-chloro-1H-pyrrolo[2,3-b]pyridine which is substituted by a [6-({[6-(trifluoromethyl)pyridin-3-yl]methyl}amino)pyridin-3-yl]methyl group at position 3. It is a potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, KIT, and FLT3 (IC50 of 20 nM, 10 nM and 160 nM, respectively). Approved by the FDA for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT).	2.21	1	0	aminopyridine; organochlorine compound; organofluorine compound; pyrrolopyridine; secondary amino compound	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pf 3845 PF 3845: inhibits fatty acid amide hydrolase	2.08	1	0	piperidines
gsk 2126458 omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.	2.08	1	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
ixazomib ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.	2.08	1	0	benzamides; boronic acids; dichlorobenzene; glycine derivative	antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor
ldn 193189 LDN 193189: inhibits bone morphogenetic protein signaling	2.08	1	0	pyrimidines
cx 5461 CX 5461: structure in first source	2.21	1	0	diazepine; naphthyridine derivative; organic heterotetracyclic compound; pyrazines; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.7.6 (RNA polymerase) inhibitor
azd2014 vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source	2.31	1	0
plx4032 [no description available]	3.14	4	0	aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide	antineoplastic agent; B-Raf inhibitor
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol [no description available]	2.08	1	0	biphenyls
gsk 1363089 GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source	2.08	1	0	aromatic ether
kin-193 [no description available]	2.08	1	0	pyridopyrimidine
glycolipids [no description available]	5.35	3	1
scyx 7158 [no description available]	3.27	1	0	(trifluoromethyl)benzenes
bay 869766 [no description available]	2.08	1	0
baricitinib [no description available]	2.31	1	0	azetidines; nitrile; pyrazoles; pyrrolopyrimidine; sulfonamide	anti-inflammatory agent; antirheumatic drug; antiviral agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; immunosuppressive agent
4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester WYE-354: an mTOR inhibitor; structure in first source	2.08	1	0	carbamate ester
piperidines Piperidines: A family of hexahydropyridines.	14.02	47	17
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone ML-265: a small molecule activator of PKM2	2.08	1	0	organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound
bryostatin 1 bryostatin 1: a protein kinase C activator; macrocyclic lactone from marine Bryozoan Bugula neritina; RN given refers to (1S-(1R,3R,5Z,7S,8E,11R,12R(2E,4E),13E,15R,17S(S),21S,23S,25R))-isomer; structure given in first source; activates protein kinase c. bryostatin 1 : A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.	4.46	1	1
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	7.13	14	2
dabrafenib [no description available]	2.08	1	0	1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide	anticoronaviral agent; antineoplastic agent; B-Raf inhibitor
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline [no description available]	2.08	1	0	benzenes; sulfonamide
cp 466722 [no description available]	2.08	1	0	quinazolines
CAY10626 [no description available]	2.08	1	0	ureas
thiopental sodium [no description available]	2.08	1	0	organochlorine compound; piperazines; pyrimidines	antineoplastic agent; tyrosine kinase inhibitor
ribociclib ribociclib: inhibits both CDK4 and CDK6	4.15	2	1
yk 4-279 YK 4-279: an antineoplastic agent that inhibits EWS-FLI1 oncoprotein; structure in first source	2.15	1	0	aromatic ketone
scutebarbatine a scutebarbatine A: has antineoplastic activity; isolated from Scutellaria barbata; structure in first source	2.13	1	0
apatinib apatinib: reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters; structure in first source	9.27	11	2
gx 15-070 obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma	3.48	1	1
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine sapanisertib: an mTOR inhibitor	4.61	1	1	benzoxazole
pha 793887 [no description available]	2.08	1	0	piperidinecarboxamide
pf 3084014 nirogacestat: an antineoplastic agent. nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment.	4.43	4	1
nvp-bsk805 [no description available]	2.08	1	0
xmd 8-92 XMD8-92 : A dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a [2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino substituent. It is an inhibitor of the BMK1 kinase pathway.	2.08	1	0	pyrimidobenzodiazepine	protein kinase inhibitor
jq1 compound [no description available]	2.08	1	0	carboxylic ester; organochlorine compound; tert-butyl ester; thienotriazolodiazepine	angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; bromodomain-containing protein 4 inhibitor; cardioprotective agent; ferroptosis inducer
jnj38877605 [no description available]	2.08	1	0	quinolines
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide [no description available]	2.08	1	0	benzothiazoles
nms p937 NMS P937: a polo-like kinase 1 inhibitor; structure in first source	2.21	1	0
calcipotriene calcipotriene: a topical dermatologic for the treatment of moderate plaque psoriasis; structure in first source. calcipotriol hydrate : A hydrate that is the monohydrate form of calcipotriol. It is used in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients.	2.31	1	0	hydrate	antipsoriatic
birinapant birinapant: a Smac mimetic with antineoplastic activity	2.11	1	0	dipeptide
torin 1 torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.08	1	0	N-acylpiperazine; N-arylpiperazine; organofluorine compound; pyridoquinoline; quinolines	antineoplastic agent; mTOR inhibitor
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	2.51	2	0	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
ly2940680 [no description available]	2.08	1	0
1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea [no description available]	2.08	1	0	ureas
ro 4929097 [no description available]	2.08	1	0	dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound	EC 3.4.23.46 (memapsin 2) inhibitor
gsk4112 GSK4112: a Rev-erbalpha agonist; structure in first source	2.08	1	0
azd4547 [no description available]	2.08	1	0	benzamides; N-arylpiperazine; pyrazoles	fibroblast growth factor receptor antagonist
methylcellulose Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.	3.18	5	0
torin 2 torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.	2.08	1	0	aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline	antineoplastic agent; mTOR inhibitor
pf-4708671 [no description available]	2.08	1	0
azd8186 [no description available]	2.54	2	0
apr-246 eprenetapopt: works in tandem with cisplatin to cause apoptosis of tumor cells; structure in first source	2.11	1	0
oligomycin a [no description available]	2.04	1	0	antibiotic antifungal agent; diketone; oligomycin; pentol	antineoplastic agent; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; nematicide
phosphomannopentaose sulfate phosphomannopentaose sulfate: structure in first source	4.4	2	2
natriuretic peptide, brain Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.	3.4	2	0	polypeptide
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	4.61	1	1
N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide [no description available]	2.08	1	0	benzamides; N-acylpiperidine
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide : A member of the class of quinazolines that is quinazoline substituted by {3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino and 3-(2-methoxyacetamido)prop-1-en-1-yl groups at positions 4 and 6, respectively.	2.08	1	0	aromatic ether; methylpyridines; olefinic compound; quinazolines; secondary amino compound; secondary carboxamide; toluenes
belinostat [no description available]	2.08	1	0	olefinic compound
heparitin sulfate Heparitin Sulfate: A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS.	2.21	1	0
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	4.27	5	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
raltegravir [no description available]	3.23	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	3.27	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	3.85	3	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	3.23	1	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	4.38	3	0
piroxicam [no description available]	3.61	2	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
roquinimex roquinimex: structure in first source	2.08	1	0	aromatic amide
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	3.87	3	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.08	1	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate: RN & structure given in first source	2.08	1	0	carboxylic acid; pyrroline
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	7.76	28	1	benzenes; hydroxycoumarin; methyl ketone
gimeracil gimeracil: a biochemical and pharmacological modulator of 5-FU	4.19	3	1	organic molecular entity
6-o-palmitoylascorbic acid [no description available]	2.13	1	0	fatty acid ester
demeclocycline Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	3.23	1	0
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	3.23	1	0	sulfonamide	antiviral drug; HIV protease inhibitor
tasquinimod tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source	4.78	2	1
minocycline hydrochloride [no description available]	2.08	1	0
tigecycline [no description available]	3.61	2	0
lornoxicam lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
clorobiocin clorobiocin: chlorine-containing antibiotic related to novobiocin	3.27	1	0
a 769662 [no description available]	2.08	1	0	biphenyls
s 1 (combination) S 1 (combination): consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer	19.48	270	82
dolutegravir [no description available]	2.15	1	0	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor
byl719 [no description available]	2.31	1	0	proline derivative
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	4.4	6	0
pf 3512676 ProMune: an anticancer adjuvant and immunostimulant	3.43	1	1
gastrin-releasing peptide Gastrin-Releasing Peptide: Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.	2.13	1	0
clay Clay: A naturally-occurring rock or soil constituent characterized by particles with a diameter of less than 0.005 mm. It is composed primarily of hydrous aluminum silicates, trace amounts of metal OXIDES, and organic matter.	2.31	1	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	6.27	12	1
LimKi 3 LIMKi3: LIMK inhibitor. LimKi 3 : A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.	2.08	1	0	1,3-thiazoles; dichlorobenzene; organofluorine compound; pyrazoles; secondary carboxamide	LIM kinase inhibitor
1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone [no description available]	2.08	1	0	pyrroles
2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole [no description available]	2.08	1	0	dipyrrins
ceritinib ceritinib: an anaplastic lymphoma kinase inhibitor. ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer.	5.34	4	1	aminopyrimidine; aromatic ether; organochlorine compound; piperidines; secondary amino compound; sulfone	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide [no description available]	2.08	1	0	tryptamines
3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione [no description available]	2.08	1	0	pyrazines
gsk837149a GSK837149A: structure in first source	2.08	1	0
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide [no description available]	2.08	1	0	quinazolines
N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide [no description available]	2.08	1	0	quinazolines
wnt-c59 2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source	2.08	1	0
5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime [no description available]	2.08	1	0	indanes
a-1155463 A-1155463: a Bcl-X(L) inhibitor; structure in first source	2.11	1	0
erdafitinib erdafitinib: inhibitor of fibroblast growth factor receptors	3.99	1	1
etirinotecan pegol [no description available]	4.45	1	1
idarucizumab [no description available]	2.41	1	0
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	5.64	5	1	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
a-1331852 A-1331852: a Bcl-X(L) inhibitor; structure in first source	2.11	1	0
agar Agar: A complex sulfated polymer of galactose units, extracted from Gelidium cartilagineum, Gracilaria confervoides, and related red algae. It is used as a gel in the preparation of solid culture media for microorganisms, as a bulk laxative, in making emulsions, and as a supporting medium for immunodiffusion and immunoelectrophoresis.. agar : A complex mixture of polysaccharides extracted from species of red algae. Its two main components are agarose and agaropectin. Agarose is the component responsible for the high-strength gelling properties of agar, while agaropectin provides the viscous properties.	2.44	2	0
cb-839 [no description available]	2.21	1	0
pf-06463922 lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein. lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.	4	2	0	aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
imetelstat [no description available]	4.78	2	1
ginsenoside rg5 ginsenoside Rg5: a major constituent of steamed Ginseng; structure in first source	2.17	1	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	6.8	12	2
caseins Caseins: A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.	2.05	1	0
ter 286 TER 286: a glutathione-based glutathione S-transferase-activated cytotoxin; TLK-286 is the ((R)-(-))-isomer	3.12	1	0
fertinex [no description available]	3.23	1	0
nov 002 NOV 002: a 1000-to-1 mixture of glutathione disulfide and cisplatin that is used to increase efficacy of chemotherapy against advanced non-small cell lung cancer; modulates cellular redox balance	4.37	1	1
oligomycins Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).	2.04	1	0
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.75	3	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.99	4	0
1 alpha,24-dihydroxyvitamin d3 1 alpha,24-dihydroxyvitamin D3: RN refers to (1alpha,3beta,5Z,7E)-isomer; formulated in ointment at a concentration of 4 microg/g, for treatment of mild psoriasis	2.77	3	0
ferric oxide, saccharated Ferric Oxide, Saccharated: A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.	3.44	1	1
hyaluronoglucosaminidase Hyaluronoglucosaminidase: An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.	5.04	3	1
apatorsen apatorsen: an antisense oligonucleotide that targets Hsp27 for support of cancer therapy	3.56	1	1
epoetin alfa Epoetin Alfa: A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients.	2.04	1	0
eldeline eldeline: Aconitum alkaloid; structure in first source	2.06	1	0
lipofectamine Lipofectamine: mediates gene transfer; a polycationic lipid reagent	2.43	2	0
cephalomannine cephalomannine: RN given refers to (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR,betaS(E)),11alpha,12alpha,12aalpha,12balpha))-isomer; RN for cpd without isomeric designation not available 7/88; structure given in first source	2.48	2	0
vitamin b 12 Vitamin B 12: A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.	4.13	3	1
oblimersen oblimersen: targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions	9.78	14	8
sermorelin Sermorelin: The biologically active fragment of human growth hormone-releasing factor, consisting of GHRH(1-29)-amide. This N-terminal sequence is identical in several mammalian species, such as human, pig, and cattle. It is used to diagnose or treat patients with GROWTH HORMONE deficiency.. sermorelin : A 29 amino acid polypeptide that is used to treat growth problems (usually in children) due to growth hormone deficiency. It is the biologically active fragment of human growth hormone-releasing factor (GHRH).	2.08	1	0
transforming growth factor alpha Transforming Growth Factor alpha: An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.	2.03	1	0
as 1411 AGRO 100: an antineoplastic agent that inhibits nuclear factor-kappaB activation; base sequence in first source	2.98	3	0
psma-617 PSMA-617: inhibits prostate-specific membrane antigen; structure in first source	4.21	2	1
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	9.88	17	5
silybin Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.	2.66	2	0
apicidin apicidin: structure in first source	2.07	1	0
lactoferrin Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.	3.21	4	0
protopanaxadiol protopanaxadiol: triterpenoid sapogenin of ginsenosides from leaves of Panax ginseng; has antineoplastic activity; acid hydrolysis results in panaxadiol. protopanaxadiol : A tetracyclic triterpenoid sapogenin (isolated from ginseng) that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 positions and in which a double bond has been introduced at the 24-25 position.	2.08	1	0
catalpol catalpol: component of dihuang; RN given refers to (1aS-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-isomer; RN for cpd without isomeric designation not avail 12/92	4.61	1	1
orabase Orabase: used in therapy of oral mucosal ulcers	3.81	10	0
apyrase Apyrase: A calcium-activated enzyme that catalyzes the hydrolysis of ATP to yield AMP and orthophosphate. It can also act on ADP and other nucleoside triphosphates and diphosphates. EC 3.6.1.5.	2.08	1	0
thromboplastin Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.	2.05	1	0
nedaplatin nedaplatin: structure given in first source	14.99	77	24
lewis y antigen [no description available]	2.43	2	0
chondroitin sulfates Chondroitin Sulfates: Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.	3.7	8	0
exudates Malaysia: A parliamentary democracy with a constitutional monarch in southeast Asia, consisting of 11 states (West Malaysia) on the Malay Peninsula and two states (East Malaysia) on the island of BORNEO. It is also called the Federation of Malaysia. Its capital is Kuala Lumpur. Before 1963 it was the Union of Malaya. It reorganized in 1948 as the Federation of Malaya, becoming independent from British Malaya in 1957 and becoming Malaysia in 1963 as a federation of Malaya, Sabah, Sarawak, and Singapore (which seceded in 1965). The form Malay- probably derives from the Tamil malay, mountain, with reference to its geography. (From Webster's New Geographical Dictionary, 1988, p715 & Room, Brewer's Dictionary of Names, 1992, p329)	4.16	3	1
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	3.61	2	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
chir 258 [no description available]	2.08	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	5.49	4	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug
osi 027 OSI 027: inhibits both mTORC1 and mTORC2; structure in first source	2.08	1	0
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	18.61	135	53	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
deoxyguanosine [no description available]	2.08	1	0	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanosine diphosphate Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.	2.92	4	0	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	4.89	11	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanine [no description available]	18.89	118	38	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	6.58	56	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
3-methyladenine N3-methyladenine: structure in first source	3.03	4	0
5'-guanylylmethylenebisphosphonate guanosine 5'-[beta,gamma-methylene]triphosphate : A nucleoside triphosphate analogue that is guanosine substituted at position 5' by a (beta,gamma-methylene)triphosphate group.	2	1	0	nucleoside triphosphate analogue
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	4.08	4	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	3.61	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	10.52	24	6	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	3.61	2	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	4.43	6	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valtrex [no description available]	2.08	1	0	organic molecular entity
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	4.96	2	1	L-valyl ester	antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	3.23	1	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	3.61	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
pralidoxime pralidoxime: RN given refers to parent cpd; chloride was minor descriptor (75-80); on-line & Index Medicus search PRALIDOXIME COMPOUNDS (66-80). pralidoxime : A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2.	2.11	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.21	1	0	2-aminopurines; propane-1,3-diols	antiviral drug
raltitrexed [no description available]	5.35	7	0	N-acyl-amino acid
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	3.23	1	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	3.91	3	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
hli 373 [no description available]	2.08	1	0
citrovorum factor [no description available]	3.61	2	0	tetrahydrofolic acid
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	3.23	1	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
rifapentine rifapentine: cyclopentyl derivative of rifampicin	3.61	2	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
bl 4162a anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.	3.23	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	3.23	1	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	20.44	188	63	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	4.02	2	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	3.02	4	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
valganciclovir Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.	3.23	1	0	L-valyl ester; purines	antiviral drug; prodrug
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	7.91	8	3	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
fosaprepitant fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.	4.5	3	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug
tegaserod maleate [no description available]	2.08	1	0	maleate salt	serotonergic agonist
rifabutin [no description available]	3.61	2	0
xav939 XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.	2.57	2	0	(trifluoromethyl)benzenes; thiopyranopyrimidine	tankyrase inhibitor
2-carboxyarabinitol 1-phosphate [no description available]	2.08	1	0
nintedanib nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer.	13.69	36	10
zd 9331 ZD 9331: BGC9331 was formerly known as ZD9331; structure in first source	3.4	1	1
9-(4-hydroxybutyl)guanine [no description available]	2.21	1	0
methylnitronitrosoguanidine Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position	2.02	1	0	nitroso compound	alkylating agent
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.08	1	0	guanosines	biomarker
amg531 [no description available]	2.08	1	0
ver 52296 luminespib : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.	2.08	1	0	aromatic amide; isoxazoles; monocarboxylic acid amide; morpholines; resorcinols	angiogenesis inhibitor; antineoplastic agent; Hsp90 inhibitor
levomefolate calcium levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.	3.23	1	0	organic calcium salt	antidepressant
sb-590885 N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine : A ketoxime that is the oxime of indan-1-one in which the hydrogen at position 5 has been replaced by an imidazol-5-yl group which has itself been substituted at positions 2 and 4 by p-[2-(dimethylamino)ethoxy]phenyl and pyridin-4-yl groups, respectively.	2.08	1	0	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound
sta 9090 [no description available]	5.14	5	2	ring assembly; triazoles
pf-477736 PF 00477736: a Chk1 inhibitor; structure in first source. PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).	2.47	2	0
fenobam fenobam: in USAN fenobam refers to monohydrate	2.08	1	0	ureas
sotorasib sotorasib: a KRAS(G12C) inhibitor. sotorasib : A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations.	2.6	1	0	acrylamides; methylpyridines; monofluorobenzenes; N-acylpiperazine; phenols; pyridopyrimidine; tertiary amino compound; tertiary carboxamide	antineoplastic agent
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one [no description available]	4.36	1	1
eye [no description available]	2.13	1	0
flutax 2 [no description available]	2.73	3	0
maltodextrin maltodextrin : A dextrin in which the D-glucose units are linked by alpha-(1->4) glycosidic bonds.	2.13	1	0
acetylcellulose acetylcellulose: coating compound. cellulose acetate : A glucan derivative obtained through the esterification of cellulose by acetic anhydride or acetic acid, resulting in the substitution of some of the hydroxy groups of cellulose by acetyl groups. It is used in a variety of applications including base material for photographic film, clothing, membrane filters, coatings, food packaging, and as a frame material for eyeglasses.	4.61	1	1
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.02	1	0
metallothionein Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.	2.46	2	0
nartograstim nartograstim: a mutein of recombinant human G-CSF	3.79	2	1
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	2.59	2	0
pyrimidinones Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.	4.83	2	1
phenanthrenes Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.	2.41	1	0

Condition	Relationship Strength	Studies	Trials
Acute Liver Injury, Drug-Induced [description not available]	7.51	11	2
Adverse Drug Event [description not available]	16.48	83	45
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	7.51	11	2
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	16.48	83	45
Benign Neoplasms [description not available]	24.49	655	216
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	24.49	655	216
Malignant Melanoma [description not available]	12.5	61	17
Experimental Neoplasms [description not available]	11.95	98	1
Cancer of Prostate [description not available]	30.62	2,515	1,088
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	12.5	61	17
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	30.62	2,515	1,088
Cancer of Head [description not available]	26.32	813	535
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	26.32	813	535
Experimental Hepatoma [description not available]	3.95	12	0
Angiogenesis, Pathologic [description not available]	14.33	85	10
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	4.6	9	0
Metastase [description not available]	28.97	1,448	939
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	28.97	1,448	939
Cancer of Ovary [description not available]	21.44	387	100
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	21.44	387	100
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	15.75	152	30
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	15.75	152	30
Genital Herpes [description not available]	2.21	1	0
Herpes Simplex Virus Infection [description not available]	2.47	2	0
Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.	2.21	1	0
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	2.47	2	0
Cancer of Pancreas [description not available]	18.8	156	61
Invasiveness, Neoplasm [description not available]	20.6	243	87
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	18.8	156	61
Colorectal Cancer [description not available]	10.46	38	4
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	10.46	38	4
Breast Cancer [description not available]	31.35	3,245	1,467
Breast Neoplasms Tumors or cancer of the human BREAST.	31.35	3,245	1,467
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	18.9	214	85
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Carcinoma, Non-Small Cell Lung [description not available]	33.06	3,864	2,985
Cancer of Lung [description not available]	33.33	4,344	3,070
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	33.06	3,864	2,985
Lung Neoplasms Tumors or cancer of the LUNG.	33.33	4,344	3,070
Androgen-Independent Prostatic Cancer [description not available]	25.18	911	216
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	25.18	911	216
Bone Cancer [description not available]	21.1	348	110
Ewing Sarcoma [description not available]	7.68	5	5
(pPNET) Peripheral Primitive Neuroectodermal Tumors [description not available]	3.7	1	1
Local Neoplasm Recurrence [description not available]	26.04	841	479
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	21.1	348	110
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	7.68	5	5
Neuroectodermal Tumors, Primitive, Peripheral A group of highly cellular primitive round cell neoplasms which occur extracranially in soft tissue and bone and are derived from embryonal neural crest cells. These tumors occur primarily in children and adolescents and share a number of characteristics with EWING SARCOMA.	3.7	1	1
Febrile Neutropenia Fever accompanied by a significant reduction in the number of NEUTROPHILS.	13.08	52	14
Bladder Cancer [description not available]	16.55	111	25
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	16.55	111	25
Adenocarcinoma, Basal Cell [description not available]	27.16	1,241	774
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	27.16	1,241	774
Lung Adenocarcinoma [description not available]	12.48	56	7
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	12.48	56	7
Cancer of Esophagus [description not available]	22.64	501	219
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	22.64	501	219
Cancer of Stomach [description not available]	25.4	856	359
Stomach Neoplasms Tumors or cancer of the STOMACH.	25.4	856	359
Hypermelanosis [description not available]	4.96	8	1
Anasarca [description not available]	12.2	33	13
Cancer of Intestines [description not available]	6.55	6	1
Sclerosis A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.	2.58	2	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	12.2	33	13
Intestinal Neoplasms Tumors or cancer of the INTESTINES.	6.55	6	1
Hyperpigmentation Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.	4.96	8	1
Epithelial Ovarian Cancer [description not available]	11.75	43	20
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	11.75	43	20
Lassitude [description not available]	16.62	76	64
Leukocytopenia [description not available]	16.4	139	93
Chemotherapy-Induced Febrile Neutropenia FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.	9.42	32	5
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	14.22	82	61
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	12.2	33	24
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	16.62	76	64
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	16.4	139	93
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	25.62	779	577
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	17.41	123	61
Aerobic Glycolysis, Oncologic [description not available]	2.31	1	0
Microsatellite Instability The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.	3.79	3	0
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	15.74	66	31
Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment.	2.57	2	0
Bleeding [description not available]	6.99	10	3
Nail Diseases Diseases of the nail plate and tissues surrounding it. The concept is limited to primates.	14.57	56	11
Onycholysis Separation of nail plate from the underlying nail bed. It can be a sign of skin disease, infection (such as ONYCHOMYCOSIS) or tissue injury.	10.49	13	5
Incontinentia Pigmenti Achromians [description not available]	4.54	5	0
Hemorrhage Bleeding or escape of blood from a vessel.	6.99	10	3
Disease Exacerbation [description not available]	27.52	989	675
Carcinoma, Squamous Cell of Head and Neck [description not available]	17.76	121	56
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	17.76	121	56
Carcinoma, Epidermoid [description not available]	28.77	1,803	1,337
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	28.77	1,803	1,337
Peripheral Nerve Diseases [description not available]	17.96	109	34
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	17.96	109	34
Ductal Carcinoma [description not available]	9.81	17	5
Adenocystic Carcinoma [description not available]	4.54	5	1
Cancer of Salivary Gland [description not available]	7.18	9	4
Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)	4.54	5	1
Salivary Gland Neoplasms Tumors or cancer of the SALIVARY GLANDS.	7.18	9	4
Carcinoma, Ductal Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.	9.81	17	5
Carcinoma, Anaplastic [description not available]	20.06	236	105
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	20.06	236	105
2019 Novel Coronavirus Disease [description not available]	10.7	16	10
Allergic Reaction [description not available]	5.55	5	1
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	5.55	5	1
Dermatoses [description not available]	10.19	20	9
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	10.19	20	9
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	7.86	11	4
Mucositis, Oral [description not available]	12.89	37	22
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	16.52	79	61
Pneumonia Infection of the lung often accompanied by inflammation.	7.86	11	4
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	12.89	37	22
Cancer of Mouth [description not available]	14.81	77	27
Mouth Neoplasms Tumors or cancer of the MOUTH.	14.81	77	27
Benign Neoplasms, Brain [description not available]	15.72	108	22
Astrocytoma, Grade IV [description not available]	7.34	34	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	15.72	108	22
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.34	34	1
Lymph Node Metastasis [description not available]	22.41	470	210
Ocular Toxicity [description not available]	2.41	1	0
Cancer of Larynx [description not available]	11.86	48	16
Cancer of Nasopharynx [description not available]	19.25	191	118
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	11.86	48	16
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	19.25	191	118
Anal Cancer [description not available]	10.46	15	9
Anus Neoplasms Tumors or cancer of the ANAL CANAL.	10.46	15	9
Sarcoma, Epithelioid [description not available]	14.44	58	24
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	14.44	58	24
Cancer, Second Primary [description not available]	10.32	40	3
Acute Edematous Pancreatitis [description not available]	2.83	3	0
Acute Disease Disease having a short and relatively severe course.	9.2	22	2
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	2.83	3	0
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	6.75	4	3
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	13.56	27	18
Dermatitis Any inflammation of the skin.	5.61	6	1
Recrudescence [description not available]	16.2	99	40
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	13.49	72	23
Hematuria Presence of blood in the urine.	2.57	2	0
Hepatocellular Carcinoma [description not available]	11.58	42	7
Cancer of Liver [description not available]	20.41	283	99
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	11.58	42	7
Liver Neoplasms Tumors or cancer of the LIVER.	20.41	283	99
Urinary Retention Inability to empty the URINARY BLADDER with voiding (URINATION).	2.6	1	0
Glial Cell Tumors [description not available]	9.56	26	4
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	9.56	26	4
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	14.52	44	28
Blood Pressure, High [description not available]	11.39	17	12
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	11.39	17	12
Polyploid [description not available]	4.42	7	0
Carcinoma, Small Cell Lung [description not available]	8.8	15	3
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	8.8	15	3
Brill-Symmers Disease [description not available]	2.41	1	0
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	2.41	1	0
Dermatitis, Radiation-Induced [description not available]	8.7	21	2
Radiodermatitis A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.	8.7	21	2
Idiopathic Inflammatory Myopathies [description not available]	4.49	7	0
Ache [description not available]	14.67	52	28
Myositis Inflammation of a muscle or muscle tissue.	4.49	7	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	14.67	52	28
Minimal Disease, Residual [description not available]	12.28	38	14
Cancer of Colon [description not available]	10.4	54	2
Colonic Neoplasms Tumors or cancer of the COLON.	10.4	54	2
Anoxemia [description not available]	6.04	9	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	6.04	9	1
Atypical Ductal Hyperplasia [description not available]	7.62	11	2
Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.	7.62	11	2
Disbacteriosis [description not available]	2.41	1	0
Encephalopathy, Toxic [description not available]	10.87	16	5
Acute Pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.	4.72	1	1
Innate Inflammatory Response [description not available]	16.99	58	38
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	16.99	58	38
Cancer of Cervix [description not available]	11.88	50	17
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	11.88	50	17
E coli Infections [description not available]	4.92	2	1
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	4.92	2	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	2.41	1	0
Chromosomal Translocation [description not available]	3.73	3	0
Itching [description not available]	5.15	3	1
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	9.12	23	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	5.15	3	1
Carcinoma, Intraepithelial [description not available]	4.75	6	1
Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.	4.75	6	1
Hypopharyngeal Cancer [description not available]	11.12	33	11
Hypopharyngeal Neoplasms Tumors or cancer of the HYPOPHARYNX.	11.12	33	11
Aortitis Inflammation of the wall of the AORTA.	3.86	3	0
Epiphora [description not available]	6.3	13	1
Central Retinal Edema, Cystoid [description not available]	3.22	5	0
Cranial Nerve II Diseases [description not available]	2.63	2	0
Lacrimal Apparatus Diseases Diseases of the LACRIMAL APPARATUS.	6.3	13	1
Macular Edema Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)	3.22	5	0
Optic Nerve Diseases Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.	2.63	2	0
Benign Meningeal Neoplasms [description not available]	5.95	9	1
Angioblastic Meningioma [description not available]	2.6	1	0
Meningeal Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.	5.95	9	1
Meningioma A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)	2.6	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	9.66	39	3
Response Evaluation Criteria in Solid Tumors An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.	8.83	14	6
Dysplastic Nevus Syndrome, Hereditary [description not available]	3.2	4	0
Cancer of Skin [description not available]	11.31	82	15
Skin Neoplasms Tumors or cancer of the SKIN.	11.31	82	15
Atypical Lipomatous Tumor [description not available]	5.16	6	0
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	5.16	6	0
Nerve Pain [description not available]	6.89	8	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	6.89	8	1
Pyrexia [description not available]	14.85	61	32
Emesis [description not available]	15.59	74	57
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	14.85	61	32
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	15.99	100	75
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	4.75	3	2
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	15.59	74	57
Cells, Neoplasm Circulating [description not available]	15.03	63	25
Alopecia Cicatrisata [description not available]	15.68	84	54
Alopecia Absence of hair from areas where it is normally present.	15.68	84	54
Coagulation, Disseminated Intravascular [description not available]	5.42	8	0
Neoplasms, Bone Marrow [description not available]	7.12	7	1
Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.	5.42	8	0
Bone Marrow Neoplasms Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.	7.12	7	1
Cardiac Toxicity [description not available]	5.8	16	1
Carditis [description not available]	4.02	9	0
Carcinoma, Thymic [description not available]	5.05	13	0
Cancer of the Thymus [description not available]	6.47	14	1
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	4.02	9	0
Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)	5.05	13	0
Thymus Neoplasms Tumors or cancer of the THYMUS GLAND.	6.47	14	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	5.8	16	1
Acute Myelogenous Leukemia [description not available]	4.11	12	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	4.11	12	0
Cancer of the Tongue [description not available]	7.47	23	2
Tongue Neoplasms Tumors or cancer of the TONGUE.	7.47	23	2
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	5.92	8	1
Complication, Postoperative [description not available]	10.19	24	5
Anastomotic Leak Breakdown of the connection and subsequent leakage of effluent (fluids, secretions, air) from a SURGICAL ANASTOMOSIS of the digestive, respiratory, genitourinary, and cardiovascular systems. Most common leakages are from the breakdown of suture lines in gastrointestinal or bowel anastomosis.	2.76	2	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	10.19	24	5
Debility [description not available]	2.6	1	0
Breast Diseases Pathological processes of the BREAST.	2.6	1	0
Chronic Illness [description not available]	5.16	5	2
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	5.16	5	2
Atherogenesis [description not available]	8.27	7	4
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	8.27	7	4
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	6.31	8	1
Allergy, Drug [description not available]	14.76	62	16
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	14.76	62	16
Leiomyosarcoma, Epithelioid [description not available]	15.83	64	24
Cancer of the Uterus [description not available]	15.16	50	24
Leiomyosarcoma A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)	15.83	64	24
Uterine Neoplasms Tumors or cancer of the UTERUS.	15.16	50	24
Extra-Mammary Paget Disease [description not available]	4.48	20	0
Paget Disease, Extramammary A rare cutaneous neoplasm that occurs in the elderly. It develops more frequently in women and predominantly involves apocrine gland-bearing areas, especially the vulva, scrotum, and perianal areas. The lesions develop as erythematous scaly patches that progress to crusted, pruritic, erythematous plaques. The clinical differential diagnosis includes squamous cell carcinoma in situ and superficial fungal infection. It is generally thought to be an adenocarcinoma of the epidermis, from which it extends into the contiguous epithelium of hair follicles and eccrine sweat ducts. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1478)	4.48	20	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	7.46	17	3
Leukoencephalopathy Syndrome, Posterior [description not available]	3.53	2	0
Bilateral Headache [description not available]	2.6	1	0
Absence Seizure [description not available]	18.29	170	169
Thrombopenia [description not available]	16.39	79	57
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	2.6	1	0
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	18.29	170	169
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	16.39	79	57
Diffuse Parenchymal Lung Disease [description not available]	10.16	29	6
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	10.16	29	6
Bone Marrow Diseases Diseases involving the BONE MARROW.	6.82	5	1
Osteolysis Dissolution of bone that particularly involves the removal or loss of calcium.	5.89	8	1
Dysgeusia A condition characterized by alterations of the sense of taste which may range from mild to severe, including gross distortions of taste quality.	6.68	6	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	14.31	41	17
Angiosarcoma [description not available]	6.91	35	0
Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)	6.91	35	0
Allergic Contact Dermatitis [description not available]	2.6	1	0
Palmoplantaris Pustulosis [description not available]	3.22	5	0
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	3.22	5	0
Dermatitis, Allergic Contact A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.	2.6	1	0
Cryptosporidium Infection [description not available]	2.6	1	0
Cryptosporidiosis Intestinal infection with organisms of the genus CRYPTOSPORIDIUM. It occurs in both animals and humans. Symptoms include severe DIARRHEA.	2.6	1	0
Synovioma [description not available]	4.74	3	2
Sarcoma, Synovial A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)	4.74	3	2
Cardiac Remodeling, Ventricular [description not available]	4.72	1	1
Asthma, Bronchial [description not available]	5.94	2	2
Auricular Fibrillation [description not available]	5.14	3	1
Allergic Conjunctivitis [description not available]	4.72	1	1
Cardiac Failure [description not available]	13.14	26	22
Hemothorax Hemorrhage within the pleural cavity.	4.72	1	1
MS (Multiple Sclerosis) [description not available]	4.87	2	1
Cardiovascular Stroke [description not available]	7.13	7	3
Dry Eye [description not available]	7.84	4	4
Cardiac Arrest, Sudden [description not available]	4.72	1	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	5.94	2	2
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	5.14	3	1
Conjunctivitis, Allergic Conjunctivitis due to hypersensitivity to various allergens.	4.72	1	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	13.14	26	22
Keratoconus A noninflammatory, usually bilateral protrusion of the cornea, the apex being displaced downward and nasally. It occurs most commonly in females at about puberty. The cause is unknown but hereditary factors may play a role. The -conus refers to the cone shape of the corneal protrusion. (From Dorland, 27th ed)	4.72	1	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	4.87	2	1
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	7.13	7	3
Dry Eye Syndromes Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.	7.84	4	4
Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)	4.72	1	1
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	3.95	2	1
Constriction, Pathological [description not available]	5.07	3	1
Dysphagia [description not available]	3.53	7	0
Esophageal Stricture [description not available]	5.33	4	1
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	5.07	3	1
Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS.	3.53	7	0
Esophageal Stenosis A stricture of the ESOPHAGUS. Most are acquired but can be congenital.	5.33	4	1
Breathlessness [description not available]	8.56	10	6
Dyspnea Difficult or labored breathing.	8.56	10	6
HPV Infection [description not available]	9.93	21	7
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	9.93	21	7
Eye Disorders [description not available]	2.25	1	0
Eye Diseases Diseases affecting the eye.	2.25	1	0
Injuries, Radiation [description not available]	8.55	20	8
Complications, Neoplastic Pregnancy [description not available]	7.06	13	0
Preterm Birth [description not available]	2.21	1	0
Stillbirth The event that a FETUS is born dead or stillborn.	2.21	1	0
Neonatal Death The death of a live-born INFANT less than 28 days of age.	2.21	1	0
Abnormalities, Congenital [description not available]	2.21	1	0
Infantile Respiratory Distress Syndrome [description not available]	2.21	1	0
Infant, Small for Gestational Age An infant having a birth weight lower than expected for its gestational age.	2.21	1	0
Respiratory Distress Syndrome, Newborn A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.	2.21	1	0
Premature Birth CHILDBIRTH before 37 weeks of PREGNANCY (259 days from the first day of the mother's last menstrual period, or 245 days after FERTILIZATION).	2.21	1	0
Adenocarcinoma, Papillary An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)	5.06	3	1
Intestinal Perforation Opening or penetration through the wall of the INTESTINES.	4.71	6	0
Adenopathy [description not available]	2.21	1	0
Experimental Mammary Neoplasms [description not available]	7.58	58	0
Chemotherapy-Induced Acral Erythema [description not available]	9.5	19	5
Hand-Foot Syndrome Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.	9.5	19	5
Thyroid Cancer, Anaplastic [description not available]	5.68	6	1
Cancer of the Thyroid [description not available]	7.48	15	2
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	7.48	15	2
Thyroid Carcinoma, Anaplastic An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.	5.68	6	1
Extravascular Hemolysis [description not available]	7.21	32	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	7.21	32	1
Enterocolitis, Neutropenic A syndrome characterized by inflammation in the ILEUM, the CECUM, and the ASCENDING COLON. It is observed in cancer patients with CHEMOTHERAPY-induced NEUTROPENIA or in other immunocompromised individuals (IMMUNOCOMPROMISED HOST).	4.49	8	0
Cancer of Endometrium [description not available]	9.19	31	10
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	9.19	31	10
Hyponatremia Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)	5.38	7	2
Nasal Bleeding [description not available]	3.12	1	0
Exanthem [description not available]	9.17	14	3
Epistaxis Bleeding from the nose.	3.12	1	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	9.17	14	3
Bacterial Infections, Gram-Positive [description not available]	2.25	1	0
Hypogammaglobulinemia [description not available]	2.25	1	0
Agammaglobulinemia An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood.	2.25	1	0
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	2.25	1	0
Cancer of the Urinary Tract [description not available]	16.73	73	58
Sarcopenia Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.	2.9	3	0
Complications, Pregnancy [description not available]	2.21	1	0
Peritoneal Carcinomatosis [description not available]	18.59	162	76
Ascites Accumulation or retention of free fluid within the peritoneal cavity.	8.3	25	3
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	18.59	162	76
Entropion The turning inward (inversion) of the edge of the eyelid, with the tarsal cartilage turned inward toward the eyeball. (Dorland, 27th ed)	2.25	1	0
Day Blindness [description not available]	3.19	5	0
Cancer of Oropharnyx [description not available]	11.98	27	10
Oropharyngeal Neoplasms Tumors or cancer of the OROPHARYNX.	11.98	27	10
Pancytopenia Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.	2.25	1	0
Genetic Predisposition [description not available]	9.59	19	3
Fibrosis, Radiation [description not available]	7.49	13	4
Radiation Pneumonitis Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.	7.49	13	4
Pleural Effusion, Malignant Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.	9.5	18	4
Acquired Vocal Cord Palsy [description not available]	2.25	1	0
Vocal Cord Paralysis Congenital or acquired paralysis of one or both VOCAL CORDS. This condition is caused by defects in the CENTRAL NERVOUS SYSTEM, the VAGUS NERVE and branches of LARYNGEAL NERVES. Common symptoms are VOICE DISORDERS including HOARSENESS or APHONIA.	2.25	1	0
Pneumatosis Cystoides Intestinalis A condition characterized by the presence of multiple gas-filled cysts in the intestinal wall, the submucosa and/or subserosa of the INTESTINE. The majority of the cysts are found in the JEJUNUM and the ILEUM.	3.68	3	0
Blood Loss, Postoperative [description not available]	3.92	2	1
Ascites, Gelatinous [description not available]	2.25	1	0
Appendiceal Cancer [description not available]	2.54	2	0
Cholecystoduodenal Fistula [description not available]	2.52	2	0
Blood Loss, Surgical Loss of blood during a surgical procedure.	3.98	2	1
Appendiceal Neoplasms Tumors or cancer of the APPENDIX.	2.54	2	0
Pseudomyxoma Peritonei A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).	2.25	1	0
Weight Gain Increase in BODY WEIGHT over existing weight.	5.67	6	3
Asialia [description not available]	4.2	3	1
Xerostomia Decreased salivary flow.	4.2	3	1
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	6.56	10	1
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	11.79	26	10
Acute Lymphoid Leukemia [description not available]	5.04	3	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	5.04	3	1
Cardiac Cancer [description not available]	5.34	12	0
Acute Kidney Failure [description not available]	5.44	7	2
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	5.44	7	2
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	18.39	186	64
Carcinoma, Lobular A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.	15.65	75	45
Adenocarcinoma Of Kidney [description not available]	12.47	23	6
Cancer of Kidney [description not available]	13.5	34	9
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	12.47	23	6
Kidney Neoplasms Tumors or cancers of the KIDNEY.	13.5	34	9
Neoplasms, Squamous Cell Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.	11.61	20	11
Breast Cancer, Male [description not available]	10.19	19	8
Breast Cancer Lymphedema Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical treatment (e.g., MASTECTOMY) or radiation treatment of breast cancer.	2.25	1	0
Breast Neoplasms, Male Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.	10.19	19	8
Cognitive Decline [description not available]	3.82	3	0
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	3.82	3	0
Birth Weight The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.	6.19	2	1
Hibernation, Myocardial [description not available]	4.43	1	1
Tuberculosis, Drug-Resistant [description not available]	4.43	1	1
Infections, Coronavirus [description not available]	10.04	11	9
Chronic Hepatitis B [description not available]	4.43	1	1
Anterior Cerebral Circulation Infarction [description not available]	4.43	1	1
Apoplexy [description not available]	4.84	2	1
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	5.28	4	1
Airflow Obstruction, Chronic [description not available]	4.43	1	1
Gastrointestinal Stromal Neoplasm [description not available]	5.83	4	2
Complications of Diabetes Mellitus [description not available]	5.12	3	1
Bone Fractures [description not available]	4.77	2	1
Chronic Kidney Diseases [description not available]	7.73	5	4
Primary Graft Dysfunction A form of ischemia-reperfusion injury occurring in the early period following transplantation. Significant pathophysiological changes in MITOCHONDRIA are the main cause of the dysfunction. It is most often seen in the transplanted lung, liver, or kidney and can lead to GRAFT REJECTION.	4.43	1	1
Lung Injury, Acute [description not available]	4.8	2	1
Airway Remodeling The structural changes in the number, mass, size and/or composition of the airway tissues.	4.43	1	1
Atheroma [description not available]	4.87	2	1
Lower Urinary Tract Symptom [description not available]	4.43	1	1
Adolescent Obesity [description not available]	4.43	1	1
Allergic Rhinitis [description not available]	4.43	1	1
Encephalopathy, Traumatic [description not available]	4.43	1	1
Familial Nonmedullary Thyroid Cancer [description not available]	4.43	1	1
Acute Confusional Senile Dementia [description not available]	8.06	6	5
Rheumatoid Arthritis [description not available]	4.78	2	1
Amaurosis [description not available]	4.43	1	1
Bone Loss, Osteoclastic [description not available]	5.05	3	1
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	4.43	1	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	6.81	13	1
Clostridioides difficile Infection [description not available]	4.8	2	1
Alloxan Diabetes [description not available]	5.11	3	1
Autoimmune Diabetes [description not available]	5.24	2	1
Diabetes Mellitus, Adult-Onset [description not available]	4.85	2	1
Cutis Elastica [description not available]	4.43	1	1
Hepatitis B Virus Infection [description not available]	7.72	5	4
Fasting Hypoglycemia HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.	4.85	2	1
Chronic Insomnia [description not available]	6.58	3	2
Hypermobility, Joint [description not available]	4.43	1	1
Chronic Kidney Failure [description not available]	6.54	10	1
Cirrhosis, Liver [description not available]	5.64	3	2
B16 Melanoma [description not available]	8.16	35	1
Muscle Disorders [description not available]	5.94	3	1
Morbid Obesity [description not available]	4.43	1	1
Age-Related Osteoporosis [description not available]	8.22	6	4
Prediabetes [description not available]	4.43	1	1
Acute Respiratory Distress Syndrome [description not available]	5.91	5	1
Acute Hypercapnic Respiratory Failure [description not available]	6.22	7	1
Hemorrhagic Shock [description not available]	4.43	1	1
Blood Clot [description not available]	6.19	6	2
Pulmonary Consumption [description not available]	4.43	1	1
Deficiency, Vitamin D [description not available]	5.29	4	1
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	4.43	1	1
Injury, Ischemia-Reperfusion [description not available]	4.78	2	1
HIV Coinfection [description not available]	6.26	7	1
Bone Loss, Perimenopausal [description not available]	4.43	1	1
Bacterial Infections, Gram-Negative [description not available]	7.55	4	4
Carcinoma, Ductal, Pancreatic [description not available]	7.62	6	2
Hangman Fracture [description not available]	4.43	1	1
Idiopathic Interstitial Pneumonia [description not available]	4.43	1	1
Eye Infections, Fungal Infection by a variety of fungi, usually through four possible mechanisms: superficial infection producing conjunctivitis, keratitis, or lacrimal obstruction; extension of infection from neighboring structures - skin, paranasal sinuses, nasopharynx; direct introduction during surgery or accidental penetrating trauma; or via the blood or lymphatic routes in patients with underlying mycoses.	4.43	1	1
Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.	4.81	2	1
Delayed Effects, Prenatal Exposure [description not available]	4.77	2	1
Brain Injuries, Traumatic A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.	4.43	1	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	7.99	7	2
Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES.	4.43	1	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	8.06	6	5
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	4.78	2	1
Blindness The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.	4.43	1	1
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	9.44	8	5
Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.	4.8	2	1
Connective Tissue Diseases A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.	4.43	1	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	6.69	10	2
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	5.24	2	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	4.85	2	1
Ehlers-Danlos Syndrome A heterogeneous group of autosomally inherited COLLAGEN DISEASES caused by defects in the synthesis or structure of FIBRILLAR COLLAGEN. There are numerous subtypes: classical, hypermobility, vascular, and others. Common clinical features include hyperextensible skin and joints, skin fragility and reduced wound healing capability.	4.43	1	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	7.72	5	4
Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.	4.85	2	1
Sleep Initiation and Maintenance Disorders Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.	6.58	3	2
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	6.54	10	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	5.64	3	2
Muscular Diseases Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.	5.94	3	1
Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.	4.43	1	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	8.22	6	4
Pneumonia, Viral Inflammation of the lung parenchyma that is caused by a viral infection.	10.04	11	9
Prediabetic State The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).	4.43	1	1
Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.	5.91	5	1
Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)	6.22	7	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	6.19	6	2
Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung.	4.43	1	1
Uveitis Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)	4.43	1	1
Vitamin D Deficiency A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)	5.29	4	1
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	4.43	1	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	4.78	2	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	6.26	7	1
Osteoporosis, Postmenopausal Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.	4.43	1	1
Spinal Fractures Broken bones in the vertebral column.	4.43	1	1
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	7.55	4	4
Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.	4.43	1	1
Coronavirus Infections Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).	10.04	11	9
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	4.43	1	1
Brain Infarction Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.	4.43	1	1
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	4.84	2	1
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	5.28	4	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	7.62	6	2
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	4.43	1	1
Gastrointestinal Stromal Tumors All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).	5.83	4	2
Fractures, Bone Breaks in bones.	4.77	2	1
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	7.73	5	4
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	4.8	2	1
Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS.	4.43	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	14	89	14
Mucositis An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).	10.84	27	13
Adenosis of Breast [description not available]	3.17	1	0
Fibrocystic Breast Disease A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.	3.17	1	0
Carcinosarcoma A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)	4.58	5	1
Infectious Myelitis [description not available]	2.25	1	0
Spinal Neoplasms New abnormal growth of tissue in the SPINE.	4.78	11	0
FMR1-Related Primary Ovarian Insufficiency [description not available]	2.83	3	0
Primary Ovarian Insufficiency Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections. The most commonly known genetic cause is the expansion of a CGG repeat to 55 to 199 copies in the 5' untranslated region in the X-linked FMR1 gene.	2.83	3	0
Enterocolitis Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses.	3.45	7	0
Acute Promyelocytic Leukemia [description not available]	2.25	1	0
Multiple Primary Neoplasms [description not available]	6.21	17	2
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2.25	1	0
Cancer of Testis [description not available]	5.25	8	0
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	5.25	8	0
Animal Mammary Carcinoma [description not available]	4.44	20	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	3.02	4	0
Cancer-Associated Pain [description not available]	5.39	4	1
Cancer Pain Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.	5.39	4	1
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	3.02	4	0
Cancer of Penis [description not available]	6.68	10	2
Cancer of the Vulva [description not available]	3.67	3	0
Penile Neoplasms Cancers or tumors of the PENIS or of its component tissues.	6.68	10	2
Vulvar Neoplasms Tumors or cancer of the VULVA.	3.67	3	0
Nails, Ingrown Excessive lateral nail growth into the nail fold. Because the lateral margin of the nail acts as a foreign body, inflammation and granulation may result. It is caused by improperly fitting shoes and by improper trimming of the nail.	2.31	1	0
Polyneuropathy, Acquired [description not available]	5.13	5	2
Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.	5.13	5	2
Cancer of the Ureter [description not available]	4.11	5	0
Ureteral Neoplasms Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.	4.11	5	0
Primary Peritonitis [description not available]	4.24	6	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	4.24	6	0
Hemangioendothelioma, Epithelioid A tumor of medium-to-large veins, composed of plump-to-spindled endothelial cells that bulge into vascular spaces in a tombstone-like fashion. These tumors are thought to have borderline aggression, where one-third develop local recurrences, but only rarely metastasize. It is unclear whether the epithelioid hemangioendothelioma is truly neoplastic or an exuberant tissue reaction, nor is it clear if this is equivalent to Kimura's disease (see ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA). (Segen, Dictionary of Modern Medicine, 1992)	2.31	1	0
Cancer of Gastrointestinal Tract [description not available]	11.47	21	7
Chromosome Instability Syndromes [description not available]	2.25	1	0
Germinoblastoma [description not available]	3.88	2	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	3.88	2	1
Taste Disorder, Anterior Tongue [description not available]	2.25	1	0
Granuloma, Hodgkin [description not available]	2.57	2	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2.57	2	0
Thoracic Neoplasms New abnormal growth of tissue in the THORAX.	4.85	7	1
Digestive System Disorders [description not available]	2.31	1	0
Blood Diseases [description not available]	16.22	69	45
Nervous System Disorders [description not available]	10.62	19	10
Digestive System Diseases Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).	2.31	1	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	16.22	69	45
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	10.62	19	10
Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)	6.56	3	3
Reproductive Sterility [description not available]	2.31	1	0
Infertility A reduced or absent capacity to reproduce.	2.31	1	0
Liver Dysfunction [description not available]	9.01	9	2
Liver Diseases Pathological processes of the LIVER.	9.01	9	2
Malignant Mesothelioma [description not available]	2.31	1	0
Osteogenic Sarcoma [description not available]	10.38	26	3
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	10.38	26	3
Gastric Outlet Obstruction The hindering of output from the STOMACH into the SMALL INTESTINE. This obstruction may be of mechanical or functional origin such as EDEMA from PEPTIC ULCER; NEOPLASMS; FOREIGN BODIES; or AGING.	2.57	2	0
Male Genital Neoplasms [description not available]	3.92	4	0
Genital Neoplasms, Male Tumor or cancer of the MALE GENITALIA.	3.92	4	0
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	2.31	1	0
Proctitis INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE).	2.31	1	0
Dysembryoma [description not available]	2.8	3	0
Teratoma A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)	2.8	3	0
Rhabdoid Tumor A rare but highly lethal childhood tumor found almost exclusively in infants. Histopathologically, it resembles RHABDOMYOSARCOMA but the tumor cells are not of myogenic origin. Although it arises primarily in the kidney, it may be found in other parts of the body. The rhabdoid cytomorphology is believed to be the expression of a very primitive malignant cell. (From Holland et al., Cancer Medicine, 3d ed, p2210)	2.58	2	0
Conus Medullaris Syndrome [description not available]	3.69	3	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	3.76	10	0
Compensatory Hyperinsulinemia A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.	2.49	2	0
Insulin Sensitivity [description not available]	2.15	1	0
Hyperinsulinism A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.	2.49	2	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.15	1	0
Allodynia [description not available]	2.52	2	0
Endolymphatic Stromal Myosis [description not available]	2.15	1	0
Cystadenocarcinoma, Papillary An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.	3.36	2	0
Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)	8.85	17	5
Ovarian Diseases Pathological processes of the OVARY.	2.15	1	0
Female Genital Neoplasms [description not available]	9.73	19	3
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	9.73	19	3
Congenital Familial Lymphedema [description not available]	6.47	9	1
Spinal Diseases Diseases involving the SPINE.	3.06	1	0
Lymphedema Edema due to obstruction of lymph vessels or disorders of the lymph nodes.	6.47	9	1
Carcinoma, Basal Cell, Pigmented [description not available]	2.76	3	0
Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)	2.76	3	0
Carcinoma, Large Cell A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)	11.8	48	23
Dermatitis Medicamentosa [description not available]	11.75	55	9
Asystole [description not available]	2.54	2	0
Heart Arrest Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.	2.54	2	0
Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.	5.46	8	2
Biliary Tract Cancer [description not available]	7.16	6	6
Biliary Tract Neoplasms Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.	7.16	6	6
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	5.68	6	1
Lymphocytopenia [description not available]	7.33	9	5
Lymphopenia Reduction in the number of lymphocytes.	7.33	9	5
EHS Tumor [description not available]	4.02	5	0
Joint Pain [description not available]	7.71	7	2
Muscle Pain [description not available]	5.52	5	1
Arthralgia Pain in the joint.	7.71	7	2
Myalgia Painful sensation in the muscles.	5.52	5	1
Micrometastases, Neoplasm [description not available]	2.15	1	0
Pulmonary Arterial Remodeling [description not available]	2.15	1	0
Cirrhosis [description not available]	3.16	5	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	3.16	5	0
Cancer of Eye [description not available]	2.57	2	0
Episcleritis [description not available]	2.15	1	0
Scleritis Refers to any inflammation of the sclera including episcleritis, a benign condition affecting only the episclera, which is generally short-lived and easily treated. Classic scleritis, on the other hand, affects deeper tissue and is characterized by higher rates of visual acuity loss and even mortality, particularly in necrotizing form. Its characteristic symptom is severe and general head pain. Scleritis has also been associated with systemic collagen disease. Etiology is unknown but is thought to involve a local immune response. Treatment is difficult and includes administration of anti-inflammatory and immunosuppressive agents such as corticosteroids. Inflammation of the sclera may also be secondary to inflammation of adjacent tissues, such as the conjunctiva.	2.15	1	0
Eye Pain A dull or sharp painful sensation associated with the outer or inner structures of the eyeball, having different causes.	2.15	1	0
Cold Fingers, Hereditary [description not available]	2.17	1	0
Sclerosis, Systemic [description not available]	2.17	1	0
Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.	2.17	1	0
Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.	2.17	1	0
Long Sleeper Syndrome [description not available]	4.82	2	1
Sleep Wake Disorders Abnormal sleep-wake schedule or pattern associated with the CIRCADIAN RHYTHM which affect the length, timing, and/or rigidity of the sleep-wake cycle relative to the day-night cycle.	4.82	2	1
Cancer of Pharynx [description not available]	5.99	9	3
Pharyngeal Neoplasms Tumors or cancer of the PHARYNX.	5.99	9	3
Hormone-Dependent Neoplasms [description not available]	18.77	134	51
Pain, Chronic [description not available]	2.17	1	0
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	2.17	1	0
Blood Poisoning [description not available]	5.59	6	3
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	5.59	6	3
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	2.77	3	0
Autoimmune Thrombocytopenia [description not available]	2.52	2	0
Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.	2.52	2	0
Perforated Appendicitis [description not available]	3.43	2	0
Abscess, Abdominal [description not available]	3.06	1	0
Appendicitis Acute inflammation of the APPENDIX. Acute appendicitis is classified as simple, gangrenous, or perforated.	3.43	2	0
Abdominal Abscess An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)	3.06	1	0
Carcinoma, Colloid [description not available]	6.58	13	4
Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)	6.58	13	4
Hospital-Acquired Condition [description not available]	2.17	1	0
Kaposi Sarcoma [description not available]	5.38	7	2
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	5.38	7	2
Granulocytic Leukemia [description not available]	5.42	5	1
Dysmyelopoietic Syndromes [description not available]	2.97	4	0
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	5.42	5	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	2.97	4	0
Cholangiocellular Carcinoma [description not available]	6	5	2
Bile Duct Cancer [description not available]	6.02	5	2
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	6.02	5	2
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	6	5	2
Paraneoplastic Syndromes In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.	4.56	5	0
Petechiae Pinhead size (3 mm) skin discolorization due to hemorrhage.	2.17	1	0
Angiitis [description not available]	2.54	2	0
Purpura Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is	2.17	1	0
Vasculitis Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.	2.54	2	0
Arrhythmia [description not available]	5.8	4	2
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	5.8	4	2
Tumour Lysis Syndrome [description not available]	2.96	4	0
Tumor Lysis Syndrome A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.	2.96	4	0
Inflammatory Response Syndrome, Systemic [description not available]	2.17	1	0
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	2.17	1	0
Epithelial Neoplasms [description not available]	12.67	45	20
Esophageal Fistula Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.	3.06	1	0
Acute Mesenteric Arterial Embolus [description not available]	2.15	1	0
Intestinal Diseases Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.	2.49	2	0
Nephritis Inflammation of any part of the KIDNEY.	2.49	2	0
Adrenal Cancer [description not available]	4.06	5	0
Pheochromocytoma, Extra-Adrenal [description not available]	2.15	1	0
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	2.15	1	0
Esophageal Perforation An opening or hole in the ESOPHAGUS that is caused by TRAUMA, injury, or pathological process.	2.82	3	0
Colicky Pain [description not available]	6.19	6	2
Dendritic Cell Sarcoma, Follicular Sarcoma of FOLLICULAR DENDRITIC CELLS most often found in the lymph nodes. This rare neoplasm occurs predominately in adults.	2.17	1	0
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	6.19	6	2
Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi.	2.17	1	0
Paronychia An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)	5.07	3	1
Bacterial Skin Diseases [description not available]	2.17	1	0
Skin Diseases, Bacterial Skin diseases caused by bacteria.	2.17	1	0
Lymphoma, Primary Cutaneous Anaplastic Large Cell Anaplastic lymphoma of the skin which develops as a primary neoplasm expressing the CD30 ANTIGEN. It is characterized by solitary nodules or ulcerated tumors.	2.17	1	0
Actinic Keratosis [description not available]	2.17	1	0
Keratosis, Actinic White or pink lesions on the arms, hands, face, or scalp that arise from sun-induced DNA DAMAGE to KERATINOCYTES in exposed areas. They are considered precursor lesions to superficial SQUAMOUS CELL CARCINOMA.	2.17	1	0
Signet Ring Cell Carcinoma [description not available]	6.94	14	2
Carcinoma, Signet Ring Cell A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.	6.94	14	2
Atypical Hemolytic-Uremic Syndrome [description not available]	2.17	1	0
Atypical Hemolytic Uremic Syndrome An hereditary hemolytic uremic syndrome associated with variations in the gene that encodes COMPLEMENT FACTOR H, or the related proteins CFHR1 and CFHR3. Disease often progresses to CHRONIC KIDNEY FAILURE without the prodromal symptoms of ENTEROCOLITIS and DIARRHEA that characterize typical hemolytic uremic syndrome.	2.17	1	0
Weight Reduction [description not available]	7.96	13	4
Weight Loss Decrease in existing BODY WEIGHT.	7.96	13	4
Angioma A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.	2.17	1	0
Cancer of Spleen [description not available]	4.36	4	1
Hemangioma A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)	2.17	1	0
Drug Withdrawal Symptoms [description not available]	3.42	2	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	3.42	2	0
Infections, Reoviridae [description not available]	4.48	1	1
Cancer of the Fallopian Tube [description not available]	11.4	30	21
Fallopian Tube Neoplasms Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.	11.4	30	21
Kahler Disease [description not available]	5.13	10	1
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	5.13	10	1
Acute Generalised Exanthematous Pustulosis [description not available]	2.78	3	0
Adenocarcinoma, Clear Cell An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)	6.99	10	3
Hematoma A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.	2.17	1	0
Oligohydramnios A condition of abnormally low AMNIOTIC FLUID volume. Principal causes include malformations of fetal URINARY TRACT; FETAL GROWTH RETARDATION; GESTATIONAL HYPERTENSION; nicotine poisoning; and PROLONGED PREGNANCY.	3.67	3	0
Diseases of Nasopharynx [description not available]	2.17	1	0
Ulcer A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.	2.47	2	0
Congenital Epulides [description not available]	3.17	5	0
Brain Swelling [description not available]	2.17	1	0
Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)	2.17	1	0
Anemias, Iron-Deficiency [description not available]	2.17	1	0
Liver Steatosis [description not available]	2.17	1	0
Hematochezia The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.	5.4	7	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	2.17	1	0
Gastrointestinal Hemorrhage Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.	5.4	7	0
Anemia, Iron-Deficiency Anemia characterized by decreased or absent iron stores, low serum iron concentration, low transferrin saturation, and low hemoglobin concentration or hematocrit value. The erythrocytes are hypochromic and microcytic and the iron binding capacity is increased.	2.17	1	0
Genome Instability [description not available]	3.09	1	0
Carcinoma, Oat Cell [description not available]	14.36	52	13
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	14.36	52	13
Cardiac Diseases [description not available]	10.59	16	4
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	10.59	16	4
Fistula Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.	2.17	1	0
EBV Infections [description not available]	5.42	7	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	5.42	7	0
Extravasation of Contrast Media [description not available]	3.98	13	0
Cancer, Radiation-Induced [description not available]	3.4	2	0
Maxillary Neoplasms Cancer or tumors of the MAXILLA or upper jaw.	3.48	2	0
Auricular Cancer [description not available]	3.12	1	0
Ear Neoplasms Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).	3.12	1	0
Eosinophilia, Tropical [description not available]	2.55	2	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	2.55	2	0
Autoimmune Disease [description not available]	3.12	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	3.12	1	0
Alcohol Abuse [description not available]	2.21	1	0
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	2.21	1	0
Carcinomatous Meningitis [description not available]	2.21	1	0
Meningeal Carcinomatosis Primary or secondary neoplasm in the ARACHNOID or SUBARACHNOID SPACE. It appears as a diffuse fibrotic thickening of the MENINGES associated with variable degrees of inflammation.	2.21	1	0
Testicular Diseases Pathological processes of the TESTIS.	2.21	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	5.45	5	1
Infection [description not available]	7.07	13	7
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	7.07	13	7
Infusion Site Adverse Event [description not available]	2.21	1	0
Periphlebitis Periphlebitis is inflammation of the outer coat of a vein or of tissues surrounding the vein.	2.47	2	0
Phlebitis Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).	2.47	2	0
Emergencies Situations or conditions requiring immediate intervention to avoid serious adverse results.	2.21	1	0
Hypercoagulability [description not available]	5.07	3	1
Inflammatory Breast Cancer [description not available]	12.1	25	20
Symptom Cluster [description not available]	5.66	11	0
Syndrome A characteristic symptom complex.	5.66	11	0
Thrombophilia A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.	5.07	3	1
Inflammatory Breast Neoplasms Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.	12.1	25	20
Margins of Excision The edges of tissue removed in a surgery for assessment of the effectiveness of a surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. When the margin is negative or not involved by tumor (e.g., CANCER) it suggests all of the tumor has been removed by the surgery.	2.25	1	0
Cancer of the Tonsil [description not available]	3.01	4	0
Tonsillar Neoplasms Tumors or cancer of the PALATINE TONSIL.	3.01	4	0
Facial Dermatoses Skin diseases involving the FACE.	2.99	4	0
Neoplasms, Skull Base [description not available]	2.21	1	0
Cancer of Parotid [description not available]	3.45	7	0
Parotid Neoplasms Tumors or cancer of the PAROTID GLAND.	3.45	7	0
Diseases, Peripheral Vascular [description not available]	3.59	1	1
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	3.59	1	1
Asthenia Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.	11.9	23	19
Allergic Alveolitis, Extrinsic [description not available]	3.65	3	0
Granulomas [description not available]	2.08	1	0
Alveolitis, Extrinsic Allergic A common interstitial lung disease caused by hypersensitivity reactions of PULMONARY ALVEOLI after inhalation of and sensitization to environmental antigens of microbial, animal, or chemical sources. The disease is characterized by lymphocytic alveolitis and granulomatous pneumonitis.	3.65	3	0
Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.	2.08	1	0
Bednar Tumor [description not available]	3.43	2	0
Chordoma A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)	3	1	0
Dermatofibrosarcoma A sarcoma of the deep layers of the skin. The tumors are locally aggressive tends to recur but rarely metastatic. It can be classified into variants depending on the cell type tumors are derived from or by its characteristics: Pigmented variant from MELANIN-containing DERMAL DENDRITIC CELLS; Myxoid variant, myxoid STROMAL CELLS; Giant cell variant characterized by GIANT CELLS in the tumors; and Fibrosarcomatous variant chracterized by tumor areas histologically indistinguishable from FIBROSARCOMA.	3.43	2	0
Pyomyositis An intramuscular suppuration of the large skeletal muscle groups. It is associated with INFECTION such as STAPHYLOCOCCUS AUREUS and PYODERMA. It was known as a tropical disease but is increasing among the immunocompromised (IMMUNOCOMPROMISED HOST). Symptoms include muscle pain, FEVER, and leucocytosis. It has been diagnosed by MRI SCANS.	2.08	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	2.44	2	0
Hematologic Malignancies [description not available]	2.77	3	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	2.77	3	0
Malignant Fibrohistiocytic Tumors [description not available]	3	4	0
Adenoma, Basal Cell [description not available]	2.08	1	0
Adenoma A benign epithelial tumor with a glandular organization.	2.08	1	0
Histiocytoma, Malignant Fibrous The most commonly diagnosed soft tissue sarcoma. It is a neoplasm with a fibrohistiocytic appearance found chiefly in later adult life, with peak incidence in the 7th decade.	3	4	0
Left Ventricular Dysfunction [description not available]	15.49	68	66
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	15.49	68	66
Adenocarcinoma, Endometrioid [description not available]	5.26	6	2
Carcinoma, Endometrioid An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.	5.26	6	2
Neoplasm Metastasis, Unknown Primary [description not available]	8.08	20	5
Cancer of Gallbladder [description not available]	6.53	9	2
Gallbladder Neoplasms Tumors or cancer of the gallbladder.	6.53	9	2
Thrombotic Microangiopathies Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.	2.47	2	0
Esophageal Diseases Pathological processes in the ESOPHAGUS.	2.08	1	0
Arterial Obstructive Diseases [description not available]	2.08	1	0
Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.	2.08	1	0
Cancer, Embryonal [description not available]	2.93	4	0
Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.	2.93	4	0
Lacrimal Duct Obstruction Interference with the secretion of tears by the lacrimal glands. Obstruction of the LACRIMAL SAC or NASOLACRIMAL DUCT causing acute or chronic inflammation of the lacrimal sac (DACRYOCYSTITIS). It is caused also in infants by failure of the nasolacrimal duct to open into the inferior meatus and occurs about the third week of life. In adults occlusion may occur spontaneously or after injury or nasal disease. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p250)	6.83	13	2
Adrenocortical Carcinoma A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.	3.83	2	1
Adrenal Cortex Cancer [description not available]	4.13	3	1
Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX.	4.13	3	1
Congenital Thrombotic Thrombocytopenic Purpura [description not available]	2.77	3	0
Purpura, Thrombotic Thrombocytopenic An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.	2.77	3	0
Cachexia General ill health, malnutrition, and weight loss, usually associated with chronic disease.	3.66	3	0
Fecal Impaction Formation of a firm impassable mass of stool in the RECTUM or distal COLON.	2.1	1	0
Acne Rosacea [description not available]	2.1	1	0
Spider Veins [description not available]	2.1	1	0
Nasal Diseases [description not available]	2.46	2	0
Rosacea A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).	2.1	1	0
Telangiectasis Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.	2.1	1	0
Bullous Dermatoses [description not available]	2.45	2	0
Hand Dermatosis [description not available]	7.33	15	1
Hand Dermatoses Skin diseases involving the HANDS.	7.33	15	1
Adenocarcinoma, Scirrhous An adenocarcinoma with a hard (Greek skirrhos, hard) structure owing to the formation of dense connective tissue in the stroma. (From Dorland, 27th ed)	3.74	10	0
Polyarthritis [description not available]	2.08	1	0
Fasciitis Inflammation of the fascia. There are three major types: 1, Eosinophilic fasciitis, an inflammatory reaction with eosinophilia, producing hard thickened skin with an orange-peel configuration suggestive of scleroderma and considered by some a variant of scleroderma; 2, Necrotizing fasciitis (FASCIITIS, NECROTIZING), a serious fulminating infection (usually by a beta hemolytic streptococcus) causing extensive necrosis of superficial fascia; 3, Nodular/Pseudosarcomatous /Proliferative fasciitis, characterized by a rapid growth of fibroblasts with mononuclear inflammatory cells and proliferating capillaries in soft tissue, often the forearm; it is not malignant but is sometimes mistaken for fibrosarcoma.	2.08	1	0
Arthritis Acute or chronic inflammation of JOINTS.	2.08	1	0
Pneumothorax, Primary Spontaneous [description not available]	2.98	4	0
Pneumothorax An accumulation of air or gas in the PLEURAL CAVITY, which may occur spontaneously or as a result of trauma or a pathological process. The gas may also be introduced deliberately during PNEUMOTHORAX, ARTIFICIAL.	2.98	4	0
Lupus Erythematosus, Cutaneous, Subacute [description not available]	4.85	7	0
Chilblains Recurrent localized itching, swelling and painful erythema on the fingers, toes or ears, produced by exposure to cold.	2.08	1	0
Lupus Erythematosus, Cutaneous A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID).	4.85	7	0
Dysesthesia [description not available]	8.9	14	4
Chills The sudden sensation of being cold. It may be accompanied by SHIVERING.	3.47	1	1
Blood Pressure, Low [description not available]	5.3	2	2
Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.	5.3	2	2
Carcinoma, Adenosquamous A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.	5.6	6	1
Pink Eye [description not available]	3.64	3	0
Conjunctivitis INFLAMMATION of the CONJUNCTIVA.	3.64	3	0
Keratitis Inflammation of the cornea.	2.1	1	0
Fibroid [description not available]	4.55	5	0
Cancer of the Vagina [description not available]	2.08	1	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	4.55	5	0
Vaginal Neoplasms Tumors or cancer of the VAGINA.	2.08	1	0
Choroid Neovascularization [description not available]	2.08	1	0
Cancer of the Urethra [description not available]	3.85	2	1
Urethral Neoplasms Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.	3.85	2	1
Asymptomatic Conditions [description not available]	3	1	0
Krukenberg Carcinoma [description not available]	3.39	2	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	4.85	7	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	4.85	7	1
Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)	4.81	7	1
Cancer of Nose [description not available]	4.97	8	1
Facial Neoplasms New abnormal growth of tissue in the FACE.	2.08	1	0
Allergic Encephalomyelitis [description not available]	2.08	1	0
Aprosodia [description not available]	2.08	1	0
Acquired Immune Deficiency Syndrome [description not available]	4.36	4	1
Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	4.36	4	1
Bisphosphonate Osteonecrosis [description not available]	2.08	1	0
Abscess, Retropharyngeal [description not available]	2.08	1	0
Sarcoma 180 An experimental sarcoma of mice.	2.99	4	0
Adenomatous Polyposis Coli, Familial [description not available]	2.08	1	0
Adenomatous Polyposis Coli A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.	2.08	1	0
Endometrial Stromal Sarcoma [description not available]	2.1	1	0
Sarcoma, Endometrial Stromal A highly malignant subset of neoplasms arising from the endometrial stroma. Tumors in this group infiltrate the stroma with a wide range of atypia cells and numerous mitoses. They are capable of widespread metastases (NEOPLASM METASTASIS).	2.1	1	0
Capillary Leak Syndrome A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously. If not treated, generalized vascular leak can lead to generalized EDEMA; SHOCK; cardiovascular collapse; and MULTIPLE ORGAN FAILURE.	2.72	3	0
Cancer of Duodenum [description not available]	4.21	6	0
Retinal Pigment Epithelial Detachment [description not available]	2.1	1	0
Choroid Neoplasms Tumors of the choroid; most common intraocular tumors are malignant melanomas of the choroid. These usually occur after puberty and increase in incidence with advancing age. Most malignant melanomas of the uveal tract develop from benign melanomas (nevi).	4.33	7	0
Retinal Detachment Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).	2.1	1	0
Neoplasms, Otorhinolaryngologic [description not available]	5.11	5	2
Funnel Chest A developmental anomaly in which the lower sternum is posteriorly dislocated and concavely deformed, resulting in a funnel-shaped thorax.	2.1	1	0
Age-Related Memory Disorders [description not available]	3.68	3	0
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	3.68	3	0
Pulsatile Tinnitus [description not available]	4.4	1	1
Tinnitus A nonspecific symptom of hearing disorder characterized by the sensation of buzzing, ringing, clicking, pulsations, and other noises in the ear. Objective tinnitus refers to noises generated from within the ear or adjacent structures that can be heard by other individuals. The term subjective tinnitus is used when the sound is audible only to the affected individual. Tinnitus may occur as a manifestation of COCHLEAR DISEASES; VESTIBULOCOCHLEAR NERVE DISEASES; INTRACRANIAL HYPERTENSION; CRANIOCEREBRAL TRAUMA; and other conditions.	4.4	1	1
Giant Cell Tumors Tumors of bone tissue or synovial or other soft tissue characterized by the presence of giant cells. The most common are giant cell tumor of tendon sheath and GIANT CELL TUMOR OF BONE.	2.08	1	0
Deep Vein Thrombosis [description not available]	5.37	7	2
Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein.	5.37	7	2
Cancer of Jejunum [description not available]	3	1	0
Lymphangitis A lymphatic disease characterized by INFLAMMATION of LYMPHATIC VESSELS.	3.67	3	0
Disease, Pulmonary [description not available]	4.82	7	1
Besnier-Boeck Disease [description not available]	2.08	1	0
Lung Diseases Pathological processes involving any part of the LUNG.	4.82	7	1
Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.	2.08	1	0
Diffuse Large B-Cell Lymphoma [description not available]	2.1	1	0
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	2.1	1	0
Sex Disorders [description not available]	3.48	1	1
Sexual Dysfunction, Physiological Physiological disturbances in normal sexual performance in either the male or the female.	3.48	1	1
Hot Flashes A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)	3.48	1	1
Back Ache [description not available]	4.9	4	2
Back Pain Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.	4.9	4	2
Cholera Infantum [description not available]	15.38	43	31
Uveal Neoplasms Tumors or cancer of the UVEA.	4.96	4	0
Choked Disk [description not available]	2.1	1	0
Papilledema Swelling of the OPTIC DISK, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of the disk margins, microhemorrhages, blind spot enlargement, and engorgement of retinal veins. Chronic papilledema may cause OPTIC ATROPHY and visual loss. (Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p175)	2.1	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	6.96	9	2
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	6.96	9	2
Central Nervous System Neoplasm [description not available]	5.59	3	2
Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.	5.59	3	2
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	8.06	7	5
Postpartum Amenorrhea [description not available]	7.51	8	4
Amenorrhea Absence of menstruation.	7.51	8	4
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	4.9	4	2
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	4.37	4	1
Cancer of Paranasal Sinus [description not available]	3.35	6	0
Paranasal Sinus Neoplasms Tumors or cancer of the PARANASAL SINUSES.	3.35	6	0
Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.	8.72	13	9
Thromboembolism, Venous [description not available]	3.9	2	1
Venous Thromboembolism Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.	3.9	2	1
Neoplasms, Bronchial [description not available]	2.1	1	0
Bronchial Neoplasms Tumors or cancer of the BRONCHI.	2.1	1	0
Delayed Hypersensitivity [description not available]	3.9	2	1
Atopic Hypersensitivity [description not available]	2.46	2	0
Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).	3.35	2	0
Colonic Diseases Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).	3.38	2	0
Neuroectodermal Tumors Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells.	2.45	2	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.11	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.11	1	0
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	2.13	1	0
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	2.13	1	0
Carcinoma, Mucoepidermoid A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)	2.47	2	0
Intestinal Obstruction Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL.	2.1	1	0
Sicca Syndrome [description not available]	2.1	1	0
Sjogren's Syndrome Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.	2.1	1	0
Anterior Urethral Stricture [description not available]	2.1	1	0
Urethral Stricture Narrowing of any part of the URETHRA. It is characterized by decreased urinary stream and often other obstructive voiding symptoms.	2.1	1	0
Impairment, Light Touch Sensation [description not available]	3.48	1	1
Air Embolism [description not available]	3.01	1	0
Intradural-Extramedullary Spinal Cord Neoplasms [description not available]	2.45	2	0
Spinal Cord Neoplasms Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.	2.45	2	0
Cancer of Pelvis [description not available]	5.23	6	2
Barrett Epithelium [description not available]	3.41	2	0
Barrett Esophagus A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.	3.41	2	0
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	2.11	1	0
Uveal Diseases Diseases of the uvea.	2.11	1	0
Ascites, Chylous [description not available]	2.11	1	0
Chylothorax The presence of chyle in the thoracic cavity. (Dorland, 27th ed)	2.46	2	0
Convulsions, Grand Mal [description not available]	3.03	1	0
Brachial Paresis [description not available]	3.39	2	0
Anton Syndrome [description not available]	3.03	1	0
Epilepsy, Tonic-Clonic A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)	3.03	1	0
Pigmentary Retinopathy [description not available]	2.11	1	0
Retinitis Pigmentosa Hereditary, progressive degeneration of the retina due to death of ROD PHOTORECEPTORS initially and subsequent death of CONE PHOTORECEPTORS. It is characterized by deposition of pigment in the retina.	2.11	1	0
Malnourishment [description not available]	2.11	1	0
Malnutrition An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.	2.11	1	0
Genito-urinary Cancer [description not available]	2.11	1	0
Urogenital Neoplasms Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.	2.11	1	0
Dermatosclerosis [description not available]	2.72	3	0
Scleroderma, Localized A term used to describe a variety of localized asymmetrical SKIN thickening that is similar to those of SYSTEMIC SCLERODERMA but without the disease features in the multiple internal organs and BLOOD VESSELS. Lesions may be characterized as patches or plaques (morphea), bands (linear), or nodules.	2.72	3	0
Musculoskeletal Pain Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.	3.51	1	1
Diffuse Cutaneous Systemic Sclerosis [description not available]	3.41	2	0
Scleroderma, Diffuse A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability.	3.41	2	0
Arterial Inflammation [description not available]	2.11	1	0
Arterial Diseases, Carotid [description not available]	2.11	1	0
Carotid Artery Diseases Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.	2.11	1	0
Neoplasms, Skull [description not available]	3.36	2	0
Neoplasms, Pleural [description not available]	6.68	12	5
Lymphangioendothelioma, Malignant [description not available]	2.11	1	0
Hypoalbuminemia A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).	2.11	1	0
Cacosmia [description not available]	3.45	2	0
Infections, Staphylococcal [description not available]	4.61	3	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	4.61	3	0
Coronary Restenosis Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.	3.36	2	0
Neoplasms, Cystic, Mucinous, and Serous Neoplasms containing cyst-like formations or producing mucin or serum.	2.49	2	0
Hydronephrosis Abnormal enlargement or swelling of a KIDNEY due to dilation of the KIDNEY CALICES and the KIDNEY PELVIS. It is often associated with obstruction of the URETER or chronic kidney diseases that prevents normal drainage of urine into the URINARY BLADDER.	3.03	1	0
Cholangiitis, Sclerosing [description not available]	2.11	1	0
Cholangitis, Sclerosing Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.	2.11	1	0
Endothelioma, Vascular [description not available]	2.13	1	0
Hemangioendothelioma A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)	2.13	1	0
Cancer of Maxillary Sinus [description not available]	5.93	5	1
Orphan Diseases Rare diseases that have not been well studied.	2.17	1	0
Bilateral Nasal Obstruction [description not available]	2.17	1	0
Nasal Obstruction Any hindrance to the passage of air into and out of the nose. The obstruction may be unilateral or bilateral, and may involve any part of the NASAL CAVITY.	2.17	1	0
Capsule Opacification Clouding or loss of transparency of the posterior lens capsule, usually following CATARACT extraction.	2.13	1	0
Chronic Lung Injury [description not available]	2.13	1	0
Chylopericardium [description not available]	5.42	5	1
Cardiac Tamponade Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse.	2.75	3	0
Pericardial Effusion Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.	5.42	5	1
Abnormalities, Autosome [description not available]	2.96	4	0
Linitis Plastica A condition where the stomach wall becomes thickened, rubbery and loses its ability to distend. The stomach assumes a leather bottle shape. It is most often seen in adenocarcinoma of the stomach. The term is often used synonymously with diffuse adenocarcinoma of the stomach.	2.13	1	0
Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)	5.06	3	1
Calcification, Pathologic [description not available]	2.13	1	0
Calcinosis Pathologic deposition of calcium salts in tissues.	2.13	1	0
Abdominal Neoplasms New abnormal growth of tissue in the ABDOMEN.	2.53	2	0
Dendritic Cell Sarcoma, Interdigitating A rare sarcoma of INTERDIGITATING CELLS found in the lymph nodes and non-lymphoid organs. They exhibit a variable immunophenotype and lack Birbeck granules.	3.04	1	0
Leanness [description not available]	3.86	2	1
Embolism, Pulmonary [description not available]	5.45	5	1
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	5.45	5	1
Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.	2.13	1	0
Gingivitis Inflammation of gum tissue (GINGIVA) without loss of connective tissue.	3.51	1	1
Deficiency, Magnesium [description not available]	2.45	2	0
Magnesium Deficiency A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936)	2.45	2	0
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	3.4	2	0
P carinii Pneumonia [description not available]	2.74	3	0
Drug-Induced Stevens Johnson Syndrome [description not available]	4.14	3	1
Pneumonia, Pneumocystis A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	2.74	3	0
Stevens-Johnson Syndrome Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.	4.14	3	1
Infection, Postoperative Wound [description not available]	3.53	1	1
Cancer of Mediastinum [description not available]	3.29	6	0
Mediastinal Neoplasms Tumors or cancer of the MEDIASTINUM.	3.29	6	0
Retroperitoneal Neoplasms New abnormal growth of tissue in the RETROPERITONEAL SPACE.	3.3	6	0
Granulocytic Leukemia, Chronic [description not available]	2.73	3	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	2.73	3	0
Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.	5.99	5	2
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	3.25	6	0
Eyelid Neoplasms Tumors of cancer of the EYELIDS.	2.04	1	0
Jaw Diseases Diseases involving the JAW.	2.96	4	0
Aseptic Necrosis of Bone [description not available]	3.14	5	0
Osteonecrosis Death of a bone or part of a bone, either atraumatic or posttraumatic.	3.14	5	0
Hypomelanosis [description not available]	2.05	1	0
Hypopigmentation A condition caused by a deficiency or a loss of melanin pigmentation in the epidermis, also known as hypomelanosis. Hypopigmentation can be localized or generalized, and may result from genetic defects, trauma, inflammation, or infections.	2.05	1	0
Hepatitis INFLAMMATION of the LIVER.	2.04	1	0
Adenocarcinoma, Alveolar [description not available]	7.4	5	4
Adenocarcinoma, Bronchiolo-Alveolar A carcinoma derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)	7.4	5	4
Ectropion The turning outward (eversion) of the edge of the eyelid, resulting in the exposure of the palpebral conjunctiva. (Dorland, 27th ed)	2.04	1	0
Chondrosarcoma, Mesenchymal A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)	2.04	1	0
B-Cell Chronic Lymphocytic Leukemia [description not available]	2.04	1	0
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2.04	1	0
Infections, Klebsiella [description not available]	2.05	1	0
Angiogranuloma [description not available]	2.05	1	0
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	2.05	1	0
Cancer of Digestive System [description not available]	4.76	2	1
Cancer of Rectum [description not available]	2.96	1	0
Digestive System Neoplasms Tumors or cancer of the DIGESTIVE SYSTEM.	4.76	2	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.96	1	0
Foot Dermatoses Skin diseases of the foot, general or unspecified.	6.86	9	1
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	6.71	9	7
Abdomen, Acute A clinical syndrome with acute abdominal pain that is severe, localized, and rapid in onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases.	2.05	1	0
Impaired Glucose Tolerance [description not available]	2.05	1	0
Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.	2.05	1	0
Paraganglioma, Gangliocytic [description not available]	2.44	2	0
Paraganglioma A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)	2.44	2	0
B-Cell Lymphoma [description not available]	2.95	4	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.95	4	0
Colonic Inertia Symptom characterized by the passage of stool once a week or less.	7.08	5	4
Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.	7.08	5	4
Nail Abnormalities [description not available]	3.13	5	0
Lethargy A general state of sluggishness, listless, or uninterested, with being tired, and having difficulty concentrating and doing simple tasks. It may be related to DEPRESSION or DRUG ADDICTION.	3.43	1	1
Acquired Autoimmune Hemolytic Anemia [description not available]	2.05	1	0
Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.	2.05	1	0
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	6.5	10	5
Leukemia, Myeloid, Acute, M4 [description not available]	2.96	1	0
Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.	2.96	1	0
Ataxia Telangiectasia Syndrome [description not available]	2.05	1	0
Ataxia Telangiectasia An autosomal recessive inherited disorder characterized by choreoathetosis beginning in childhood, progressive CEREBELLAR ATAXIA; TELANGIECTASIS of CONJUNCTIVA and SKIN; DYSARTHRIA; B- and T-cell immunodeficiency, and RADIOSENSITIVITY to IONIZING RADIATION. Affected individuals are prone to recurrent sinobronchopulmonary infections, lymphoreticular neoplasms, and other malignancies. Serum ALPHA-FETOPROTEINS are usually elevated. (Menkes, Textbook of Child Neurology, 5th ed, p688) The gene for this disorder (ATM) encodes a cell cycle checkpoint protein kinase and has been mapped to chromosome 11 (11q22-q23).	2.05	1	0
Sterility, Male [description not available]	2.05	1	0
Infertility, Male The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.	2.05	1	0
Granulomatosis, Wegener's [description not available]	2.08	1	0
Granulomatosis with Polyangiitis A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.	2.08	1	0
Colitis Gravis [description not available]	2.05	1	0
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.05	1	0
Drop Attack [description not available]	2.05	1	0
Syncope A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)	2.05	1	0
Cystadenoma, Mucinous A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.	3.43	1	1
Cystadenoma, Serous A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)	3.43	1	1
Infections, Pseudomonas [description not available]	2.05	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.05	1	0
Palsy [description not available]	2.43	2	0
Autonomic Dysfunction, Paraneoplastic [description not available]	2.05	1	0
Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)	2.43	2	0
Convulsions, Febrile [description not available]	2.05	1	0
Seizures, Febrile Seizures that occur during a febrile episode. It is a common condition, affecting 2-5% of children aged 3 months to five years. An autosomal dominant pattern of inheritance has been identified in some families. The majority are simple febrile seizures (generally defined as generalized onset, single seizures with a duration of less than 30 minutes). Complex febrile seizures are characterized by focal onset, duration greater than 30 minutes, and/or more than one seizure in a 24 hour period. The likelihood of developing epilepsy (i.e., a nonfebrile seizure disorder) following simple febrile seizures is low. Complex febrile seizures are associated with a moderately increased incidence of epilepsy. (From Menkes, Textbook of Child Neurology, 5th ed, p784)	2.05	1	0
Acute Brain Injuries [description not available]	3.44	1	1
Anterior Choroidal Artery Infarction [description not available]	5.04	3	1
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	3.44	1	1
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	5.04	3	1
Aldosteronism [description not available]	7.48	4	4
Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.	7.48	4	4
T-Cell Lymphoma [description not available]	2.74	3	0
Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.	2.74	3	0
Dermatitis, Contact, Phototoxic [description not available]	2.47	2	0
Gasser Syndrome [description not available]	3.35	2	0
Hemolytic-Uremic Syndrome A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.	3.35	2	0
Dental Tissue Neoplasms [description not available]	2.97	1	0
Mandibular Neoplasms Tumors or cancer of the MANDIBLE.	3.66	3	0
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	2.97	1	0
Foot Diseases Anatomical and functional disorders affecting the foot.	7.65	5	4
Phlegmon [description not available]	3.44	1	1
Cellulitis An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.	3.44	1	1
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.05	1	0
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	2.05	1	0
Submandibular Gland Neoplasms New abnormal growth of tissue in the SUBMANDIBULAR GLAND.	2.05	1	0
Pellagra A disease due to deficiency of NIACIN, a B-complex vitamin, or its precursor TRYPTOPHAN. It is characterized by scaly DERMATITIS which is often associated with DIARRHEA and DEMENTIA (the three D's).	2.05	1	0
Acute Bacterial Prostatitis [description not available]	4.93	4	0
Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.	4.93	4	0
Urinary Incontinence Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.	4.93	4	0
Cystic Fibrosis of Pancreas [description not available]	3.44	1	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	3.44	1	1
Anemia, Hypoplastic [description not available]	2.05	1	0
Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.	2.05	1	0
Tracheal Stenosis A pathological narrowing of the TRACHEA.	2.05	1	0
Tracheal Neoplasms New abnormal growth of tissue in the TRACHEA.	2.93	4	0
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	2.06	1	0
Achalasia [description not available]	2.06	1	0
Cancer Syndromes, Hereditary [description not available]	2.44	2	0
Cronkhite-Canada Syndrome A nonfamilial polyposis syndrome that is characterized by the presence of diffuse gastrointestinal polyposis, DIARRHEA, and PROTEIN-LOSING ENTEROPATHY. It was first reported by Cronkhite and Canada in 1955.	2.06	1	0
Esophageal Achalasia A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus).	2.06	1	0
Mixed Tumor, Mullerian A tumor, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of estrogen has been postulated as a possible etiological factor in this tumor. (Holland et al., Cancer Medicine, 3d ed, p1703)	3.35	2	0
Muscular Weakness [description not available]	6.36	9	0
Sensation Disorders Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).	6.45	10	0
Muscle Weakness A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)	6.36	9	0
Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	2.06	1	0
Cancer of Muscle [description not available]	2.72	3	0
DDD MPGNII [description not available]	2.06	1	0
Glomerulonephritis, Membranoproliferative Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.	2.06	1	0
Metaplasia A condition in which there is a change of one adult cell type to another similar adult cell type.	2.74	3	0
Hyperlipemia [description not available]	2.06	1	0
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.06	1	0
Alcoholic Intoxication An acute brain syndrome which results from the excessive ingestion of ETHANOL or ALCOHOLIC BEVERAGES.	3.83	2	1
Anaphylactic Reaction [description not available]	3.82	2	0
Anaphylaxis An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.	3.82	2	0
Drug Overdose Accidental or deliberate use of a medication or street drug in excess of normal dosage.	2.06	1	0
Mastitis INFLAMMATION of the BREAST, or MAMMARY GLAND.	2.06	1	0
Rectovaginal Fistula An abnormal anatomical passage between the RECTUM and the VAGINA.	2.06	1	0
Urinary Bladder Fistula An abnormal passage in the URINARY BLADDER or between the bladder and any surrounding organ.	2.06	1	0
Cyst [description not available]	2.07	1	0
Hemoptysis Expectoration or spitting of blood originating from any part of the RESPIRATORY TRACT, usually from hemorrhage in the lung parenchyma (PULMONARY ALVEOLI) and the BRONCHIAL ARTERIES.	2.07	1	0
Leucocythaemia [description not available]	6.33	5	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	6.33	5	1
Androgenization [description not available]	2.98	1	0
Androblastoma [description not available]	2.98	1	0
Coronary Heart Disease [description not available]	2.98	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	2.98	1	0
Acute-Phase Reaction An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.	2.07	1	0
Carcinoma, Medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)	5.81	4	2
Sunburn An injury to the skin causing erythema, tenderness, and sometimes blistering and resulting from excessive exposure to the sun. The reaction is produced by the ultraviolet radiation in sunlight.	2.06	1	0
Experimental Leukemia [description not available]	4.74	4	0
Bacterial Disease [description not available]	6.14	4	3
Bacterial Infections Infections by bacteria, general or unspecified.	6.14	4	3
Marasmus [description not available]	2.07	1	0
Protein-Energy Malnutrition The lack of sufficient energy or protein to meet the body's metabolic demands, as a result of either an inadequate dietary intake of protein, intake of poor quality dietary protein, increased demands due to disease, or increased nutrient losses.	2.07	1	0
Cerebral Nocardiosis [description not available]	2.07	1	0
Dehydration The condition that results from excessive loss of water from a living organism.	3.86	2	1
Gastric Rupture [description not available]	2.06	1	0
Abdominal Aortic Aneurysm [description not available]	2.07	1	0
Aortic Aneurysm, Abdominal An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.	2.07	1	0
Hairy Cell Leukemia [description not available]	2.07	1	0
Langerhans Cell Sarcoma Rare malignant neoplasm of dendritic LANGERHANS CELLS exhibiting atypical cytology, frequent mitoses, and aggressive clinical behavior. They can be distinguished from other histiocytic and dendritic proliferations by immunohistochemical and ultrastructure studies. Cytologically benign proliferations of Langerhans cells are called LANGERHANS CELL HISTIOCYTOSIS.	2.07	1	0
Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.	2.07	1	0
Pleurisy INFLAMMATION of PLEURA, the lining of the LUNG. When PARIETAL PLEURA is involved, there is pleuritic CHEST PAIN.	2.06	1	0
Anemia, Hypochromic Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)	2.06	1	0
Scalp Dermatoses Skin diseases involving the SCALP.	3.86	2	1
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	2.07	1	0
Leukocyte Disorders Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.	3.46	1	1
Hemolysis, Elevated Liver Enzymes, Lowered Platelets [description not available]	2.99	1	0
Edema-Proteinuria-Hypertension Gestosis [description not available]	2.99	1	0
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.	2.99	1	0
HELLP Syndrome A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.	2.99	1	0
Cardiac Free Wall Rupture [description not available]	2.07	1	0
Appetite Disorders [description not available]	3.4	2	0
Feeding and Eating Disorders A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.	3.4	2	0
Hepatoblastoma A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)	2.07	1	0
Cancer of Jaw [description not available]	2.07	1	0
Ductal, Lobular, and Medullary Neoplasms [description not available]	2.44	2	0
Basal Cell Cancer [description not available]	2.07	1	0
Prosthesis Durability [description not available]	2.07	1	0
Dermatitis, Eczematous [description not available]	3.48	1	1
Eczema A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).	3.48	1	1
Deficiency of Glucose-6-Phosphate Dehydrogenase [description not available]	2.07	1	0
Glucosephosphate Dehydrogenase Deficiency A disease-producing enzyme deficiency subject to many variants, some of which cause a deficiency of GLUCOSE-6-PHOSPHATE DEHYDROGENASE activity in erythrocytes, leading to hemolytic anemia.	2.07	1	0
Grippe [description not available]	2.44	2	0
Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.	2.44	2	0
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.07	1	0
Cancer of Sigmoid [description not available]	2.07	1	0
Chromosomal Breakage [description not available]	2.07	1	0
Antidiuretic Hormone, Inappropriate Secretion [description not available]	2.72	3	0
Inappropriate ADH Syndrome A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.	2.72	3	0
Canine Diseases [description not available]	4.41	2	2
Angiomyxoma [description not available]	2.99	1	0
Adenoma, Oxyphilic A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.	2.07	1	0
Actinic Reticuloid Syndrome [description not available]	2.07	1	0
Choriocarcinoma, Non-gestational A highly malignant CHORIOCARCINOMA derived from the non-placental origin such as the totipotent cells in the TESTIS, the OVARY, and the PINEAL GLAND. It produces high levels of CHORIONIC GONADOTROPIN and can metastasize widely through the bloodstream to the lungs, brain, liver, bone, and other viscera by the time of diagnosis.	2.07	1	0
Cancer of Granulosa Cells [description not available]	2.07	1	0
Milk-Alkali Syndrome [description not available]	2.43	2	0
Hypercalcemia Abnormally high level of calcium in the blood.	2.43	2	0
Sweat Gland Diseases Diseases of the SWEAT GLANDS.	2.44	2	0
Apical Ballooning Syndrome [description not available]	3	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	3	1	0
Takotsubo Cardiomyopathy A transient left ventricular apical dysfunction or ballooning accompanied by electrocardiographic (ECG) T wave inversions. This abnormality is associated with high levels of CATECHOLAMINES, either administered or endogenously secreted from a tumor or during extreme stress.	3	1	0
Melanoma, Amelanotic An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)	2.08	1	0
Hoarseness An unnaturally deep or rough quality of voice.	2.08	1	0
Smoking Cessation Discontinuing the habit of SMOKING.	2.08	1	0
MODS [description not available]	2.01	1	0
Multiple Organ Failure A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.	2.01	1	0
Brain Disorders [description not available]	3.33	2	0
Anticipatory Vomiting [description not available]	7.05	6	2
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	3.33	2	0
Pachymeningitis [description not available]	4.1	3	1
Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)	4.1	3	1
Candida Infection [description not available]	2.01	1	0
Cytomegalic Inclusion Disease [description not available]	2.41	2	0
B Virus Infection [description not available]	2.01	1	0
CD4-Positive T-Lymphocytopenia, Idiopathic [description not available]	2.01	1	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.01	1	0
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	2.41	2	0
T-Lymphocytopenia, Idiopathic CD4-Positive Reproducible depletion of CD4+ lymphocytes below 300 per cubic millimeter in the absence of HIV infection or other known causes of immunodeficiency. This is a rare, heterogeneous syndrome and does not appear to be caused by a transmissible agent.	2.01	1	0
Anemia, Hemolytic, Acquired [description not available]	2.01	1	0
Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).	2.01	1	0
Viral Hepatitis, Human [description not available]	2.01	1	0
Hepatic Failure [description not available]	4.32	4	1
Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).	2.01	1	0
Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)	4.32	4	1
Angina at Rest [description not available]	2.01	1	0
Angina, Unstable Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.	2.01	1	0
Jaundice, Cholestatic [description not available]	2.43	2	0
Antibiotic-Associated Colitis [description not available]	4.08	3	1
Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.	4.08	3	1
Jaundice, Obstructive Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.	2.43	2	0
Alveolitis, Fibrosing [description not available]	3.4	1	1
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	3.4	1	1
Neoplasms, Sebaceous Gland [description not available]	2.01	1	0
Chemical Dependence [description not available]	2.93	1	0
Substance-Related Disorders Disorders related to substance use or abuse.	2.93	1	0
Cardiomyopathies, Primary [description not available]	4.71	2	1
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	4.71	2	1
Tricuspid Incompetence [description not available]	2.01	1	0
Carcinoid Heart Disease Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.	2.01	1	0
Bleb [description not available]	2.41	2	0
Tachyarrhythmia [description not available]	2.02	1	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	2.02	1	0
Erythema Multiforme A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic bull's-eye lesions usually occurring on the dorsal aspect of the hands and forearms.	2.42	2	0
Infections, Helicobacter [description not available]	2.02	1	0
Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.	2.02	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	2.02	1	0
Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.	2.02	1	0
Necrotizing Enterocolitis [description not available]	2.02	1	0
Chronic Idiopathic Intestinal Pseudo-Obstruction [description not available]	2.02	1	0
Intestinal Pseudo-Obstruction A type of ILEUS, a functional not mechanical obstruction of the INTESTINES. This syndrome is caused by a large number of disorders involving the smooth muscles (MUSCLE, SMOOTH) or the NERVOUS SYSTEM.	2.02	1	0
Enterocolitis, Necrotizing ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.	2.02	1	0
Water-Electrolyte Imbalance Disturbances in the body's WATER-ELECTROLYTE BALANCE.	5.97	5	2
Argentaffinoma [description not available]	3.4	1	1
Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)	3.4	1	1
Fibrous Tissue Neoplasms [description not available]	2.02	1	0
Monosomy The condition in which one chromosome of a pair is missing. In a normally diploid cell it is represented symbolically as 2N-1.	2.02	1	0
Pus [description not available]	2.43	2	0
Rupture Forcible or traumatic tear or break of an organ or other soft part of the body.	2.94	1	0
Cecal Diseases Pathological developments in the CECUM.	3.32	2	0
Gynandroblastoma A sex cord-gonadal stromal tumor, composed of cells of both the OVARY and the TESTIS. It produces both male and female GONADAL STEROID HORMONES.	2.02	1	0
Sex Cord-Gonadal Stromal Tumors Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.	2.02	1	0
Atrophy, Muscular, Peroneal [description not available]	2.02	1	0
Charcot-Marie-Tooth Disease A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)	2.02	1	0
Neoplasms, Sweat Gland [description not available]	2.7	3	0
Acrospiroma A rare cutaneous tumor of apocrine or eccrine SWEAT GLAND origin. It is most commonly found on the extremities and is usually benign. It appears as a solitary nodule or cyst and may be solid or produce a watery discharge. It is related to POROMA except in acrospiroma it does not involve the epidermis. There is no indication that heredity or external agents cause these tumors.	2.42	2	0
Asbestosis A form of pneumoconiosis caused by inhalation of asbestos fibers which elicit potent inflammatory responses in the parenchyma of the lung. The disease is characterized by interstitial fibrosis of the lung, varying from scattered sites to extensive scarring of the alveolar interstitium.	2.02	1	0
Bowel Diseases, Inflammatory [description not available]	2.02	1	0
Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.	2.02	1	0
Coronary Artery Stenosis [description not available]	3.81	2	1
Cardiomyopathy, Congestive [description not available]	3.41	1	1
Cardiomyopathy, Dilated A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.	3.41	1	1
Coronary Stenosis Narrowing or constriction of a coronary artery.	3.81	2	1
Adenoma, Pleomorphic A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)	2.03	1	0
Aphthae [description not available]	2.02	1	0
Stomatitis, Aphthous A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742)	2.02	1	0
Neoplasm Seeding The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.	2.02	1	0
Colitis, Ischemic Inflammation of the COLON due to colonic ISCHEMIA resulting from alterations in systemic circulation or local vasculature.	2.02	1	0
Central Diabetes Insipidus [description not available]	2.02	1	0
Cancer of Pituitary [description not available]	2.02	1	0
Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.	2.02	1	0
Diabetes Insipidus, Neurogenic A genetic or acquired polyuric disorder caused by a deficiency of VASOPRESSINS secreted by the NEUROHYPOPHYSIS. Clinical signs include the excretion of large volumes of dilute URINE; HYPERNATREMIA; THIRST; and polydipsia. Etiologies include HEAD TRAUMA; surgeries and diseases involving the HYPOTHALAMUS and the PITUITARY GLAND. This disorder may also be caused by mutations of genes such as ARVP encoding vasopressin and its corresponding neurophysin (NEUROPHYSINS).	2.02	1	0
BOOP [description not available]	2.03	1	0
Diabetic Glomerulosclerosis [description not available]	2.03	1	0
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.03	1	0
Respiratory Tract Neoplasms New abnormal growth of tissue in the RESPIRATORY SYSTEM.	3.41	1	1
Rupture, Spontaneous Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.	2.03	1	0
Urinary Tract Diseases [description not available]	2.94	1	0
Pain, Intractable Persistent pain that is refractory to some or all forms of treatment.	2.03	1	0
Sublingual Gland Neoplasms Neoplasms of the sublingual glands.	2.03	1	0
Seminoma A radiosensitive, malignant neoplasm of the testis, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. There are three variants: classical (typical), the most common type; anaplastic; and spermatocytic. The classical seminoma is composed of fairly well differentiated sheets or cords of uniform polygonal or round cells (seminoma cells), each cell having abundant clear cytoplasm, distinct cell membranes, a centrally placed round nucleus, and one or more nucleoli. In the female, a grossly and histologically identical neoplasm, known as dysgerminoma, occurs. (Dorland, 27th ed)	2.03	1	0
Vaginal Diseases Pathological processes of the VAGINA.	2.03	1	0
Cardiac Edema [description not available]	2.03	1	0
Edema, Pulmonary [description not available]	2.7	3	0
Edema, Cardiac Abnormal fluid retention by the body due to impaired cardiac function or heart failure. It is usually characterized by increase in venous and capillary pressure, and swollen legs when standing. It is different from the generalized edema caused by renal dysfunction (NEPHROTIC SYNDROME).	2.03	1	0
Pulmonary Edema Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.	2.7	3	0
Neoplasms, Vascular [description not available]	2.03	1	0
Bilateral Wilms Tumor [description not available]	2.03	1	0
Wilms Tumor A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.	2.03	1	0
Deficiency, Protein C [description not available]	2.95	1	0
Brain Hemorrhage, Cerebral [description not available]	2.95	1	0
Phlegmasia Alba Dolens Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.	3.82	2	0
Anti-Phospholipid Antibody Syndrome [description not available]	2.95	1	0
Deficiency, Protein S [description not available]	2.95	1	0
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	2.95	1	0
Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS).	3.82	2	0
Antiphospholipid Syndrome The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).	2.95	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	2.03	1	0
Chalazia [description not available]	2.03	1	0
Eyelid Diseases Diseases involving the EYELIDS.	2.03	1	0
Chalazion A non-neoplastic cyst of the MEIBOMIAN GLANDS of the eyelid.	2.03	1	0
Skin Ulcer An ULCER of the skin and underlying tissues.	2.41	2	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	2.95	1	0
Brachial Plexopathy [description not available]	2.03	1	0
Brachial Plexus Neuropathies Diseases of the cervical (and first thoracic) roots, nerve trunks, cords, and peripheral nerve components of the BRACHIAL PLEXUS. Clinical manifestations include regional pain, PARESTHESIA; MUSCLE WEAKNESS, and decreased sensation (HYPESTHESIA) in the upper extremity. These disorders may be associated with trauma (including BIRTH INJURIES); THORACIC OUTLET SYNDROME; NEOPLASMS; NEURITIS; RADIOTHERAPY; and other conditions. (From Adams et al., Principles of Neurology, 6th ed, pp1351-2)	2.03	1	0
Metabolic Acidosis [description not available]	2.03	1	0
Acidosis A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.	2.03	1	0
Hypothermia, Accidental [description not available]	2.04	1	0
Hypothermia Lower than normal body temperature, especially in warm-blooded animals.	2.04	1	0
Hypocalcemia Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)	5.58	3	2
Aesthesioneuroblastoma [description not available]	2.04	1	0
Esthesioneuroblastoma, Olfactory A malignant olfactory neuroblastoma arising from the olfactory epithelium of the superior nasal cavity and cribriform plate. It is uncommon (3% of nasal tumors) and rarely is associated with the production of excess hormones (e.g., SIADH, Cushing Syndrome). It has a high propensity for multiple local recurrences and bony metastases. (From Holland et al., Cancer Medicine, 3rd ed, p1245; J Laryngol Otol 1998 Jul;112(7):628-33)	2.04	1	0
Auricular Flutter [description not available]	2.04	1	0
Atrial Flutter Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).	2.04	1	0
Amentia [description not available]	2.95	1	0
Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.	2.95	1	0
Leukemia, Acute Monocytic [description not available]	2.04	1	0
Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.	2.04	1	0
Acute Porphyria [description not available]	2.04	1	0
Porphyria Variegata [description not available]	2.04	1	0
Porphyria, Acute Intermittent An autosomal dominant porphyria that is due to a deficiency of HYDROXYMETHYLBILANE SYNTHASE in the LIVER, the third enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features are recurrent and life-threatening neurologic disturbances, ABDOMINAL PAIN, and elevated level of AMINOLEVULINIC ACID and PORPHOBILINOGEN in the urine.	2.04	1	0
Porphyria, Variegate An autosomal dominant porphyria that is due to a deficiency of protoporphyrinogen oxidase (EC 1.3.3.4) in the LIVER, the seventh enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features include both neurological symptoms and cutaneous lesions. Patients excrete increased levels of porphyrin precursors, COPROPORPHYRINS and protoporphyrinogen.	2.04	1	0
Plasmodium falciparum Malaria [description not available]	1.98	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	1.98	1	0
Di Guglielmo Disease [description not available]	2.39	2	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	2.39	2	0
Ovoid Neutrophil Nuclei, Developmental Delay, Epilepsy and Skeletal Abnormalities [description not available]	1.99	1	0
Ileal Diseases Pathological development in the ILEUM including the ILEOCECAL VALVE.	1.99	1	0
Anterior Horn Cell Disease [description not available]	1.99	1	0
Motor Neuron Disease Diseases characterized by a selective degeneration of the motor neurons of the spinal cord, brainstem, or motor cortex. Clinical subtypes are distinguished by the major site of degeneration. In AMYOTROPHIC LATERAL SCLEROSIS there is involvement of upper, lower, and brainstem motor neurons. In progressive muscular atrophy and related syndromes (see MUSCULAR ATROPHY, SPINAL) the motor neurons in the spinal cord are primarily affected. With progressive bulbar palsy (BULBAR PALSY, PROGRESSIVE), the initial degeneration occurs in the brainstem. In primary lateral sclerosis, the cortical neurons are affected in isolation. (Adams et al., Principles of Neurology, 6th ed, p1089)	1.99	1	0
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	1.99	1	0
Infections, Plasmodium [description not available]	1.99	1	0
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	1.99	1	0
Cystadenocarcinoma, Mucinous A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)	1.99	1	0
Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.	1.99	1	0
Myelopathy [description not available]	3.38	1	1
Spinal Cord Diseases Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.	3.38	1	1
Carcinoma, Bronchial [description not available]	2.91	1	0
Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.	2.91	1	0
Chronic Primary Open Angle Glaucoma [description not available]	2	1	0
Glaucoma, Open-Angle Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.	2	1	0
Intraocular Pressure The pressure of the fluids in the eye.	2	1	0
Venous Insufficiency Impaired venous blood flow or venous return (venous stasis), usually caused by inadequate venous valves. Venous insufficiency often occurs in the legs, and is associated with EDEMA and sometimes with VENOUS STASIS ULCERS at the ankle.	2	1	0
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	3.39	1	1
Mesenteric Vascular Occlusion Obstruction of the flow in the SPLANCHNIC CIRCULATION by ATHEROSCLEROSIS; EMBOLISM; THROMBOSIS; STENOSIS; TRAUMA; and compression or intrinsic pressure from adjacent tumors. Rare causes are drugs, intestinal parasites, and vascular immunoinflammatory diseases such as PERIARTERITIS NODOSA and THROMBOANGIITIS OBLITERANS. (From Juergens et al., Peripheral Vascular Diseases, 5th ed, pp295-6)	2	1	0
Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)	2	1	0
Amyotonia Congenita [description not available]	2.92	1	0
Neuromuscular Diseases A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.	2.92	1	0
Hyperprolactinaemia [description not available]	3.39	1	1
Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)	3.39	1	1
Clubbed Fingers [description not available]	2	1	0
Yolk Sac Tumor [description not available]	2	1	0
Endodermal Sinus Tumor An unusual and aggressive tumor of germ-cell origin that reproduces the extraembryonic structures of the early embryo. It is the most common malignant germ cell tumor found in children. It is characterized by a labyrinthine glandular pattern of flat epithelial cells and rounded papillary processes with a central capillary (Schiller-Duval body). The tumor is rarely bilateral. Before the use of combination chemotherapy, the tumor was almost invariably fatal. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1189)	2	1	0
A-V Dissociation [description not available]	2	1	0
Complication, Intraoperative [description not available]	2	1	0
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2	1	0
Health Care Associated Infection [description not available]	2	1	0
Cross Infection Any infection which a patient contracts in a health-care institution.	2	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2.01	1	0
Gastric Diseases [description not available]	2.01	1	0
Emphysema A pathological accumulation of air in tissues or organs.	2.01	1	0
Superior Vena Cava Obstruction [description not available]	2.01	1	0
Leukemia, Lymphocytic [description not available]	1.97	1	0
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	1.97	1	0

docetaxel anhydrous

Description

Cross-References

Synonyms (121)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (2)

Pathways (1)

Protein Targets (33)

Potency Measurements

Inhibition Measurements

Biological Processes (302)

Molecular Functions (85)

Ceullar Components (57)

Bioassays (393)

Research

Studies (11,566)

Market Indicators

Research Demand Index: 18.79

Study Types